

Qualifying Therapeutic Discovery Project Grants

The listings below represent the applicants that have been awarded a Qualifying Therapeutic Discovery Program Grant.

The project descriptions below were extracted from the applicant certification forms as submitted.

Alabama \$3,708,304.65

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Agenta Biotechnologies Inc	Molecular Heparan Sulfate Delivery in Barrier Membranes and Soft Tissue Wound Closure	\$59,614.76	\$184,864.48
AGENTA BIOTECHNOLOGIES INC	DELIVERY OF GROWTH-FACTOR CO-RECEPTOR HEPARAN SULFATE IN BONE GRAFT SUBSTITUTES FOR REPAIR	\$169,808.39	\$6,666.50
BioCryst Pharmaceuticals Inc	BCX4208 for Treatment of Gout	\$244,479.25	
BioCryst Pharmaceuticals, Inc	Peramivir for Treatment of Influenza	\$244,479.25	
BioCryst Pharmaceuticals, Inc	Forodesine for Treatment of CLL and CTCL	\$244,479.25	
BioCryst Pharmaceuticals, Inc.	BCX4161 for Treatment of Hereditary Angioedema		\$86,380.89
BioCryst Pharmaceuticals, Inc.	JAK Inhibitors for Treatment of Psoriasis, Ankylosing Spondylitis, & Multiple Sclerosis	\$244,479.25	
Diatherix Laboratories, Inc.	Disease Diagnostic Panel Development Utilizing the TEM-PCR Method	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
EGEN INC	EGEN-001 in Platinum-Resistant Ovarian Cancer	\$244,479.25	
EGEN, INC.	EGEN TheraSilence	\$244,479.25	
iCubate, Inc	Development of an Apparatus for Performing am-PCR	\$244,479.25	
PNP Therapeutics Inc	Phase 1, Open-label Syudy Evaluating the Safety of Escalating Doses of Ad/PNP-F-araAMP	\$244,479.25	
Serina Therapeutics, Inc	SER-201 for the treatment of colorectal and ovarian cancer	\$244,479.25	
Vaxin Inc.	Development of an Adenovirus-Vectored Nasal Anthrax Vaccine	\$244,479.25	
Vaxin Inc.	Replication-Defective Adenovirus-Vectored Influenza Vaccine Development	\$161,175.00	\$83,304.25
Vista Engineering Inc	Nanotechnology Enabled Temporomandibular Joint (TMJ) Prosthesis	\$29,059.63	\$32,059.00
Volatile Analysis Corporation	Development of sorptive nasal stent for diagnostic biomarker detection	\$23,600.00	\$182,500.00

Arizona \$7,503,090.80

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
AmpliMed Corporation	Development of small-molecule anti-cancer drugs	\$244,479.24	
Aphthera, Inc.	NeuVax-adjuvant treatment for node positive breast cancer with	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	low to intermediate HER2		
Ardent Sound Inc.	Development of Ultrasound Therapy Device for Sebaceous and Sweat Gland Treatment	\$244,479.25	
Ascalon International Inc	IV Fenretinide	\$106,406.50	\$138,072.74
bioVidria, Inc.	Integrated platform for glycoform biomarker discovery	\$47,799.50	\$114,302.50
BLUE HORSE LABS, INC.	TGEN COLLABORATION: GENETIC RISK FACTORS FOR ALZHEIMER'S DISEASE (PHASE II)	\$179,589.50	\$8,301.50
Blue Horse Labs, Inc.	Oxidative stress markers in multiple matrices as biomarkers for disease	\$7,160.00	\$88,697.00
Calimmune, Inc.	Hematopoietic Stem Cell Therapy for HIV/AIDS Using RNAi to Reduce Expression of CCR5	\$244,479.25	
Cancer Prevention Pharmaceuticals Inc	Eflornithine	\$189,893.77	\$54,585.48
Capstone Therapeutics Corp	AZX100 for Idiopathic Pulmonary Fibrosis (IPF)	\$78,150.00	\$166,329.24
Cold Plasma Medical Technologies	Harmonic Cold Plasma medical Technology for the Repair of Living Cells, Tissue and organs.		\$244,479.25
Eye Care and Cure Corporation	Extra-Ocular Motility Monitor (EOMM)		\$63,720.71
Eye Care and Cure Corporation	I-CORE		\$53,221.15
Gary A Flynn PhD/Spacefill Enterprises LLC	Multi-targeted Kinase Inhibitors as Imaging and Therapeutic Agents		\$27,000.00
High Throughout	qNPA miRNA Development	\$41,483.00	\$5,419.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Genomics, Inc.	Project		
High Throughput Genomics, Inc	Mid Density Platform Development Project	\$73,830.00	\$79,962.00
High Throughput Genomics, Inc	qBead Development Project	\$67,940.00	\$38,392.00
High Throughput Genomics, Inc	Fusin Gene-SNV Mutation Tests Development Project	\$26,268.50	\$28,273.50
High Throughput Genomics, Inc	Pathogen Assay Development Project	\$11,131.00	\$23,394.00
High Throughput Genomics, Inc	DLBCL & Cell of Origin Development Project	\$16,408.50	\$8,707.00
High Throughput Genomics, Inc	qSelect Assay Archive Development Project	\$16,026.50	\$41,378.50
High Throughput Genomics, Inc	qNPA Platform Technology Development Project	\$71,709.50	\$117,348.00
High Throughput Genomics, Inc	Melanoma Screening Development Project		\$20,359.50
High Throughput Genomics, Inc	Radiation Exposure Monitoring Assay Development Project	\$13,797.00	\$2,081.00
Hope Medical Enterprises, Inc	Treatment of Acute Myocardial Infarction		\$17,542.28
Hope Medical Enterprises, Inc.	Treatment of Sickle Cell Disease	\$3,250.00	\$36,907.86
HumaGene Inc	Recombinant fibrogen & thrombin	\$17,985.00	\$14,500.00
InNexus Biotechnology, Inc.	DXL 625	\$116,760.00	
INSYS Therapeutics, Inc	Fentanyl Sublingual Spray	\$244,479.24	
INSYS Therapeutics, Inc	Dronabinol Oral Solution		\$244,479.25
Kinetic Muscles Inc	Neuro Telerehabilitation System	\$221,667.65	\$22,811.59

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
MedApps, Inc	Utilizing the MedApps System for Remotely Monitoring Clinical Drug Therapies	\$244,479.24	
MSDx Multiple Sclerosis Diagnostics, LLC	Biomarkers for Monitoring Multiple Sclerosis Patients - A Window into the Brain	\$82,908.19	\$47,063.66
MSDx, Inc	Biomarkers for Monitoring Multiple Sclerosis Patients - A window into the Brain		\$74,700.00
PathoGene, LLC	Development of molecular assays for the identification and resistance profiling of MRSA.		\$37,850.50
Protein Genomics	Engineered Small-Diameter Artery Grafts Using Synthesized Human Elastin	\$120,342.50	\$124,136.75
Provista Life Sciences, LLC	Fibrinogen and fibrin degradation product lung cancer assay		\$137,175.27
Provista Life Sciences, LLC	Multivariate Breast Cancer Detection and Screening Assay	\$221,153.46	
Provista Life Sciences, LLC	Epigenetic Test for Alzheimer's Disease		\$244,479.25
Provista Life Sciences, LLC	Lymphocyte Proliferation Test for Early Alzheimer's Detection	\$180,664.68	
Prugen IP Holdings Inc	Drug Bioavailability Enhancement Delivery System	\$244,479.25	
Rowpar Pharmaceuticals, Inc	Stabilized Chlorine Dioxide for Treatment & Prevention of Oral Candidiasis	\$1,402.50	\$3,673.00
Rowpar Pharmaceuticals, Inc	0.5% Stabilized Chlorine Dioxide for the Treatment and Prevention for Gingivitis	\$2,881.00	\$20,782.50
SALUTARIS MEDICAL	SMD-A	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
DEVICES, INC.			
Sensys Medical Inc	Non-invasive blood glucose monitor for the diagnosis & treatment of diabetes	\$244,479.24	
Southwest Scientific Editing & Consulting, LLC	Dietary supplements enhanced for bioflavonoids and antioxidants to treat human disease	\$2,850.00	\$26,200.00
Susavion Biosciences, Inc	Discovery of Immunotherapeutic Drugs Against Viral Infections	\$85,997.50	\$117,631.00
Synbuild LLC	Kit for noninvasive early detection of pancreatic cancer		\$11,157.12
SYNCARDIA SYSTEMS, INC	COMPANION 2 DRIVER		\$54,080.75
Thayer Medical Corporation	Inline actuator for pMDI medication delivery in ventilator circuits with 15 mm connection.	\$66,050.50	\$112,333.50
Transmed Oncology Inc	Pre-Clinical and Clinical Development of DNMT1 inhibiting Compounds	\$70,784.50	
Valley Fever Solutions, Inc.	Late Stage Valley Fever - Phase II		\$244,479.25
Vomaris Innovations, Inc	The Use of Bioelectric Wound Care Devices for Improving Healthcare		\$244,479.25

Arkansas \$730,294.80

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
BioStrategies, LC	Mucosal and Cell Targeted RTB Delivery of Novel Plant Produced Protein Therapeutics	\$118,994.00	\$125,485.25
Pacific Vet	Pre-clinical Trials for Unique	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Group - USA Inc.	Competitive Exclusion Treatment for Gastrointestinal Disease		
Stage I Diagnostics, Inc.	New Biomarker Assays for Monitoring and Diagnosis of Ovarian Cancer	\$171,756.22	\$69,580.08

California \$276,141,790.10

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
3-V BIOSCIENCES INC	BROAD SPECTRUM HOST FACTOR DIRECTED ANTIVIRAL THERAPEUTIC	\$244,479.24	
5iSciences, Inc.	Application of continous negative external pressure (cNEP) to the upper airway	\$22,834.35	\$141,124.00
A.P. Pharma, Inc	APF530- Prevention of Chemotherapy-induced Nausea and Vomiting	\$244,479.25	
Aaken Laboratories	Guided Electrical Stimulation	\$49,026.40	\$36,267.00
Aardvark Medical, Inc.	Nasal Irrigation/Aspiration System	\$244,479.24	
Ablation Numerics Inc	Rapid and Simple Cure for Atrial Fibrillation	\$500.00	\$243,979.25
Acadia Pharmaceuticals Inc.	Pimavanserin	\$244,479.25	
Acaduceus Pharmaceutics Inc	Developing Novel Platinum based Targeted-Nanoparticles for Anti-Cancer Drugs	\$12,400.00	\$132,500.00
Acaduceus Pharmaceutics	Developing Targeted Probe for PET imaging of Primary and	\$56,150.00	\$180,000.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Inc	Metastatic Melanoma		
Accelalox Inc.	Acceleration of Bone Fracture Healing	\$54,062.50	\$132,430.00
Access Scientific Inc	The Wand	\$244,479.25	
Accumetrics, Inc	Gravitas: Gauging Responsiveness With a VerifyNow Assay-impact on Thrombosis & Safety	\$244,479.25	
ACEA Biosciences Inc.	Development of and cancer treatment with Bis(4-fluorobenzyl)trisulfide (BFBTS)	\$244,479.25	
AcelRx Pharmaceuticals, Inc	Sufentanil NanoTab TM Patient Controlled Analgesia (PCA) System	\$244,479.25	
AcelRx Pharmaceuticals, Inc.	Triazolam/Sufentanil NanoTab TM	\$244,479.24	
Achaogen, Inc	ACHN-490 - A Novel Second-Generation Aminoglycoside Antibiotic for the Treatment of Resistant Bacterial Infections	\$244,479.25	
Achaogen, Inc	Novel Expanded-Spectrum Aminoglycosides (ES-AGs) for the Treatment of Pan-Resistant Bacterial Infections Caused by Pseudomonas aeruginosa or Acinetobacter baumannii	\$244,479.25	
Achaogen, Inc	Discovery and Development of a Novel Class of Antibacterials, LpxC Inhibitors for the Treatment of Multi-Drug Resistant Bacterial Infections Caused by Gram-Negative Bacteria	\$244,479.25	
Achaogen, Inc.	Discovery & Development of a Novel Orally Bioavailable Beta-	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Lactam for the Treatment of MRSA and Other Multi-Drug resistant Bacterial Infections		
Acologix Inc	AC 100	\$88,245.46	
Acologix, Inc.	AC820	\$244,479.25	
Acologix, Inc.	AC 200	\$170,732.65	
Acorn Biomedical Inc	T-Fusion™ Platform for oral Delivery of Recombinant Proteins	\$125,005.10	\$119,474.15
Acorn Biomedical Inc	Development of Adenosine A3 Receptor Antagoinst for the Treatment of Glaucoma.	\$172,773.37	\$71,705.88
Act Biotech , Inc	Telatinib is a new cancer drug that can readily combine with chemotherapy.	\$244,479.25	
ACT Biotech Inc	ACTB1003 a novel anti-cancer drug for treatment of cancers with FGFR gene alterations	\$244,479.25	
Active Life Scientific, Inc.	Early Diagnosis of Osteoporosis	\$82,273.03	\$162,206.22
ActiveSite Pharmaceuticals, Inc	Preclinical & Early Clinical Development of a NCE Targeting Diabetic Macular Edema	\$136,104.50	\$108,374.74
A-Cube Inc	Bi-specific c-Mat anitbodies to treat abnormal angiogenesis in eye disease and cancer	\$244,479.25	
AcuFocus, Inc.	ACI 7000PDT	\$244,479.25	
Adamas Pharmaceuticals, Inc.	Once-daily Fixed Dose Combination (FDC) for Moderate-Severe Dementia Alzheimer's Type	\$244,479.25	
Adamas Pharmaceuticals, Inc.	Triple Combination Antiviral Drug Therapy for the Treatment of Infulenza	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Adamas Pharmaceuticals, Inc.	Extended-Release Amantadine for Treatment of Levodopa-induced Dyskinesia in Parkinson's	\$244,479.25	
Aduro BioTech	Thermotherapy for the treatment of Cancer	\$197,978.50	
Aduro BioTech	Listeria-Based Immunotherapy for Cancer and Infectious Disease	\$235,971.50	\$8,507.75
Advanced Bifurcation Systems	Advanced Bifurcation Systems Platform for Complete Bifurcation and Side Branch Stenting	\$150,636.50	\$93,842.75
Advanced Cell Diagnostics, Inc	Diagnostic tests based on in situ RNA detection for personalized cancer management	\$244,479.25	
Advanced Cell Technology Inc	Pluripotent Stem Cell Therapy for the Treatment of Stargardt's Macular Dystrophy	\$244,479.25	
Advanced Cell Technology, Inc.	Autologous Skeletal Myoblast Transplantation to Treat Ischemic Cardiomyopathy	\$244,479.25	
Advanced Cell Technology, Inc.	Generation of Pluripotent Embryonic Stem Cells without Destruction of Donor Embryo	\$244,479.25	
Advanced Cell Technology, Inc.	Inducing Pluripotency from Differentiated Somatic Cells for Autologus Stem Cell Therapy	\$244,479.25	
Advanced Genetic Systems	Development of a Novel RNA-protein Complex Inhibitor for Treatment of HIV	\$117,108.50	\$127,370.75
Advanced Targeting Systems Inc	A Novel Cancer Pain Therapeutic	\$19,705.50	\$21,576.50
Advantageous Systems, LLC	ADS-NPTMZ-1, A Novel Nanotherapeutic for Selective Treatment of Advanced Melanoma	\$27,428.00	\$63,714.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Adventrx Pharmaceuticals, Inc	ANX-530	\$244,479.25	
ADVENTRX Pharmaceuticals, Inc.	ANX-514	\$244,479.25	
AEGEA Medical Incorporation	endometrial ablation	\$244,479.25	
Aeolus Pharmaceuticals, Inc.	Development of AEOL11207 as a treatment for Parkinson's disease	\$92,406.00	
Aeolus Pharmaceuticals, Inc.	Development of AEOL10150 as a treatment for ARS/DEARE	\$244,479.25	
Aespis Biopharmaceutical Company	A Novel Cancer Therapeutic		\$244,479.25
Afferent Pharmaceuticals, Inc	Development of a Novel Pharmaceutical, AF-219		\$244,479.25
Affinity Pharmaceuticals	Tumor microenvironment activated prodrug	\$244,479.25	
Affinity Pharmaceuticals	PET imaging agents of tumor microenvironment	\$244,479.25	
Affymax, Inc.	Peginesatide	\$244,479.25	
Afraxis, Inc	Afraxis PAK inhibitor project	\$244,479.24	
Aires Pharmaceuticals Inc	Development of Aironite to Treat Pulmonary Arterial Hypertension	\$244,479.24	
Aleeva Medical Inc	Alleviate back pain with disc shunt	\$21,732.00	\$222,747.25
Alexza Pharmaceuticals, Inc.	Staccato Loxapine	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Alion Pharmaceuticals Inc	Development of a new Alzheimer's Therapeutic		\$167,000.00
Alios BioPharma Inc	ALS-2135 Improving Nucleoside Antiviral Properties through a Novel Prodrug Technology	\$244,479.24	
Alios BioPharma Inc	ALS-012117 - A Broad-Spectrum Antiviral that Activates the RNase L Pathway	\$244,479.25	
Alios BioPharma, Inc	ALS-2160 - Novel Sugar Substituted Nucleoside for the Treatment of Chronic Hepatitis C	\$244,479.24	
Alios BioPharma, Inc	Glycoferon- A Hyperglycosylated interferon with Improved Pharmacokinetic Properties	\$244,479.24	
Allele Biotechnology & Pharmaceuticals Inc	DNA Ratio Change Technology for Prenatal Diagnosis	\$12,458.50	\$232,020.75
Allele Biotechnology & Pharmaceuticals Inc	STEAP4 as a Target for Obesity and Diabetes Therapy	\$17,799.00	\$24,170.00
Allele Biotechnology & Pharmaceuticals, Inc	Use of UV-Absorbing Biological products for Skin Protection	\$26,168.50	\$51,717.00
Allon Therapeutics Inc	Davunetide for the treatment of PSP	\$244,479.24	
Allon Therapeutics, Inc.	AL-309 for the treatment of peripheral neuropathy	\$137,166.50	\$107,312.74
Allvivo Vascular, Inc.	Dual Function Antimicrobial Catheter	\$142,899.52	\$101,579.73
ALPHA	ReleF Technology	\$59,290.00	\$185,189.24

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
ORTHOPAEDICS, INC			
Alpha Source LLC	System for Production of Medical Radioisotopes	\$238,271.21	\$6,208.03
Altermune Technologies, LLC	Altermune: Chemically Programmable Immunity		\$244,479.24
Altheos Inc.	ATS907: Development of a Novel Topical Rho Kinase Inhibitor for Treatment of Glaucoma	\$10,689.00	\$233,790.24
Altura Medical, Inc	Altura Medical AAA endograft system to repair abdominal aortic aneurysms	\$244,479.25	
Alvine Pharmaceuticals Inc	ALV003 Therapeutic Development Project	\$244,479.24	
Alvine Pharmaceuticals Inc	ALV003 2nd Generation Therapeutic Development Project	\$68,374.00	\$176,105.25
Alvine Pharmaceuticals, Inc	Celiac Disease Biomarker development Project	\$23,076.50	\$143,160.00
Amaranth Medical Inc	Coronary Artery Vascular Restoration Therapy Drug Eluting Bioresorbable Stent	\$244,479.24	
Amaranth Medical, Inc	Drug Eluting Bioresorbable Stent for PVD Vascular Restoration Therapy	\$244,479.24	
Ambit Biosciences Inc	AC220 (FLT3) Program	\$244,479.24	
Ambit Biosciences Inc	CSF1R/AC710 Kinase Program	\$244,479.24	
Ambit	AC480 Treatment Program	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Biosciences Inc			
AMBIT BIOSCIENCES, INC.	AC430 JAK2 KINASE PROGRAM	\$244,479.24	
Ambrx Inc	PEG-Leptin for the treatment of obesity and Type 1 Diabetes	\$244,479.25	
Ambrx Inc	ARX-Trail for the treatment of metastatic colon cancer	\$217,366.50	\$27,112.75
AMBRX, INC	ANTIHER2-DOLOSTAIN ANTIBODY ("ARX-AHD) for the treatment of breast cancer	\$244,479.25	
Ambrx, Inc	Anti-VEGF-Anti-Ang2 for the treatment of newvascular age related macular degeneration	\$244,479.25	
AMBRX, INC	ARX618(FGF21) for the treatment Type II Diabetes	\$244,479.25	
American Life Science Pharmaceuticals, Inc.	Alzheimer's Disease Cathepsin-B Inhibitor Therapeutics	\$244,479.24	
AMIRA PHARMACEUTICALS, INC	Lysophosphatidic Acid Receptor Antagonist and Inhibitor (LPA)	\$244,479.25	
AMIRA PHARMACEUTICALS, INC	PROSTAGLANDIN D2 RECEPTOR ANTAGONIST (DP2)	\$244,479.25	
Amplix Pharmaceuticals Inc	A Hybrid Therapeutic with superior Efficacy Against Resistant Infections		\$54,626.50
Amplix Pharmaceuticals, Inc	Novel Taxane with Greatly Reduced Peripheral Neuropathy for Cancer Therapy		\$96,445.50
Amplix Pharmaceuticals,	A Novel Carbapenem Antibiotic to improve Therapeutic Outcomes	\$81,777.50	\$83,514.50

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Inc			
Amplix Pharmaceuticals, Inc	Novel, Targeted HIV Protease Inhibitor to Improve Therapeutic Outcomes	\$149,473.50	\$71,016.50
Amunix Inc	Genetic Deficiency		\$69,238.29
Amunix Inc	CANCER		\$139,116.83
Amunix Inc	Immune Diseases		\$172,881.67
Anacor Pharmaceuticals, Inc	AN2898, a topical anti-inflammatory therapy for the treatment of atopic dermatitis	\$244,479.25	
Anacor Pharmaceuticals, Inc	AN5973, a novel agent for treatment of Enterobacteriaceae infections caused by Enterobacteriaceai bacteria.	\$244,479.25	
Anacor Pharmaceuticals, Inc	Novel agents to treat Community-Acquired Respiratory Tract Infections. Novel boron-containing small molecule antibacteria agents to treat community-acquired respiratory tract infections (CART1)	\$244,479.25	
Anacor Pharmaceuticals, Inc	AN2728, a novel topical anti-inflammatory therapy for psoriasis	\$244,479.25	
Anacor Pharmaceuticals, Inc	AN2690, a novel, broad spectrum antifungal therapy for onychomycosis	\$136,082.50	\$108,396.75
Anacor Pharmaceuticals, Inc.	AN2718, a topical antifungal therapy for tinea pedis	\$244,479.25	
Anadys Pharmaceuticals Inc	ANA598	\$244,479.25	
Anadys	ANA773	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Pharmaceuticals Inc			
Anaphore, Inc.	TL1A-Atrimer Therapeutic	\$206,740.50	\$37,738.75
Anaphore, Inc.	TRAIL-R-Atrimer Therapeutic	\$244,479.25	
Anaphore, Inc.	IL-23R/IL-10R-Atrimer Therapeutic	\$244,479.25	
AnaptysBio Inc	A Novel Therapeutic Antibody for the Treatment of Chronic Autoimmune Disease (ANA04)	\$244,479.25	
AnaptysBio Inc	A Novel Therapeutic Antibody for the Treatment of Bone Loss (ANA01).	\$237,033.00	
AnaptysBio Inc	A Novel Therapeutic Antibody for the Treatment of Chronic Pain (ANA01)	\$244,479.25	
AnaptysBio Inc	A Novel Therapeutic Antibody for the Treatment of Complement Mediated Diseases (ANA06)	\$48,992.00	\$85,498.50
AndroScience Corporation	A New Class of Anti-Androgen Targeting Androgen Receptor (AR)	\$244,479.25	
Angelica Therapeutics Inc	Nonimmunogenic Fusion Toxin Platform for Cancer Therapy	\$244,479.25	
Angstrom Pharmaceuticals, Inc	A6 a Novel CD44 Targeting Cancer Therapeutic	\$244,479.25	
ANTHERA PHARMACEUTICALS INC	A-001	\$244,479.25	
Anthera Pharmaceuticals Inc	A-623 for Rheumatoid Arthritis	\$10,966.00	\$233,513.25
Anthera Pharmaceuticals,	A-002	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Inc			
ANTHERA PHARMACEUTICALS, INC.	A-623	\$10,966.00	\$233,513.25
AntiCancer, Inc.	Targeted Tumor-Killing Bacteria	\$87,322.16	\$83,804.41
Apama Medical Inc	RF Project	\$101,461.50	\$143,017.75
Applied BioCode Inc	Barcoded Magnetic Beads (BMB) for Molecular Diagnostics	\$244,479.25	
Applied Biotechnology Institute, Inc.	An Orally Delivered Hepatitis B Vaccine	\$123,187.50	\$115,568.50
APT Pharmaceuticals, Inc.	Cyclosporine Inhalation Solution to prevent and treat rejection following lung transplant	\$244,479.25	
Aptus Endosystems, Inc	The Aptus Endostape in the prevention and treatment of abdominal aortic aneurysms	\$244,479.25	
AqueSys Inc	Aquesys Microfistula Implant	\$244,479.25	
Ara Medical, LLC	Sprayable biodegradable polymers as adhesion barriers & drug delivery modality	\$183,828.00	\$60,651.25
Aradigm Corporation	ARD-3100-Liposomal Ciprofloxacin for the treatment of Cystic Fibrosis	\$244,479.25	
ARADIGM CORPORATION	ARD-3100 -- Liposomal Ciprofloxacin for the Treatment of Non-Cf Bronchiectasis	\$244,479.25	
ARADIGM CORPORATION	ARD-3150-Liposomal Ciprofloxacin for the Treatment of Non-CF Bronchiectasis	\$244,479.25	
Aragon Pharmaceuticals, Inc	3rd Generation Anti-Androgens	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Aragon Pharmaceuticals, Inc	ARN-509	\$244,479.25	
Aragon Pharmaceuticals, Inc.	SERD	\$244,479.25	
Aravasc Inc	Multi-modal drug delivery system for local delivery of Cancer Chemotherapy	\$135,274.28	\$109,204.97
Arbor Vita Corporation	NA-1	\$244,479.25	
Arbor Vita Corporation	AVC Avantage HPV E6 Test	\$244,479.25	
Arbor Vita Corporation	Anvantage A/H5N1 Flu Test	\$244,479.25	
Ardea Biosciences Inc	Next-generation URAT1 Therapeutic Discovery Project	\$244,479.25	
Ardea Biosciences Inc	RDEA119-MEK Inhibitor Therapeutic Discovery Project	\$244,479.25	
Ardea Biosciences Inc	RDEA594-URAT1 Therapeutics Discovery Project	\$244,479.25	
Ardelys Inc.	RDX5791 for the treatment of CIC, IBS-C predominant and OBD	\$244,479.25	
Ardelyx Inc.	RDX002 for the treatment of elevated phosphorus in chronic kidney disease	\$244,479.25	
Ardelyx, Inc	RDX008 treatment of salt and fluid overload in heart failure, CKD and hypertension patients congestive heart failure (CHF), chronic kidney disease and hypertension.	\$119,704.00	\$124,775.25
Argusina, Inc.	Novel Small Molecular Modulator	\$171,732.44	\$72,746.80

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	of GLP1 Receptor for Anti-Diabetes/Obesity Treatment		
Aridis Pharmaceuticals LLC	Aridis Formulation Technology Program	\$244,479.25	
Aridis Pharmaceuticals, LLC	Aridis Novel Anti-Infective Therapies Program	\$244,479.25	
ArKal Medical Inc	ArKal Continuous Glucose Monitor	\$244,479.24	
ArmaGen Technologies Inc	Drug Development of Brain-Penetrating Biopharmaceuticals	\$244,479.24	
Arresto Biosciences, Inc	AB0024, a Novel Inhibitor of LOXL2 for the Treatment of Cancer and Fibrotic Diseases	\$244,479.25	
Arrowhead Research Corporation	Rondel	\$244,479.25	
Arstasis, Inc.	ArtasisONE Vascular Access System	\$244,479.25	
Artemis Health, Inc.	Noninvasive Prenatal Diagnosis of Down Syndrome Using Next-Generation DNA Sequencing	\$244,479.25	
Artery Therapeutic, Inc	Artery Therapeutic, Inc: Diagnostic Program	\$41,602.96	\$202,876.29
Artery Therapeutics, Inc	Artery Therapeutic, Inc: Therapeutic Program	\$172,743.80	\$71,735.45
Aryx Therapeutics Inc	Tecarfarin Novel Oral Anticoagulant Therapeutic	\$244,479.24	
Aryx Therapeutics Inc	ATI-7505 for the treatment of gastrointestinal motility dysfunctions	\$148,714.50	\$95,764.74
ARYX THERAPEUTIC	Budiodarone oral therapeutic for the treatment of atrial fibrillation	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
S INC			
ARYX THERAPEUTIC S, INC.	ATI-9242 for the treatment of schizophrenia and depression	\$111,106.50	\$99,439.50
Asante Solutions, Inc.	Personal Infusion System	\$244,479.24	
Asthmatx, Inc.	TREATING CHRONIC RESPIRATORY DISEASES WITH ALAIR SYSTEM	\$244,479.25	
ASTRAEA THERAPEUTIC S, LLC	POLYDRUG ADDICTION TREATMENT	\$4,682.50	\$93,112.00
Astraea Therapeutics, LLC	Novel Therapies for Parkinsons Disease and Dyskinesia		\$38,713.50
Astute Medical, Inc	A Novel Biomaker Panel for the Early Detection of Acute Kidney Injury	\$244,479.24	
AtheroMed, Inc.	Phoenix Atherectomy System	\$244,479.25	
aTyr Pharma Inc.	Tmax, an Innovative Biological Therapy for Thrombocytopenia	\$244,479.24	
aTyr Pharma Inc.	ATYR1920, a novel immunomodulatory agent for IBD	\$244,479.24	
Auritec Pharmaceuticals	Sustained Release Apomorphine for the Treatment of Parkinson's Disease	\$80,827.37	\$46,125.17
Auritec Pharmaceuticals	Intravaginal ring releasing acyclovir for the prevention of HSV transmission	\$105,580.61	\$92,197.62
Auritec Pharmaceuticals	Sustained Release Cyclosporine for the Prevention of Graft Rejection	\$51,081.86	\$193,397.39
Auritec Pharmaceuticals	Sustained Release Nevirapine for the Treatment of HIV	\$65,989.98	\$14,366.85

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Auritec Pharmaceuticals	Sustained Release Olanzapine for the Treatment of Schizophrenia and Mania		\$68,881.55
Auspex Pharmaceuticals, Inc.	SD-560-Deuterated pirfenidone analog for treatment of idiopathic pulmonary fibrosis	\$239,933.37	\$4,545.88
Automedics Medical Systems, Inc.	HepGuide Decision Support Software	\$157,334.50	\$87,144.74
Autonomic Technologies Inc	Delivery of Therapeutics for Migraine and Cluster Headache	\$244,479.25	
Avanir Pharmaceuticals, Inc	Zenvia	\$244,479.25	
Avantis Medical Systems	Development and Clinical Trials of the Third Eye Retroscope, a Device to Enhance Detection and Treatment of Colonic Adenomas and Prevent Colorectal Cancer	\$244,479.25	
AvidBiotics Corp	R-Type Pyocins as Novel Antibacterials	\$244,479.24	
AvidBiotics Corp	Targeted MICA Molecules to Recruit Innate Immunity Cells to Kill Specific Viruses	\$38,082.50	\$82,718.00
Aviir, Inc.	Aviir Blood Test for Heart Disease	\$244,479.24	
Axikin Pharmaceuticals, Inc.	Axikin Pharmaceuticals: Novel Small Molecule Therapy for Asthma	\$244,479.25	
Azee Inc.	Development of a new class of antibacterial and antiviral drugs using SMAT technology	\$27,619.85	\$77,000.00
Balance Therapeutics, Inc	Developing the first potential drug to treat the cognitive impairment in Down Syndrome	\$14,389.84	\$230,089.41

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
BARnova, Inc	TransPyloric Shuttle	\$244,479.24	
BaroSense Inc	Trans-oral Endoscopic Restrictive Implant System (TERIS)	\$244,479.24	
BARRX MEDICAL INC.	Ablation of Squamous Neoplasia and Esophageal Squamous Cell Carcinoma	\$43,364.00	\$69,826.00
BARRX MEDICAL INC.	Ablation of Intestinal Metaplasia (AIM) Dysplasia Extension of follow-up to 5 years	\$218,622.50	\$25,856.75
BARRX MEDICAL INC.	Halo Patient Registry- Ablation of Barrett's Esophagus	\$244,479.25	
BARRX MEDICAL INC.	Micro-Layer Ablation of Barrett's Metaplasia- Extension of Follow-Up to 5 years	\$52,077.00	
Bayhill Therapeutics	BHT - 3021	\$244,479.25	
Bayhill Therapeutics	BHT - 3034	\$244,479.25	
Bebaas Inc	Cyprem	\$242,500.00	\$1,979.25
Bebaas Inc	Cobacan	\$242,500.00	\$1,979.25
BeneChill, Inc	RhinoChill	\$244,479.24	
Beyond Lucid Technologies, Incorporated	MEDIVIEW DX by Beyond Lucid Technologies, Inc.	\$9,477.83	\$157,022.86
BFIONOVO, Inc.	MENERBA	\$244,479.25	
Bio Time Inc	Induced Pluripotent Stem Cell Technologies	\$112,580.75	\$131,898.50
Bio3 Research Inc.	HMGB1 for accelerated wound healing	\$20,439.00	\$32,032.00
BioAssay Systems LLC	Development of Pharmacodynamic and Diagnostic	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Assays for Cancer Drug Targets		
BioAtla, LLC	Development of a High Affinity Antibody for nonHodgkin's Lymphomas	\$28,500.00	\$37,350.00
BioCardia, Inc	Helical Infusion System for Heart Failure	\$244,479.25	
Biocept, Inc.	CEE Cell Enrichment and Extraction Platform Technology	\$244,479.25	
Biodesy LLC	Discovery of a highly specific and potent therapeutic for Parkinson's disease	\$71,058.50	\$39,996.50
BioDx Partners LLC	Development and Commercialization of a Blood Test for Non-Small Cell Lung Cancer	\$3,450.50	\$138,599.50
Bioenergenix, LLC	BioEnergenix	\$244,479.25	
BioGenex Laboratories	Develop fully automated tools for quantitative gene expression profiling in situ for cancer.	\$244,479.25	
Biological Dynamics, Inc.	Point of Care Cancer Diagnostic Device		\$244,479.25
Biomatrix Inc	Development of Molecular Diagnostic Tools for High-Sensitivity Cancer Detection	\$244,479.25	
BioMedicure LLC	Developing Cancer Vaccines to Prevent and Treat Cancer including Melanoma	\$196,047.50	\$48,431.74
Biomerica Inc	Enzyme-Linked Immunosorbent Assays (ELISA)	\$172,890.28	\$71,588.97
Biomerica, Inc	Microalbumin Project	\$44,185.60	\$68,811.41
BIONOVO, INC	BEZIELLE	\$244,479.25	
BioTechPlex	SUPRAER:High Dose-Rate	\$19,271.00	\$36,681.50

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Corporation	Aerosol Delivery of Biotherapeutics		
BioTime Inc	ACTCellerate Embryonic Progenitor Cells	\$244,479.25	
BioTime, Inc	Chondrocyte Progenitor Cells	\$119,663.74	\$124,815.51
BioVascular Inc	Anagrelide Control Release for Cardiovascular Risk Reduction	\$244,479.24	
BioVascular Inc.	Development of Saratin to increase vascular graft survival	\$244,479.24	
Bioxiness Pharmaceuticals	Development of Novel and New Class of Antimicrobial Therapeutics	\$18,780.00	\$225,699.25
BN Immuno Therapeutics Inc	MVA-BN-HER2	\$244,479.25	
BN Immuno Therapeutics Inc	PROSTVAC	\$244,479.25	
BrainCells Inc	BCI-632	\$244,479.25	
BrainCells Inc.	BCI-540	\$244,479.25	
BrainCells Inc.	BCI-952	\$244,479.25	
BrainCells Inc.	BCI-224	\$244,479.25	
Broncus Technologies, Inc	LungPoint Planning and Navigation Systems	\$244,479.25	
Broncus Technologies, Inc.	Airway Bypass with Drug-Eluting Stents	\$244,479.25	
Broncus Technologies, Inc.	FleXNeedle Tissue Sampler (18 Gauge)	\$244,479.24	
Bruin Biometrics, LLC	Sub-epidermal moisture scanning device	\$244,479.25	
C2 Therapeutics,	Cryoballon Ablation System for	\$176,887.51	\$67,591.74

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Inc	Barrett's Esophagus		
C3 Jian, Inc.	Specifically-targeted antimicrobial peptides ("STAMPs)	\$244,479.25	
C8 MediSensors, Inc.	HG-1c Noninvasive Glucose Monitor	\$244,479.25	
Cadence Pharmaceuticals, Inc.	OFIRMEV, A NEW INTRAVENOUS TREATMENT FOR ACUTE PAIN AND FEVER	\$244,479.25	
Caerus Molecular Diagnostics Inc.	Low-Cost Diagnostic Platform using Millikan Sequencing		\$150,000.00
CalciMedica, Inc	Novel therapies for autoimmune diseases	\$244,479.24	
Caldera Medical, Inc	POP SI	\$117,025.76	\$127,453.49
Caldera Medical, Inc.	Desara Mini	\$140,691.80	\$103,787.44
Calibra Medical, Inc.	Finesse Personal Insulin Delivery System	\$244,479.24	
Califia Bio, Inc.	Discovery of Novel Therapeutics for the Treatment of HIV-associated Neurological Disease	\$128,113.00	\$116,366.25
California Stem Cell Inc	MotorGraft	\$244,479.25	
Calithera Biosciences Inc	Caspase Activator Program		\$244,479.25
Cameron Health, Inc	S-ICD System, Subcutaneous Implantable Defibrillator to Treat Sudden Cardia Death	\$244,479.25	
Cantimer Incorporated	Osmo Point-of-Care Dehydration Diagnostic System	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Capnia, Inc.	A Novel Therapeutic Product for Treating Migraine	\$244,479.24	
Capnia, Inc.	A Novel Therapeutic Product for Allergic Rhinitis	\$244,479.24	
Capnia, Inc.	A Novel Diagnostic Device for Detecting Hemolysis	\$3,915.00	\$240,564.24
Capricor, Inc.	Cardiosphere-derived stem cell therapy for advanced heart failure	\$129,094.00	\$115,385.25
Capso Vision Inc	CapsoCam Colon Capsule Endoscope	\$244,479.25	
Carbylan Biosurgery Inc.	Hydros TA	\$244,479.25	
Cardero Therapeutics, Inc	Mitochondrial Protection and Stimulation (MIPS) Drug Development Program	\$95,437.50	\$149,041.75
Cardigant Medical Inc	Project Nautilus	\$60,200.00	\$110,550.00
Cardima, Inc.	Catheter ablation technology	\$244,479.24	
CARDIODX INC	Corus SCA (sudden cardiac arrest)genetic test for the detection of cardiac arrhythmia risk	\$244,479.24	
CardioDx, Inc.	Corus CAD gene expression test for obstructive coronary disease (CAD)	\$244,479.24	
Cardiogenesis Corporation and Subsidiaries	Phoenix Project	\$195,528.76	\$48,950.49
Cardiovascular Simulation Inc	CT Flow: Non-Invasive Assessment of Coronary Artery Disease	\$119,606.00	\$124,873.25
Cardium Therapeutics, Inc.	Generx ® ("Generx")	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Carmot Therapeutics, Inc	Identification of novel anticancer drugs		\$244,479.24
Carolus Therapeutics, Inc	Peptide Therapeutic-CT-2008	\$244,479.25	
Catalyst Biosciences, Inc.	Improved recombinant human Factor VIIa	\$244,479.24	
Catalyst Biosciences, Inc.	Anti-complement Alterase TM therapeutic program	\$244,479.24	
Catalyst Biosciences, Inc.	Improved recombinant human Factor IX	\$244,479.24	
CEBIX Incorporated	C-Peptide Replacement Therapy	\$244,479.24	
Cell Biosciences, Inc	Nanoimmunoassay for Biomarker Detection	\$244,479.24	
Cell Viable Corp	Small Molecule to treat Neurodegenerative Disease such as Alzheimers		\$17,250.00
Celladon Corporation	MYDICAR (AAV1/SERCA2a) for treatment of NYHA Class III/IV symptoms of heart failure	\$244,479.24	
CellScape Corporation	CellScape NIPD System	\$244,479.24	
CellSight Technologies Inc	Imaging cell trafficking to advance clinical translation of cell and gene therapeutics		\$105,795.00
Celprogen Inc.	Therapeutic agents for the treatment of Breast Cancer triple negative patients	\$107,500.00	\$136,979.24
Celula Inc	High-Capacity Single-Cell Molecular Diagnostics for Non-Invasive Prenatal Genetic Testing	\$244,479.25	
Cenna Biosciences Inc	Peptide Drugs to Treat Alzheimer's Disease	\$16,248.50	\$228,230.75

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Ceregene, Inc	Ceregene, Inc	\$244,479.25	
Ceregene, Inc	Neurotrophic Factor Therapy (AAV-NGF) for the Treatment of Alzheimer's Disease (CERE-110)	\$244,479.25	
Ceregene, Inc.	Delivery of NT-4 for the Treatment of Degenerative Ocular Diseases (CERE-140)	\$244,479.25	
Cerimon Pharmaceuticals	Diclofenac sodium topical patch for treatment of acute musculoskeletal pain	\$244,479.24	
Cerus Corporation	INTERCEPT Pathoogen Inactivation for Platelets	\$244,479.25	
Cerus Corporation	INTERCEPT Pathogen Inactivation for Red Blood Cells	\$244,479.25	
Charisela Technologies Inc	Charisela Technologies: Advanced Reagent Technologies		\$213,581.03
CHEM DIV INC	NOVEL SMALL MOLECULE HEDGEHOG PATHWAY INHIBITORS AS ANTICANCER AGENTS	\$73,690.00	\$65,481.00
ChemGenex Pharmaceuticals, Inc.	Omacetaxine Mepesuccinate	\$244,479.24	
ChemoCentryx Inc	Treating Chronic Hepatitis with C0334578	\$244,479.25	
ChemoCentryx, Inc	Treating Glioblastoma Cancers with CCX662	\$244,479.24	
ChemoCentryx, Inc	Treating Vasculitis with CCX168	\$244,479.24	
ChemoCentryx, Inc	Treating Rheumatoid Arthritis with CCX354	\$244,479.24	
ChemoCentryx, Inc.	Treating Inflammatory Bowel Disease (IBD) with CCX282	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
ChemoCentryx, Inc.	Treating Type 2 Diabetes with CCX140	\$244,479.24	
ChemoCentryx, Inc.	Treating Atopic Dermatitis with C0333158	\$125,808.00	\$118,671.25
ChemoCentryx, Inc.	Treating Inflammatory Bowel Disease (IBD) with CCx025	\$244,479.24	
ChemRegen, Inc.	New Stem Cell Therapies for Heart Disease		\$244,479.25
CHF Technologies Inc	PliCath HF System	\$244,479.24	
ChromoLogic LLC	Ocular Radiation Dosimeter (OCDOS)		\$244,479.25
ChromoLogic LLC	Rapid brain injury dosimeter (RAPIDOS)		\$29,394.00
ChromoLogic LLC	Amplified Refractometric interference Analysis System	\$48,256.00	\$20,344.00
ChromoLogic LLC	Debridement and Vitality Assessment System (DAVANIS)	\$6,429.00	\$29,587.00
ChromoLogic LLC	Reactie Chest Seal (ReSEAL)	\$7,842.00	\$14,863.50
ChromoLogic LLC	Fluid preservation system (FPS)		\$28,191.00
ChromoLogic LLC	Label free integrated biofilm analysis (LIBA) system	\$16,109.00	\$16,385.00
ChromoLogic, LLC	Ocular Hydration Monitor (OCHYMO)	\$110,770.50	\$120,380.00
Chronix Biomedical, Inc.	Apoptosis Blood DNA Test to Guide Therapeutic Decisions in Cancer Management	\$244,479.25	
Cianna Medical, Inc	SAVI Applicator System	\$244,479.25	
Claremont	Rapid Sample Preparation and	\$234,671.10	\$9,808.15

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Biosolutions LLC	Detection of C. diff. and Other Pathogens		
Claret Medical, Inc	Dual Filter Embolic Stroke Prevention Catheter	\$77,166.00	\$154,500.00
Clarity Medical Systems, Inc	Holos, a unique, high resolution, real time optical measurement technology for ophthalmology	\$192,231.50	\$52,247.75
Clarity Medical Systems, Inc	Advanced Next Generation System for Diagnostic Ocular Imaging	\$244,479.25	
Clinical Micro Sensors, Inc	K-ras mutation cancer treatment	\$8,188.50	\$236,290.75
Clinical Micro Sensors Inc	AD-8 DNA System	\$171,256.00	\$73,223.25
Clinical Micro Sensors, Inc	Plavix Sensitivity Drug	\$60,588.00	\$183,891.25
Clinical Micro Sensors, Inc	Warfarin Sensitivity Test	\$110,390.50	\$68,026.00
Clinical Micro Sensors, Inc.	Thrombophilia Risk Test (TRT)	\$244,479.25	
Clinical Micro Sensors, Inc.	Respiratory Viral Panel (RVP)	\$244,479.25	
Clinical Micro Sensors, Inc.	Cystic Fibrosis Genotyping (CF)	\$244,479.25	
CoaguSense, Inc	CoaguSense Coagulometer Project	\$244,479.25	
CoaguSense, Inc.	Hemophilia Therapeutic Monitoring Project		\$220,220.50
Coda Therapeutics, Inc	Nexagon ® For the Treatment of Venous Leg Ulcers	\$244,479.25	
Colby Pharmaceutical Company	Development of a New Chemical Entity Inhibiting JunD Activation of the Androgen Receptor		\$244,479.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Colby Pharmaceutical Company	Clinical Development of CPC-100 for Recurrent Prostrate Cancer	\$51,500.00	\$192,979.25
Colby Pharmaceutical Company	Androgen Receptor DNA Vaccine for Prostate Cancer Patient in Vivo Immunization		\$244,479.25
Colby Pharmaceutical Company	Tempol-based Radioprotective Solid State Oral Drug Formation for US stockpile		\$244,479.25
COMBIMATRIX CORPORATION	COMPREHENSIVE CANCER ARRAY, OR "CCA"	\$244,479.24	
Combimatrix Molecular Diagnostics, Inc	Array Comparative Genomic Hybridization, or "aCGH"	\$244,479.24	
CoMentis Inc	BACEi	\$244,479.25	
Complete Genomics, Inc.	Complete Human Genome Sequencing for Personal Medicine	\$244,479.24	
CONATUS PHARMACEUTICALS INC.	CTS-1027	\$244,479.24	
CONCENTRIC MEDICAL, INC	The Trevo system provides rapid clot integration and removal in patients experiencing acute ischemic stroke.	\$244,479.25	
Conkwest Inc.	NK-92	\$17,594.05	\$179,775.00
Corcept Therapeutics Incorporated	Selective GR-II Antagonist-CORT 108297- Treatment of Antipsychotic Induced Weight Gain	\$244,479.25	
Corcept Therapeutics Incorporated	CORLUX for Treatment of Endogenous Cushing's Syndrome	\$244,479.25	
Corcept	CORLUX for the treatment of	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Therapeutics, Incorporated	Psychotic Depression		
Corium International Inc	MicroCor PTH(1-34) transdermal delivery system for osteoporosis	\$244,479.25	
Cortene Inc	Hercules		\$244,479.24
Cortex Pharmaceuticals Inc	CX1739 A novel Ampakine Molecule for Neurological and Psychiatric Disorders	\$244,479.24	
Crescendo Bioscience, Inc	Vectra TM DA (Disease Activity Test)	\$244,479.25	
Crescendo Bioscience, Inc.	Crescendo Structural Damage Test	\$244,479.25	
CRISI Medical Systems, Inc	Advanced Cardiac Life Support (ACLS) Drug Delivery System	\$1,938.05	\$242,541.20
Cura Medical Technologies LLC	Range Compensator and Aperture Development for Proton Beam Radiation Therapy		\$244,479.24
CuraSeal Inc	PICS therapeutics delivery system	\$244,479.24	
Customized Therapeutics LLC	Biomarker for predicting response to chemotherapy in prostate cancer patients	\$31,666.67	\$60,000.00
Customized Therapeutics LLC	Biomarker for predicting response to chemotherapy in breast cancer patients	\$36,666.67	\$105,000.00
Cylene Pharmaceuticals Inc	CX-7000 next generation CK2 inhibitor as a personalized anticancer agent with accompanying diagnostic kit	\$244,479.24	
Cylene Pharmaceuticals Inc	FIRST-IN-CLASS CX-6258 PAN-PIM KINASE INHIBITOR AS A PERSONALIZED ANTICANCER AGENT WITH ACCOMPANYING DIAGNOSTIC KIT	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
CYLENE PHARMACEUTICALS, INC	FIRST-IN-CLASS RNA POLYMERASE I INHIBITORS AS PERSONALIZED ANTICANCER AGENTS	\$244,479.24	
Cylene Pharmaceuticals, Inc	FIRST-IN-CLASS CX-4945 INHIBITORS AS PERSONALIZED ANTICANCER AGENTS with accompanying diagnostic kit	\$244,479.24	
Cynvenio Biosystems, Inc.	Liquid Biopsy: Oncogenetic analysis of Cancerous Circulating Tumor Cells	\$229,743.50	\$14,735.74
CytoDesign Inc (CDI)	Homogeneous Assay Platform for Clinical Diagnostics	\$23,288.00	
CytoDesign, Inc (CDI)	Engineering Proteolytic Therapeutics for Biodefense	\$45,637.50	
CytoDesign, Inc. (CDI)	Engineering Proteolytic Therapeutics for Psoriasis	\$80,099.00	\$78,151.50
Cytokinetics, Inc	Cardiac Muscle Activators for Heart Failure	\$244,479.24	
Cytokinetics, Inc	Skeletal Muscle Activators	\$244,479.24	
Cytokinetics, Incorporated	Smooth Muscle Myosin Inhibitors	\$244,479.24	
CytomX Therapeutics, LLC	Armed Probedies for the Treatment of Colon and Head & Neck Cancer and GBM	\$175,983.50	\$68,495.74
CytomX Therapeutics, LLC	Probedies for the Treatment of Triple Negative Breast Cancer and Pancreatic Cancer	\$171,354.00	\$73,125.24
Cytori Therapeutics Inc	The Celution System for the delivery of adipose derived stem and regenerative cells	\$244,479.25	
CytoScale Diagnostics ,	New-Generation CTC Cancer Diagnostic Devices		\$244,479.24

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
LLC			
Cytotech Labs LLC	Cytotech Labs, Api 31510	\$244,479.24	
CytRx Corporation	INNO-206 a prodrug of doxorubicin, which selectively becomes active in tumors.	\$244,479.25	
CytRx Corporation	Tamibarotene, a novel retinoid drug for treatment of a rare form of leukemia	\$244,479.25	
CytRx Corporation	Clinical trials with Bafetinib	\$146,172.50	\$98,306.75
DataPhysics Research, Inc	CaseReader: Healthcare Image Processing System	\$173,150.00	\$71,329.24
Dean Allgeyer, M.D	Simplified Vital Signs Acquisition for the Medical Home	\$3,252.50	\$5,397.50
Depomed, Inc	DM-1992 for the Treatment of Parkinson's Disease	\$244,479.24	
Depomed, Inc	Serada for the Treatment of Menopausal Hot Flashes	\$244,479.25	
DermTech International	Epidermal Genetic Information Retrieval	\$244,479.24	
Deton Corp	Cough analyzer of airborne bacteria for tuberculosis and pulmonary disease diagnosis		\$66,463.50
Devax, Inc	Axxess Drug Eluting Bifurcation Stent	\$244,479.24	
Dfine, Inc	StabiliT therapeutic delivery system	\$244,479.24	
DNAMicroarray, Inc.	Chemically Induced Reprogrammed Human Somatic Stem Cells for Treatment of Human Medi	\$244,479.25	
DOSE Medical	DOSE Medical Drug Delivery		\$244,479.24

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Corporation	Platform		
Duke Vascular, In.	Taheri LaDuca Endograft	\$161,302.23	\$83,177.02
Direct Corporation	ORADUR	\$244,479.25	
DURECT CORPORATION	POSIDUR PROGRAM	\$244,479.25	
DURECT CORPORATION	BIOBETTERS PROGRAM	\$244,479.25	
DxTerity Diagnostics Incorporated	Rapid Point of Care Genetic Testing Platform for Complex Gene Expression Assays	\$177,025.00	\$67,454.24
Dynavax Technologies Corporation	HEPLISAV, Hepatitis B Vaccine	\$244,479.25	
Dynavax Technologies Corporation	DV1179 for the Treatment of Systemic Lupus Erythematosus	\$244,479.25	
Dynavax Technologies Corporation	Universal Flu Vaccine N8295/IIVSA	\$244,479.25	
Edison Pharmaceuticals, Inc.	EPI-743	\$244,479.25	
Edison Pharmaceuticals, Inc.	CNTO-530		\$244,479.25
Eiger Biopharmaceuticals, Inc	EBP921	\$138,813.50	\$105,665.75
EIGER BIOPHARMACEUTICALS, INC	CLEMIZOLE AND BACK UPS	\$244,479.25	
Elcelyx	Targeting Gut Chemosensory	\$62,465.50	\$182,013.75

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Therapeutics Inc	Receptors to Treat Obesity and Diabetes		
Elevation Pharmaceuticals, Inc	EP-101(LAMA)	\$244,479.24	
Elixir Medical Corporation	Drug Eluting Stent (DES)	\$244,479.25	
Elixir Medical Corporation	Fully Bioresorbable Drug Eluting Stent (BDES)	\$244,479.25	
ELIXIR MEDICAL CORPORATION	Oncology Platforms	\$199,084.50	\$45,394.75
Elixir Medical Corporation	Ophthalmis Drug Eluting Implants	\$199,094.00	\$45,385.25
Elixir Medical Corporation	Drug Eluting Stent (DES) with Bioabsorbable Coating (DESyneBD)	\$244,479.25	
Ellipse Technologies Inc	Ellipse MAGEC Technology	\$244,479.24	
Emiliem, Inc	Translational Development of a Novel mTOR Pathway inhibitor for Unmet Medical Needs		\$244,479.25
EMKinetics Inc.	An Electromagnetic neurostimulator for treatment of overactive bladder (OAB)	\$244,479.25	
EndogenX Inc.	Endothelin Antagonist in Non-Opiate Analgesia	\$52,778.00	\$191,701.25
ENDOLOGIX, INC.	PEVAR	\$58,092.00	\$186,387.25
Endoscopic Technologies, Inc DBA Estech	Treatment of Atrial Fibrillation Utilizing Temperature Controlled Radio Frequency Surgery	\$244,479.24	
EndoSphere Inc.	SatiSphere Duodenal Insert	\$221,690.50	\$22,788.75

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
EnGen Bio, Inc.	Recombinant Human Albumin from an Optimized Expression Sstem		\$244,479.24
Entelos Inc	Hematopiesis Compound Evaluation	\$88,712.50	
Entelos, Inc	Rheumatoid Arthritis Inflammatory Evaluation Project	\$65,750.00	\$27,387.50
Entelos, Inc	Rheumatoid Arthritis Inflammatory Targets Evaluatuion	\$58,118.00	
EntroGen Inc	development of a diagnostic test to aid in therapeutic decisions for colorectal cancer patients	\$244,479.24	
ENVY MEDICAL INC	Novel oligopeptides for the treatment and prevention of melanoma	\$68,250.00	\$139,190.00
Eos Neuroscience Inc.	Development of EOS-013, a Therapy to Restore Vision to Blind RP and AMD Patients	\$53,377.13	\$191,102.12
EPEIUS BIOTECHNOLOGIES CORPORATION	REXIN-G, TARGETED MOLECULAR GENE THERAPY FOR CANCER	\$244,479.25	
Epic Sciences, Inc.	CTC-HRP, predicting the response to anti-hormone receptor drugs in cancer patients	\$226,377.50	\$18,101.75
Epicardial Technologies Inc.	Epicardial Treatment and Diagnosis of Cardiac Arrhythmias		\$244,479.24
Epicerter Software	Biologist Oriented Workbench for Genomic Integration.	\$108,042.00	\$108,500.00
Epigen Biosciences Inc.	Discovery and development of novel agents for the treatment of pruritis		\$716.40
Epigen	Discovery and development of		\$3,023.16

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Biosciences, Inc.	novel agents for the treatment of renal fibrosis		
Epinex Diagnostics, Inc	G1A Rapid Diabetes Monitoring Index Test	\$244,479.24	
Epiphany Biosciences, Inc.	Phase 2 Clinical Development of Valomaciclovir	\$244,479.25	
EPITOGENESIS INC	VACCINE FORMULATION		\$244,479.25
Epitomics, Inc.	Development of Therapeutic Monoclonal Antibodies Against Her3	\$135,139.00	\$109,340.25
Escape Therapeutics, Inc.	Development of an immune tolerant hESC source for allogeneic cell therapy applications	\$242,668.26	\$1,810.98
Essentialis, Inc.	Diazoxide Choline Controlled Release Tablets in the treatment of hypertriglyceridemia	\$244,479.24	
Eureka Therapeutics, Inc.	MAGE 101: A Next-Generation anti-Her2 Antibody for Metastatic Breast Cancer Treatment	\$244,479.25	
EVOKE PHARMA, INC	EVK-001	\$244,479.25	
Excaliard Pharmaceuticals, Inc.	Anti-Fibrosis Skin Scarring	\$244,479.24	
Existence Genetics, LLC	Fully integrated and dynamic genetic testing, analysis, and reporting system	\$87,449.20	\$157,030.05
Expression Drug Designs	Biologic antagonism of S1P3 for the treatment of breast cancer	\$45,866.49	\$54,844.39
EyeCyte, Inc.	Drug-Mediated Cell Therapy For Diabetic Retinopathy	\$244,479.24	
Eye-Predict LLC	Assessing brain disorders based	\$42,139.00	\$202,340.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	on natural gaze features		
Fabrus LLC	Anti-Angiogenic DLL4 Antibody Therapy for Cancer	\$244,479.25	
Fallbrook Engineering Inc	Advanced Cord Blood Collection System	\$108,145.50	\$95,902.00
Fate Therapeutics, Inc	Novel bone Regenerative Therapy to Improve Healing and Reduce Healthcare Costs	\$244,479.25	
Fate Therapeutics, Inc	Novel Regenerative Therapeutic to Restore Pancreatic Function to Cure Diabetes		\$244,479.25
Fate Therapeutics, Inc.	Patient-matched Cell Therapy to Cure Parkinson's Disease	\$244,479.25	
Fate Therapeutics, Inc.	Novel therapy Targeting Cancer Stem Cells to Treat Highly Aggressive Cancers	\$244,479.25	
Fate Therapeutics, Inc.	FT1050 to Improve Hematopoietic Stem Cell Transplants to Cure Leukemia/Lymphoma	\$244,479.25	
FEMTA PHARMACEUTICALS, INC	FM101:Anti human IL-6 Monoclonal Antibody	\$244,479.24	
Ferrokin BioSciences, Inc.	FBS0701:A novel iron chelator for the treatment of iron overload	\$244,479.25	
FFA Sciences LLC	Diagnosing Acute Coronary Syndromes	\$44,864.50	\$158,370.50
Fibrogen Inc	FG-65155 for treatment of ischemia reperfusion injury post-myocardial infarction	\$244,479.25	
FIBROGEN INC	Development of FG-3019 for treatment of locally advanced and metastatic pancreatic cancer	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Fibrogen Inc.	FG-6874 Development for the Treatment of Oncologic Anemias	\$244,479.25	
FIBROGEN INC.	FG-4592 Development for the treatment of Anemia of Chronic Kidney Disease	\$244,479.25	
Five Prime Therapeutics Inc	FP-1039 (FGFR1c:Fc), a Novel Anti-Cancer Agent Acting as an Antagonist of Multiple Fibroblast Growth Factor Ligands, for the Treatment of patients of with Advance CancerMalignancies.	\$244,479.24	
Five Prime Therapeutics, Inc	FP-1069 (CSF1Rc), a Novel Antagonist of CSC-1 and IL-34 for the Treatment of patients with Inflammatory Disease and Cancer.	\$244,479.24	
Flex Partners, Inc	Micro Fluidics Therapeutic Delivery Pump	\$65,559.00	\$178,920.24
Flow Pharma Inc.	Microencapsulation for Next Generation HIV Vaccine	\$244,479.25	
Flow Pharma, Inc.	Implantable, Microencapsulated Antibiotic	\$244,479.25	
Fluidigm Corporation	Non-invasive prenatal diagnostic development	\$244,479.25	
Fluigence, LLC	Development of a Handheld Bilirubin Biosensor for Rapid Diagnosis of Neonatal Jaundice	\$21,897.00	\$23,758.50
Fluxion Biosciences, Inc.	The IsoFlux cancer diagnostic system	\$244,479.25	
ForSight VISION4, Inc	Rechargeable drug delivery device for treatment of ocular disease	\$244,479.25	
FP Technology	OCT-Based Non-Invasive Glucose Monitor	\$137,617.50	\$106,861.75

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
FQUBED Inc	fqubed's Development Project of NRI-1013 as a topical ibuprofen gel	\$90,155.16	\$132,480.47
FQUBED Inc	NRI-1018: Topical Etoricoxib for Treatment of Osteoarthritis	\$139,127.99	\$105,351.26
FQUBED, Inc	NRI-ANA: Topical Lidocaine for the Treatment of Acute Herpes Zoster	\$63,888.97	\$133,330.84
FQUBED, Inc	NuPro and OxoFoam for Improved Treatment of Chronic Wounds	\$89,938.86	\$97,309.69
FQUBED, Inc.	Effective Topical Treatment of Nail Fungal Infection	\$110,959.88	\$109,943.72
FQUBED, Inc.	Topical Diclofenac for Relief of Osteoarthritis	\$244,479.25	
FREEDOM MEDITECH INC	NON-INVASIVE OPHTHALMIC GLUCOSE MONITORING DEVICE	\$53,896.16	\$74,430.37
Freedom Meditech Inc	Non-Invasive Ophthalmic Diabetes Screening Device.	\$31,180.54	\$74,031.12
FZIOMED, INC.	OXIPILEX SPINE GEL	\$244,479.24	
Galaxy Biotech, LLC	Humanized monoclonal antibody to FGF receptor 2 for treatment of gastric and other cancers	\$78,034.50	\$55,497.50
Galaxy Biotech, LLC	Humanized monoclonal antibody to Sonic Hedgehog protein (SHH) for treatment of cancer	\$106,162.50	\$95,657.50
Galaxy Biotech, LLC	Humanized monoclonal antibody to FGF2 for treatment of hepatoma and other cancers	\$61,817.50	\$40,705.50
Galaxy Biotech, LLC	Humanized monoclonal antibody to Wnt co-receptor LRP6 for treatment of cancer	\$13,123.50	\$92,915.00
Gamma Medica -	SPECT-MRI Hybrid Molecular	\$84,754.00	\$158,494.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Ideas (USA) Inc	Imaging		
Gamma Medica-Ideas (USA) Inc	Molecular Breast Imaging	\$244,479.25	
Gamma Medica-Ideas (USA), Inc.	Translational Molecular Imaging	\$244,479.25	
GangaGen Inc.	Prevention and Treatment of Staphylococcus aureus (MRSA) infection	\$244,479.24	
Gemmus Pharma Inc	Novel treatment for influenza infections	\$20,508.50	\$141,689.50
Genalyte Inc	Silicon photonic sensor system for highly multiplexed diagnosis of multiple diseases	\$244,479.24	
GenapSys Inc	Development of inexpensive, ultra-high throughput micro-electronic medical DNA sequencer.		\$244,479.25
GENE SECURITY NETWORK INC	ARRAY INFORMATICS TO UNDERSTAND PLOIDY CONCORDANCE	\$196,010.00	\$48,469.25
Gene Therapy Systems Inc	Creation & testing of a novel gene targeting vector for gene therapy	\$84,060.99	\$84,643.75
Gene Therapy Systems Inc	apid serodiagnostic test for active tuberculosis	\$46,072.63	\$45,612.74
Genefluidics Inc	Rapid phenotypic antibiotic susceptibility testing for evidence-based treatment for infection diseases.	\$244,479.25	
Genelux Corporation	GL-ONC1	\$244,479.24	
Geron Corporation	GRNIC1: hESC-derived pancreatic islet cells for the treatment of diabetes	\$244,479.24	
Geron	GRNCM1: Human Embryonic	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Corporation	Stem Cell-Derived Cardiomyocytes for Heart Disease		
Geron Corporation	GRNOPC1: hESC-derived oligodendrocyte progenitors for SCI & neurodegenerative disease	\$244,479.24	
Geron Corporation	GRNVAC1, autologous therapeutic cancer vaccine	\$244,479.24	
Geron Corporation	Imetelstat (GRN163L)	\$244,479.24	
GigaGen Inc.	Personalized Companion Diagnostics for Myelodysplastic Syndrome	\$7,500.00	\$236,979.25
Glaukos Corporation	The iStent® Trabecular Micro-Bypass Stent	\$244,479.24	
Glumetrics, Inc.	GluCath Intravascular Continuous Glucose Monitoring System	\$244,479.24	
GlySens Inc	Implantable Glucose Monitor for Therapeutic Furtherance	\$244,479.25	
GT LIFE SCIENCES, INC.	SYSTEMS BIOLOGY BASED BIOTHERAPEUTIC PRODUCTION	\$244,479.25	
Guided Delivery Systems, Inc	Subcutaneous Mitral Valve Repair	\$244,479.25	
HALCYON Molecular Inc	High-throughput single-molecule quantitative transcriptional profiling by EM	\$244,479.25	
Halcyon Molecular, Inc	DNA sequencing using electron microscopy	\$244,479.25	
Halozyme, Inc. & Subsidiary	Recombinant human hyaluronidase (rHuPH20) for subcutaneous drug delivery	\$244,479.25	
Halozyme, Inc. & Subsidiary	Recombinant Human Cathepsin L for the treatment of collogan deposition disorders	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Halozyme, Inc. and Subsidiary	PEGPH20, a novel treatment for solid tumors such as pancreatic cancer	\$244,479.25	
Halozyme, Inc. and Subsidiary	Insulin-PH20-Ultrafast insulin for superior glycemic control in the treatment of diabetes	\$244,479.25	
Hana Biosciences Inc	MARQIBO Cancer Therapeutic	\$244,479.25	
HANA BIOSCIENCES INC.	Alocrest Cancer Therapeutic	\$148,327.67	\$67,373.84
HANA BIOSCIENCES INC.	Menadione Topical Lotion	\$244,479.25	
Hansen Medical Inc	VASCULAR CATHETER CONTROL SYSTEM	\$244,479.25	
Harbor BioSciences Inc	Triolex	\$244,479.25	
Harbor BioSciences Inc	Apoptone	\$244,479.25	
Harbor Medical Inc DBA Sprixx	Sprizz hand hygiene system	\$68,547.18	
HEMO THERAPEUTICS	AQUAPHERESIS	\$118,362.50	
HOTSPUR TECHNOLOGIES INC	PTA-PLUS	\$239,697.11	\$4,782.14
HOTSPUR TECHNOLOGIES, INC	MACERATOR-ASPIRATOR		\$244,479.25
Hotspur Technologies, Inc	EMBO-PLUS	\$178,946.39	\$65,532.86

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Hotspur Technologies, Inc.	PTA DUO	\$56,404.83	\$155,193.88
HourGlass Technologies, Inc	Transoral Restrictive Intra Gastric Mesh Incisionless Gastric Banding system for weight loss	\$244,479.25	
Hunter Laboratories Inc	HunterHeart	\$199,634.00	\$44,845.25
Hunter Laboratories Inc	HPV OncoTect Cancer Detection Diagnostic	\$244,479.25	
Huya Bioscience International LLC	Development of HBI-8000: A Novel HDAC Inhibitor for Treatment of Cancer	\$244,479.24	
HydraDx Inc	Importance of HydraDx Dehydration Diagnostic For Diagnosis and Monitoring State of Hydration	\$244,479.25	
Hyperion Therapeutics, Inc.	HPN-100 (GPB) in Urea Cycle Disorders and Hepatic Encephalopathy	\$244,479.25	
ICB International Inc	Diagnosis and treatment of Alzheimer's disease (AD)	\$244,479.24	
Ichor Medical Systems Inc	Novel Delivery Platform for DNA Vaccine Delivery in Skin	\$49,356.09	\$100,233.07
Ichor Medical Systems, Inc	A xenogeneic DNA Vaccine for Melanoma	\$53,672.80	\$91,831.78
Ichor Medical Systems, Inc	IND-Enabling Biodistribution and Integration GLP Assays for DNA Drugs	\$13,022.30	\$42,151.33
Ichor Medical Systems, Inc	DNA Drugs Delivered with Novel Intramuscular Electroporation Technology	\$117,452.35	\$117,648.59
Ichor Medical Systems, Inc.	Therapeutic HBV DNA Vaccine Delivered with Ichor's TDS	\$106,663.02	\$137,816.23

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Electroporation Technology		
Icon Bioscience, Inc	Versiome Ophthalmic Drug Delivery System	\$244,479.25	
Icon Bioscience, Inc.	IBI-10090 for Intraocular Injection	\$187,126.84	\$57,352.41
Icon Bioscience, Inc.	IBI-20089 for Intravitreal Injection	\$244,479.25	
ID FISH Technologies, Inc.	Fluorescent in site hybridization assay kits (FISH kits)	\$226,876.00	\$17,603.25
Idolo Biotechnology LLC	Idolo	\$35,000.00	\$57,933.50
IGeneX, Inc	Bartonella FISH Diagnostic	\$211,861.57	\$32,617.68
Igenica, Inc	Novel Therapeutic Monoclonal Antibodies for Cancer	\$244,479.25	
Igenica, Inc.	Novel Monoclonal Antibody for Treating Acute Myelogenous Leukemia		\$244,479.25
IGT LLC dba Eigen	Apollo: Robotic Needle Guidance System		\$244,479.24
IGT, LLC dba Eigen	Artemis:3D Imaging Workstation	\$244,479.24	
Imaginab, Inc.	Contract Manufacturing of an in vivo Molecular Diagnostic for Imaging Agent of Prostate Cancer	\$12,244.30	\$232,234.95
Imaginab, Inc.	Contract Manufacturing of an in vivo Molecular Diagnostic for Imaging Autoimmune Disease	\$111,251.62	\$133,227.63
iMetrikus, Inc	System for Health Monitoring in Populations	\$244,479.25	
ImmPORT Therapeutics Inc.	Novel non-invasive diagnostics for liver diseases	\$94,750.00	\$149,729.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
dba Antigen Discovery Inc			
ImmPORT Therapeutics, Inc (dba) Antigen Discovery, Inc	Safe and efficacious vaccine against Chlymedia	\$244,479.25	
ImmPORT Therapeutics, Inc. (dba). Antigen Discovery. Inc.	Accurate and robust serodiagnostic test for Lyme Disease	\$130,404.50	\$114,074.75
ImmunGene Inc.	Development for the treatment of non-Hodgkins's lymphoma patients with genetic resistance.	\$200,326.57	\$44,152.68
ImmunoCellular Therapeutics Ltd	Development of a Cancer Vaccine for Glioblastoma (Brain Cancer)	\$244,479.25	
ImmunoScience, Inc.	Salivax	\$244,479.25	
IMTEC Biomedical Inc	IMTEC VasConnect and VasPort System for Vascular Access	\$48,114.00	\$115,540.00
Imthera Medical Inc	THN Sleep Therapy for Obstructive Sleep Apnea (OSA)	\$244,479.24	
IncellDx, Inc.	E6, E7 mRNA Cervical and Anal Cancer Diagnostic	\$39,857.50	\$204,621.75
Incline Therapeutics, Inc.	IT101		\$244,479.25
InCode BioPharmaceutics, Inc.	C3 Complement Depletor Project	\$229,735.50	\$14,743.75
Ingenuity Systems Inc	Drug Respositioning, Biomarker and Therapeutic Target Discovery Program	\$244,479.25	
Inhibrx, Inc	Development of a therapeutic antibody for the treatment of		\$244,479.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	vascularized tumors		
Innovative Cell Technologies, Inc.	Developing Clinical Grade Cell Dissociation Reagent for Embryonic Stem Cell Manufacturing	\$6,250.00	\$61,375.00
Innovative Micro Technology Inc	Early cancer detection : A MEMS-based cell sorter for CTC enumeration and functional testing	\$244,479.25	
Insera Therapeutics, Inc.	Novel clot-retrieval and clot-filtering device for Stroke treatment including intra-arterial thrombolysis	\$125,000.00	\$119,479.25
InSite Medical Technologies, Inc.	Epiphany Epidural Access System	\$136,117.00	\$108,362.25
InSite Vision, Inc	ISV-303 Ocular Anti-Inflammatory Therapeutic	\$244,479.25	
InSite Vision, Inc.	ISV-502 Therapeutic for Blepharitis and Lid Margin Disease	\$244,479.25	
Inspiration Biopharmaceuticals, Inc	Recombinant Factor IX for the treatment of Hemophilia B	\$244,479.25	
Inspiration Biopharmaceuticals, Inc.	Recombinant Porcine Factor VIII (OBI-1) for the Treatment of Acquired Hemophilia		\$244,479.25
Intarcia Therapeutics, Inc	Continuous, Subcutaneous Delivery of an Incretin Mimetic to Treat Type 2 Diabetes	\$244,479.25	
IntegenX Inc	Apollo 200	\$244,479.25	
IntegenX Inc	Apollo 396		\$244,479.25
IntegenX Inc	Apollo 324		\$244,479.25
IntegenX, Inc	Apollo 100	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Integrated Endoscopy, Inc	Single use HD Endoscope	\$21,783.33	\$25,000.00
Integrated Medical Systems Inc	Life Support for trauma and transport commercialization	\$71,707.00	
InteKrin Therapeutics Inc	INT131 A Safe Insulin Sensitizer for Treatment of Type 2 Diabetes	\$244,479.25	
Intellikine, Inc.	Development of INK1117 for treatment of hematologic malignancies	\$132,457.00	\$112,022.25
Intellikine, Inc.	Development of INK1117 for treatment of solid tumors	\$244,479.25	
Intellikine, Inc.	Development of INK1117 for treatment of solid tumors and hematologic malignancies	\$244,479.25	
Intellikine, Inc.	Development of INK1117 for treatment of rheumatoid arthritis	\$244,479.25	
Intermune Inc.	PIRFENIDONE FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS	\$244,479.25	
INTERMUNE, INC	Danoprevir Development Program	\$244,479.25	
Intermune, Inc.	Next Generation HCV Therapeutic Discovery Program	\$244,479.25	
International Stem Cell Corporation and Subsidiaries	hPSC	\$244,479.25	
Intersect ENT, Inc	SpiderRX	\$244,479.25	
Intersect ENT, Inc	CrownRX	\$244,479.25	
Interventional Spine Inc	Percudyn System ("PDS")	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Intradigm Corporation (Silence Therapeutics, plc)	Silence Therapeutics: Novel RNAi Therapeutics	\$244,479.24	
IntraOp Medical Corporation	Mobetron IOERT and Etanidazole Radiation Sensitizing Drug	\$244,479.24	
Intrinsic LifeSciences, LLC	Development of FDA-approved Hepcidin Diagnostic Devices for Clinical Medicine	\$75,420.73	\$169,058.51
Intuity Medical, Inc.	POGO™	\$244,479.25	
Ion Torrent Systems, Inc	Development of Next Generation Sequencing Platform for Molecular Diagnostic Applications	\$244,479.25	
iPierian Inc	New Drugs for Amyotrophic Lateral Sclerosis (ALS) Discovered using iPS Cells	\$236,827.00	\$7,652.25
iPierian, Inc.	New Drugs for Spinal Muscular Atrophy Discovered using Induced Pluripotent Stem Cells	\$244,479.25	
IR2DX Inc	Physician Office Metabolic Assessment		\$37,500.00
IR2Dx, Inc	Laboratory Panel - Metabolic and Atherosclerlerosis Assessment		\$111,500.00
iRhythm Technologies Inc.	The Zio [tm] Patch and ZEUS Project.	\$244,479.24	
IRIDEX Corporation	Premixed, Sterile Single Dose Gas (Eye Gas) for Treatment of Retinal Detachments		\$58,853.87
Iris BioTechnologies, Inc.	Optimizing Personalized and Targeted Medical Treatment Using	\$34,808.50	\$209,670.75

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
iScience Interventional	iScience Microcatheter, for treatment of Macular Edema	\$244,479.25	
iScience Interventional	iScience Canaloplasty Project	\$244,479.25	
Islet Sheet Medical LLC	Novel Islet Sheets Method for Treating Diabetes	\$53,746.57	\$148,946.96
Itero Biopharmaceuticals Inc	A newly formulated and differentiated recombinant follicle stimulating hormone, or rFSH.	\$244,479.25	
Itherx Pharmaceuticals	Development of Novel Entry Inhibitors for Hepatitis C	\$244,479.25	
IVANTIS INC.	Hydrus Aqueous Implant	\$244,479.25	
Jaden BioScience Inc AKA Jade BioScience inc	Ultrasensitive cell surface detection of B-cell chronic lymphocytic leukemia(B-CLL)	\$26,089.00	\$57,115.50
Jan Medical Inc.	Jan Medical DCX Project	\$228,658.50	\$15,820.74
Jazz Pharmaceuticals, Inc.	JZP-6 Sodium Oxybate for the Treatment of Fibromyalgia	\$244,479.25	
Jazz Pharmaceuticals, Inc.	PLE-1 Twice-Nightly Immediate Release Solid Oral Dosage Form of Sodium Oxybate	\$203,019.50	\$41,459.75
Jazz Pharmaceuticals, Inc.	JZP-8 Intranasal Clonazepam for the Treatment of Acute Repetitive Seizures	\$218,133.00	\$26,346.25
Jazz Pharmaceuticals, Inc.	PLE-2 Once-Nightly Controlled-Release Solid Oral Dosage Form of Sodium Oxybate	\$147,883.00	\$96,596.25
Jennerex Inc	Intravenous Treatment of Advanced Metastatic Colorectal Cancer with JX-594	\$244,479.24	
Jennerex Inc.	JX-2011: A Novel Product for Advanced Metastatic Prostate Cancer	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Jennerex, Inc	JX-594: A Novel Therapeutic for Direct Injection into Liver Tumor	\$244,479.25	
JN Biosciences, LLC	Development of an immunosuppressive therapeutic antibody	\$109,300.00	\$135,179.24
Juvaris Bio Therapeutics, Inc.	Use of JVRS-100 to protect against ionizing radiation	\$244,479.25	
Juvaris BioTherapeutics Inc	Use of JVRS-100 as an immunotherapeutic to treat Acute Myelogenous Leukemia	\$244,479.25	
Juvaris BioTherapeutics, Inc	Combination of JVRS-100 with Francisella tularensis membrane fraction	\$244,479.25	
Juvaris BioTherapeutics, Inc.	Use of JVRS-100 to protect against reperfusion injury	\$244,479.25	
KAI Pharmaceuticals, Inc	KAI-1678 for Neurpathic Pain	\$244,479.25	
KAI Pharmaceuticals, Inc.	KAI-9803 for Acute Myocardial Infarction	\$244,479.25	
KAI Pharmaceuticals, Inc.	KAI-4169 for Secondary Hyperparathyroidism (SHPT)	\$244,479.25	
KaloBios Pharmaceuticals, Inc.	Humaneered Monoclonal Antibody (KB003) for the Treatment of Rheumatoid Arthritis	\$244,479.24	
KaloBios Pharmaceuticals, Inc.	Therapeutic Antibody (KB004) FOR THE Treatment of Hematological Malignancies	\$244,479.24	
KaloBios Pharmaceuticals,	KB001-A for Treatment of Pseudomonas Aeruginosea in	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Inc.	Cystic Fibrosis Patients		
KaloBios Pharmaceuticals, Inc.	KB001- A for Treatment of Mechanically Ventilated Patients	\$244,479.24	
Kalos Therapeutics, Inc	Kalos Therapeutics, Inc. Development of KT-220	\$66,633.00	\$177,846.25
Kalypsys, Inc.	H4R Antagonist Project	\$244,479.25	
KenHealth LLC	Percutaneous Closure Device		\$244,479.25
KeraMed Inc	New Artificial Cornea and Implantation Method for Treatment of Blindness	\$152,044.12	
Keren Parmaceutical, Inc.	Development of External Guide Sequence (EGS) therapeutics for inflammatory lung disease	\$9,970.50	\$12,612.50
KI Biotechnologies	Automated Hight Throughput cRBC Stem Cell Hematopoietic Processing System		\$244,479.24
KM Biotech, Inc.	GM602 for treatment of Stroke and Parkinson's Disease indications	\$244,479.25	
Kona Medical	Noninvasive Device Based Treatment for Hypertension		\$244,479.25
Konan Medical USA, Inc	Bionocular Analytic Dynamic Pupillometer		\$115,000.00
Kythera Biopharmaceutic als Inc	Nanoencapsulation of Therapeutic Proteins		\$196,473.00
Kythera Biopharmaceutic als Inc	ATX-101	\$244,479.24	
Kythera Biopharmaceutic als, Inc	ATX-104	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Kythera Biopharmaceuticals, Inc	ATX-202	\$244,479.24	
LAAX, INC	STROKE- LAAX PROJECT	\$244,479.25	
LakePharma, Inc	Development of a Novel Recombinant Protein For The Treatment Of Diabetes And Cancer	\$40,850.00	\$118,915.00
Lasmed Limited Liability Company	Infrared diode-laser tools for pain diagnostics and management	\$117,426.24	\$127,053.01
LENR Solutions, Inc.	LENR LipoSector	\$76,631.00	\$167,848.25
Lerner Medical Devices, Inc	Targeted Phototherapeutic Treatment of Psoriasis at Home	\$244,479.25	
Leuchemix Inc	CLINICAL STUDIES OF THE NOVEL ANTI-CANCER AGENT LC-1	\$240,189.50	\$4,289.74
Leukocyte, Inc.	CytoPaint Extreme Analysis Software for Flow Cytometry	\$2,730.50	\$241,748.75
Ligand Pharmaceuticals Inc	Selective Androgen Receptor Modulators (SARM), LGD-4033	\$244,479.25	
LIGAND PHARMACEUTICALS INC	Thrombopoietin (TPO) LGD-4665	\$244,479.25	
Ligand Pharmaceuticals Inc	DARA	\$244,479.25	
LIGAND PHARMACEUTICALS INC	Organon Collaboration	\$244,479.25	
Ligand Pharmaceuticals	Erythropoietin (EPO) Research Program	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Inc			
Limerick BioPharma Inc	LIM-075 ATP-binding cassette activator for safer immunosuppressant therapy in transplants	\$244,479.25	
Limerick BioPharma, Inc	Limerick's Lipid Chaperones for treating metabolic disorders	\$244,479.25	
Livermore Instruments Inc	BioAerosol Mass Spectrometry for Tuberculosis Diagnosis		\$ 146,001.50
Loma Vista Medical, Inc	Mult-Layer Medical Balloons	\$244,479.24	
Lonestar Heart Inc	Cardiogenic Stem Cell Modulators	\$244,479.25	
Lpath, Inc.	Development of ASONEP™ for the treatment of Cancer	\$244,479.24	
Lpath, Inc.	Development of iSONEP(TM) for the treatment of Age-related Macular Degeneration	\$244,479.24	
Lumen Therapeutics, LLC	Nona-L-Arginine for Prevention of Saphenous Vein Graft Disease	\$53,472.49	\$82,801.38
Luminous Medical Inc.	Luminous Blood Glucose Monitor (LBGM)	\$244,479.25	
Lutran Industries Inc.	DRH12 Acute Viral Nasopharyngitis		\$244,479.25
Lutran Industries Inc.	DRH12 Chronic Bronchitis		\$244,479.25
Lutran Industries Inc.	DRH12 Mother to Child Transmission of Gonorrhea		\$244,479.25
Lutran Industries Inc.	DRH12 Mother to Child Transmission of Chlamydia		\$244,479.25
Lutran Industries	DRH12 Mother to Child		\$244,479.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Inc.	Transmission of Hepatitis		
Lutran Industries Inc.	DRH12 Mother to Child Transmission of HPV		\$244,479.25
Lypro Biosciences Inc	Nano Disks	\$220,262.84	\$24,216.40
MabPrex, Inc.	Brain penetrating BMP-4 as a cancer stem cell differentiation therapy against glioblastoma	\$22,494.00	\$221,985.24
Mabvax Threapeutics Inc	Human Monoclonal Antibodies from Immunized patient Lymphocytes	\$244,479.24	
Mabvax Threapeutics, Inc	Phase II Clinical Trial to determine efficacy of a vaccine to prevent recurrent sarcoma carbohydrate antigens in stage IV patients rendered disease free with the objective of preventing recurrent sarcoma	\$244,479.24	
Madera Biosciences, Inc.	Small molecule angiogenesis inhibitors for cancer therapy	\$1,481.13	\$8,500.00
MagArray, Inc	Magnetic Nanoparticle Immunoassay System for Cancer Diagnostics	\$189,439.67	\$55,039.57
Magellan Spine Technologies, Inc	Magellan DART Technology	\$244,479.24	
Magnesensors, Inc	Optimized magnetic nanoparticle labels for ultra-sensitive magnetic detection of pathogens		\$48,995.00
Magnesensors, Inc	Ultra-sensitive magnetic rare cell assays for leukemia	\$201,707.50	\$42,771.75
Magnesensors, Inc	Quantitive detection of nucleic acids without amplification for sepsis diagnostics	\$38,479.00	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Magnetecs Corporation	Catheter guidance control & imaging apparatus(CGCI)	\$244,479.25	
MandalMed, Inc.	Galectin-3C for treatment of cancer and prevention of metastasis	\$30,264.00	\$4,486.00
MAP Pharmaceuticals Inc	LEVADEX TM	\$244,479.25	
Mapp Biopharmaceutical Inc	Vaginal Microbicide Antibodies	\$102,274.34	\$9,063.39
Mapp Biopharmaceutical, Inc	Biodefense Monoclonal Antibodies	\$244,479.25	
Mapp Biopharmaceutical, Inc	Clostridium Difficile Monoclonal Antibodies	\$244,479.25	
Mapp Biopharmaceutical, Inc	Alzheimer's Monoclonal Antibodies	\$151,031.76	\$93,447.49
Mapp Biopharmaceutical, Inc.	Respiratory Syncytial Virus Antibodies	\$14,598.24	
Mariposa Biotechnology Inc	Automated osmolality control for cryogenic freezing or thawing	\$244,479.25	
Masimo Laboratories, Inc	Improved Glucose Strip Reader		\$244,479.25
Masimo Laboratories, Inc.	Glucose 1 Non-Invasive Glucose Diagnostic Device	\$244,479.25	
Matrix Sensors, Inc.	Matrix Sensors, Inc.	\$244,479.25	
Maven Technologies	LFIRE	\$197,015.00	\$47,464.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
LLC			
Maya Medical Inc	Maya System		\$244,479.25
Medbiocom	Selective tumor vascular thrombogen	\$244,479.24	
Medbiocom	Anti cancer prodrug activated by proteases of the coagulation cascade	\$244,479.25	
Medbiocom	Cancer immune therapy targeting tumor associated macrophage	\$244,479.25	
Medical Tactile Inc	SureTouch breast cancer detection and diagnostics	\$95,483.73	\$148,995.51
MEDIVATION NEUROLOGY, INC	Dimebon for the treatment of Huntington Disease	\$244,479.25	
MEDIVATION NEUROLOGY, INC	Dimebon for the treatment of Alzheimer's Disease	\$244,479.25	
Medivation Prostate Therapeutics Inc	MDV3100 for the treatment of advanced prostate cancer	\$244,479.25	
MedSolve Technologies, Inc	Low Cost Micro Infusion Pump for the Treatment of Diabetes (Type 1 and Type 2)	\$35,412.50	
Mercator MedSystems, Inc.	Catheter-directed renal sympathectomy to reduce hypertension	\$45,642.09	\$198,837.16
MERITAGE PHARMA, INC	ORAL VISCOUS BUDESONIDE	\$244,479.24	
Metabasis Therapeutics Inc	Thyroid Receptor-beta Agonist	\$244,479.25	
METABASIS THERAPEUTICS INC	Glucagon Receptor Agonist Program	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Metabolex Inc	Development of MBX-3254 a GPR119 receptor agonist for the treatment of Type 2 Diabetes	\$185,654.00	
Metabolex Inc	Development of MBX-2982 a GPR119 agonist for the treatment of Type 2 Diabetes	\$244,479.24	
Metabolex Inc	Small molecule agonists of the bile acid receptor GPR131 for the treatment of type 2 diabetes	\$125,300.00	\$119,179.24
Metabolex Inc	Development of MBX-102 for the treatment of gout.	\$244,479.24	
Metabolex Inc	Agonists of the anti-lipolytic receptor GPR81 for the treatment of Coronary Artery Disease	\$43,000.00	
Metabolex Inc	Agonists of the fatty acid receptor GPR 120 for the treatment of type 2 diabetes	\$244,479.24	
Metabolex, Inc.	Development of TRPM5 Activators for the treatment of Type 2 Diabetes		\$229,396.00
Metabolex, Inc.	MBX-8025 is a potential first-in-class therapy to treat mixed dyslipidemia	\$244,479.24	
Metronom Health, Inc.	Continuous Glucose Monitoring System with Hypoglycemic Detection		\$244,479.25
MiCardia Corporation	MiCardia Encor Dynamic Heart Valve Repair Technology	\$244,479.24	
MicroCube LLC	A Novel device("Wrist") for precise delivery of therapeutics/devices	\$147,000.00	\$97,479.25
MicroCube LLC	Novel Office-based Menorrhagia Treatment	\$244,479.25	
Micropoint	Developing POC In-Vitro	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Bioscience, Inc	Diagnostic Rapid Tests of Chronic and Acute Diseases		
MINDFRAME, INC	Mindframe Interventional Recanalization is Ischemic Stroke (IRIIS) System	\$244,479.25	
Minerva Surgical, Inc	Aurora System	\$244,479.25	
MingSight Pharmaceuticals	MS-553, A Novel Oral Therapy For the Treatment of Diabetic Eye Diseases and Uveitis		\$61,901.00
Minnow Medical Inc	Peripheral Vascular System (PVS)	\$244,479.24	
Mitos Pharmaceuticals, Inc	Use of Tempol to improve radiation treatments in head, neck, breast, and brain cancer.	\$244,479.24	
MLC Dx Inc	DNA sequencing based recurrence test for Non-Hodgkin lymphoma	\$92,909.48	\$151,569.77
Modulated Imaging Inc	Advanced Medical Camera for Tissue Health Assessment	\$69,673.50	\$154,201.00
Molecular GPS Technologies and Subsidiaries	Molecular GPS Technologies' Influenza Vaccine 1230 Project	\$231,861.17	\$12,618.08
Molecular GPS Technologies and Subsidiaries	Molecular GPS Technologies' Aspergillus Program	\$170,310.90	\$42,500.00
Molecular GPS Technologies and Subsidiaries	Minisurf™ and Minisurf-R™	\$136,453.51	\$108,025.74
Molecular GPS Technologies and Subsidiaries	Development Project of a New HSV2 Vaccine for Herpes genitalis (GH)	\$146,616.47	\$97,862.78
Molecular Imaging and	Development of single chain antibody conjugates against a		\$244,479.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Therapeutics, Incorporated	unique prostate cancer antigen		
Molecular Response, LLC	Tumor Anatomy Characterization - Developing a Validated Test for EGFRi Therapies		\$244,479.25
Molecular Response, LLC	Gene Expression Tests for Predicting Lung Cancer Patient to EGFRi and HSP90i Therapy		\$244,479.25
Mountain View Pharmaceuticals, Inc.	PharmaPEG Technology for PEG-protein Drug Conjugates with Decreased Immunoreactivity	\$122,810.00	\$121,669.25
Moximed, Inc	Kinespring Knee implant system	\$244,479.25	
Mpex Pharmaceuticals, Inc.	AEROQUIN TM (MP-376: Levofloxacin Inhalation Solution)	\$244,479.25	
Multimeric Biotherapeutics, Inc.	Precision immunization vaccine for nicotine and other drugs of abuse	\$3,518.68	\$77,251.04
MyeloRx LLC	Development of a triptolide derivative for acute myeloid leukemia and other cancers	\$32,748.00	\$211,731.24
Mynosys Cellular Devices Inc	Surgical Device For The Treatment Of Childhood Blindness Due to Lens Cataract	\$80,050.00	\$164,429.24
NanoComposix, Inc	Hollow Porous Silica Nanoparticles (HOPS Nanoparticles)	\$24,617.32	\$82,257.18
NanoComposix, Inc.	Gold Nanoparticle Matrices for MALDI-MS Diagnostic Applications	\$120,956.26	\$101,819.19
NanoIVD, Inc	Nanotechnology-based Cancer IVD Platform and Point-of-care Test	\$244,479.24	
NANOMIX,	Cardiac early detection biosensor	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
INC.			
NanoPacific Holdings, Inc	Nanodevice Cancer Drug Delivery	\$244,479.25	
Nanostim Inc	Nanostim's Leadless Cardiac Pacemaker	\$244,479.25	
NANOVASC INC	NANOVASC DRUG-ELUTING VASCULAR GRAFT	\$244,479.24	
Napo Pharmaceuticals, Inc	Development of crofelemer for treatment of secretory diarrhea	\$244,479.25	
Nativis Inc	Digitax Therapeutic Treatment for Brain Cancer	\$244,479.25	
Nativis, Inc	a-PCSK9s Therapeutic Treatment for Hypercholesterolemia	\$244,479.25	
Navigenics, Inc.	Navigenics pharmacogenomics panel to predict medication response and risk of side effects	\$244,479.25	
NAVISCAN, INC	POSITRON EMISSION MAMMOGRAPHY SCANNER FOR BREAST CANCER DIAGNOSIS	\$244,479.25	
Neodyne Biosciences, Inc	Neodyne Device for Improved Healing and Scar Reduction	\$244,479.25	
NEOLAC, INC.	PURIFIED SECRETORY IMMUNOGLOBIN TO PREVENT & TREAT NECROTIZING ENTERCOLITIS	\$11,350.09	\$233,129.16
Neonc Technologies, Inc	Development of Intranasal Delivery to the Brain	\$49,029.00	\$195,450.25
Neostasis Inc	T15 monoclonal antibody for the treatment of autoimmune disease.	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
NeoSync Inc	Neuro-EEG Synchronization Therapy	\$244,479.25	
NeoVista, Inc.	CABERNET	\$244,479.24	
Nereus Pharmaceuticals, Inc	Marizomib (NPI-0052	\$244,479.25	
NEREUS PHARMACEUTICALS, INC.	PLINABULIN	\$244,479.25	
Neugenes Corporation	Development of a Recombinant Influenza Virus-Like Particle Pandemic(H5N1)Vaccine	\$244,479.25	
NEUGENESIS CORPORATION	Development of a cost effective polyclonal therapeutic against MRSA	\$55,398.00	\$189,081.25
Neugenes Corporation	Develop Recombinant Virus-Like Particle Trivalent Seasonal Influenza Vaccine	\$244,479.25	
Neumedicines Inc	NM-Gene Therapy	\$85,975.29	\$43,947.23
Neumedicines, Inc	HHS1: Characterization and Manufacturing Development of a Novel Anti-Tumor Therapeutic	\$23,414.67	\$114,553.90
Neumedicines, Inc.	HemaMax Advancement for Multiple Unmet Medical Needs in hematology/Oncology	\$244,479.24	
Neuralieve, Inc.	Single pulse transcranial magnetic stimulation device for treatment/management of migraine.	\$244,479.25	
Neuraltus Pharmaceutical, Inc	Neuraltus NP003 - Developing a treatment for Lysosomal Storage Disorders	\$176,543.50	\$67,935.74
Neuraltus	Neuraltus NP001 - Developing a	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Pharmaceuticals, Inc.	treatment for ALS and other neurodegenerative diseases		
Neuraltus Pharmaceuticals, Inc.	Neuratus NP002 - A treatment for dyskinesias caused by l-dopa treatment of Parkinson's	\$244,479.24	
Neurocine Biosciences, Inc	Development of GnRH antagonists (Elagolix) for endometriosis related pain	\$244,479.24	
Neurocrine Biosciences Inc	Development of G protein-coupled receptor agonists or antagonists	\$244,479.24	
Neurocrine Biosciences, Inc.	Development of Selective GPR119 Receptor Agonists for the Treatment of Type 2 Diabetes	\$244,479.24	
Neurocrine Biosciences, Inc.	Development of VMAT 2 inhibitors for hyperkinetic movement disorders	\$244,479.24	
NEUROGEN CORPORATION	Aplindore	\$244,479.25	
Neurogenetic Pharmaceuticals, Inc.	Novel therapeutics for the prevention of Alzheimer's disease	\$169,963.00	\$74,516.24
NeurogesX Inc	Quetenza (capsaicin)8% patch	\$244,479.25	
NEUROGESX, INC	NGX-1998-LIQUID HIGH CONCENTRATION TOPICAL CAPSAICIN	\$156,101.50	\$88,377.75
NeurogesX, Inc.	Acetaminophen Prodrugs	\$6,408.00	\$137,913.00
NeuroPace, Inc.	Responsive Neurostimulator Systems for Treating Neurological Diseases	\$244,479.25	
Nevro Corporation	Senza SCS	\$244,479.25	
NewLife Sciences LLC,	Final Phase Full-Scale US Launch of TMR Technology	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
dba Scientific Imaginetics			
NEXMED	PREVONCO FOR THE TREATMENT OF LIVER CANCER		\$244,479.25
NEXMED	Femprox for female sexual arousal disorder		\$244,479.25
NEXMED Inc	VITAROS FOR REYNAUD'S PHENOMENON		\$244,479.25
NextWave Pharmaceuticals Inc	Methylphenidate HCl Extended-Release Powder for Oral Suspension	\$244,479.25	
NextWave Pharmaceuticals Inc	Mexocopl XR Tablet - clonidine extended release tablet	\$244,479.25	
NextWave Pharmaceuticals Inc	Methylphenidate Extended Release Chewable Tablet	\$25,766.50	\$218,712.75
NextWave Pharmaceuticals Inc	Nexiclon XR Liquid - clonidine extended release liquid suspension	\$244,479.25	
NextWave Pharmaceuticals, Inc.	Dexmethylphenidate Extended Release Formulation	\$57,486.00	\$186,993.25
Nexus Dx Inc	High Sensitivity cardiac panel	\$244,479.25	
Nexus Dx Inc	Flu-ID	\$244,479.25	
NGM Biopharmaceuticals	NPT1162 for Type 2 Diabetes Mellitus	\$244,479.25	
NGM Biopharmaceuticals, Inc.	Disease Modifying Therapeutics for Type 2 Diabetes Mellitus	\$244,479.25	
NGM Biopharmaceutical	Therapeutics to Enhance Compromised Muscle Function	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
als, Inc.			
Nile Therapeutics, Inc	CD-NP-Acute Heart Failure	\$244,479.24	
NOCIMED LLC	NOCISCAN-MR Spectroscopy for Molecular Diagnosis of Discogenic Low Back Pain	\$233,732.16	\$10,747.09
Nodality Inc	Development of Molecular Diagnostics for Prediction of Treatment Response in AML	\$244,479.24	
Nodality Inc	Molecular Diagnostics for Patient-Specific Characterization of Immune Dysfunction	\$74,491.00	\$169,988.24
Nodality Inc	Molecular Diagnostics for Drug Pathway Profiling in Hematologic Malignancies	\$244,479.24	
Nodality Inc	Development of Molecule Diagnostics for Prediction of Treatment Response in MDS	\$244,479.24	
Nodality Inc	Molecular Diagnostics for Prediction of Disease Progression and Treatment Response in CLL	\$244,479.24	
NovaBay Pharmaceuticals, Inc.	Treatment of Impetigo	\$244,479.24	
NovaRx Corporation	Pivotal phase III clinical trial of Lucanix for non-small cell lung cancer	\$244,479.24	
Novelix Pharmaceuticals, Inc.	NVX-207	\$16,741.00	\$227,738.25
Novici Biotech, LLC	Empirical Codon Optimization Technology for Biopharmaceutical & DNA Vaccine Improvement		\$36,662.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
NovoMedix , LLC	Treatment of Triple Negative Breast Cancer	\$5,060.50	\$95,729.00
NovoMedix, LLC	Treatment of Type II Diabetes	\$155,828.00	\$26,264.50
NuCardia Inc	HeartFlow	\$244,479.24	
NuMask, Inc.	NuMask IntraOral Mask and Oropharyngeal Airway Research and Development	\$71,187.50	
NuMask, Inc.	NuMask IntraOral Mask and Oropharyngeal Airway, Clinical Research		\$142,829.50
Numedii	using computational drug repositioning to develop novel lung cancer therapeutics	\$4,150.00	\$240,329.25
Numerate Inc	Novel drug products for treating latent and drug-resistant tuberculosis	\$170,689.46	\$73,789.78
Numerate, Inc	A novel drug for treating celiac sprue	\$159,084.28	\$85,394.97
Numerate, Inc.	A novel drug for treating hepatitis C virus infections	\$189,658.15	\$54,821.09
Nuon Therapeutics Inc	NU3450 (tranilast) for the treatment of rheumatoid arthritis	\$244,479.25	
Nuon Therapeutics Inc.	NU1618 for the treatment of chronic gout	\$244,479.25	
Nuveta, Inc	IVF Technology	\$96,446.81	\$21,883.50
Ocera Therapeutics Inc	OCR-002 for Hyperammonemia & Resultant Hepatic Encephalopathy in Chronic Liver Disease	\$244,479.25	
Ocera Therapeutics Inc	OCR-002 for Hyperammonemia & Resultant Hepatic Encephalopathy in Acute Liver Failure	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Ocera Therapeutics Inc	AST-120 for the Treatment of Non-Constipating Irritable Bowel Syndrome (nc-IBS)	\$244,479.25	
Odyssey Thera, Inc	miRNA Oncology Target Validation and Therapeutic Development	\$244,479.25	
Odyssey Thera, Inc.	Development of Multi-Targeted Oncology Therapeutics	\$244,479.25	
Olema Pharmaceuticals, Inc.	Oral Complete Anti-estrogens for the Treatment of Metastatic Breast cancer	\$144,092.60	\$100,386.65
Oligasis, LLC	A breakthrough technology for pharmaceuticals: Validating and commercializing an enabling platform and manufacturing technology in collaboration with multiple pharmaceutical partners.	\$244,479.24	
Omniox, Inc.	Overcoming Tumor Hypoxia with OMX-0004 to Revolutionize Chemo/Radiation Outcomes	\$230,794.86	\$13,684.38
Omnueron Inc	Therapeutic Technology for Real Time Functional MRI	\$244,479.25	
OMP, Inc	Treatment for Melasma, NuDerm	\$244,479.25	
On Demand Therapeutics, Inc	Laser activated, ophthalmic drug delivery implant for treating retinal diseases	\$244,479.25	
Oncolytics Biotech (U.S..) Inc.	Reolysin	\$244,479.24	
OncoMed Pharmaceuticals Inc.	OMP-21M18: Targeting DLL4 in Cancer Stem Cells for the treatment of cancer.	\$244,479.24	
OncoMed Pharmaceuticals, Inc	OMP-59R5: Targeting Notch Receptors in Cancer Stem Cells for the treatment of Cancer	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
OncoMed Pharmaceuticals, Inc	Antibodies Targeting Notch Pathway Ligands for the Treatment of Cancer	\$244,479.24	
OncoMed Pharmaceuticals, Inc	Inhibiting the Wnt Pathway for the Treatment of Cancer	\$244,479.24	
OncoMed Pharmaceuticals, Inc.	OMP-18R5 Targeting the Wnt Pathway in Cancer Stem Cells for the Treatment of Cancer	\$244,479.24	
OncoTx Inc	Isoforms of gene transcription proteins: Development of novel tools for cancer diagnosis	\$107,777.00	\$136,702.25
Onset Medical Corporation	Onset Controlled Deployment Technology	\$244,479.25	
Opal Therapeutics Inc	Opal HIV - An Immunotherapy for HIV	\$11,469.50	\$64,335.00
Open Monoclonal Technology Inc	Monoclonal Antibody Cocktail Therapy	\$244,479.25	
Ophidion, Inc.	Novel Cholinergic Therapeutics for Cognitive Enhancement	\$111,568.50	\$97,650.00
Optimedica Corporation	Image-guided femtosecond laser cataract surgery	\$244,479.25	
Optimer Pharmaceutical, nc.	Fidaxomicin, a novel therapy for Clostridium difficile infections (CDI)	\$244,479.25	
OptiScan Biomedical Corporation	Closed Loop Insulin delivery with an ICU Continuous Glucose Monitor	\$244,479.24	
Optovue Inc	iVue	\$244,479.25	
OPTOVUE, Inc	ACVUE	\$85,382.00	\$159,097.25
Opus Pharmaceuticals, Inc	L-FABP drugs as novel therapeutics for fatty liver disease, elevated lipids and obesity	\$49,880.50	\$44,768.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Oramic, LLC	Electro-Fluidic Thrombolysis microcatherter for the clearing of vascular occlusions	\$20,138.50	\$109,700.00
O-Ray Pharmaceuticals	Sustained Release Inner Ear Delivery of Corticosteroid	\$22,500.00	\$101,966.67
Orexigen Therapeutics, Inc	Contrave	\$244,479.24	
Orexigen Therapeutics, Inc.	Empatic	\$244,479.24	
Organovo Inc	Biological 3D Bioprinted Blood Vessel	\$152,808.68	
Organovo Inc	NovoGen 3D Bioprinter Development	\$184,735.50	\$59,743.75
Orphagen Pharmaceuticals	Novel Small Molecule Drug Class for the Treatment of Retinal Degeneration	\$88,752.50	\$57,265.00
Orphagen Pharmaceuticals	Novel Small Molecule Drug Class for the Treatment of Autoimmune Disease	\$176,533.50	\$67,945.75
Orphagen Pharmaceuticals	A novel drug class for treating adrenocortical cancer, prostate cancer and endometriosis.	\$29,494.00	\$202,980.50
ORTHALIGN, INC.	KneeAlign	\$244,479.25	
Osel, Inc.	LACTIN-V-Preventing Recurrence of Female Urinary Tract Infections	\$162,466.00	\$33,378.00
Osel, Inc.	MucoCept-Development of a Novel Anti-HIV Microbicide	\$244,479.24	
Osseon Therapeutics, Inc.	Osseoflex Balloon Tamp		\$142,500.00
Otonomy, Inc	OTO-203: Ciprofloxation +		\$244,479.24

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Dexamethasone Gel for Use During Tympanostomy Tube Surgery		
Otonomy, Inc.	OTO-104: Sustained Release Dexamethasone Gel for Treatment of Meniere's Disease	\$244,479.24	
OvaGene Oncology	Creation of a Cell Line System for Companion Diagnostic Development		\$125,000.00
OvaGene Oncology	Validation of STMN1 as a Predictor of Endometrial Cancer Recurrence		\$147,500.00
OvaGene Oncology	Molecular Definition of Atypical Endometrial Hyperplasia		\$244,479.24
OXiGENE, Inc	Development of CA4P as a Topical Treatment for Abnormal Vascular Ophthalmic Diseases	\$244,479.24	
OXiGENE, Inc	Development of CA4P for the Treatment of Solid Tumor Cancers	\$244,479.24	
OXiGENE, Inc.	Development of CA1P (OXi4503) for the Treatment of Solid Tumor and Hemotologic Cancers	\$244,479.24	
Pacira Pharmaceuticals Inc	DepoNSAID - sustained release drug for improved treatment of pain and inflammation	\$35,796.71	\$46,464.93
Pacira Pharmaceuticals, Inc	EXPAREL™ -sustained release drug for postoperative pain relief and reduced opiod usage	\$244,479.25	
Pacira Pharmaceuticals, Inc.	DepoMTX - sustained release drug for rheumatoid arthritis	\$124,187.58	\$61,706.39
Pain Therapeutics	PTI-721	\$111,513.00	\$132,966.24

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Pain Therapeutics Inc	PTI-421	\$116,870.00	\$127,609.24
Pain Therapeutics, Inc	PTI-320	\$244,479.24	
Pain Therapeutics, Inc	Remoxy	\$244,479.24	
Pain Therapeutics, Inc	Alzheimer's Treatment	\$11,745.00	\$31,918.50
Pain Therapeutics, Inc.	PTI-301	\$244,479.24	
Pain Therapeutics, Inc.	PTI-221	\$117,643.00	\$126,836.24
Pain Therapeutics, Inc.	PTI-DX304	\$38,630.00	\$21,335.00
Pain Therapeutics, Inc.	PTI-609	\$244,479.24	
Pain Therapeutics, Inc.	PTI-303	\$244,479.24	
Panorama Research, Inc	Inotropic Antibodies	\$40,293.65	\$59,329.81
Panorama Research, Inc	Novel Multiplex Assay for Biomarkers of Alzheimer's Disease	\$5,988.08	\$72,399.00
Panorama Research, Inc	Novel Therapy for Pemphigus Vulgaris by Treatment with a Cholinergic Agonist	\$7,193.96	\$77,883.00
Panorama Research, Inc	Novel TACE Inhibitors for Breast Cancer Therapy	\$61,536.98	\$24,611.43
Panorama	Novel Therapy for Diabetic	\$168,624.62	\$69,362.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Research, Inc	Complications Using RAGE-Fc		
Panorama Research, Inc	Kinetic Assembly of Bispecific Antibodies	\$76,103.69	
Panorama Research, Inc	Myocardial Repair by Targeted Stem Cells	\$244,479.25	
Panorama Research, Inc	Multiplex Biomarkers for Prostate Cancer	\$49,054.35	\$38,586.50
Panorama Research, Inc.	Anti-inflammatory Nicotinic Agonists for Therapy of Ulcerative Colitis	\$34,111.23	\$147,003.00
Paracor Medical, Inc.	HeartNet System	\$244,479.24	
Parallel Synthesis Technologies Inc	Multiplex Serodiagnostic Test for Chagas Disease	\$244,479.25	
Pathologica, LLC	Pathologica	\$244,479.25	
Pathwork Diagnostics, Inc	Tissue of Origin Test	\$244,479.24	
Paul H Chen	Corneal Epithelial Transplant Device-Jet Contact Lens	\$244,479.25	
Pavilion Medical Innovations LLC	Pavilion Reversible Vena Cava Filter	\$64,964.50	\$179,514.74
PaxVax Inc	PaxVax - Cholera Vaccine	\$93,760.50	\$150,718.75
PaxVax, Inc	PaxVax - influenza vaccines	\$244,479.25	
PaxVax, Inc	PaxVax - HIV Vaccine	\$83,323.00	\$161,156.25
PaxVax, Inc.	PaxVax - anthrax vaccine	\$244,479.25	
PEAK Surgical, Inc.	PEAK Plasmablade Improving Patient Treatment Outcomes	\$244,479.25	
Pearl Therapeutics, Inc.	PT003 - formoterol-glycopyrrolate combination HFA-MDI for COPD	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Pearl Therapeutics, Inc.	PT001- glycopyrrolate HFA-MDI for treatment of COPD	\$244,479.25	
Pearl Therapeutics, Inc.	PT010 - formoterol/glycopyrrolate/mometasone combination HFA-MDI for COPD	\$96,654.00	\$147,825.25
PENUMBRA INC	THE PENUMBRA EMBOLIZATION SYSTEM	\$244,479.25	
PENUMBRA, INC.	THE PENUMBRA SYSTEM	\$244,479.25	
Peregrine Pharmaceuticals Inc	Bavituximab for the treatment of Refractory of Non-small Cell Lung Cancer	\$244,479.25	
Peregrine Pharmaceuticals Inc	Bavituximab for the treatment of Non-Small Lung Cancer (Front-line Therapy)	\$244,479.25	
Peregrine Pharmaceuticals Inc	Bavituximab for the treatment of patients Co-infected with HCV-HIV	\$238,783.50	\$5,695.75
Peregrine Pharmaceuticals, Inc	Cotara for the treatment of Glioblastoma Multiforme (GBM)	\$244,479.25	
Perseid Therapeutics LLC	BA	\$96,183.50	\$148,295.74
Perseid Therapeutics LLC	PTLA	\$37,850.50	\$206,628.74
Perseid Therapeutics LLC	Maxy-4	\$244,479.24	
Phage Pharmaceuticals	Therapeutic treatment of chronic tympanic membrane perforation by fibroblast growth factor.		\$244,479.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
PharmacoFore, Inc.	Tamper-and-Abuse-Resistant Hydromorphone Prodrug	\$244,479.25	
PharmacoFore, Inc.	PF0713: Safer IV Sedative-Hypnotic Agent	\$244,479.25	
PharmacoFore, Inc.	PF03 MPAD: Multi-Pill Abuse-Deterrent (MPAD) Hydromorphone Prodrug	\$213,354.73	\$31,124.52
Pharmaco-Kinesis Corporation	Metronomic Biofeedback Pump (MBP)	\$244,479.25	
Pharmacyclics Inc	Factor VIIa Inhibitor PCI-27483	\$244,479.25	
Pharmacyclics Inc	HDAC Inhibitor PCI-24781	\$244,479.25	
Pharmacyclics, Inc.	Btk Inhibitor PCI-32765	\$244,479.25	
Pherin Pharmaceuticals, Inc.	PH80	\$102,708.25	
Pherin Pharmaceuticals, Inc.	PH94B	\$131,068.25	
PHILOMETRON INC	VENOUS STASIS ULCER THERAPY MANAGEMENT SYSTEM	\$68,413.00	\$28,590.00
PhiloMetron, Inc	Weight Management System	\$60,216.00	\$106,989.00
PhiloMetron, Inc.	Integrated Vascular Access stenosis Mitigation System	\$27,258.50	\$74,813.50
Phoenix Biosystem Inc	Rapid POC STD Molecular Diagnostics	\$143,760.00	\$100,719.25
PhotoThera, Inc.	NeuroThera Laser System and TLT for the Treatment of Acute Ischemic Stroke	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
PIKAMAB Inc	Development and Commercialization of ADCC Therasight™.		\$244,479.25
PIKAMAB, Inc.	Development and Commercialization of Lupus Therasight		\$244,479.25
Piper Medical dba Odyssey Medical Technologies	Portable, battery operated, low cost (<\$500), Tactical CO2 Asthma and COPD Respiratory Therapy Device	\$22,262.00	\$11,975.00
Piper Medical dba Odyssey Medical Technologies	Quixie Cancer Drug Inhalation Therapy	\$8,415.50	\$9,547.50
Planet Biotechnology Inc	TEM-8Fc, An Anti-Cancer Immunoadhesin Made in Plants	\$13,948.50	\$16,850.00
Planet Biotechnology Inc	PBI-220 A Novel Therapy for Inhalational Anthrax	\$244,479.24	
Planet Biotechnology Inc	PBI-230, a therapy for treatment of botulism	\$135,834.50	\$108,644.74
PlenSat, Inc.	Digestible Balloon Obesity Treatment	\$216,951.50	\$27,527.74
Plexxikon Inc	Small molecule inhibitors of CRAF kinase for the treatment of polycystic kidney disease	\$244,479.25	
Plexxikon Inc.	Small molecule inhibitors of Fms receptor tyrosine kinase for the treatment of cancers	\$244,479.25	
Plexxikon Inc.	Small molecule inhibitors of BRAF kinase for treatment of cancers	\$244,479.25	
PneumRx, Inc.	RePneu ® Lung Volume	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Reduction Coil (LVRC) System		
Poincare Systems Inc	AccuSwept MIS Surgical Device		\$97,673.50
Portaero, Inc.	Trans-Thoracic Wall Assisted Therapeutic Drug Administration for Emphysema	\$244,479.25	
Portola Pharmaceuticals Inc	Elinogrel - Novel direct-acting competitive reversible P2Y12 inhibitor	\$244,479.25	
Portola Pharmaceuticals Inc	PRT061103	\$244,479.25	
Portola Pharmaceuticals, Inc	PRT062607-Novel, oral Syk-specific inhibitor	\$244,479.25	
Portola Pharmaceuticals, Inc	Betrixaban-Novel, oral, direct, Factor Xa inhibitor	\$244,479.25	
Portola Pharmaceuticals, Inc	PRT062070 - Novel, oral Syk-Jak kinase inhibitor	\$36,720.50	\$207,758.75
Portola Pharmaceuticals, Inc.	PRT064445 - Universal Factor Xa Antidote	\$244,479.25	
Posit Science Corporation	Plasticity-based Adaptive Cognitive Remedation (PACR)	\$244,479.25	
Praevium Research Inc	Ultra-High Speed and Ultra-broadband Sources for Optical Coherence Tomography	\$148,096.50	\$71,230.50
Precise Light Surgical	Acute Ischemic Stroke treatment with localized tPA delivery	\$29,710.00	\$214,769.25
Prediction Sciences LLC	Theranostic for ischemic stroke	\$244,479.24	
PRESIDIO	NS5B		\$244,479.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
PHARMACEUTICALS, INC			
PRESIDIO PHARMACEUTICALS, INC	NS5A	\$244,479.25	
Proacta	HSMKI development program	\$244,479.24	
Proacta, Inc.	PR104 development program	\$244,479.24	
Probactive Biotech, Inc	Antibody targeted Liposomal Etoposide (provisionally referred as "ATLE")	\$242,539.52	\$1,939.72
Probactive Biotech, Inc.	Radioimmunotherapy (RIT) Iodine - 131 Antinuclear Antibody (ANA)	\$244,479.24	
Prodo Laboratories Inc.	Human Islet Expansion	\$141,723.83	\$102,755.42
Prodo Laboratories Inc.	Human Islets For Research Resourcing & Distribution	\$134,137.63	\$110,341.62
Progentech-USA, Inc.	Progentech Integrated Molecular Diagnostic System	\$244,479.25	
Prognosys Biosciences Inc	Technology for Mapping Protease Activity Across the Proteome	\$16,693.50	\$68,236.50
Prognosys Biosciences, Inc.	Technology for Multiplexed Profiling of Protease Activity		\$103,875.50
Prognosys Biosciences, Inc.	Technology for Mapping Protein Kinase Activity Across the Proteome		\$66,428.50
Prolynx LLC	Macromolecule-Drug Conjugate Delivery Platform	\$65,330.00	\$179,149.24
ProSci Inc	Novel HIV/AIDS Vaccine Project	\$244,479.25	
Prosetta Bioconformatics Inc	BioConformatics	\$149,267.91	\$95,211.34

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Prosetta Bioconformatics, Inc	Anti-Virals	\$244,479.25	
PROTELIX, INC. d/b/a PROTELICA	A universal bioinformatics based Antibody Mimic Platform for the Discovery and Development of Novel Therapeutics	\$244,479.25	
Proteus Biomedical, Inc.	Chipskin Technology	\$244,479.25	
Proteus Biomedical, Inc.	The Raisin system	\$244,479.25	
Protigen Inc	Development of Nephrlin for the treatment of diabetic complications and cancer	\$126,311.00	\$118,168.24
Proveri Inc.	Prostate Cancer Diagnostics and Prognostics	\$74,967.50	\$169,511.74
Providence Medical Technology, Inc	DTRAX Delivery System	\$244,479.24	
Psylin Neurosciences Inc	Peptid Therapeutics for the treatment of Schizophrenia	\$244,479.25	
PSYLIN NEUROSCIENCES, INC.	Peptide therapeutics for the treatment of depression	\$244,479.24	
PULMONX INC	Chartis Pulmonary Assessment System and Zephyr Endobronchial Valve for Emphysema	\$244,479.25	
QLT Plug Delivery Inc	Novel Punctal Plug Sustained Release Drug Delivery System - Ophthalmics	\$244,479.24	
QUALIGEN INC	ALPHA GST	\$31,531.00	\$182,238.50

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
QuantaLife, Inc.	Rapid low-cost MRSA diagnostics	\$244,479.25	
Quark Pharmaceuticals, Inc	QPI-1007 for non-arteritic ischemic optic neuropathy (NAION)	\$244,479.24	
Quark Pharmaceuticals, Inc	QPI-1002 (I5NP) for Delayed Graft Function (DGF) in Kidney Transplant	\$244,479.24	
Quark Pharmaceuticals, Inc.	QPI-1002 (I5NP) for Acute Kidney Injury (AKI)	\$244,479.24	
Quexta, Inc	Low inventory, low cost eyeglasses	\$80,950.50	\$93,750.00
Quiescence Medical, Inc	Pharyngeal Stent to Treat Sleep Apnea	\$53,200.00	\$191,279.25
RadioRx, Inc	RRx-001	\$244,479.25	
Raptor Discoveries Inc	WntTide, a peptide targeting LRP6 positive breast cancers	\$83,078.00	\$137,450.00
Raptor Discoveries Inc.	HepTide, a drug targeting peptide for the potential treatment of liver disease	\$111,027.00	\$7,500.00
Raptor Therapeutics Inc	DR Cysteamine for the potential treatment of Huntington's Disease	\$220,167.50	\$24,311.75
Raptor Therapeutics Inc	DR Cysteamine for the potential treatment of non-alcoholic steatohepatitis (NASH)	\$215,299.50	\$29,179.75
Raptor Therapeutics Inc	DR Cysteamine for the potential treatment of Cystinosis	\$244,479.25	
Receptos Inc	Inhibition of lung inflammation associated with influenza viral infection	\$160,570.00	\$83,909.25
Receptos Inc	Small Molecule GLP1R Agonist Program	\$103,397.00	\$141,082.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Reduction Technologies Inc.	Novel Therapy for the Non-Fusion Treatment of Adolescent Idiopathic Scoliosis	\$210,119.36	\$34,359.89
Redwood Bioscience Inc	Universal Carrier Scaffolds for Drug Delivery	\$58,352.96	\$186,126.28
Regulus Therapeutics Inc	Novel microRNA therapeutics for treatment of hepatitis C viral infection	\$244,479.25	
Regulus Therapeutics, Inc	Novel microRNA therapeutics for treatment of fibrosis	\$244,479.25	
Relevare Pharmaceuticals Inc	Combination therapy for the treatment of chronic neuropathic pain conditions	\$244,479.25	
Relia Diagnostic Systems, Inc	Relia Diagnostic Systems, Inc	\$244,479.25	
Relypsa, Inc.	RLY 106 polymer bile acid sequestrant ("BAS") for lowering cholesterol and glucose levels	\$244,479.24	
Relypsa, Inc.	RLY 5016 Potassium Management	\$244,479.24	
Renova Therapeutics, Inc	Gene Therapy Transfer for Clinical Congestive Heart Failure	\$119,388.50	\$125,090.75
Renovorx	An Endovascular Catheter for Targeted Delivery of Drug/Cells to the Pancreas	\$6,250.00	\$22,750.00
Replenish Inc	Implantable Anterior MicroPump System for Glaucoma	\$244,479.25	
Replenish Inc	Implantable Ophthalmic MicroPump for Retina Drug injections	\$244,479.25	
Resolution Biomedical Inc.	ClearPrep Cytology Solution and Test Kit	\$25,106.07	\$219,373.18
Response Genetics Inc	Genetic Profile Product Development	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Retina Pharma Inc	To develop an Anti -Angiogenic Therapeutic for Wet Age related Macular Degeneration (AMD).		\$244,479.25
RetroVirox, Inc	Novel therapies for the treatment of HIV infection	\$35,914.69	\$171,794.75
REVA Medical Inc	Peripheral Biodegradable Drug Delivery Stent		\$244,479.25
REVA Medical, Inc	REVA's Bioresorbable Drug-Eluting Stent	\$244,479.25	
REVA Medical, Inc.	Structural Alloplastic Bone Graft (SABG)	\$127,415.50	\$29,161.00
REVA Medical, Inc.	Bioresorbable, Radiopaque Embolic Microspheres (BREMS)	\$60,250.00	\$8,357.50
Revanche Therapeutics, Inc.	RT001 Topical Botulinum Toxin A for Plantar Fasciitis	\$244,479.25	
Revascular Therapeutics Inc	Revascular Chronic Total Occlusion System	\$244,479.25	
Reverse Medical Corporation	ACUTE STROKE INFUSION THROMBECTOMY CATHETER PROJECT	\$244,479.24	
ReVision Therapeutics Inc	Development of Fenretinide for the Treatment of age-related macular Degeneration		\$244,479.24
REVIVA PHARMACEUTICALS INC	RP5000 PROGRAM FOR SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDERS	\$146,982.00	\$97,497.25
Ridge Diagnostics, Inc.	Blood-based tests for the diagnosis and monitoring of Neuropsychiatric disorders	\$211,457.00	\$33,022.24
Rigel Pharmaceuticals Inc	Syk Inhibitors with Improved Specificity for the Treatment of Rheumatoid Arthritis	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Rigel Pharmaceuticals Inc	Janus Kinase 2(JAK2) Inhibitor for the Treatment of Myeloproliferative Neoplasms	\$165,761.00	\$65,927.00
Rigel Pharmaceuticals Inc	PKC-theta inhibitors for the Treatment of Multiple Sclerosis	\$244,479.25	
RIGEL PHARMACEUTICALS INC	Adiponectin Mimetics for the Treatment of Type 2 Diabetes	\$244,479.25	
Rigel Pharmaceuticals, Inc	Spleen tyrosine kinase (Syk) Inhibitors for Treating Non-Hodgkins Lymphoma	\$244,479.25	
Rigel Pharmaceuticals, Inc	JanUS Kinase 1/3 inhibitors for the Treatment and Prevention of Organ Transplant Rejection	\$244,479.25	
Rigel Pharmaceuticals, Inc.	Inhibitors of Axl Kinase for the Treatment of Metastatic Disease	\$164,647.00	\$8,356.50
Rigel Pharmaceuticals, Inc.	Novel Treatments for Muscle Wasting	\$244,479.25	
Rigel Pharmaceuticals, Inc.	Fostamatinib disodium (FosD), an oral syk inhibitor for treating Rheumatoid Arthritis (RA)	\$244,479.25	
Rigel Pharmaceuticals, Inc.	Topical JAK 1/3 Inhibitors for the Treatment of Psoriasis	\$91,784.00	\$152,695.25
Ritter Pharmaceuticals, Inc.	RP-G28 A Novel Treatment of Lactose Intolerance	\$244,479.25	
Roxro Pharma, Inc	SPRIX	\$244,479.24	
Ruga Corporation	Targeted Cancer drug for Multiple Myeloma		\$108,990.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
RUGA Corporation	Cancer treatment targeting glucose metabolism		\$244,479.25
Sadra Medical Inc.	Lotus™ Valve System for transcatheter aortic valve replacement therapy	\$244,479.25	
SafeLife Corp	Antimicrobial Catheters	\$194,891.50	\$49,587.75
SafeLife Corp.	Antimicrobial Respirator	\$244,479.25	
SanBio, Inc.	SB623 Cell Therapy for the Recovery of Function from Disability Caused by Ischemic Stroke	\$244,479.25	
Sangamo BioScience, Inc.	SB-313-xTZ for Recurrent or Refractory Glioblastoma Multiforme (GBM)	\$244,479.25	
Sangamo BioSciences, Inc	SB-728-T for Human Immunodeficiency Virus/Acquired immunodeficiency Syndrome (HIV/AIDS)	\$244,479.25	
Sangamo BioSciences, Inc.	SB-509 for Diabetic Peripheral Neuropathy(DPN)	\$244,479.25	
Sangamo BioSciences, Inc.	SB-509 for Amyotrophic Lateral Sclerosis (ALS)	\$244,479.25	
Sanovas, Inc.	Sanovas Interventional Drug Therapy	\$244,479.25	
SanRx Pharmaceuticals Inc	Dipterinyl Calcium Pentahydrate (DCP)	\$14,847.50	\$229,631.74
Sapheon Inc	Sapheon Closure System	\$244,479.24	
SARCODE CORPORATION	SARcode SAR 1118 Ophthalmic Solution	\$244,479.25	
Satiety, Inc	TOGA	\$244,479.25	
Satiogen	Colon/Rectum targeted GPBAR1	\$51,039.00	\$50,829.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Pharmaceuticals Inc	agonists for the treatment of obesity		
SATIOGEN PHARMACEUTICALS, INC	AN ORAL, SMALL MOLECULE INHIBITOR OF THE ASBT FOR THE TREATMENT OF OBESITY	\$114,216.00	\$71,488.00
SBIO Inc.	SBIO SB1518 JAK2/FLK3 Inhibitor	\$244,479.24	
Scharp Technologies, Inc	Burn and Wound Dressing Treatment		\$244,479.25
SciClone Pharmaceuticals, Inc	SciClone Oral Mucositis	\$244,479.25	
SciClone Pharmaceuticals, Inc	SciClone Hepatitis C	\$244,479.25	
SciClone Pharmaceuticals, Inc.	SciClone Vaccine Enhancer	\$221,306.50	\$23,172.75
SciClone Pharmaceuticals, Inc.	SciClone Oncology		\$244,479.25
SCIGENE CORPORATION	Automated genetic analysis system for human disease	\$216,842.50	\$27,636.74
SCRIPPS LABORATORIES, INC.	DIABETES - LOW COST HEMOGLOBIN A1C METER AND TEST	\$244,479.24	
SeaChange Pharmaceuticals, Inc	Drug Repurposing using Chemoinformatic Links		\$48,051.61
Sechrist Industries Inc	Technological Advancements	\$172,045.00	\$72,434.25
Sechrist	Utility of Large Hyperbaric	\$203,864.00	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Industries Inc	Chamber		
SEKRIS Corporation	Pro-Apoptotic DNA Vaccination for the treatment of type 1 diabetes		\$244,479.25
Selby Life Science LP	Antiangiogenic Surrobodyes™ for the treatment of multiple cancers	\$208,891.58	\$35,587.67
Selby Life Sciences LP	Surrobodyes [tm] for the treatment of Multiple Solid Tumor Cancers	\$219,832.84	\$24,646.41
Selby Life Sciences, LP	Surrobodyes™ for the Treatment of Breast and Other Cancer	\$244,479.25	
Selby Life Sciences, LP	Passive Immunity and Therapeutic Treatment of Seasonal Influenza	\$106,735.67	\$137,743.58
Selby Life Sciences, LP	Proapoptotic Surrobodyes™ for the Treatment of Multiple Cancers	\$222,872.70	\$21,606.54
Selby Life Sciences, LP	Surrobodyes™ for the Treatment of Diabetes and Obesity	\$196,036.18	\$48,443.07
Selexagen Therapeutics, Inc	Hedgehog Pathway Inhibitor for the Treatment of Cancer	\$27,108.48	\$217,370.77
Selexagen Therapeutics, Inc.	Oncogenic BRAF Kinase (V600E) Inhibitor for the treatment of cancer	\$2,087.29	\$242,391.96
Senomyx, Inc.	Sweet Enhancer Program	\$244,479.25	
Sensor Innovations, Incorporated (DBA Sensorin)	Improved diabetes therapeutics administration via novel self-calibrating glucose sensor	\$244,479.24	
SentreHEART, Inc	PLACE: Permanent Left Auricular Closure & Exclusion in Patients with Atrial Fibrillation	\$244,479.24	
Sequel Pharmaceuticals, Inc	K201: a novel treatment for Atrial fibrillation	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Sequenom, Inc	Age-related macular degeneration test		\$244,479.25
SEQUENOM, INC.	PRENATAL TESTING FOR TRISOMY 21 (DOWNSYNDROME)	\$244,479.25	
Sequent Medical Inc	Woven EndoBridge Cerebral Aneurysm Embolization Device (WEB)	\$244,479.25	
Sialix Inc (formerly Gc-Free Inc)	N-glycolyneuraminic Acid in the Pathogenesis and Progression of Rheumatoid Arthritis	\$6,376.00	\$59,123.50
Sialix Inc (formerly Gc-Free Inc)	Detection of Non-Human Sialic Acid in Biotherapeutic Applications	\$52,127.50	\$42,714.50
Sialix, Inc (formerly Gc-Free, Inc.)	Neu5Gc-Glycan Arrays for Discovery and Validation of Human Cancer Biomarkers	\$28,370.50	\$86,694.50
Sierra Surgical Technologies Inc.	Minimally Invasive System	\$244,479.24	
Silk Road Medical Inc	FAST-CAS(Flow Altered Short Transcervical Carotid Artery Stenting) Research/Development	\$244,479.24	
Silver Lake Research Corporation	Rapid Diagnostic Test Kit for Urinary Tract Infections	\$73,817.51	\$145,222.90
Silver Lake Research Corporation	Development of Rapid Diagnostic test Kit for Methicillin-Resistant Staph. Aureus		\$53,665.12
Silver Lake Research Corporation	EAP-Derived Monoclonal Antibodies for Cancer Diagnostics by Immunohistochemistry	\$23,802.44	\$31,071.09
Silver Medical, Inc.	Intra-operative monitoring of stroke in high-risk patient populations	\$10,868.50	\$135,500.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Solulink, Inc	Highly multiplexed cancer biomarker assays.	\$41,622.00	\$155,749.50
SomaGenics, Inc	An RNA-based therapeutic for hepatitis C	\$244,479.25	
SomaGenics, Inc.	miR-ID, a novel diagnostic platform for microRNAs and other small RNAs	\$76,535.82	\$25,904.69
Somaxon Pharmaceuticals, Inc.	Silenor (doxepin hydrochloride), a pharmaceutical treatment for insomnia	\$244,479.25	
Sonexa Therapeutics, Inc.	ST101 Compound for Alzheimer's Disease	\$244,479.24	
Sorbent Therapeutics Inc	CLP(Cross Linked Polyelectrolyte)	\$244,479.24	
Sorrento Therapeutics, Inc	STI-MRSV		\$150,000.00
Sorrento Therapeutics, Inc.	STI-MRSA	\$195,089.50	\$49,389.74
Sotera Wireless, Inc.	ViSiMobile System	\$244,479.24	
Specialized Vascular Technologies, Inc	EndoCoat Drug-Eluting Stent	\$244,479.24	
Spectral Molecular Imaging, Inc	Early Melanoma Detection Device Using Hyperspectral Imaging	\$32,622.00	\$157,550.00
SpectraScience Inc	WavSTAT Optical Biopsy System-Inflammatory Bowel Disease-Cancer		\$202,308.50
SpectraScience, Inc	WavSTAT optical Biopsy System - Esophageal Cancer	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
SpectraScience, Inc.	LUMA Cervical Imaging System - FDA Post Approval Study	\$73,480.00	\$41,731.00
SPECTROS CORPORATION	NON-INVASIVE, TRANS-ABDOMINAL BROADBAND OXIMETER FOR EARLY-STAGE NEC DIAGNOSIS	\$79,006.00	\$108,375.00
Spectros Corporation	Real-Time Detection of Colon Ischemia During Abdominal Aortic Aneurysm Surgery	\$76,988.00	\$55,908.50
Spectros Corporation	ProstaFluor FDA Trail for Real-Time Margin Detection During Protatectomy	\$39,409.00	\$205,070.24
Spectros Corporation	Broadband Spectroscopic Localization of Breast Cancer	\$244,479.24	
Spectrum Pharmaceuticals Inc	Renazorb	\$244,479.25	
Spectrum Pharmaceuticals Inc	Zevalin	\$244,479.25	
Spectrum Pharmaceuticals, Inc.	Apaziquone	\$244,479.25	
Spectrum Pharmaceuticals, Inc.	Belinostat, a novel anti-cancer agent		\$244,479.25
SpinalMotion, Inc	Artificial Spinal Discs to Treat Back Pain More Effectively at Lower Cost than Spinal Fusion	\$244,479.24	
SpineAlign Medical Inc	VerteLift	\$244,479.25	
Spiracur Inc	SNaP	\$244,479.24	
Stategics, Inc	Small molecule erythropoietin mimetics for the treatment of	\$28,629.82	\$23,433.34

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	neurological disorders		
Stellar Biotechnologies, Inc	Diagnostic Immune Status Monitoring in Patients with Immunodeficiency	\$244,479.24	
STELLAR BIOTECHNOLOGIES, INC.	ENABLING ICH-S8 IMMUNOTOXICITY TESTING WITH KEYHOLE LIMPET HEMOCYANIN	\$244,479.25	
Stem CentRx, LLC	Identification and Therapeutic of Solid Tumor Cancer Stem Cells	\$244,479.25	
StemCells California Inc	HuCNS-SC Eye	\$244,479.25	
StemCells California, Inc.	HuCNS-SC Spinal Cord Injury	\$244,479.25	
StemCells California, Inc.	hLEC Project	\$244,479.25	
StemCells California, Inc.	HuCNS-SC Brain	\$244,479.25	
Stemcyte Inc	Chronic Spinal Cord Injury Treatment	\$244,479.25	
Stemcyte, Inc.	Chronic Stroke	\$157,177.50	\$87,301.75
Stemedica Cell Technologies, Inc.	Allogenic Mesenchymal Stem Cell Therapy Stroke in the USA	\$244,479.25	
Stephen J Peroutka MD PhD	Opioid Dose Reduction Taper Pack Device	\$4,805.00	\$120,100.10
STKR, Inc.	STKR QwikJect	\$143,516.50	\$100,962.75
String Therapeutics Inc	Creation of safe and effective PAP for development of immunotoxin for lupus		\$175,000.00
String Therapeutics Inc	Direct Intracranial administration of BMP-4 as Therapy Against		\$220,000.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Glioblastoma		
Stroma Medical Corporation	Iris Stroma Retraction and Depigmentation	\$106,917.10	\$137,562.15
Sunesis Pharmaceuticals, Inc	Development of voreloxin for the treatment of patients with acute myeloid leukemia	\$244,479.24	
Suneva Medical, Inc.	Artefill for the Treatment of HIV-Associated Lipoatrophy	\$2,000.00	\$242,479.25
SuperGen Inc	SGI-1776-PIM Kinase Inhibitor (an anti-cancer compound)	\$244,479.25	
Sutro Biopharma, Inc	Commercial Scale Cell-Free Production Enabling Novel Neutropenia Therapies	\$244,479.25	
SuviCa Inc.	Lead optimization and biomarker identification for novel anti-cancer therapies		\$102,500.00
Symor, Inc	Symthetic TGF-beta ligands for bone repair and diseases		\$244,479.24
Synedgen, Inc	Novel Therapeutics to Treat Bacterial Infections including Drug Resistant Bacteria	\$218,735.00	\$25,744.24
Synergogenesis Inc	MNC-1000	\$20,964.71	\$81,703.77
Synosia Therapeutics, Inc	Clinical development of SYN115: a new chemical entity for treating Parkinson's Disease (PD)	\$244,479.25	
Synosia Therapeutics, Inc.	Clinical development of SYN120: a new treatment for Alzheimer's disease (AD)	\$244,479.25	
Synthasome Inc	Therapeutic Delivery for Tendon Repair	\$244,479.25	
T F Instruments	Phase X-ray Diagnostic Imaging		\$222,000.00
Tacere Therapeutics,	Ocular (SMK-01/03)		\$244,479.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Inc.			
Tacere Therapeutics, Inc.	Hepatitis C (TT-034)	\$244,479.25	
TaiMed Biologics USA	Tamiphosphor for influenza infections	\$28,738.00	\$54,213.50
TaiMed Biologics USA	Ibalizumab for HIV-1 infections	\$244,479.24	
Talima Therapeutics, Inc	Terbinafine Micro Implant (TMI-358)	\$244,479.25	
Tandem Diabetes Care Inc.	T-Slim Infusion Pump - Diabetes	\$244,479.24	
Tandem Diagnostics, Inc	Non-invasive prenatal diagnosis of fetal genetic abnormalities	\$111,484.38	\$132,994.86
Taraxos, Inc.	Novel Topical Analgesic for Peripheral Neuropathy	\$39,623.11	\$57,500.00
Targeson Inc.	Diagnostic Test for Crohn's Disease	\$112,793.00	\$131,686.25
TARGETED MEDICAL PHARMA, INC	Novel Treatment for Sleep Disorders in the Elderly	\$244,479.25	
TARGETED MEDICAL PHARMA, INC	NEW THERAPY TO REDUCE SIDE EFFECTS OF PAIN DRUGS	\$244,479.25	
TARGETED MEDICAL PHARMA, INC.	A safe and effective treatment for Gulf War illness	\$244,479.25	
Telik, Inc	Phase 2 Randomized Clinical Trial of Telintra for Treatment of Severe Chronic Neutropenia.	\$208,368.00	\$36,111.24
Telik, Inc	Phase 2 Clinical trial of Telcyta for the treatment of Refractory Lymphoma & Multiple Myeloma	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Telik, Inc.	Phase2 Clinical Trial of Telintra® in Low to Intermediate-1 Risk Myelodysplastic Syndrome	\$244,479.24	
Telik, Inc.	Clinical Trial of Telintra® & Revlimid® in Patients with Myelodysplastic Syndrome (MDS).	\$213,536.50	\$30,942.74
Telik, Inc.	Development of a Novel Inhibitor of Aurora and VEGFR Kinases for the Treatment of Cancer.	\$244,479.24	
Tethys Bioscience Inc	Cardiovascular Event Prevention	\$244,479.25	
Tethys Bioscience, Inc.	PreDx Diabetes Risk Score	\$244,479.25	
Tethys Bioscience, Inc.	Diagnostics for the Prevention and Management of Cardiometabolic Disease		\$142,933.00
TheraCell Inc.	Stem Cell Separation and Gene Transfection Device'	\$137,527.00	\$106,952.25
THERACOS INC	THR-1442	\$244,479.24	
Theracos, Inc	THR-4450	\$244,479.24	
Therapeutics Clinical Research, A Medical Corporation	Carbazole	\$11,551.92	\$175,760.76
Therapeutics Clinical Research, A Medical Corporation	Super-Potent Corticosteroid Lotion	\$49,392.00	\$195,087.25
Therapheresis, Inc	TheraSystem I	\$130,545.00	\$113,934.25
Theravance Inc	A novel approach to the	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	management of congestive heart failure		
Theravance Inc	Improving the quality of life for patients with opioid-induced constipation	\$244,479.24	
Theravance Inc	A novel approach to the management of uncontrolled hyper tension	\$244,479.24	
Theravance Inv	Novel symptomatic and disease approach to the treatment of Alzheimer's Disease	\$244,479.24	
Theravance, Inc	A novel treatment designed to cure Hepatitis C and prevent hepatocellular carcinoma	\$244,479.24	
Theravance, Inc	Novel bifunctional muscarinic antagaonist-beta2 agonist for respiratory disorders	\$219,000.00	\$25,479.24
Theravance, Inc	A novel oral therapy for the treatment of pulmonary arterial hypertension	\$244,479.24	
Theravance, Inc	A novel lung-selective muscarinic antagonist for chronic obstructive pulmonary disease	\$244,479.24	
Theravance, Inc	A Novel analgesic optimized to reduce or replace opioid-based therapies for chronic pain	\$244,479.24	
Theravance, Inc.	Novel approach to the treatment of resistant Gram-positive bacterial infections	\$244,479.24	
Theravance, Inc.	Novel approaches for the tratment of Gram-negative bacterial infections	\$244,479.24	
THERAVIDA INC	THVD-102	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Theregen Inc.	Clinical development of Anginera™ for the Treatment of Refractory Angina/Ischemia	\$244,479.25	
Therinject LLC	Sustained Release Anti-Cancer Immuno-therapeutic Formulation Development	\$32,596.00	\$7,664.00
Thermogenesis Corp.	Res-Q 60 BMA	\$244,479.25	
TherOx, Inc.	SSO2 Therapy for the Treatment of Heart Attack	\$244,479.24	
Threshold Pharmaceuticals Inc	Hypoxia-Activated prodrug technology platform for cancer drug discovery and development	\$244,479.25	
Threshold Pharmaceuticals, Inc.	Clinical Development of Hypoxia Activated Prodrug TH-302 for the Treatment of Cancer	\$244,479.24	
Tioga Pharmaceuticals, Inc	Asimadoline for the Treatment of Irritable Bowel Syndrome	\$244,479.24	
TLC Biopharmaceuticals, Inc.	Lipotecan® TLC388 Anti-Tumor Therapeutic	\$241,979.50	\$2,499.74
TM3 Therapeutics LLC	A novel method of generating Therapeutic HIV vaccines	\$39,844.50	\$204,634.75
TM3 Therapeutics LLC	A respiratory prophylactic vaccine	\$29,883.50	\$195,422.00
TM3 Therapeutics LLC	A novel method of generating fully human monoclonal antibody therapeutics	\$29,883.50	\$158,500.00
Tocagen Inc.	Toca 511 with 5-FC to Significantly Improve Glioblastoma Multiforme Cancer Patient Survival	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Topica Pharmaceuticals, Inc	Development of a Novel Antifungal, Luliconazole, for Onychomycosis	\$244,479.25	
Tosk, Inc	TK-112690 for the Prevention of Cancer Chemotherapy Induced Mucositis	\$244,479.24	
Tosk, Inc.	TK-115339 for the Prevention of Chemotherapy Induced Cardiotoxicity	\$95,220.35	\$149,258.90
Tragara Pharmaceuticals Inc	Capoxigem (apricoxib, TG01) an Oral COX-2 Inhibitor for the Treatment of Cancer	\$244,479.24	
Tragara Pharmaceuticals, Inc	TG02, an Oral Multi-kinase Inhibitor for the Treatment of Cancer	\$244,479.24	
Transcend Medical Inc	Drug-Eluting Microstent for Glaucoma Treatment	\$244,479.25	
Transcept Pharma, Inc	INTERMEZZO	\$244,479.25	
Transdel Pharmaceuticals, Inc.	Efficacy and Safety of Ketoprofen Cream in the Treatment of Acute Pain	\$244,479.25	
Transpose Medical LLC	UGIB Therapy		\$147,550.00
Transvivo, Inc.	OMNI-OA	\$244,479.25	
Traversa Therapeutics, Inc	Development of the PTD-DRBD delivery technology for siRNA drug therapies	\$244,479.25	
Traversa Therapeutics, Inc	Development of RNA interference-based drug candidates for human brain cancer	\$243,868.00	\$611.25
Trellis Bioscience, LLC	Development of a human-derived antibody to prevent maternal-fetal transmission of CMV		\$244,479.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Trellis Bioscience, LLC	Development of a human-derived antibody for pandemic influenza with broad strain efficacy		\$244,479.25
TriAct Therapeutics, Inc.	TT-100		\$222,500.00
Trillium Engineering Inc	Image-guided Liver Tumor Ablation using Internal Energy (Vapor)	\$34,517.50	\$82,500.00
Trius Therapeutics, Inc.	Torezolid research & Development	\$244,479.24	
TriVascular, Inc	TriVascular's Ovation™ Abdominal Stent Graft System(Ovation™ /ASGS)	\$244,479.25	
TriVascular, Inc.	TriVascular's Thoracic Stent-Graft System	\$244,479.25	
Ultrawave Labs	UltraWave Imaging Technology	\$62,747.49	\$181,731.75
Universal Stabilization Technologies Inc	Thermostable Rabies Vaccines for Oral Delivery	\$61,365.00	\$131,694.00
Universal Stabilization Technologies Inc.	Thermostable Measles Vaccines for Pulmonary Delivery	\$28,750.00	
US Biotest, Inc	Progenitor Cell Engraftment	\$129,384.10	\$115,095.14
US Biotest, Inc	Treatment of Multiple-Cytopenias with TXA127	\$244,479.24	
US Biotest, Inc	Treatment of Acute Respiratory Distress Syndrome with TXA127.		\$214,005.55
USGI Medical, Inc	Development of Incisionless Operating Platform and procedure for the treatment of obesity	\$244,479.25	
Valent	VAL-083	\$12,579.50	\$231,899.74

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Technologies LLC			
Valentx, Inc	ENDO BYPASS SYSTEM	\$244,479.25	
Vascular Biosciences	CAR Peptide for Targeted Drug Delivery	\$66,876.00	\$115,000.00
Vascular Designs, Inc.	IsoFlow Ainfusion Catheter	\$158,850.50	\$85,628.75
Vascular Imaging Corporation	Intravascular ultrasound steerable imaging guidewire	\$244,479.24	
VasoNova, Inc.	VasoNova-VPS	\$244,479.25	
Vaxart Inc	Pediatric formulation for oral vaccines	\$38,704.50	\$88,505.00
Vaxart Inc	Vaccine for Venezeulan equine encephalitis	\$157,061.00	\$87,418.25
Vaxart Inc	Vaccine for Herpes Simplex Virus type 2	\$16,366.00	
Vaxart Inc	Vaccine to prevent pandemic avian influenza	\$92,701.50	\$151,777.75
Vaxart Inc	Oral-delivery vaccine for seasonal influenza	\$42,823.00	\$41,095.00
Vaxion Therapeutics, Inc.	Commercialization of a novel, minicell-based, nano-sized targeted drug and RNAi delivery platform technology	\$117,783.00	\$126,696.24
Velomedix Inc	Novel Automated Peritoneal Lavage System for Controlled Induction of Therapeutic Hypothermia	\$244,479.25	
VentiRx Pharmaceuticals Inc	TLR8 Agonist (VTX-2337): Targeted Novel Immunotherapy for Multiple Oncology Indications	\$244,479.24	
VentiRx	TLR8 Agonist (VTX-1463):	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Pharmaceuticals, Inc.	Novel Immunomodulatory Agent for Allergic Rhinitis and Asthma		
Veracyte, Inc	Molecular profiling of thyroid nodules to determine benign or malignant cancer	\$244,479.25	
Veracyte, Inc.	Lung Nodule Genomic Marker Panel Test	\$24,810.00	\$122,442.00
Vermillion Inc	A novel diagnostic test for the diagnosis of early stage ovarian cancer (OVA2)		\$244,479.25
Vermillion Inc	A novel diagnostic test for the diagnosis of peripheral artery disease (PAD)		\$244,479.25
Vertos Medical, Inc	Vertos mild for Lumbar Spinal Stenosis	\$244,479.25	
VIA PHARMACEUTICALS, Inc	VIA-2291	\$244,479.25	
ViaCyte, Inc	Cell Therapy for Diabetes	\$244,479.25	
Vical Incorporated	Allovectin-7	\$244,479.24	
Vical Incorporated	TransVax	\$244,479.24	
Virobay Inc	Preclinical and Clinical Development of Cathepsin S inhibitor VBY-8911	\$244,479.25	
VIROBAY, INC.	Clinical Development of Cathepsin B Inhibitor VBY-376 for Liver Fibrosis	\$244,479.25	
Virogenics Inc	A novel Immune Modulator/Adjuvant for HIV Vaccines	\$85,080.50	\$16,544.50
Virogenics, Inc	FIV Vectors for Treatment of Hemophilia A		\$191,188.50

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
VisionCare Ophthalmic Technologies Inc	IMT Project #002	\$244,479.25	
Vital Therapies Inc	ELAD Bioartificial Liver	\$244,479.24	
Vitalea Science Inc	A finger-prick medical diagnostic for vitamin B12 malabsorption: An early intervention tool	\$219,682.44	\$24,796.80
VITAPATH GENETICS, INC	SPINA BIFIDA PREVENTION ASSAY	\$244,479.24	
VitaPath Genetics, Inc.	Cleft Palate Prevention Assay	\$244,479.24	
VIVUS, INC.	Qnexa	\$244,479.25	
VM Discovery, Inc	Preclinical Development of VMD-902 for Chronic Neuropathic Pain	\$225,743.84	\$18,735.40
Voyage Medical, Inc.	Cardiac Ablation Under Direct Visualization	\$244,479.25	
Voyage Medical, Inc.	Direct Visualization Cardiac Catheter for Transseptal Puncture and Drug Delivery IRIS™	\$244,479.25	
WaferGen Biosystems Inc.	SmartChip Genetic Analysis for Molecular Identification of Disease States & Therapy Selection	\$244,479.25	
Wave 80 Biosciences, Inc.	Molecular Diagnostic Assays and Instrumentation for HIV Viral Load Measurement	\$244,479.25	
Wintherix, LLC	Wnt pathway inhibitor drug for epithelial and leukemic cancers	\$244,479.24	
Wiseman Research Initiatives LLC	SV-BR-1-GM, a Whole-Cell Vaccine to Treat Various Types of Advanced Cancer	\$40,378.50	\$20,189.50
XDX, Inc	XDx Lupus Molecular	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Diagnostics		
XDX, Inc.	XDx AlloMap: Molecular Diagnostic for Heart Transplant Acute Cellular Rejection	\$244,479.25	
Xencor Inc	Development of biosuperior antibodies with extended half-life	\$244,479.25	
XENCOR INC	Clinial development of XmAb5574 an antibody treating Chronic Lymphocytic Leukemia	\$244,479.25	
XENCOR, INC	Clinical development of XmAb2513, a therapeutic antibody treating Hodgkin Lymphoma	\$244,479.25	
XENCOR, INC.	Clinical development of XmAb5871, an antibody treating Lupus and other diseases	\$244,479.25	
XenoPort, Inc	XP21279 - A Transported Prodrug of L-Dopa for the treatment of Parkinson's Disease	\$244,479.25	
XenoPort, Inc.	Arbaclofen Placarbil, or AP - A Transported Prodrug of R-baclofen	\$244,479.25	
Xoft Inc	Electronic brachytherapy for the treatment of Gynecological Cancers	\$244,479.25	
Xoft, Inc	Electronic Brachytherapy for the Treatment of Breast Cancer	\$244,479.25	
XOMA Ltd	XOMA Monoclonal Antibody Therapeutics for the Treatment of Oncologic Diseases	\$244,479.24	
Xoma Ltd	XOMA's Heptavalent Anti-Botulinum Toxin Monoclonal Antibody Program	\$244,479.24	
XOMA Ltd	XOMA Monoclonal Antibody	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Therapeutics for the Treatment of Metabolic Diseases		
Xoma Ltd	XOMA 052, Gevokizumab, Anti-IL 1Beta, Anti-inflammatory therapeutic monoclonal antibody	\$244,479.24	
Zacharon Pharmaceuticals, Inc	Sensi-Pro Diagnostic for the Mucopolysaccharidoses (MPS)	\$219,911.00	\$24,568.24
Zacharon Pharmaceuticals, Inc	Development of ZP2571: The first inhibitor of 6-O sulfation of heparan sulfate for cancer	\$244,479.24	
Zacharon Pharmaceuticals, Inc.	Development of AP10295: A novel ganglioside inhibitor for the treatment of cancer	\$244,479.24	
Zacharon Pharmaceuticals, Inc.	ZP2345: The First inhibitor of 2-O sulfation of heparan sulfate for the Mucopolysaccharidoses	\$181,546.50	\$62,932.74
Zenobia Therapeutic, Inc	Discovery of inhibitors of G2019S LRRK2 kinase for the treatment of Parkinson's disease	\$31,630.00	
Zenobia Therapeutics, Inc.	Discovery of inhibitors of caspase 6 kinase for the treatment of Huntington's disease	\$12,500.00	
Zogenix Inc	DosePro	\$244,479.25	
Zogenix, Inc.	ZX002	\$244,479.25	
ZOGENIX, INC.	Sumavel DosePro	\$244,479.25	
Zosano Pharma, Inc.	Novel PTH Microprojection System for improved treatment of severe osteoporosis	\$244,479.25	
ZYDX. Inc	Prostate Cancer Multi-Analyte Diagnostic Test		\$46,100.00
Zyomyx, Inc	A novel CD4 point-of-care diagnostic test for HIV monitoring	\$244,479.24	

Colorado \$22,418,899.79

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Accelr8 Technology Corporation	BACcel Rapid Diagnostic	\$244,479.24	
Actium Biosystems, LLC	Electromagnetic radio frequency excitation of nanoparticles for the external, non-invasive treatment of cancer via physical means.		\$244,479.25
Allos Therapeutics, Inc	Pralatrexate for the Treatment of Relapsed/Refractory Cutaneous T-cell Lymphoma (CTCL)	\$244,479.24	
Allos Therapeutics, Inc	Pralatrexate for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (NHL)	\$244,479.24	
Allos Therapeutics, Inc	Pralatrexate as treatment for urinary bladder transitional cell carcinomas (TCCs).	\$244,479.24	
Allos Therapeutics, Inc	Pralatrexate for the Treatment of Advanced Non-small Cell lung Cancer (NSCLC)	\$244,479.24	
Allos Therapeutics, Inc	Pralatrexate for the Treatment of Advanced/Metastatic Breast Cancer	\$244,479.24	
Allos Therapeutics, Inc.	Pralatrexate for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma	\$244,479.24	
ApopLogic Pharmaceuticals, Inc	AP-300 to treat superficial bladder cancer	\$105,313.00	
ApopLogic Pharmaceuticals, Inc.	B201-acetate to treat small lung cancer and other hard to treat cancers	\$201,419.00	\$3,032.50
Aqueous Biomedical Inc.	Oculieve glaucoma shunt development	\$70,736.52	\$155,000.00
ARCA Biopharma	Gencaro (Bucindolol) CHF	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Inc	Therapeutic		
ARCA biopharma, Inc	NU172 Short-acting anticoagulant for cardiac procedures.	\$244,479.25	
ArcScan, Inc.	Artemis 3	\$244,479.25	
AspenBio Pharma Inc	AppyScore™	\$244,479.25	
Beacon Biotechnology LLC	BrightSPOT diagnostic technology	\$180,126.83	\$64,352.42
BioAMPS International, Inc	Novel Therapeutics for the Treatment of Drug-resistant Bacterial Infections		\$70,773.50
Biodesix Inc	Mass Spectrometry for Prostate Cancer Detection	\$155,268.50	\$89,210.75
BIODESIX INC	Researching Immunosuppressive Agents for Improved EGFR-I Therapy Effectiveness	\$97,831.00	\$146,648.25
Biodesix, Inc	Mass Spectrometry for Diagnosis of Inflammatory Colitis	\$83,601.00	\$118,757.50
BIODESIX, INC	VeriStrat® : For Guiding Epidermal Growth Factor Receptor inhibitor Therapy in Cancer	\$244,479.25	
Biodesix, Inc	Mass Spectrometry for Autoimmune Liver Disease Diagnosis	\$101,018.50	\$118,757.50
Biodesix, Inc.	CancerDetect: For early diagnostic of lung cancer (LC)	\$162,120.00	\$82,359.25
BiOptix Diagnostics, Inc.	BiOptix Accolade Project	\$227,575.00	\$16,904.25
Bolder Biotechnology Inc.	Novel Erythropoiesis-Stimulating Protein for Chronic Kidney Disease and Cancer	\$41,763.53	\$202,715.72
Bolder	Novel, Long-Acting Growth	\$125,951.74	\$118,527.51

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Biotechnology Inc.	Hormane Analog for Treatment Short Stature and Lipodystrophy		
Bolder Biotechnology Inc.	Novel long-acting G-CSF analog for treating acute radiation syndrome and cancer	\$17,523.68	\$196,704.31
Bolder Biotechnology Inc.	Novel long-acting beta interferon analog for treating multiple sclerosis and cancer	\$119,991.28	\$124,487.97
Bolder Biotechnology Inc.	Novel, long-acting GM-CSF analog for treating acute radiation exposure and cancer-associated neutropenia.	\$21,682.98	\$222,796.27
Cell Point	EC Technology	\$244,479.24	
CeMines Inc	Molecular Diagnostic Project for Lung Cancer	\$197,725.50	
Cerapedics Inc	Peptide Enhancement Anorganic Bone Mineral for Cervical Spinal Fusion Surgery	\$244,479.24	
Cerapedics Inc	Optimized Delivery Matrices for Augmenting Pluipotent {Stem} Cell Repair of Hard Tissue	\$244,479.24	
Cerapedics Inc	Lyophilized Peptide Enhanced Bone Graft Conjugates For Trauma Applications	\$244,479.24	
CereScan Corp	Development of tools to diagnose diseases and conditions of the brain	\$244,479.25	
Chata Biosystems, Inc	A Stronger, Broad Spectrum, Environmentally safe Disinfectant	\$67,799.50	\$176,679.75
Clovis Oncology Inc	Development of CO-1.01 and companion diagnostic test for treatment of pancreatic cancer	\$244,479.25	
Clovis Oncology, Inc.	Development of EMSI and companion diagnostic for		\$244,479.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	treatment of non-small cell lung cancer		
Corgenix Medical Corporation	Determination of predictive value of AtherOx for atherosclerotic cardiovascular disease.	\$26,250.00	\$72,500.00
Crestone, Inc	PoIC Inhibitors as Novel herapeutics for Antibiotic-Resistant Gram-Positive Infections	\$8,900.00	\$138,840.00
Crestone, Inc.	REP3123 as a Novel Therapeutic for Treatment of Clostridium difficile Infection	\$37,233.00	\$60,885.00
EndoShape, Inc	A nonmetallic, Shape Memory Polymer AAA Endograft to expand patient applicability, etc	\$130,608.00	\$109,080.50
EndoShape, Inc	An SMP fallopian tube occlusion device for non-surgical, permanent female sterilization, etc	\$61,230.00	\$99,954.00
Eveia Medical, Inc	Development of a Coagulation Test for Clinic and Home Use		\$244,479.25
GlobeImmune, Inc.	GI-6207 as active immunotherapy for the treatment of CEA over-expressing cancers.	\$241,869.50	\$2,609.74
GlobeImmune, Inc.	GI-4000 as active immunotherapy for the treatment of mutated-Ras cancers.	\$244,479.24	
GlobeImmune, Inc.	GI-5005 as active immunotherapy for the treatment of chronic hepatitis C virus infection	\$244,479.24	
Greffex, Inc	Fully Deleted Helper-Virus Independent Vectors as Vaccine Carriers	\$244,479.24	
Hiberna Corporation	Python Project	\$63,550.50	\$33,591.50
ICVRX LLC	CNS Site Specific Medication		\$244,479.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Delivery to Improve Outcomes for Refractory Epilepsy Patients		
Inviragen, Inc	Recombinant attenuated chikungunya vaccine	\$113,013.50	\$131,465.75
Inviragen, Inc	A recombinant, tetravalent vaccine to prevent dengue fever	\$244,479.25	
Isogenis, Inc	Protection of Tissue & Organ Transplants by Engineered Veto	\$244,479.24	
Kestrel Labs, Inc	Noninvasive CO-Oximeter for Measuring Multiple Hemoglobin Species	\$244,479.25	
Lanx, Inc.	Biomimetic Approach for the Delivery of Bone Morphogenic Proteins	\$119,000.00	\$125,479.25
Leap Frogg, LLC	Frogg Dynamic Compression system (FDCS)	\$189,969.50	\$54,509.75
MBC Pharma Inc	Novel bone-targeted therapeutics for cancer-induced bone disease	\$244,479.24	
Micro-Imaging Solutions LLC	Rigid and Articulating-tipped (flexible), disposable CMOS-based endoscopes	\$244,479.24	
MicroPhage Inc	Development of a Novel Rapid MRSA/MSSA Blood Culture Test	\$244,479.24	
MicroPhage, Inc	Development of a Novel and Rapid Skin Tissue Antibiotic Susceptibility Test	\$244,479.24	
Miragen Therapeutics, Inc.	Developing microRNA based therapies to transform the course of Cardiovascular Disease	\$244,479.25	
Myocept, Inc	Myocept Project	\$78,224.16	\$166,255.09
N30 Pharmaceuticals, LLC	Inhibitors of S-nitrosoglutathione reductase (GSNOR)		\$244,479.24

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Ocutronics, LLC	OC100	\$76,411.00	\$168,068.25
Otologics, LLC	Carina Project	\$244,479.25	
Parascript, LLC	AccuDetect	\$244,479.25	
PARE Surgical, Inc.	Flexible Endoscopic Instruments	\$127,457.00	\$117,022.24
Pathogen Systems, Inc.	Pathogenic Microbe Detection Device	\$244,479.25	
PharmaJet Inc	Novel Delivery of Drugs and Vaccines Enabled by Intradermal Jet Injection Technology	\$91,876.26	\$152,602.99
Precision Photonics Corp	Point-of-care(POC) diagnostic device for critical infectious disease panel testing	\$244,479.24	
ProFoldRx, Inc dba BaroFold, Inc	High Pressure Refolding of protein Aggregates for Novel Therapeutics and Biosimilars		\$244,479.25
Protectstyle Corporation	Preventative Therapeutic Antimicrobial Textiles		\$244,479.24
Pyxant Labs Inc	LC/MSMS Bioassay for Physiologic Iron Biomarkers		\$27,703.45
Pyxant Labs, Inc	Trastuzumab Bioanalytical Assay for Regulatory Development Studies		\$71,029.59
Quest Product Development Corporation	Cardiac Sync Technology for Improved CPR Therapy	\$244,479.25	
Quest Product Development Corpotaion	MicroFlex Endoscopes for Improved Diagnosis and Surgery	\$244,479.25	
Rocky Mountain Biosystems, Inc.	Adtivated Thermoset Adhesive for Wound Closure	\$244,479.25	
Rocky Mountain Biosystems, Inc.	Skin Patch for Drug Delivery after Controlled Stratum Corneum Ablation.	\$29,281.00	\$73,049.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Somallogic Inc	A Simple Blood Test for the Early Detection of Mesothelioma	\$130,028.00	\$114,451.25
SomaLogic, Inc	A Simple and inexpensive Blood Test for the Early Detection of Non-Small Cell Lung Cancer	\$244,479.25	
SomaLogic, Inc	Novel Therapeutics for the Treatment of Cancer	\$244,479.25	
SomaLogic, Inc	A Simple and inexpensive Blood Test for the Early Detection of Ovarian Cancer	\$244,479.25	
SomaLogic, Inc.	A Simple Blood Test for the Early Detection of Pancreatic Cancer	\$875.00	\$193,137.00
SomaLogic, Inc.	Novel Neuroprotective and Neuroregenerative Therapeutics for Neurodegenerative Diseases	\$244,479.25	
SomaLogic, Inc.	Aggregation of Blood Test for Multiple Diseases into an Inexpensive Multiplexed Diagnostic	\$244,479.25	
SomaLogic, Inc	A Simple and Inexpensive Blood Test for the Early Detection of Chronic Kidney Disease	\$86,685.50	\$157,793.75
Sophonon Inc	Sophonon Alpha 1 magnetic hearing prosthesis	\$82,120.82	\$162,358.43
Source Precision Medicine Inc dba Source MDx	Develop & Validate a Breast Cancer Early Detection Molecular Diagnostic Test	\$38,836.00	\$205,643.25
Source Precision Medicine Inc dba Source MDx	Develop & Validate a Molecular Diagnostic Test Predictive of Prostate Biopsy Outcomes	\$244,479.25	
Source Precision Medicine Inc dba Source MDx	Develop & Validate a Lung Cancer Early Detection Molecular Diagnostic Test	\$244,479.25	
St Cardio	Z6 Cardiac Stimulator	\$186,138.50	\$58,340.75

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Technologies			
St. Renatus LLC	Nasal Mist Dental Anesthetic	\$244,479.25	
Sundance Diagnostics, Inc	Whole Genome Sequencing for Diagnostic Test for Suicidal Ideation	\$244,479.25	
Surefire Medical, Inc	Paladin Embolization Infusion System	\$12,576.00	\$231,903.25
ValveXchange, Inc	Vitality™ and Vanguard™ heart valve systems	\$244,479.24	
Ventria Bioscience	Development of an oral delivery platform biologics	\$111,500.00	\$71,000.00
Ventria Bioscience	Prevention of Antibiotic Associated Diarrhea	\$33,938.50	\$210,540.75
Ventria Bioscience	Treatment for spontaneous bacterial peritonitis	\$244,479.25	
Vitrolife Inc	HELP- Human Ex-Vivo Lung Preservation and Reconditioning	\$244,479.24	

Connecticut \$13,847,706.16

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Achillion Pharmaceuticals, Inc.	ACH-2881	\$166,432.50	\$78,046.75
Achillion Pharmaceuticals, Inc.	ACH-1625	\$244,479.25	
Achillion Pharmaceuticals, Inc.	ACH-2684	\$244,479.25	
Achillion Pharmaceuticals, Inc.	Elvucitabine	\$131,052.00	\$113,427.25
Achillion Pharmaceuticals,	ACH-2928	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Inc.			
Achillion Pharmaceuticals, Inc.	ACH-1095	\$244,479.25	
Achillion Pharmaceuticals, Inc.	ACH-702	\$244,479.25	
Achillion Pharmaceuticals, Inc.	ACH-2892	\$244,479.25	
AllerQuest, LLC	Penicillin Minor Determinants (PMD)		\$244,479.24
AllerQuest, LLC	PrePen	\$51,598.50	
AMARIN PHARMACEUTICALS, INC.	AMR101	\$244,479.25	
Applied Spine Technologies, Inc	Stabilimax Spine Stabilization System	\$244,479.24	
Artificial Cell Technologies	Nanoparticulate Vaccine Against Respiratory Syncytial Virus	\$244,479.25	
Axerion Therapeutics	Nogo receptor (NgR)protein therapy to treat chronic spinal cord injury		\$244,479.25
Axerion Therapeutics	Cellular Prion Protein (PrP) as a treatment for Alzheimer's Disease		\$122,818.50
Beta Pharma, Inc	Icotinib, a novel drug for the treatment of EGFR-mutated cancer diseases.	\$87,192.09	\$157,287.16
Biodel Inc	Smart Basal	\$244,479.25	
Biodel, Inc	VIAject	\$244,479.25	
Biodel, Inc.	Improved Glargine	\$244,479.25	
Biodel, Inc.	Glucagon	\$244,479.25	
Biodel, Inc.	VIAtab	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Biomedisyn Corporation	Huperzine for the Treatment of Schizophrenia	\$21,405.80	\$137,070.98
BioRelix, Inc.	Novel riboswitch-targeting treatments for multi-drug resistant and hypervirulent bacteria	\$244,479.24	
Biowave Corporation	Prescription Peripheral Neuromodulation Pain System	\$48,055.00	\$95,700.00
Brain Tunnelgenix Technologies Corp	Discovery of the Brain Temperature Tunnel (BTT) and the world's first non-invasive brain temperature monitoring device	\$244,479.24	
Cara Therapeutics Inc	Development of A Novel Analgesic, CR845	\$244,479.24	
CAS Medical Systems Inc	Non-Invasive Cerebral/Tissue Oximetry	\$244,479.25	
Cheminpharma LLC	MEK Inhibitor for Treatment of Cancer	\$59,362.50	
Cytogel Pharma, LLC	Cyt-1010	\$244,479.24	
CyVek, Inc (FKA CyVek, LLC)	CyVek: Enabling Proteomics	\$21,281.00	\$223,198.25
Genomas, Inc	Phyziotype System:Improve Treatment Outcome of Drugs for Mental Illness & Heart Disease	\$156,399.00	\$88,080.24
HistoRx Inc	AQUA technology Diagnostics Enabling Better Treatment Decision	\$244,479.25	
Ikonisys Inc	OncoFISH cervical test	\$244,479.24	
IVFonline.com DBA Zenith Biotech, LLC	Develop and make liver biomatrix for extended	\$81,500.00	\$63,000.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	hepatocyte functionality for drug discovery		
IVFonline.com DBA Zenith Biotech, LLC	Novel Predictive Model for Hepatocytes Toxicity in Preclinical Drug Screening	\$95,000.00	\$107,500.00
IVFonline.com DBA Zenith Biotech, LLC.	Scalable Human Neural Stem Cells for High Throughput Screening	\$122,500.00	\$118,000.00
Kolltan Pharmaceuticals, Inc	RTK Project No. 5	\$244,479.25	
Kolltan Pharmaceuticals, Inc	RTK Project No.4	\$244,479.25	
Kolltan Pharmaceuticals, Inc	RTK Project No.3	\$244,479.25	
Kolltan Pharmaceuticals, Inc.	RTK Project No. 1	\$244,479.25	
Kolltan Pharmaceuticals, Inc.	RTK Project No. 2	\$244,479.25	
Kolltan Pharmaceuticals, Inc.	RTK Project No. 6	\$244,479.25	
Kotinos Pharmaceuticals Inc	Development of Tigapotide (PCK3145) as novel therapy for prostate cancer	\$196,017.00	\$48,462.24
Marinus Pharmaceuticals Inc.	Ganaxolone for Adjunctive Treatment of Partial Onset Seizures	\$244,479.25	
Marinus Pharmaceuticals Inc.	Ganaxolone for Treatment of Posttraumatic Stress Disorder (PTSD)	\$244,479.25	
MEDADHERENCE LLC	DIABETES REMOTE MANAGEMENT SYSTEM	\$244,479.25	
Molecular Neuroimaging LLC	Biomarkers for the Diagnosis of Parkinson's Disease	\$222,854.00	\$21,625.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Molecular Neuroimaging LLC	Biomarkers for the Diagnosis of Alzheimer Disease	\$202,974.50	\$41,504.75
Myometrics, LLC	A small molecule agonist for enhancing alveolar bone regeneration in tooth extraction	\$10,043.50	\$1,230.50
Optherion, Inc	rhCFHp - Recombinant Human Factor H	\$244,479.24	
Protein Sciences Corporation	FluBlok	\$244,479.25	
Protein Sciences Corporation	PanBlok	\$244,479.25	
RIB-X PHARMACEUTICALS INC	RX-04 Completely New Antibiotics to Treat Multi-drug Resistant Infections	\$244,479.25	
RIB-X PHARMACEUTICALS, INC.	Delafloxacin: a broad spectrum antibiotic for the treatment of multi-drug resistant infections	\$244,479.25	
RIB-X PHARMACEUTICALS, INC.	RX-02: Enhanced Macrolides for Treating Drug-Resistant Community Infections	\$244,479.25	
RIB-X PHARMACEUTICALS, INC.	Radezolid: A Novel Oxazolidinone Antibiotic for Resistant Gram-positive Infections	\$244,479.25	
Sibtech Inc	Guiding Cancer Therapy by imaging VEGF Receptors	\$244,479.25	
SurgiQuest, Inc.	AirSeal ® Trocar & Cannula System	\$244,479.25	
The Bronx Project Inc	The Bronx Project	\$26,739.00	\$217,740.25
The Institutes for	Arginase Inhibitor Program	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Pharmaceutical Discovery LLC			
The Institutes for Pharmaceutical Discovery LLV	Urinary Peptide Assay		\$244,479.24

Delaware \$1,907,078.03

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Incyte Corporation	Development of INCB24360 as a treatment for cancerous solid tumors.	\$244,479.25	
Incyte Corporation	Development of INCB7839 as a treatment for metastatic breast cancer.	\$244,479.25	
Incyte Corporation	Development of INCB18424 as a treatment for myelofibrosis	\$244,479.25	
Lake Biosciences LLC	Nerve Stimulation for the Treatment of Stroke		\$217,500.00
Lake Biosciences LLC	Haptoglobin Type as a Prognostic Test for Vasospasm After Subarachnoid Hemorrhage		\$102,500.00
OrPro Therapeutics, Inc	ORP100 Inhaled Mucolytic		\$24,000.00
QPS Holdings LLC	Octreotide Phytate for Injectable Suspension (OPIS)	\$129,669.47	\$104,738.52
QPS Holdings,	Leuprolide Mesylate for	\$81,053.15	\$110,893.23

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
LLC	Injectable Suspension (LMIS)		
QPS Holdings, LLC	Design, synthesis and development of highly selective matrix metalloprotease inhibitors	\$96,431.23	\$62,375.43
Respiratory Management Technology, Inc	Aerosol-Dispersion	\$6,747.22	\$237,732.03

District of Columbia \$518,667.34

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Bionutrigen Inc.	Clinical Trial of Liver Health Formulation of Ingredients Derived From Edible Plant Sources		\$43,055.25
Ergon Pharmaceuticals	Branched-chained aminotransferase-1 (Bcat-1) inhibitors as therapeutic products for the treatment of metastatic cancer and rheumatoid arthritis	\$6,494.84	\$15,015.00
Foligo Therapeutics Inc	Foligo 002 & OvaDetect	\$57,364.50	
Onconon LLC	Onconon LLC	\$12,132.50	\$12,000.00
Thegreencell Inc	Aloe Therapeutic Protein Production Platform and Delivery System	\$57,126.00	\$71,000.00
Warner OB/GYN Associates, PC	Green Pregnancy	\$244,479.25	

Florida \$26,057,929.04

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
.Decimal Inc.	Development and Commercialization of Electron Conformal Therapy Bolos	\$144,260.68	\$77,112.17
Accentia Biopharmaceuticals Inc	Revimmune ReBOOT for the treatment of Multiple Sclerosis	\$75,187.50	\$169,291.75
Accu-Break Pharmaceuticals Inc and Subsidiaries	Accu-Break Wafarin	\$244,479.25	
Adhaere Pharmaceuticals Inc	Novel therapeutic strategies for preserving vascular access graft in hemodialysis patients		\$45,390.00
Altor Bioscience Corporation	Altor QTD Project #5 - Development of IL-15 Superagonists for Cancer	\$1,631.65	\$132,923.11
Altor Bioscience Corporation	Altor QTD Project #2 - Development of ALT-802 for Cancer	\$163,352.23	\$81,127.01
Altor Bioscience Corporation	Altor QTD Project #1- Development of ALT-801 for Cancer	\$244,479.24	
Altor Bioscience Corporation	Altor QTD Project #6 - Development of DPC-1528, an Antisense Drug for Acne	\$171,144.86	\$19,428.32
Altor Bioscience Corporation	ALtor QTD Project #3 - Development of ALT-836 for ALI/ARDS		\$60,512.03
AOI Medical Inc	Ascendx Spine Technology	\$244,479.25	
Applied Genetic Technologies Corp	Alpha One Trial	\$244,479.25	
Applied Genetic Technologies Corp	Achromatopsia Project	\$244,479.25	
Applied Genetic	XLRS Project	\$7,446.74	\$237,032.51

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Technologies Corporation			
Applied Genetic Technologies Corporation	LCA Trial	\$188,664.43	\$55,814.82
Aquatrove Biosciences Inc	Novel stratiefies for the treatment of vaginal dryness in trying to conceive patients	\$33,506.00	\$95,000.00
Aspiration Medical Technology LLC	FoodDivurzrn (FD) Weight Management System	\$244,479.24	
Atlas Spine, Inc.	APELO	\$244,479.24	
Banyan Biomarkers, Inc.	Biomarkers of Brain Injury: Magnitude, Secondary Insults and Outcome	\$244,479.25	
Bioheart, Inc.	MARVEL Trial REGEN Trial	\$244,479.24	
Bio-Nucleonics Inc	Novel Peptidomimetic for Unstable Atherosclerotic Plague detection and differentiation.	\$244,479.24	
Bio-Nucleonics Inc	Rubidium	\$244,479.25	
Bio-Nucleonics, Inc.	Gallium-68/Germanium-68 Radionuclide Generator	\$244,479.25	
Bio-Nucleonics, Inc.	Gynocyte	\$244,479.25	
Biovest International Inc.	BiovaxID - a patient-specific vaccine for B-cell Non-Hodgkin's Lymphoma	\$244,479.25	
Catalyst Pharmaceutical Partners, Inc	CPP-109 For The Treatment Of Stimulant Dependence	\$244,479.24	
Catalyst Pharmaceutical Partners, Inc	CPP-115 for the treatment of various forms of Epilepsy and stimulant dependence	\$110,454.66	\$134,024.58
CHS RESOURCES, LLC	TOPICAL TREATMENT FOR SKIN CANCER AND OTHER	\$60,442.50	\$184,036.75

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	PRE-CANCEROUS CONDITIONS.		
Claro Scientific, LLC	SpectraWave Blood and Blood Culture Diagnostic System	\$244,479.25	
Concordia Pharmaceuticals, Inc.	Salirasib	\$244,479.24	
Converge Biotech Inc	Biohybrid Device for Treatment of Diabetes	\$94,570.00	\$84,932.00
Convergent Engineering	eToco Maternal Fetal Monitoring	\$25,162.00	\$9,564.50
Convergent Engineering Inc.	ID-Cap	\$28,385.50	
CORD:USE Cord Blood Bank, Inc	Allogeneic Cord Blood Banking	\$244,479.25	
Cytorex Biosciences, Inc.	Cytoreg®	\$244,479.25	
Dharma Biomedical, LLC	Isolation and Synthesis of Bioactive Molecules from Commiphora wightii Bark Oleoresin	\$48,612.54	\$52,025.56
Electrostim Medical Services Inc. dba EMSI	Iglucotouch		\$244,479.24
EnCor Biotechnology Inc.	Development of diagnostic biomarkers of CNS damage and disease states	\$85,303.50	\$159,175.75
Envoy Therapeutics, Inc	A New Oral Therapy for Treating Cognitive Deficits Associated with Schizophrenia	\$10,827.50	\$233,651.75
Envoy Therapeutics, Inc.	A Novel, Non Dopamine-Based oral Therapy for Parkinson's Disease	\$20,437.50	\$224,041.75
Envoy Therapeutics, Inc.	An Oral Therapy for Parkinson's Disease designed to mimic Deep Brain Stimulation	\$20,437.50	\$224,041.75

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
eTect LLC	ID Cap	\$21,539.06	\$173,403.94
Eyetechn Inc	The Macugen ER Project	\$141,639.50	\$102,839.74
Florida Cancer Care Network, LLC	Radiation Therapy Oncology management Program		\$244,479.25
GeneEx, Inc	A Rapid Point-of-Care Diagnostic for Active Periodontal Disease	\$244,479.25	
GeneEx, Inc	A Rapid Point-of-Care Diagnostic for Active Group A Streptococcal Pharyngitis		\$244,479.25
GeNO LLC	A ultra-pure inhaled Nitric Oxide drug for chronic treatment of multiple pulmonary diseases for unmet medical needs	\$244,479.24	
GLG Pharma LLC	GLG-202 Manufacturing and IND-Enabling Pre-Clinical Toxicology Studies		\$244,479.25
GLG Pharma LLC	GLG-401 Manufacturing and IND-Enabling Pre-clinical Toxicology Studies		\$244,479.25
GLG Pharma, LLC	GLG-302 Manufacturing and IND-Enabling Pre-Clinical Toxicology Studies		\$244,479.24
Heat Biologics Inc	HS-System	\$82,044.68	\$162,434.56
Imigene Inc	High Clinical Relevancy Point of Care Blood Borne Bacteria Detection	\$91,800.00	\$152,679.25
InnFocus	a Novel Drug/Medical Device Treatment for Glaucoma	\$244,479.24	
Intezyne Technologies, Inc	Polymer Polyplex	\$52,231.88	\$43,059.02
Intezyne Technologies, Inc	Ivect Technology	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
iSense, LLC	Colorimetric Breath Analyzer for Lung Cancer Diagnosis	\$156,605.83	\$87,873.42
Ivax Diagnostics, Inc.	Mago4S and diagnostic ELISA and IFA assays	\$244,479.25	
LifeSync Corporation	WECGII	\$244,479.25	
LINGUAFLEX, INC	LINGUAFLEX TONGUE RETRACTOR (LTR)	\$244,479.24	
Mergen Medical, Inc	HiFLO HFT with Airway Pressure Monitoring	\$200,174.50	\$44,304.74
Metabogenix Technologies, Inc	Combining inhibitors of glycolysis with cancer chemotherapy to increase treatment efficacy	\$244,479.25	
Metabogenix Technologies, Inc.	Fenofibrate induces endoplasmic reticulum stress leading to selective toxicity in multiple myeloma cells	\$244,479.25	
Morphogenesis, Inc	ImmuneFx™ Cancer immunotherapy	\$161,560.50	\$82,918.74
Nanotherapeutics Inc	NanoDOX 1% Doxycycline Monohydrate Hydrogel for the treatment of Chronic Wounds	\$91,995.13	\$98,718.24
Nanotherapeutics, Inc.	NanoBUP Buprenorphine/Naloxone Capsule for the Treatment of Opioid Addiction	\$74,617.68	\$169,861.57
Nanotherapeutics, Inc.	NanoFOVIR™ Inhaled Cidofovir Dry-Powder Formulation for Postexposure	\$244,479.25	
Nanotherapeutics, Inc.	NonoGENT™ Gentamicin Sulfate Inhalation Powder for post-exposure prophylaxis of pneumonic plague (<i>Yersinia pestis</i>)	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
NeoGenomics Inc	Melanoma FISH Test	\$244,479.24	
NeoGenomics Laboratories Inc	Barrett's esophagus FISH Test		\$130,000.00
Neuro Assisted Recovery Inc	NTMD for treatment of Comorbid Substance abuse disorders	\$234,715.00	\$9,764.25
Nutra Pharma Corporation	Development of Recet for the treatment of pain		\$244,479.25
Ocean Ridge Biosciences, LLC	Serum MicroRNAs as Prognostic Markers of Emphysema	\$34,873.00	\$34,562.00
OPKO Instrumentation, LLC a single member LLC of OPKO Health, Inc	Aquashunt	\$244,479.25	
OPKO Pharmaceuticals LLC	Rolapitant	\$244,479.25	
OPKO Pharmaceuticals LLC a single member LLC of OPKO Health, Inc	Bevasiranib	\$244,479.25	
Optima Neuroscience, Inc.	High Performance Automated Seizure Detection	\$244,479.25	
Oragenics Inc	Novel Antibiotics for the Treatment of Healthcare Associated Infections	\$132,041.27	\$112,437.97
Oragenics, Inc	Rapid and Sensitive Id. Of Novel Diagnostic Biomarkers for Cancer for Cancer and Infectious Diseases	\$186,971.87	\$57,507.37
Oragenics, Inc	Prevention of Tooth Decay using SMaRT Replacement Therapy	\$52,206.00	\$192,273.24
Orbus Neich Medical, Inc	Combo Bio-engineered Sirolimus-eluting Stent (Combo	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Stent)		
OxThera, Inc	Development of Oxabact(R) for the Treatment of Primary Hyperoxaluria	\$244,479.24	
ParinGenix, Inc.	Prevention of heparin-induced thrombocytopenia and associated thrombosis	\$26,693.00	\$125,648.00
ParinGenix, Inc.	Development of a treatment of pediatric protein-losing enteropathy	\$19,938.50	\$204,564.50
Pioma Inc	TAME-DX: A blood based diagnostic for evidence-based treatment of brain cancer.	\$63,885.00	\$180,594.25
Precision Medical Devices, Inc	Flow Control Device	\$105,038.00	\$139,441.25
Quantum Immunologics Inc	Development of Oncofetal Antigen/immature Laminin Receptor Protein (OFA/iLRP) peptides for the treatment of cancer	\$66,922.72	\$137,628.09
Quantum Immunologics Inc	A Phase I/II Study with Autologous Dendritic Cells Loaded with Oncofetal Antigen/iL RP in Patients with Metastatic Breast Cancer	\$244,479.25	
Quantum Immunologics, Inc	Developmental of Monoclonal Antibodies against OFA/iLRP	\$59,506.57	\$137,628.09
Quick-Med Technologies, Inc	NIMBUS Wound Dressings/Drain (DWD)	\$244,479.25	
SafeStitch Medical, Inc. and Subsidiaries	AMID Stapler for Simplified Stapled Lichtenstein Procedure (SSLP)	\$244,479.25	
Seraph Pharmaceuticals	Ketogenic diet in a pill with antioxidant activity for control of epileptic seizures	\$10,750.00	\$35,000.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Sinapis Pharma Inc	IV Methamphetamine for Stroke and other acute ischemic conditions	\$186,112.00	\$58,367.24
SKELETAL DYNAMICS LLC	INTERNAL JOINT STABILIZER FOR THE ELBOW	\$134,395.88	\$110,083.36
Skeletal Dynamics LLC	Align Radial Head Arthroplasty System	\$152,094.98	\$92,384.26
Syntheon LLC	Milwaukee Project	\$244,479.25	
TauTaTis, Inc	Evaluation of the kinase inhibitor TTT-3002 for neurodegenerative diseases and cancer	\$109,391.50	\$135,087.74
Tele Home Care Solutions Company	The Tele Home Care Solution Project		\$152,410.83
Tigris Pharmaceuticals, Inc	AFP-464	\$244,479.25	
Tigris Pharmaceuticals, Inc.	GGTI-2418	\$244,479.25	
Tissue Tech, Inc	Treatment for Demodex Infestation by Active Ingredient from Tea Tree Oil	\$31,783.50	\$162,450.50
Tissue Tech, Inc	Novel Therapeutics based on Amniotic Membrane Extract and its Purified Component	\$164,862.00	\$79,617.25
Tissue Tech,Inc	development of a Novel Device to deliver Therapeutics to Ocular Surface	\$51,019.50	\$90,106.00
Tissuetech,Inc	Novel Ex Vivo Expansion of Limbal stem Cells	\$189,002.50	\$55,476.75
Tyrogenex Inc	X-82 VEGFR/PDGFR small molecule kinase inhibitor	\$155,311.00	\$89,168.25
Venx LLC	Device Strategies for the management of Venous Stasis	\$39,549.00	\$165,950.50

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Winprobe Corporation	The Ultravision Research Project	\$244,479.25	
Xcelience	SKL-10406	\$61,698.47	\$17,564.24
Xcelience Holdings LLC	PX-866	\$39,831.05	\$27,468.85
Xcelience Holdings LLC	CTO	\$18,562.47	\$7,738.27
Xcelience Holdings, LLC	DAS-181	\$21,073.91	\$54,300.04
Xcelience Holdings, LLC	AM-152		\$53,076.00
Xcelience Holdings, LLC	CC-930	\$156,629.47	\$87,849.78
Xcelience Holdings, LLC	AT-406	\$26,236.82	\$13,418.48
Xcelience Holdings, LLC	OSI-296	\$50,273.75	\$28,662.85
Xcelience Holdings, LLC	Acuracet	\$165,781.99	\$78,697.26
Xcelience Holdings, LLC	Duodopa		\$22,118.87
Xcelience Holdings, LLC	AP24534	\$52,264.27	\$192,214.98
Xcelience Holdings, LLC	Alpha-tocherolquinone	\$60,602.00	\$183,877.25
Xcelience Holdings, LLC	Loperamide	\$69,003.32	\$54,202.23
Xcellience Holdings, LLC	PN-3602	\$89,974.23	\$143,487.74
Xcovery Holding Company LLC	X-379 c-Met small molecule kinase inhibitor	\$35,661.50	\$208,817.75
Xcovery Holding Company LLC	x-387 mTor (TORC1/TORC2) small molecule kinase inhibitor	\$177,961.50	\$66,517.75

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Xcovery Holding Company LLC	X-396 (ALK) small molecule kinase inhibitor	\$41,638.00	\$202,841.25
Xhale diagnostics, Inc	One Breath: a non-invasive glucose self-monitoring system using exhaled breath	\$244,479.25	
Xhale, Inc.	Next generation evidential breath-based ethanol sensor to diagnose and treat alcohol abuse	\$69,604.00	\$108,888.00

Foreign \$733,437.74

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Enobia Pharma, Inc.	ENB-0040	\$244,479.25	
mtm laboratories AG	Clinical evaluation of the CINtec Histology Kit	\$244,479.24	
Pluristem Therapeutics Inc.	Placenta derived cells (PLX) for the treatment of patients suffering from PAD and CLI	\$244,479.25	

Georgia \$15,165,946.20

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Abeome Corporation	Discovery of monoclonal antibodies for cancer therapeutic and biomarker development	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Access Product Marketing, LLC	Project APM01050 - Patient friendly delivery of glucagon for emergency treatment of severe hypoglycemia	\$207,410.00	\$37,069.25
AerovectRx Corporation	AerovectRx disposable drug cartridge (DDC) compatibility and stability	\$32,200.00	\$90,800.00
Alaven Pharmaceutical LLC	CALM-UC Clinical Assessment of Low Dose Mesalamine in Ucerative Colitis	\$244,479.25	
Alimera Sciences Inc.	Iluvien for the Treatment of Diabetic Macular Edema	\$244,479.25	
ALTEA THERAPEUTICS	ENOXPARIN SODIUM PASSPORT ® SYSTEM	\$244,479.25	
ALTEA THERAPEUTICS CORP	EXENATIDE PASSPORT(R)STEM	\$244,479.25	
Altiris Therapeutics, Inc.	ALT-118	\$244,479.25	
Apeliotus Vision Science, Inc.	Diagnostic for Age-Related Macular Degeneration	\$96,546.00	\$147,933.25
Argent Diagnostics Inc	High Sensitivity Nano-Optical Method to Detect Measles Virus	\$6,222.00	\$28,904.50
Atlanta Catheter Therapies, Inc (ACT)	Prototype development and Pre-Clinical testing of Occlusion Perfusion Catheter	\$160,112.00	\$84,367.24
Axona Inc. (dba AxoTect, Inc.)	Calpain inhibitors for Cancer Related Neuropathies	\$64,939.50	\$87,500.00
Cardiac regeneration Technologies, LLC	CardioGold Project	\$174,527.00	\$69,952.25
CardioMEMS Inc	CardioMEMS Heart Failure System (CardioMEMS HF-system)	\$244,479.25	
Carticept Medical,	Navigator™ Delivery System	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Inc			
Cell Constructs Inc	Autologous Stem Cell Therapy Dressing for Chronic Wounds	\$15,787.50	\$108,808.00
CeloNova BioSciences, Inc.	Safety and Efficacy of Embozene Microspheres for Uterine Artery Embolization for SUF		\$244,479.25
CeloNova BioSciences, Inc.	Safety and Efficacy of a Newly Designed Coronary Stent Coated with Polyzene-F		\$244,479.25
CeloNova BioSciences, Inc.	Target Drug Delivery Device: OncoZene Drug Eluting Microspheres	\$244,479.25	
Celtaxsys Inc	Chemorepulsion Project	\$244,479.24	
CorMatrix Cardiovascular Inc	ECM Emulsion Injection Therapy to Treat Myocardial Ischemia	\$244,479.24	
CorMatrix Cardiovascular Inc	Reduction of Postoperative Atrial Fibrillation using Co-Matrix ECM	\$170,526.57	\$73,952.67
CorMatrix Cardiovascular Inc	Tissue Regenerating ECM for Vascular Applications	\$108,602.13	\$135,877.11
CorMatrix Cardiovascular Inc	New method to decellularize and sterilize Xenografts for optimized host integration		\$220,709.83
CorMatrix Cardiovascular Inc	Drug-eluting ECM for Pericardial Reconstruction		\$213,668.94
Effcon Laboratories Inc	Alcohol Abuse Treatment	\$2,730.00	\$167,775.00
Effcon Laboratories, Inc.	Glaucoma Project	\$76,540.00	\$167,939.25
Effcon Laboratories, Inc.	Lice Project	\$8,190.00	\$236,289.25
Effcon Laboratories, Inc.	Dystonia Project	\$22,800.50	\$221,678.75

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Envisionier Medical Technologies, Inc	endogo®HD, endoscopic imaging system	\$159,992.00	\$48,504.50
Femasys Inc.	FemVue Systems	\$244,479.25	
Femasys Inc.	FemBloc Permanent Contraceptive System	\$244,479.25	
GeneCure LLC	Development of therapeutic HIV vaccines	\$244,479.24	
GeoVax, Inc	HIV/AIDS Vaccine	\$244,479.24	
Glycosensors and Diagnostics, LLC	High-specificity affinity reagents for N-glycosylation site mapping and glycomics	\$33,307.98	\$84,709.16
Guided Therapeutics, Inc.	Cost Effective Noninvasive Cervical Cancer Detection System	\$244,479.24	
Health Discovery Corporation	Health Discovery Corporation's SVM and RFE-SVM Technology	\$109,323.02	\$135,156.23
ICON Interventional Systems, Inc.	ICON® NULOY® Drug Eluting Stent (DES) Platform	\$244,479.25	
Iconic Therapeutics, Inc.	Iconic Therapeutics, Inc.: Development of I-con1	\$244,479.25	
Inhibikase Therapeutics Inc	Host-targeted antiviral for seasonal and pandemic influenza	\$76,207.50	\$168,271.74
Inhibikase Therapeutics Inc	Antiviral treatment for progressive multifocal leukoencephalopathy	\$61,799.50	\$182,679.74
Inhibikase Therapeutics Inc	Antiviral treatment for polyomavirus-associated nephropathy	\$61,799.50	\$182,679.74
INHIBITEX, INC	FV-100	\$244,479.24	
INHIBITEX, INC	INX-189	\$244,479.24	
InVasc Therapeutics, Inc	INV-140 Series	\$137,557.00	\$106,922.25
LEXICOR MEDICAL	NEBA-M(NEUROPSYCHIATRIC EEG-		\$244,479.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
TECHNOLOGY, LLC	BASED ASSESSMENT AID-Major Depressive Disorder)		
Lexicor Medical Techonology LLC	NEBA (neuropsychiatric eeg-based ADHD assessment Aid	\$244,479.24	
Luminomics Inc	Degenerative Disease models in zebrafish	\$184,394.18	\$60,085.07
MD Innovate, Inc	PneumoniaCheck-A Therapeutic Discovery Project		\$244,479.25
Metabolic Testing Services, Inc.	Metabolic Testing for Early Detection & Treatment of Heart Disease	\$244,479.24	
MiMedx Group, Inc.	CollaFix Therapeutic Delivery	\$244,479.25	
NeurOp, Inc	Neuroprotection by pH Sensitive Antagonists to the NMDA NR2B Receptor	\$198,809.00	\$45,670.25
Revogenex, Inc.	RVX-108 (CDP-CB) IND 105,579 Chlorideazepoxide Hydrochloride	\$244,479.25	
Revogenex, Inc.	RVX-100 (L-HS) IND 105,364 Hysocamine Sulfate	\$244,479.25	
Revogenex, Inc.	RVX-109 (TRML) Tramadol Hydrochloride for Injection (IV)	\$204,277.25	\$40,202.00
Salutria Pharmaceuticals LLC	Development of Succinobucol to Reduce Cardiovascular Risk in Type 2 Diabetes Patients	\$244,479.24	
Sanuwave Inc	dermaPace FDA IDE study for treating chrinic diabetic Foot ulcers	\$244,479.24	
Sebacia, Inc	Sebacia Acne Therapy		\$244,479.24
Serrg Savannah Inc	CB-01-02/01 (Cosmo)	\$5,241.50	
Serrg Savannah Inc	PTK 0796-CSSSI-0804	\$26,206.50	
Serrg Savannah Inc	NXL 103/2002 (Novexel)	\$20,965.00	
Serrg Savannah Inc	GSK TOC110978	\$7,748.50	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
SoloHealth, Inc	SoloHealth Health and Wellness Kiosk	\$244,479.25	
Southeast Regional Research Group Inc	CB-01-02/01(Cosmo)	\$2,305.00	
Southeast Regional Research Group Inc	PTK 0796-CSSSI-0804	\$13,825.00	
Southeast Regional Research Group Inc	GSK TOC110978	\$4,608.50	
Southeast Regional Research Group, Inc	CE06-300(Cempra ABSSSI)	\$9,216.50	
Southeast Regional Research Group, Inc.	CVRX	\$18,433.00	
Tissue Regeneration Technologies, LLC	Software	\$126,172.00	\$118,307.25
Transfusion & Transplantation Technologies INC.	Aegis Automated Blood Analyzer	\$198,769.50	\$45,709.75
Velocity Medical Solutions, LLC	Imaging for Treatment Assessment and Response to Cancer Therapies	\$244,479.25	
Visioneering Technologies, Inc	Development of a Novel Therapeutic to Treat and Prevent Myopia	\$244,479.25	
Zenda Technologies, Inc.	DETECT - an immersive solution for neuropsychological testing in a primary care setting	\$167,354.00	\$77,125.25
Zirus Inc	The Development of Broadly Active and Orally Bioavailable Antiviral Drugs	\$244,479.24	

Hawaii \$4,494,694.93

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
-----------------------	---------------------	--------------------------------	--------------------------------

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Cardax Pharmaceuticals, Inc.	CDX-085 A novel drug from Cardax Pharmaceuticals, for inflammatory Disease	\$244,479.25	
Cellular Bioengineering Inc	Bioengineered Artificial Cornea for Restoration of Vision	\$244,479.24	
Cellular Bioengineering Inc. (CBI)	Technology for Secure and Accurate Delivery of Therapeutics and Dosage	\$244,479.24	
Cellular Bioengineering, Inc.	Treatment and Removal of Absorbed Radioactive and Carcinogenic Chemicals	\$244,479.24	
Hawaii Biotech, Inc	Dengue Recombinant Subunit Vaccine	\$244,479.24	
Hawaii Biotech, Inc	West Nile Recombinant Subunit Vaccine	\$244,479.24	
Hoana Medical Inc	Lifebed/Lifegurney Patient Vigilance System	\$244,479.25	
Nanopoint Inc.	Implementation of novel microfluidics platform for infertility treatment	\$244,479.24	
Oceanit Laboratories Inc	Nanovector Drug Delivery System	\$13,150.00	\$74,808.50
Oceanit Laboratories, Inc	Laser Actuated Transcranial Hemostasis (LATCH)	\$59,566.50	\$30,865.00
OCEANIT LABORATORIES, INC.	RAPID ADVERSE IDENTIFIER FOR DRUG AND EVALUATION RESOURCE	\$244,479.25	
Pacific Biotech, LLC	Identification and evaluation of a potent angiogenesis inhibitor	\$148,891.50	\$95,587.74
Panthera Biopharma LLC	Discovery & Development of Anti-Viral small molecule therapeutics for flaviral infections.	\$152,793.50	\$41,360.50
Panthera Biopharma	Development of a Multi-Valent	\$138,685.00	\$22,898.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
LLC	recumbinant subunit for filovirus infections		
Panthera Biopharma LLC	Discovery & Development of small molecule Anti-Toxin Therapeutics for Anthrax	\$244,479.25	
PANTHERA BIOPHARMA, LLC	DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE ANTI-TOXIN THERAPEUTICS FOR BOTULISM	\$193,647.50	\$50,831.75
Skai Technologies LLC	Development of Bioengineered Soft Tissue Graft Technology		\$48,900.00
STI Medical System, LLC	Colon Cancer (Colonocad) Program	\$175,582.50	\$68,896.75
STI Medical Systems, LLC	ULTRASIGHTHD® COLPOSCOPY SYSTEM w/ IMAGESENSE™ DIAGNOSTIC ENHANCEMENT TECHNOLOGIES	\$244,479.25	
TEAMPRAXIS, LLC	Poplulation Health Management (PHM) Module of Allscripts Clinical Quality Solution (CQS)	\$100,313.50	\$144,165.75
Tissue Genesis, Inc.	Tissue Genesis / Adipose derived cell therapy and regenerative medicine	\$244,479.25	

Illinois \$13,953,940.11

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
AbaStar MDx Inc	ABS-21: Schizophrenia Diagnostic Product Development	\$52,600.00	\$191,879.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Abiant Inc.	Early, Accurate Detection and Measurement of Therapeutic Response for Dementias	\$38,826.50	\$59,270.00
Academic Pharmaceuticals Inc	Development of an Intravenous Formulation of Metolazone	\$4,500.00	\$131,500.00
Academic Pharmaceuticals LP	Aqueous Amiodarone for Treatment & Prevention of Ventricular Tachycardia & Fibrillation	\$76,848.00	\$85,300.00
Acura Pharmaceuticals, Inc.	AveRox	\$50,000.00	\$194,479.25
Acura Pharmaceuticals, Inc.	Prazatrex	\$51,650.00	\$19,450.00
ADVANCED COOLING THERAPY, LLC	Development of an Esophageal Temperature Management Product	\$10,000.00	\$27,500.00
Advanced Life Sciences Inc	Cethromycin for Respiratory Tract Infections	\$244,479.25	
Advanced Scanning Inc.	Rapid Screening Device for Young Adults to Prevent Sudden Death	\$34,188.00	\$149,000.00
AJ Medical Devices Inc	Implanted Cardiac Arrest Alarm	\$244,479.24	
Arphion LTD	Oral Brush Cytology RNA Screening for Oral Cancer	\$12,038.50	
AtCor Medical Inc USA	Treatment of Patients with Heart Failure through Aggressive Cardiac Load Reduction	\$109,240.00	\$26,397.00
AuraSense, LLC	Nano-Flare Platform for Intracellular Assays	\$4,455.00	\$240,024.24
AURORA LIFE SCIENCES LLC	AutoImmune Diagnostic Array (ADA)		\$244,479.25
B&G Partners	Novel Mucin-Directed TGF-B		\$244,479.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	ALK5 Inhibitors Targeted for Muc4		
B&H Biotechnologies LLC	A drug candidate for prevention and treatment of serious influenza infections	\$38,940.00	\$61,000.00
BioSante Pharmaceuticals, Inc.	Phase II Development of LibiGel for Low Sexual Desire, A Significant Unmet Medical Need	\$244,479.25	
CDG Therapeutics, Inc	Novel therapy for advanced refractory tumors	\$244,479.25	
Corpak Medsystems, Inc.	Project Triangle - Cortrak 11	\$244,479.25	
Endotronix Inc	Reducing the Heart Failure Cost Burden: Anytime, Anywhere Pulmonary Pressure Monitoring	\$244,479.25	
Entopy Research LLC	Gastrointestinal allergy diagnostic device and method		\$43,750.00
Errant Gene Therapeutics, LLC	Thalagen, a Novel Gene Therapy for the treatment of B Thalassemia Major and Sickle Cell Anemia	\$244,479.25	
Genomics USA, Inc.	Next-Generation Microarray Technology, For Low-Cost HLA-Typing	\$244,479.24	
Horizon Therapeutics, Inc	HZT-501, Ibuprofen/famotidine Proprietary Combination Tablet	\$244,479.25	
Immune Cell Therapy	Immune Cell Therapy's Autologous Cancer Vaccines		\$29,955.00
Innovative Visual Systems LLC	Discovery	\$128,122.50	\$116,356.75
Jina Pharmaceuticals Inc.	Development of Endoxifen: A New Cornerstone for Breast Cancer Prevention and Therapy	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Kim Laboratories, Inc	Disinfectant and Diagnostic tests for Norovirus	\$170,817.50	\$73,661.75
Lavax, Inc.	Infant Formula Blocks HIV Transmission Via Breastfeeding		\$95,346.50
Lenticular Research Group LLC	Management of the growth of the human crystalline lens		\$244,479.25
Lohocla Research Corporation	Novel Markers for Alcohol Intake and Alcohol-Induced Organ Damage	\$141,389.57	\$103,089.68
Metritrack LLC	Automated Free Hand Breast Ultrasound Screening and Diagnostic system	\$11,861.19	\$33,791.69
Nanoink Inc	NanoEncryption	\$244,479.24	
Nanoink, Inc.	NanoStemCell	\$244,479.24	
NANOSPHERE, INC	Diagnostic tests for the early detection of cancer	\$244,479.25	
NANOSPHERE, INC	Diagnostic tests for the detection of infectious diseases	\$244,479.25	
NANOSPHERE, INC.	Diagnostic tests for the early detection of immune system disorders	\$244,479.25	
NANOSPHERE, INC.	Diagnostic tests for the detection and prevention of cardiac and vascular diseases.	\$244,479.25	
Nanotope, Inc.	Peptide-Amphiphile Nanofiber Matrix	\$244,479.25	
Naurex, Inc	Improved CNS Therapies Through Development of Novel Drugs to Modulate NMDA Receptor	\$244,479.24	
NeoPharm Inc	Clinical Evaluation of LEP-ETU in Cancer Patients	\$244,479.25	
NeoPharm Inc	IL 13-PE as a novel, targeted	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	therapy for Idopathic Pulmonary Fibrosis		
Nerve Access, Inc	The Alzheimer Project		\$244,479.25
NeuRDS Inc.	Enabling Wireless Delivery of Electrical Stimulation Therapy	\$22,053.00	\$105,842.00
Neuro Therapeutics Pharma Inc	NTP-2014	\$244,479.24	
NeuroTherapeutics Pharm, Inc	NTP-6009	\$9,692.50	\$234,786.74
NovaDrug, LLC	Development of novel anti-hepatitis C virus (HCV) drugs	\$244,479.25	
Novian Health Inc.	Novilase Interstitial Laser Therapy	\$244,479.24	
OHMX Corporation	Versatile, cost-effective point-of-care medical diagnostic device for chronic diseases	\$244,479.25	
Rhoexotech. LLC	Controlled coronary reperfusion during PCI for acute ischemia	\$2,379.50	\$233,750.00
Siwa Corporation	Treatment of adverse complications of diabetes through enhanced clearance of AGE-modifie		\$65,125.00
SNAP Diagnostics	SNAP Model 8	\$104,115.50	\$109,079.50
SteadySleepRx Company	Obstructive Sleep Apnea Drug Program	\$244,479.24	
SWORD DIAGNOSTICS, INC.	Improve immunoassay sensitivity & accuracy in disease ID & quantitation of biomarkers.	\$244,479.25	
Synergenz BioScience, Inc.	Respiragene Lung Cancer risk Predictive test	\$20,095.00	\$74,741.50
Tactic Pharma, LLC	ATN-161		\$244,479.24

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Tactic Pharma, LLC	huATN-658		\$244,479.24
Tolerogenics Inc	Use of a Bispecific Antibody for Treating Type I Diabetes	\$29,042.51	\$51,364.31
Toltec Pharmaceuticals LLC	Development of TOL-463: a vaginal biofilm disruptor for the treatment of vaginitis		\$229,946.50
VASSOL, Inc	NOVA toolkit for quantitative Magnetic Resonance Angiography (qMRA)	\$242,287.50	\$2,191.75
VesselTek BioMedical LLC	Drug-eluting, elastomer-coated vascular graft	\$40,554.16	\$40,548.16
VidaGene	Identification of biomarkers for VDR activation	\$96,685.50	\$117,064.50
Vidasym	Novel VDR Modulators with Expanded Therapeutic Index and Cardio-Renal Protective Effects	\$46,779.00	\$81,987.00
ViMedicus, LLC.	ViMedicus HER 301		\$244,479.25
Winston Laboratories, Inc	Civamide Capsule	\$221,647.38	\$22,831.86
Winston Laboratories, Inc.	Civamide Nasal Spray	\$12,545.81	\$231,933.43
Winston Laboratories, Inc.	Civamide Cream	\$244,479.24	
Winston Laboratories, Inc.	Civamide Patch	\$151,319.33	\$93,159.91
zuChem inc	Xylitol	\$107,207.21	\$38,583.28
zuChem Inc	Therapeutic Oligosaccharides and Glycosylated Small Molecules	\$98,427.25	\$86,651.26

Indiana \$10,293,530.56

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Aarden Pharmaceuticals Inc	Development of Novel Drugs Targeting Key Protein Tyrosine Phosphatase Disease Targets	\$86,772.79	\$157,706.45
Admiral Medical Supply, Inc	Qualifying Therapeutic Discovery Project Credit		\$180,750.00
AgeneBio Inc	Development of Low Dose Levetiracetam Therapy for Amnesic Mild Cognitive Impairment	\$28,750.00	\$50,750.00
AgeneBio Inc	Development of GABAA $\alpha 5$ agonists for treatment of amnesic Mild Cognitive Impairment (aMCI); these compounds may also modify or slow progression to Alzheimer's Disease.	\$30,387.50	\$206,500.00
Akina, Inc.	Microfabrication	\$144,623.50	
ApeX Therapeutics, Inc	Development of APE1 Inhibitors for Treatment of Cancers and Retinal Diseases	\$14,842.52	\$164,063.04
Ash Access Technology, Inc	Zuragen Catheter Lock Solution	\$244,479.25	
Ash Access Technology, Inc	ZuraPrep Preoperative Skin Preparation	\$164,370.59	\$64,472.88
BIOSCIENCE VACCINES INC	The Development of Improved Vaccines for Human Use	\$44,692.50	\$199,786.74
Chemigen, LLC	CC100 Project ALS	\$92,371.50	\$152,107.75
CS-Keys, Inc	Definitive cancer diagnosis with a conserved biomarker of malignancy	\$244,479.24	
Dunigan Medical Inc	Proton/Photon flexible dosimetry and organ displacement catheters	\$75,000.00	\$65,000.00
Elona Biotechnologies	USP Insulin	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Inc			
EndGenitor Technologies, Inc	Neovascular Cell Therapeutic for Cardiovascular Disease	\$199,566.00	\$44,913.25
Endocyte Inc	EC20	\$244,479.25	
Endocyte Inc	PSMA	\$244,479.25	
Endocyte Inc	EC0489	\$244,479.25	
Endocyte Inc	EC145	\$244,479.25	
Endocyte, Inc	EC0531	\$185,000.50	\$59,478.75
Endocyte, Inc	Inflammation	\$244,479.25	
Focus Surgery inc	Development of Laparoscopic Probe to treat of metastatic cancers {prostate pancreas, ect }	\$244,479.25	
General Bio Technology, LLC	Therapeutic Angiogenesis by Universal Donor Endometrial Regenerative Cells	\$24,523.99	\$70,145.27
General Bio Technology, LLC	A Novel Approach to GMP Production of Tooth Derived Stem Cells	\$115,913.17	\$128,566.07
General Bio Technology, LLC	Automated Closed System for DMSO Removal from Peripheral Blood Stem Cells	\$244,479.24	
General BioTechnology, LLC	A public umbilical cord blood bank to facilitate allogenic cord blood transplantation	\$85,639.72	\$148,771.26
Glucago LLC	Innovative Delivery Device For a Wide Rangeof Lyophilized Drugs	\$11,800.51	\$232,678.74
GRest Inc	Reversible Gastric Sleeve Implant for Substantial Weight Loss with Preserved Anatomy	\$110,178.50	\$134,300.75
Horizon Biotechnologies, LLC	AVN316		\$244,479.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
IKOTECH LLC	Magnetic Sorter Channels for Stem Cells.	\$70,242.45	\$89,760.96
IVDiagnostics LLC	IVD Onco Dx - CTC Platform	\$106,021.00	\$138,458.24
Kylin Therapeutics Inc	KT-105 a pRNA nanoparticle for cancer treatment	\$244,479.24	
Marcadia Biotech, Inc.	GIP/GLP - 1 Dual Agonist for Treatment of Diabetes and Obesity	\$244,479.25	
Matrix Bio, Inc.	Metabolite Profiling Technology	\$100,284.50	\$84,000.00
Morris Innovative Inc.	Femoral Introducer Sheath and Hemostasis Device	\$244,479.25	
NOX Technologies, Inc.	Oral arNOX inhibitors for Atherogenesis Prevention and Skin Health	\$93,954.50	\$150,524.74
Park Funding, LLC d/b/a Semafore Pharmaceuticals	SF1126-Dual mTOR-P13K Inhibition For Next Generation Cancer Treatment	\$244,479.25	
PDS BIOTECHNOLOGY CORPORATION	DEVELOPMENT OF POTENT, SAFE AND COST EFFECTIVE THERAPEUTIC (CURATIVE) CANCER VACCINES	\$244,479.24	
Pericardial Access, Inc	Rapid, Safe, Controlled Access to the Pericardial Space for Left Ventricle Lead Delivery	\$152,888.50	\$91,590.75
Pharmacophotonics, Inc	FAST GFR System	\$244,479.24	
Preclinomics, Inc	Fatzo mouse, obese diabetic (type II) mouse model without leptin/leptin-receptor defects	\$64,308.00	\$54,050.00
Preclinomics, Inc	ZDSD rat, an obese diabetic (typeII) rat model without leptin/leptin-receptor defects	\$227,381.50	\$17,097.74

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
ProCure Treatment Centers, Inc.	Negative Pressure Breast Stabilization Device (BSD)	\$158,700.00	\$85,779.24
Solstice Medical,LLC	RFSuite System	\$244,479.25	
SonarMed, Inc	SonarMed Airway Monitoring System (AMS)	\$244,479.25	
Symbios Holdings, Inc	GOPump Rapid Recovery System	\$244,479.25	
SynTherix Inc	Therapeutic Compounds for the treatment of Cancer	\$164,725.00	\$79,754.25

Iowa \$1,744,960.41

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Advanced Analytical Technologies Inc	DNA Profiler for Rapid Pathogen identification	\$244,479.25	
Cellular Engineering Technologies, Inc	Development of regenerative medicine tools for preclinical drug development	\$68,982.50	\$68,982.50
J & J Solutions Inc	Innovative Medical Device for Safe Effective Delivery & Administration of Chemotherapeutics	\$136,086.00	\$108,393.25
KemPharm, Inc	KP106: A Treatment for Attention Deficit/Hyperactivity Disorder (ADHD)	\$244,479.25	
KemPharm, Inc.	KP303: A Treatment for Schizophrenia and Bipolar Disorder	\$175,678.00	\$68,801.25
MedCara Pharmaceuticals,	WartPEEL	\$57,079.78	\$41,561.13

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
LLC			
MTI BIOTECH INCORPORATED	3MH BIOMARKER	\$11,997.00	\$29,482.00
NewLink Genetics Corp	HyperAcute Vaccines for Cancer	\$244,479.25	
Terpenoid Therapeutics Incorporated	Developing Terpenes as Anti-cancer Therapeutics	\$244,479.25	

Kansas \$3,818,255.68

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
CritiTech, Inc	Nanotax®: sustained drug release from pure drug nanoparticles to treat ovarian cancer	\$150,954.50	\$93,524.74
CritiTech, Inc.	Nanothecin™: sustained drug release from pure drug nanoparticles to treat peritoneal cancer	\$133,544.50	\$110,934.74
CyDex Pharmaceuticals Inc	Melphalan HC1 for Injection(Propylene Glycol Free)	\$244,479.24	
CyDex Pharmaceuticals Inc	New Dosage Form of Clopidogrel-Rapid Onset Injectable	\$133,059.00	\$111,420.24
Edenspace Systems Corporation	An oral Therapeutic Agent for Ischemic, Inflammatory and Immune Disorders	\$3,316.00	\$68,826.00
ImmunoGenetix Therapeutics, Inc	GenePro™ (4SHIVku2)- a DNA vaccine therapeutic for HIV patients	\$57,552.08	\$15,420.00
KC BioMedix, Inc	Ntrainer System ®	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Madeira Therapeutics LLC	Novel Analgesic Oral Solution to Treat Pain in Children.		\$154,500.00
Maderia Therapeutics, LLC	Novel Simvastatian Oral Solution to Treat High Cholesterol in Children	\$198,050.00	\$46,429.24
NanoScale Corporation	Functionalized Core/Shell Fe/Fe304 Stealth Nanoparticles for Cancer Diagnosis & Treatment		\$78,000.00
NanoScale Corporation	Intelligent Low-Toxicity Materials for Cancer Diagnosis and Treatment.	\$66,869.00	\$54,807.46
Nexus Medical, LLC	Nexus TKO	\$187,678.50	\$56,800.75
Oncimmune (USA) LLC	EarlyCDT-Lung-a novel blood test to aid in the early detection of cancer	\$244,479.24	
Orbis Biosciences, Inc	Precision Particle Fabrication Technology for improving Therapeutics through API Control	\$149,637.14	\$94,842.10
Pulse NeedleFree Systems, Inc.	Multi-Use Needle-Free Injection Device	\$53,817.50	\$86,917.50
Spinal Simplicity, LLC	Minuteman & Scarab Interspinous Process Fusion Cage Devices	\$120,187.78	\$124,291.47
TVAX Biomedical, LLC	TVI-Brain-1 as a Treatment for Malignant Cancer	\$9,183.50	\$235,295.74
VasoGenix Pharmaceuticals Inc	Novel Sustained Treatment of Heart Failure	\$244,479.24	
Verrow Pharmaceuticals Inc	Development of a new kidney protective x-ray contrast dye	\$235,199.50	\$9,279.74

Kentucky \$4,292,588.43

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Advanced Genomic Technology, LLC	Circulating RNA diagnostic for metastatic ovarian carcinoma:an animal model study		\$244,479.25
ALLTranz Inc	Abuse Deterrent Transdermal Buprenorphine for Treatment of Pain and Opiate Addiction	\$79,584.13	\$68,561.57
ALLTRANZ Inc	Transdermal Cannabinoid Prodrug Treatment	\$90,303.08	\$154,176.16
Alltranz Inc	Transdermal Cannabidiol for Treatment of Osteoarthritis, Alcoholism, And Other Diseases	\$114,288.70	\$85,744.68
ALT BioScience LLC	Periodontal diagnostic strip	\$244,479.25	
Apellis Pharmaceuticals, Inc.	Complement Inhibitors as a Therapeutic for Asthma		\$244,479.25
ApoImmue, Inc	ApoVax104 as a Novel Vaccine Platform Technology	\$244,479.25	
Assenti LLC	IOP and Therapeutic Monitoring System for Glaucoma Patients	\$54,310.50	
CeeLA Naturals	Burn Treatment Adjuvant Therapies	\$60,503.50	\$114,405.00
CTI Science Inc	NBMI Drug Approval	\$230,691.00	\$13,788.24
EndoProtech, Inc.	Novel Therapy to improve outcomes in cardiac transplantation	\$166,515.50	\$77,963.74
Kentucky Pharmaceuticals Inc	Inflammation-Targeting theragnostic nanocomposite system for the eye		\$244,479.25
NeoCytex	Novel Neuroregenerative Drug	\$115,894.93	\$38,209.84

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Biopharma Inc.	Therapy for Stroke		
OrthoData, Inc	Diagnostic improvements in spinal fusion	\$244,479.25	
Potentia Pharmaceuticals, Inc	POT-4	\$244,479.25	
Pradama, Inc.	Bone-targeted Vancomycin for the Treatment of Osteomyelitis (Bone Infection)	\$43,771.50	\$133,681.00
Re-Borne Inc	Re-Borne Prosperity Project		\$73,500.00
Regenerex. LLC	FCRx for Safe Bone Marrow Transplantation	\$167,516.00	\$76,963.25
RhinoCyte, Inc.	The use of olfactory of stem cells for neurodegeneration	\$244,479.24	
Summit Biosciences Inc.	THC-nasal spray		\$138,247.00
Summit Biosciences LLC	THC- nasal spray	\$9,639.00	
Vindico NanoBio Technology, Inc.	Polymersomes, a nonoparticle-based delivery platform	\$40,291.27	\$188,204.85

Louisiana \$1,955,833.96

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Autoimmune Technologies, LLC	Flufirvitide-3: A Broad-Spectrum Entry-inhibiting Seasonal and Pandemic Influenza Drug	\$216,310.35	\$28,168.90
DEKK-Tec, Inc.	The Clinical Development of 4-Demethylcholesterloxy carbonylpenclomedine. The Clinical Development of 4-Demethylcholesteryloxy carbonylpenclomedine (DM-CHOC-PEN) for the Treatment of Cancers Involving the Central Nervous System	\$126,990.50	\$117,488.74

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Embera Neuro Therapeutics, Inc.	EMB-001: A novel pharmaceutical product for the treatment of addictive disorders	\$244,479.24	
Esperance Pharmaceuticals, Inc	The Development of a Cationic Lytic Peptide (CLYPTM) Technology Platform	\$244,479.24	
Meta Logos Inc	Trace-level biosensing for early detection, and treatment, of cancer and other diseases.	\$137,500.00	\$106,979.24
NuPotential, Inc.	A new Approach to Regenerative Medicine Development	\$244,479.25	
TCA Cellular Therapy LLC	TCA Cellular Therapies for treatment of cardiovascular and neurological disease.	\$168,075.93	\$76,403.32
TRANSGENRX, INC.	Engineered glycosylated interferons for the treatment of viral diseases, Melanoma and MS	\$244,479.25	

Maine \$275,654.24

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
AIKO Biotechnology Inc	AIKO 150: Drug Therapy for Treatment Constipation associated with Opioid USE		\$43,867.74
Bar Harbor BioTechnology	Bar Harbor BioTechnology-Diagnostic Initiative	\$77,770.50	\$82,018.50
Sea Run Holdings Inc	Salmon Fibrin for inflammation and pain	\$71,997.50	

Maryland \$48,745,215.69

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
20/20 GeneSystems Inc	Diagnostic for the Early	\$165,935.50	\$78,543.74

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Detection of Lung Cancer		
20/20 GeneSystems Inc	PredicTOR cancer diagnostic	\$244,479.24	
A&G Pharmaceuticals, Inc	Development of Anti-GP88 Drug & Diagnostic: Novel Therapy for Chemoresistant Cancer	\$244,479.25	
Adlyfe, Inc.	Adlyfe Alzheimer's Diagnostic Assay	\$244,479.25	
Advanced Biomimetic Sensors, Inc	Development of an Accurate, Pain-free and Reagent-free Blood Glucose Monitoring Device	\$73,757.09	\$32,007.02
Akonni Biosystems, Inc.	Simultaneous PCR & Microarray Detection, TruArray Test	\$244,479.25	
Akonni Biosystems, Inc.	The Multiplexed Respiratory Infection POC Testing in 15 Minutes	\$244,479.25	
Alan Penn & Associates, Inc.	CAD system to improve sensitivity of breast MRI using diffusion weighted imaging	\$25,376.24	\$7,511.99
Alper Biotech LLC	Biomarker Platform Technology for Breast Cancer Diagnosis and Treatment	\$116,052.70	\$128,426.55
Ambay Immune Sensors and Controls LLC	Immune Sensor for Early Detection of Breast Cancer in Blood	\$8,082.50	
American Gene Technology International Inc.	Safe Lentiviral Delivery of Multiple Therapeutic Molecules for the Treatment of Cancer	\$140,816.50	\$103,662.75
Amplimmune, Inc	AMP-224 A novel Drug for the Treatment of Cancer and Infectious Disease	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Amplimmune, Inc	AMP-110: A Novel Product Candidate for the Treatment of Autoimmune Disease	\$244,479.24	
AnGes, Inc	Therapeutic angiogenesis with HGF plasmid (collatogene)in critical limb ischemia (CLI)	\$244,479.25	
Aparna Biosciences Corporation	Ligand-Targeted Lentiviral Vectors for Systemic Gene Therapy	\$161,029.00	\$83,450.25
Aparna Biosciences Corporation	Antifungal therapeutic for life-threatening invasive fungal infections	\$68,282.00	\$27,592.00
Aparna Biosciences Corporation	Nanoparticle Based Dual-antigen Anthrax Vaccine	\$52,457.50	\$152,753.50
Aparna Biosciences Corporation	In vivo targeted siRNA nanoparticles for non-small cell lung cancer	\$177,183.00	\$67,296.25
Applied Sensor Research & Development Corporation	Acoustic array biosensor for multiplexed point of care diagnosis of infectious agents	\$51,340.23	\$80,350.34
Arcion Therapeutics, Inc	ARC-2022	\$244,479.25	
Arcion Therapeutics, Inc	ARC-4558	\$244,479.25	
Astha Consultancy, Inc	Discovery of prophylactic antimalarials, oral delivery cutaneous antileishmanial and blood-brain barrier crossing Acetylcholine esterase-Organophate reactivator drugs for the war fighter	\$36,501.50	\$50,616.00
BioAssay Works, LLC	Development of Rapid, Point of Care) Diagnostics for HIV & Methicillin-Resistant Staph.	\$16,338.00	\$6,319.50
BioAssay Works, LLC	Development of rapid, Lateral-Flow and ELISA	\$31,967.50	\$26,555.50

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Research Assays for Kidney Injury Molecule		
BioAssay Works, LLC	Development of rapid, Lateral-Flow Diagnostic Assays for Various Infectious Diseases	\$7,583.00	\$9,674.50
BioAssay Works, LLC	Modification/Conjugation of Antibodies to Thyroid Stimulating Hormone & Cardiac Troponin	\$2,795.00	\$7,909.00
BioAssay Works, LLC	Development of rapid, Lateral-Flow Diagnostic Assay to Detect PROM in pregnant women	\$12,189.50	\$16,592.00
BioElectronics Corporation	Third Molar Extraction Pain		\$128,270.00
BIOFACTURA, INC.	SMALLPOX BIODEFENSE THERAPEUTIC	\$204,793.72	\$39,685.52
Biological Mimetics, Inc	Immune Refocusing Technology	\$232,631.50	\$11,847.75
BioMarker Strategies	SnapPath™ Biomarker Testing System for Cancer		\$244,479.25
Biospheric Incorporated	Development of D-tagatose for treatment of hypertriglyceridemia		\$225,000.00
Biospherics, Inc	Development of D-tagatose oral prescription medicine for treatment of Type 2 diabetes	\$244,479.24	
BioSurface Engineering Technologies Inc	BioSET F2A Reparative Mesh	\$36,325.50	\$31,310.00
BioSurface Engineering Technologies Inc	BioSET Amplex with B2A	\$244,479.25	
BioSurface Engineering Technologies, Inc	BioSET PreFix with B2A	\$244,479.25	
Biosynexus Incorporated	Pagibaximab	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Blue Torch Medical Technologies Inc	Vitruvian Robotic Diagnostics Platform for Cancer Surgery Advancement		\$213,900.00
BrainScope Company Inc	BrainScope Ahead M-100	\$244,479.24	
CCC Diagnostics, LLC	Pharmacodiagnostic Molecular Test Panels to Optimize Chemotherapy Selection	\$244,479.25	
Celadon Laboratories Inc.	Molecular Diagnostics for Tuberculosis and African-American Public Health.	\$151,820.50	\$92,658.74
Celek Pharmaceuticals LLC	Development of CEL-031, a targeted therapeutic for non-muscle invasive bladder cancer.		\$38,783.80
Celek Pharmaceuticals LLC	Development of CEL-021 for the treatment of interstitial cystis/painful bladder syndrome	\$500.00	\$19,592.50
Celek Pharmaceuticals LLC	Development of CEL-011, an innovative bladder cancer therapy	\$18,281.98	\$17,294.89
Cellex, Inc	Qflu Influenza Diagnostic and Drug Resistance Combo Tes	\$114,051.38	\$130,427.87
Cellex, Inc.	A Quantitative Bacterial Vaginosis Test for Point-of-Care Use	\$139,396.13	\$105,083.12
Cellona Therapeutics, Inc	CT-10, a new class of compound and targeted cancer drug		\$244,479.24
Cellphire, Inc.	Cellphire platelet Stabilization Therapeutic	\$244,479.25	
Celsion Corporation	ThermoDox®-A heat activated Liposomal Encapsulation of Doxorubicin	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	to treat HCC		
Centegen, Inc	A Novel Approach to Treat Staphylococcus Aureus Infections (Including MRSA)	\$65,541.67	\$178,937.58
Centegen, Inc.	A Novel Vaccine to Prevent Staphylococcus Aureus Infections (Including MRSA)	\$8,583.34	\$42,375.00
CHAMPIONS BIOTECHNOLOGY INC	Development of Single Chain Antibody Fragment Targeting Mutant p53 for the Treatment of Cancer	\$140,927.00	\$103,552.25
Champions Biotechnology, Inc	Development of Personalized Tumorgraft Models to Identify Biomarkers and Guide Personalized Cancer Therapies	\$118,653.50	\$124,142.00
Champions Biotechnology, Inc.	Development of Small Molecule Autotaxin Inhibitor Bithionol for the Treatment of Cancer	\$147,870.00	\$96,609.25
Champions Biotechnology, Inc.	Development of a Novel Predictive Preclinical Tumorgraft Platform to Enhance and Accelerate Oncology Drug Development	\$244,479.25	
Champions Biotechnology, Inc.	Development of Irinophore-C™ a Novel Nanoparticle Formulation of Irinotecan as an Anti-Cancer Therapy	\$118,803.50	\$125,675.75
Champions Biotechnology, Inc.	Development of Small Molecule Tubulin Inhibitor SG410 for the Treatment of Cancer	\$190,057.50	\$54,421.75
Clarassance, Inc.	Recombinant human CC10 protein for prevention of neonatal BPD	\$77,769.00	\$166,710.24

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Columbia Biosystems Inc	Point-of-Care Diagnostics of Infectious Diseases Using Molecularly Imprinted Polymers	\$131,580.00	\$105,044.00
Cordex Systems, LLC	Development of the Cordex Cardiovascular Device		\$222,606.00
Correlogic Systems Inc	Development of diagnostic Multi-variate Assays for Ovarian and Breast Cancers	\$244,479.24	
Corridor Pharmaceuticals, Inc	The therapeutic application of C-122 in Pulmonary Arterial Hypertension (PAH)	\$244,479.24	
Corridor Pharmaceuticals, Inc	Therapeutic application of Arginase inhibitors for the treatment of endothelial dysfunction	\$244,479.24	
CSA Medical, Inc.	TruFreeze Spray Cryotherapy Therapeutic Agent Delivery Platform	\$244,479.24	
CytImmune Sciences, Inc	Pegylated Colloidal Gold Nanoparticles: The Core of a Family of Novel Nanomedicines	\$244,479.25	
DioGenix Inc	Development of a Blood Test for the Early Detection of Multiple Sclerosis	\$244,479.24	
Entremed Inc.	ENMD-2076	\$244,479.24	
ExonHit	Dx21	\$244,479.25	
ExonHit Therapeutics, Inc.	Program 107	\$3,253.50	\$79,222.00
FASgen, Inc.	Treatment of Recurrent Ovarian Cancer	\$244,479.25	
FLAVORx, Inc. & Subsidiary	Medicinal Compliance	\$71,098.00	\$76,925.50
Functional Genetics, Inc	Development of a Broad	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Spectrum Antiviral Antibody Therapeutic Targeting TSG 101		
Functional Genetics, Inc	Development of a Broad Spectrum Small Molecule Antiviral Therapeutic Targeting TSG-101	\$244,479.24	
Fyodor Biotechnologies Inc	Urine Malaria Test (UMT)	\$94,584.27	\$149,894.98
GenArraytion Inc	Development of Biomarkers for Clinical Assessment of Occult Infections	\$93,159.50	
GeneCopoeia, Inc.	Plasmeprin V Inhibitor Therapeutics for Malaria Infection		\$223,750.00
GeneCopoeia, Inc.	p53 Fusion Protein Therapeutics for Pancreatic Liver Cancer	\$244,479.25	
GeneCopoeia, Inc.	Mutant MicroPlasmin Therapeutics	\$244,479.25	
GeneCopoeia, Inc.	Recombinant alpha 1-Antitrypsin Therapeutics	\$244,479.25	
GenVec, Inc.	TNFrade™ Biologic	\$244,479.25	
Gliknik Inc	GL-2045, A stradomer for the treatment of ITP, RA other Chronic Autoimmune diseases	\$244,479.24	
Gliknik Inc	Clinical stage immunomodulators GL-0810 and GL-0817 for the treatment of cancer	\$8,574.00	\$235,905.24
Gliknik, Inc	GB-2542, a stradobody for the treatment of breast cancer and other cancers	\$236,068.50	\$8,410.74
Glycomimetics, Inc	GMI-1070	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Glycotex, Inc.	GLYC-101 Gel investigational product for treatment of acute and chronic wounds	\$132,917.50	\$111,561.74
Hitech Analytical and Diagnostic Solutions LLC	Prognostic Test Development for Recurrent Spontaneous Abortions and Viable Pregnancy	\$10,700.00	
Iatrica, Inc	Dev. Of novel tumor-targeted antibody-based fusion proteins for immunotherapy of cancer	\$195,392.00	\$49,087.25
ILSbio, LLC.	Development of Universal Research Specimen Sets	\$190,293.80	\$54,185.44
Imagilin Technology LLC	Novel approach to treat autoimmune hemolytic anemia {AIHA}, an autoimmune disease.	\$110,000.00	\$134,479.25
Imperium, Inc.	Speckle Free C-scan Ultrasound Video Imaging Camera for Clinical Diagnostics	\$141,524.00	\$102,955.25
ImQuest BioSciences, Inc	Carbendazim/Benzamidazoles Broad Based Anti-Tumor Agent Project	\$50,000.00	\$194,479.25
ImQuest BioSciences, Inc	Novel Carbamate-based HIV Replication Inhibitor Project	\$50,000.00	\$194,479.25
ImQuest BioSciences, Inc	Novel DNA Oligonucleotide development as a Topical Microbicide (ISIS 5320) Project	\$244,479.25	
ImQuest BioSciences, Inc	Novel Pyrimidinedione Small Molecule as a Topical Microbicide Project	\$244,479.25	
ImQuest BioSciences, Inc	PG 301029 Anti-HCV Program	\$64,794.50	\$179,684.75

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
ImQuest Pharmaceuticals Inc	Novel Piperazine Project	\$70,525.00	\$173,954.25
ImQuest Pharmaceuticals, Inc.	Novel Pyrimidinedione Project-IQP0410	\$244,479.25	
Infinite Biomedical Technologies, LLC.	EEG headband for Automated Seizure Detection with Telemedicine Review	\$208,417.84	\$36,061.41
Infinite Biomedical Technologies	Cortical Health Index Monitor - Regulatory Approval	\$143,724.63	\$79,462.56
Infinite Biomedical Technologies, LLC	Laser Speckle Imaging to Study Brain Tumor Vasculature	\$72,586.82	\$14,467.76
Infinite Biomedical Technologies, LLC	A dexterous prosthetic controller for multi-fingered hands	\$165,848.70	\$78,630.55
Infinite Biomedical Technologies, LLC.	Neonatal Neurological Monitor - Regulatory Approval	\$244,479.25	
InfraTrac, Inc	Protecting the Integrity of the Drug Supply with Spectroscopic Verification	\$19,062.50	\$33,650.00
Innovative Biosensors, Inc	Development of a CANARY® - based rapid clinical diagnostic test for MRSA.	\$244,479.25	
Integrated Biotherapeutics, Inc.	Therapeutics for Staph aureus and related toxic shock	\$244,479.24	
Integrated Biotherapeutics, Inc.	Staphylococcus aureus Vaccine Program	\$74,250.77	\$100,000.00
Kirkegaard & Perry Laboratories, Inc	In vitro-diagnostic grade antibodies for whole bacteria capture and detection	\$90,899.15	\$153,580.09
Lentigen Corporation	LG1041 Breakthrough Therapy/Cure for Hunter's		\$132,289.85

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Syndrome		
Lentigen Corporation	LG911 Novel Broad-Spectrum Cancer Therapy for Solid Tumors	\$5,833.05	\$57,088.32
Lentigen Corporation	LG912 Novel Hepatitis C/Liver Cancer Therapeutic Vaccine	\$11,988.24	\$82,594.26
Lentigen Corporation	Advanced Bioproduction Platform for US Military	\$138,997.66	\$79,624.52
Lentigen Corporation	LG611 High Potential Pandemic Influenza Vaccine	\$244,479.25	
Lentigen Corporation	LG723 Novel Anticancer Melanoma Therapy	\$4,601.27	\$223,730.34
Lentigen Corporation	LG631 Novel Therapy for Glioblastoma		\$142,487.08
Lentigen Corporation	LG970 Next Generation Preventative Vaccine for HIV/AIDS	\$1,655.14	\$109,936.87
Luminescent MD, LLC	Development of Fully Automated Chemiluminescent Enzyme Immunoassay System	\$10,643.85	\$4,930.09
MacroGenics Inc	MGAH22	\$244,479.25	
MacroGenics Inc	mAb Pipeline	\$244,479.25	
MacroGenics, Inc	T-Dart	\$244,479.25	
MacroGenics, Inc	MGAWN1	\$244,479.25	
MacroGenics, Inc.	Cancer Stem Cells	\$244,479.25	
MacroGenics, Inc.	Teplizumab	\$244,479.25	
MacroGenics, Inc.	MGA271	\$244,479.25	
Mastix Medica LLC	Effect of chitosan gum on serum phosphate in ESRD patients		\$19,371.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
MaxCyte Inc.	MaxCyte Cell Modification Technology Platform for Therapeutic Development and Discovery	\$244,479.25	
MetaMorphix, Inc.	Myostatin Inhibitors to Accelerate Tissue Growth	\$113,923.50	\$39,353.50
NABI BIOPHARMACEUTICALS	DEVELOPMENT OF NICVAX	\$244,479.24	
NEURALSTEM INC	Development of an allogeneic human neural stem cell product for treatment of ALS	\$244,479.25	
Neuralstem, Inc	Development of an IGF1-expressing human neural stem cell product for treatment of ALS	\$165,463.00	\$79,016.25
Neuralstem, Inc.	Neurogenic Compound to Treat Major Depression	\$165,463.50	\$79,015.75
Neuronascent Inc	Novel Small-Molecule Neurogenic Preclinical Candidates as Therapeutics for Chronic Neurodegenerative Disorders	\$43,081.00	\$63,025.00
NEW HORIZONS DIAGNOSTICS CORPORATION	A simple and Rapid Diagnostic Test for Pancreatic Cancer Using Novel Serum Biomarkers	\$66,053.50	\$137,000.00
New Horizons Diagnostics Corporation	The use of phage lytic enzymes as non-resistant anti-microbials	\$99,080.50	\$145,398.74
Northwest Biotherapeutics Inc	Clinical Development of DCVaz	\$244,479.25	
Northwest Biotherapeutics Inc	Development of DCVax-Direct	\$244,479.25	
Novavax, Inc.	Respiratory Syncytial Virus Vaccine Development	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Novavax, Inc.	Varicella-Zoster Virus Vaccine Development	\$69,000.00	\$175,479.25
Novavax, Inc.	Pandemic Influenza Vaccine Development	\$244,479.25	
Novavax, Inc.	Seasonal Influenza Vaccine Development	\$244,479.25	
Ocular Proteomics LLC	The Vitreous Proteome	\$244,479.24	
OpGen, Inc	Rapid Microbial Infection Identification	\$244,479.25	
OriGene Technologies, Inc	OriGene Autoantibodies Early Screening Test for Ovarian Cancer	\$244,479.25	
Osiris Therapeutics, Inc.	Prochymal	\$244,479.25	
Paragon Bioservices, Inc	Induction of Hypoxia Tolerance at the Cellular Level		\$244,479.25
Pearl Lifescience Partners, LLC	Bioengineering host cells to produce superior vaccines against envelop viruses	\$87,630.92	\$156,848.32
PharmAthene Inc	recombinant BChE Alternate Expression System Development Program	\$1,040.00	\$114,705.65
PharmAthene Inc	Protexia Drug Development Program	\$244,479.25	
PharmAthene, Inc	rPA Drug Development Program	\$7,500.00	\$235,580.41
PharmAthene, Inc.	Valortim Biologic Development Program	\$244,479.25	
PlantVax Inc	BChE	\$45,902.00	\$58,324.00
PlantVax, Inc	MA b	\$61,936.50	\$45,893.50
Profectus BioSciences Inc	NF-kB Rel inhibitors for the treatment of Cancer	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Profectus BioSciences, Inc	Therapeutic and prophylactic vaccines against HIV	\$244,479.25	
Psyadon Pharmaceuticals, Inc	Ecopipam for the Treatment of Lesch-Nyhan Disease	\$244,479.24	
Quantum Medical Metrics LLC	Phase-contrast enhanced X-ray imaging system for small joint of hand	\$4,000.00	\$80,500.00
RAFAGEN, Inc.	Development of cancer-selective replication-competent retrovirus therapy for neuroblastoma	\$118,375.82	\$126,103.42
Raland Technologies LLC	RxFusion Infusion Switch Device	\$25,500.00	\$218,979.25
RAPID LABORATORIES, INC.	Chemokine Receptor Antagonists That Treat HIV Viral Reservoirs & Chronic Inflamm. Disease	\$244,479.24	
RegeneRx Biopharmaceuticals Inc	RGN-352 for Cardiac and Neuronal Tissue Regeneration	\$244,479.25	
RegenexRx Biopharmaceuticals Inc	RGN-137 for Dermal Tissue Regeneration	\$244,479.25	
RegenRx Biopharmaceuticals Inc	RGN-259 for Corneal Tissue Regeneration and Other Anterior Eye Pathologies	\$244,479.25	
RetroTherapy LLC	Reprogramming gene expression in stem cells	\$114,605.54	\$129,873.71
Rexahn Pharmaceuticals, Inc	Zoraxel	\$154,426.35	\$90,052.89
Rexahn Pharmaceuticals, Inc.	Anti-Cancer Drugs	\$244,479.24	
Rexahn Pharmaceuticals, Inc.	Poly HPMA System for Drug Delivery	\$33,239.23	\$55,460.59
Rexahn Pharmaceuticals, Inc.	Serdaxin	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Sanaria, Inc.	Live Attenuated Plasmodium Falciparum Sporozoite (malaria) Vaccine	\$244,479.24	
Seguro Surgical Inc.	Post Operative Adhesion reduction	\$20,163.50	\$118,310.50
Sequella Inc	SQ641: A Novel Translocase-1 Inhibitor for Treatment of Mycobacterial Infections	\$244,479.25	
Sequella, Inc	B-SMART: a novel rapid platform technology to detect bacterial drug resistance	\$83,717.50	\$103,915.00
Sequella, Inc.	SQ109: A Potential Foundation Drug for a New Regimen to Cure Tuberculosis	\$244,479.25	
Sequella, Inc	SQ609: A Potent New Drug for Treatment of multidrug-resistant Tuberculosis	\$162,295.50	\$25,927.50
Sequoia Pharmaceuticals Inc	Development of Novel HCV Protease Inhibitors	\$244,479.24	
Sequoia Pharmaceuticals, Inc.	Development of Pharmacokinetically Enhanced Fixed Dose Combinations for HIV and Cancer	\$244,479.24	
Sequoia Pharmaceuticals, Inc.	Clinical Development of a Pharmacokinetic Enhancer	\$244,479.24	
Shreis Scalene Sciences, LLC	The Cythotron-a novel, stand-alone therapeutic device utilizing non-ionizing RFQMR to treat cancer and improve drug targeting & delivery through nano-permeabilization		\$244,479.25
SLEEP METHODS, INC.	Obstructive Sleep Apnea Therapeutic System	\$108,553.00	\$135,926.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Sleep Solutions Inc	NovaSom II	\$75,705.00	\$168,774.25
Sucampo Pharma Americas, inc	A Study of the Efficacy and Safety of Lubiprostone in Patients with OBD		\$244,479.25
SUCAMPO PHARMA AMERICAS, INC	A STUDY OF COBIPROSTONE FOR THE PREVENTION OF NSAID-INDUCED ULCERS	\$244,479.25	
SUCAMPO PHARMA AMERICAS, INC.	UNOPROSTONE ISOPROPYL FOR DRY AMD RETINITIS PIGMENTOSA	\$244,479.25	
Supemus Pharmaceuticals, Inc	Zalvari™ A new therapy to treat persistent conduct problems in children with ADHD	\$244,479.25	
Supernus Pharmaceuticals Inc	A Novel Non-Stimulant Treatment for ADHD	\$244,479.25	
Symphony Evolution Inc	XL647 RTK Cancer Therapeutics	\$244,479.24	
Symphony Evolution, Inc	XL784 for Abominal Aortic Aneurysm	\$157,998.50	\$86,480.74
Synaptic Research, LLC	Development of Clostridial toxin based therapies for Botulism, Cancer, AKS, and Stem Cells	\$63,349.27	\$123,191.53
SynerGene Therapeutics, Inc	A Novel Tumor-targeting Cancer Nanomedicine Eliminates, and Prevents Recurrence of, Solid Tumors	\$140,177.93	\$104,301.32
Synergy America Inc	Product Development for Invasive Pneumoccal Diseases	\$244,479.25	
TDP Biotechnology	YK-4-279 as a Novel Therapy for Cancer		\$159,070.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Tetracore, Inc	FAS- Detect ELISA Test	\$181,204.18	\$63,275.06
Theranostics Health Inc.	Novel Diagnostic Test for Directing Molecular Targeted Therapies in Metastatic Cancer	\$151,670.50	\$92,808.75
Therataxis LLC	Brain Disease Treatment Simulator	\$14,150.00	
TissueGene, Inc	Noninvasive regenerative therapy for the treatment of osteoarthritis	\$244,479.24	
Trevigen Inc	Knockdown Cell Lines	\$134,640.52	\$88,851.69
Trevigen Inc	PARP in vivo pharmacodynamic Assay II	\$58,906.64	\$5,227.27
Trophogen Inc	Development of TSH Superagonist Analogs for Diagnosis and Treatment of Thyroid Cancer	\$244,479.24	
TROPHOGEN, INC.	Development of FSH Superagonist Analogs for Infertility and Ovarian Cancer	\$6,969.22	\$196,483.90
Validus Biopharma, Inc.	Development of VBP15 for the treatment of Duchenne Muscular Dystrophy	\$81,728.23	\$162,751.02
Vallinex Inc	VNX-4975 for the treatment of severe knee osteoarthritis and Morton's neuroms		\$244,479.25
Vanda Pharmaceuticals Inc.	Development VZP-758 compound to treat Raynaud's Phenomenon	\$244,479.25	
Vanda Pharmaceuticals Inc.	Development of tasimelteon to treat Non-24-Hour Sleep/Wake Disorder in blind individuals.	\$244,479.25	
Vapotherm Inc.	Adaptive Oxygen Control	\$3,664.54	\$63,540.52

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Vapotherm Inc.	Nasal Drug Delivery	\$18,358.20	\$62,554.29
VectorLogics, Inc	Cancer Virotherapeutics	\$244,479.24	
Vesta Therapeutics	Grafting Strategies for Liver Cell Therapies	\$225,856.25	\$18,623.00
Vesta Therapeutics	Allogeneic Hepatic Progenitor Cell Therapy for Liver Diseases	\$244,479.25	
Viracine Therapeutics Corporation	NoVR	\$50,575.10	\$193,904.15
ViroDefense Inc	AntiViral Drug for Enterovirus 71 Neurologic Infections	\$244,479.24	
ViroDefense Inc	Antiviral drug Essential for Polio Eradication	\$244,479.25	
VIRxSYS Corporation	Lexgenleucel-T	\$244,479.25	
VIRxSYS Corporation	VRX1273	\$244,479.24	
VIRXsys Corporation	VRX1243	\$211,840.00	\$32,639.25
Weinberg Medical Physics, LLC	Ultra Fast Magnetic Field Generator	\$202,673.22	\$41,806.02
Weinberg Medical Physics, LLC	MRI-Compatible PEM Scanner		\$109,350.06
Weinberg Medical Physics, LLC	Real-Time Guidance System for Monitoring Proton Therapy	\$51,756.97	\$87,316.04
Wellstat Biologics Corporation	PV701 Oncolytic Virus for the Treatment of Cancer	\$244,479.24	
WELLSTAT DIAGNOSTICS LLC	Electrochemiluminescent based RNA detection platform for POC diagnosis of cancers and pathogens	\$244,479.24	
WELLSTAT DIAGNOSTICS LLC	Rapid POC blood-based diagnostic test for	\$80,232.00	\$164,247.24

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	nonalcoholic fatty liver disease and steatohepatitis		
Wellstat Diagnostics LLC	Rapid point-of-care Lyme disease blood-based diagnostic test		\$85,974.50
WellStat Diagnostics, LLC	A novel antibiotic combination to treat infections of drug resistant Staphylococcus aureus.	\$82,262.00	\$162,217.24
WELLSTAT IMMUNO THERAPEUTICS LLC	WIT-301 for prevention and treatment of Type 1 Diabetes	\$79,667.00	\$87,203.00
Wellstat Immuno Therapeutics LLC	WIT-201: Tolerogenic protein for treatment of multiple sclerosis		\$66,653.00
WELLSTAT IMMUNO THERAPEUTICS LLC	ZPS polysaccharide for treatment of inflammatory diseases	\$244,043.50	\$435.74
Wellstat Ophthalmics Corporation	Sustained Delivery of Novel Therapeutics for the Treatment of Ocular Diseases	\$244,479.24	
WELLSTAT THERAPEUTICS CORP	pn2107 FOR THE TREATMENT OF HYPERURICEMIA AND GOUT	\$244,479.25	
Wellstat Therapeutics Corporation	Invitro-generated T-progenitor cells for T-cell reconstitution in hematopoietic stem cell transplantation	\$42,781.50	\$178,795.00
WELLSTAT THERAPEUTICS CORPORATION	PN403 for the treatment of mitochondrial disease and Alzheimer's disease	\$244,479.25	
Wellstat Therapeutics Corporation	pn401 FOR THE Treatment of Cancer Patients	\$244,479.25	
WELLSTAT	PN951 for ex vivo expansion	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
THERAPEUTICS CORPORATION	of cord blood stem cells for transplants		
Wellstat Vaccines LLC	A novel Neisseria meningitidis Group B polysaccharide Conjugate vaccine	\$156,919.50	\$87,559.74
WELLSTAT VACCINES LLC	Neisseria meningitidis Groups C and Y/Haemophilus influenzae type b conjugate vaccine	\$176,142.50	\$68,336.74
Xcision Medical Systems, LLC	Method and Equipment for Image-Guided Stereotactic Radiosurgery of Breast Cancer	\$244,479.24	
Zyngenia, Inc	Single protein, multi-specific therapeutics for Cancer	\$244,479.24	
Zyngenia, Inc.	Single, protein, multispecific therapeutics in Chronic Autoimmune and Inflammatory Diseases	\$244,479.24	

Massachusetts \$124,271,278.13

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
3G Biotech, LLC	Use of Zinc Chelators to inhibit Biofilm Formation		\$244,479.24
3W Consulting Co	Multiparameter Screening Method and Multicomponent Drug for Cardiovascular Disease	\$240,250.00	\$4,229.24
4s3 Bioscience, Inc	Intravenous Protein Therapy by Myotonic Dystrophy Type 1	\$189,538.00	\$54,941.24
Acceleron Pharma, Inc	ACE-031	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Acceleron Pharma, Inc.	ACE-536	\$244,479.25	
Acceleron Pharma, Inc.	ACE-435	\$244,479.24	
Acceleron Pharma, Inc.	ACE-011 Anemia	\$244,479.24	
Acceleron Pharma, Inc.	ACE-041	\$244,479.24	
Acetylon Pharmaceuticals Inc	Development of novel cancer drug candidate ACY-1215	\$244,479.25	
ACETYLON PHARMACEUTICALS, INC.	ACY-257 A NOVEL HDAC6 INHIBITOR DRUG CANDIDATE FOR INFLAMMATORY DISEASES	\$152,965.50	\$91,513.75
Aciex Therapeutics, Inc	AC-100 Treatmenty for Signs and Symptoms of Dry Eye Syndrome	\$244,479.24	
Aciex Therapeutics, Inc.	AC-120 TREATMENT FOR CHRONIC EYELID EDEMA	\$244,479.24	
Aciex Therapeutics, Inc.	AC-200- Treatment for Meibomian Gland Disease	\$244,479.24	
ACIEX THERAPEUTICS, INC.	AC-150- TREATMENT FOR COMPREHENSIVE ALLERGIC CONJUNCTIVITIS	\$244,479.24	
Acton Pharmaceuticals, Inc.	Aerospan (flunisolide hfa 80 mcg) Inhalation Aerosol	\$244,479.25	
Acusphere, Inc	AI-700- (perflubutane polymer microspheres) for Injectable Suspension	\$244,479.25	
AdvanDx Inc.	PNA FISH	\$244,479.24	
Advantagene Inc	Development of PancAtak for Panceatic Cancer	\$20,290.00	\$124,128.00
Advantagene, Inc.	Development of GliAtak for malignant brain tumors	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Advantagene, Inc.	Development of ProstAtak™ for Prostate Cancer	\$101,602.00	\$142,877.25
AesRX, LLC	AES-103: A new targeted treatment of Sickle Cell Disease	\$173,806.92	\$70,672.33
Agios Pharmaceuticals	Developing novel cancer therapies targeting the key metabolic enzyme PKM2	\$244,479.25	
Agios Pharmaceuticals	Developing novel targeted therapies for gliomas & AML harboring IDH2 & IDH2 mutations	\$244,479.25	
Aileron Therapeutics, Inc	BIM Mimetic for Oncology	\$244,479.24	
Aileron Therapeutics, Inc.	Stapled Peptide Therapeutic Pipeline	\$244,479.24	
Alfama, Inc.	Development of a novel drug to treat acetaminophen-induced acute liver failure (ALF)	\$244,479.24	
Alfama, Inc.	Synthesis of improved CORMs to treat acute liver failure and post-operative ileus	\$244,479.24	
Alfama, Inc.	Development of a novel drug to prevent to treat post-operative ileus (POI).	\$63,658.34	\$47,794.70
Alkeus Pharmaceuticals Inc	Assessment of ALK001 for the prevention of vision loss in dry macular degeneration	\$129,437.00	\$115,042.25
Allegro Diagnostics	Product Development for BronchoGen (AEGIS Trial)	\$244,479.25	
Alnylam Pharmaceuticals Inc	Single Strand RNAi Technology Platform	\$244,479.24	
Alnylam Pharmaceuticals Inc	Alnylam Biotherapeutics	\$244,479.24	
Alnylam Pharmaceuticals Inc.	ALN-VSP for Liver Cancer	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Alnylam Pharmaceuticals, Inc	RNAi Therapeutic Delivery Platform	\$244,479.24	
Alnylam Pharmaceuticals, Inc	ALN-HTT for Huntington's Disease	\$244,479.24	
Alnylam Pharmaceuticals, Inc	ALN-PCS for the treatment of Hypercholesterolemia	\$244,479.24	
Alnylam Pharmaceuticals, Inc.	ALN-RSV for Respiratory Syncytial Virus (RSV) infection	\$244,479.24	
Alnylam Pharmaceuticals, Inc.	ALN-TTR for the Treatment of Transthyrein-mediated Amyloidosis (ATTR)	\$244,479.24	
Alzcor Pharmaceuticals Inc	Modulators of Amyloid Precursor protein(APP)Processing		\$2,000.00
AmberGen, Inc.	Development of Diagnostic and Prognostic Cancer Assays For Personalized Medicine	\$244,479.25	
AmelioMed, LLC	Minimally Invasive Targeted Therapeutic Hypothermia for the Treatment of Spinal Cord Injury		\$4,755.93
Anchor Therapeutics, Inc.	Novel long-lived peptide allosteric G protein coupled receptor modulators	\$244,479.25	
Ancora Pharmaceuticals Inc	Synthetic Carbohydrate-Based Staphylococcal Vaccine Program	\$244,479.25	
Ancora Pharmaceuticals, Inc	Synthetic Carbohydrate-Based Malaria Vaccine Program	\$220,853.50	\$23,625.75
Anexon Inc	ANX-042 treatment of acute decompensated haert failure (ADHF)	\$244,479.25	
Antigen Express Inc	Ii-Key Her-2/neu Peptide Vaccine, AE37, for the	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	treatment of breast cancer.		
Antigen Express, Inc	li-Key Her-2/neu Peptide Vaccine, AE37, for the treatment of prostate cancer	\$244,479.25	
Antigenics Inc.	AG-707, Inveestigational therapeutic vaccine for treatment of genital herpes	\$59,891.00	\$120,350.00
Antigenics Inc.(a Massachusetts corporation)	QS-21, Vaccine adjuvant under development to treat infections, cancers, and Alzheimers	\$244,479.25	
Antisoma Inc	Amonafide: evading drug resistance in leukemia	\$244,479.24	
Aphios Corporation	Development of Zindol, a Novel Anti-Nausea Drug	\$80,968.50	\$106,759.00
Aphios Corporation	Phospholipid Nanosomes Drug Delivery	\$82,652.50	\$51,873.50
Aphios Corporation	Pathogen Inactivation of Human Plasma	\$83,801.00	\$160,678.25
AQUILUS PHARMACEUTICALS INC	Development of AQU-010 for Neuropathic Pain	\$5,460.00	\$11,714.50
Archemix Corp	Hemophilia-ARC19499	\$244,479.25	
ARIAD PHARMACEUTICALS, INC	mTOR Inhibitor-Ridaforolimus	\$244,479.24	
ARIAD PHARMACEUTICALS, INC	ALK Inhibitor-AP26113	\$244,479.24	
ARIAD PHARMACEUTICALS, INC	Pan BCR-ABL Inhibitor-AP24534	\$244,479.24	
ARIETIS CORPORATION	Antifungal therapies for the treatment of recalcitrant and recurrent Candida albicans	\$76,354.91	\$168,124.34

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	infection		
Arisaph Pharmaceuticals Inc	Niacin Mimetics	\$244,479.25	
Arisaph Pharmaceuticals Inc	APO A1 Mimetics	\$102,759.50	\$132,924.00
Arisaph Pharmaceuticals Inc	GLP-1	\$120,236.00	\$117,636.00
Arisaph Pharmaceuticals Inc.	Endothelial Lipase Inhibitors	\$148,986.00	\$95,493.25
Arisaph Pharmaceuticals, Inc	Small Molecule Enhancers for Cancer Vaccines	\$179,287.50	\$65,191.75
Arisaph Pharmaceuticals, Inc	Stabilized Peptide Hormones	\$111,473.50	\$67,985.50
Arisaph Pharmaceuticals, Inc	Tumor-Activated Prodrugs	\$244,479.25	
ARISAPH PHARMACEUTICALS, INC	OBESITY/METABOLIC DISORDERS- MULTIMEDIATORS	\$198,579.00	\$45,900.25
Arisaph Pharmaceuticals, Inc	Tumor Diagnostics	\$150,059.50	\$94,419.75
Arisaph Pharmaceuticals, Inc.	DPP-4 Inhibitors	\$244,479.25	
Arisaph Pharmaceuticals, Inc.	Kinetically Dosed Tumor Selective Proteosome Inhibitors	\$181,868.50	\$62,610.75
Arisaph Pharmaceuticals, Inc.	Stable NPY Analogs	\$111,046.50	\$67,610.50
Arqule Inc	Inhibitors of Mutant BRAF Kinase in Cancer	\$244,479.24	
Arqule Inc	ARQ 621 Cancer Drug Project	\$244,479.24	
Arqule, Inc.	ARQ-197 Cencer Drug Development Project	\$244,479.24	
Arqule, Inc.	ARQ -087 Fibroblast Growth	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Factor Receptor (FGFR) inhibitor Project		
Arsenal Medical, Inc.	Therapeutic Drug Delivery Bioabsorbable Vascular Stent	\$244,479.25	
Artisan Pharma Inc	ART-123	\$244,479.25	
Aspen Medisys LLC	Magnetic Hanoportide Thermathempy for treating cancer		\$244,479.25
Attention Therapeutics, Inc.	Development of Attention Therapeutic System for regulatory clearance/commercialization.		\$173,371.50
Audax Medical, Inc	Twin-base linker (TBL) bone augmentation		\$206,885.00
Augmenix, Inc	SpaceOAR	\$244,479.25	
Aura Biosciences Inc	Development of a topical self-administered treatment for cervical and anal dysplasia	\$244,479.24	
Aura Medsystems, Inc.	Light-activated Soft Tissue Repair (laSTR)	\$206,804.50	\$37,674.75
Auxocell laboratories, Inc.	Co - Transplanation of Wharton's Jelly Stem Cells and Cord Blood Stem Cells	\$244,479.24	
Auxocell Laboratories, Inc.	Medical Device to Process Wharton's Jelly Stem Cells	\$200,000.00	\$44,479.24
Avaxia Biologics, Inc	Development of AVX-470 for the treatment of Gastrointestinal Inflammatory Disorders	\$24,168.78	\$220,310.46
Avedro, Inc.	Novel Therapy Using Microwave and Ultraviolet Energy to Treat Degenerative Corneal Disease	\$244,479.25	
AVEO Pharmaceuticals, Inc	Tivozanib-A Potent and Selective Triple VEGF-R	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Inhibitor		
AVEO Pharmaceuticals, Inc	AV-299- A Novel HGF/c-Met Inhibitor	\$244,479.25	
AVEO Pharmaceuticals, Inc.	Human Response Platform™ and Antibody Programs	\$244,479.25	
Avila Therapeutics Inc.	Inhibition of Bruton's tyrosine kinase [Btk} to treat blood cancers and autoimmune diseases.	\$244,479.24	
Avila Therapeutics, Inc	Development of novel therapies, AVL-181 and AVL-192 to treat Hepatitis C Virus infection	\$244,479.24	
Bach Pharma, Inc	a novel neuroprotective agent	\$244,479.24	
BG Medicine Inc	The BGM Galectin-3 blood test for predicting development and progression of heart failure	\$244,479.25	
BG Medicine, Inc.	AMIPredict™ : A novel molecular diagnostic for near-term heart attack or stroke	\$244,479.25	
Bikam Pharmaceuticals	Pharmacotherapeutics for the Treatment of Retinitis Pigmentosa	\$244,479.24	
Bind Biosciences, Inc	Development of targeted nanoparticle therapeutics containing highly potent cytonixic agents	\$244,479.24	
BIND Biosciences, Inc	Development of BIND-014--a solid tumor-targeted nanoparticle containing docetaxel	\$244,479.24	
BIND Biosciences, Inc	Develop a Medicinal Nanoengineering™ platform for polymer-based targeted nanoparticle	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
BIO2 Technologies, Inc.	Surface Active Tissue Engineering Scaffold	\$18,614.00	\$225,865.24
BIO2 Technologies, Inc.	Resorbable Tissue Engineering Scaffold	\$55,445.50	\$189,033.74
BioAssets Development Corp	Development of a TNF Inhibitor Drug for the Treatments of Sciatica.	\$244,479.24	
BioBehavioral Diagnostics Company	Expansion of Use of the Quotient ADHD System	\$230,018.50	\$14,460.75
BioChemics Inc	Transdermal Diabetic Neuropathy Treatment (BC-DN-01)	\$147,004.66	\$97,474.59
BioNevia Pharmaceuticals Inc	Arresting progression of diabetic Neuropathy with Epalrestat (BNV-222)	\$162,689.50	\$81,789.74
BioScale, Inc	ViBe platform and AMMP assay for biomarker measurement in therapeutics and Dx	\$244,479.25	
BioSensics LLC	Sensor-based Auto-BioFeedback and Health Monitoring System	\$9,250.00	\$104,230.00
Bio-Tree Systems, Inc	OncoTree discovery	\$244,479.25	
Biousian Biosystems Inc	Novel Therapeutics for the treatment of Chronic Pain and Diabetes	\$61,464.50	\$73,113.00
BioVex, Inc.	The OPTiHaN Trial: A Phase 3 Trial to Evaluate OncoVEX in Head and Neck Cancer	\$2,962.50	\$241,516.74
BioVex, Inc.	The OPTiM Trial: A Randomized Phase 3 Clinical Trial to Evaluate OncoVEX	\$244,479.24	
Birch Tree Medical, Inc.	Use of longterm patient-controlled heat to relieve		\$206,000.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Restless leg Syndrome		
Boston Biomedical, Inc	BB15600 Anti-Cancer Stem Cell Drug Discovery and Deveopment Program	\$7,673.39	\$236,805.85
Boston Biomedical, Inc.	BBI8000 Anti-Cancer Drug Discovery and Development Program	\$4,024.94	\$240,454.31
Boston Biomedical, Inc.	BB16000 Anti-Cancer Stem Cell Drug Discovery and Development Program	\$244,479.24	
Boston Endoscopic Engineering Corporation	Therapeutic Gastrointestinal Delivery Platform for EUS fine needle aspiration	\$185,052.50	\$59,426.74
Boston Microfluidics Inc	Rapid Point-of-Care Test Platform	\$244,479.24	
Braintree Laboratories, Inc	BLI801- SULFATE LAXATIVE	\$64,956.50	\$146,603.50
Braintree Laboratories, Inc.	BLI1100-MEDIDERMIS	\$152,698.50	\$91,780.75
Braintree Laboratories, Inc.	PCD03 - METRONIDAZOLE 10% Ointment		\$244,479.25
Cambrooke Foods, LLC	BetterMilk with Glycomacropeptide for Phenylketonuria(PKU)	\$80,095.50	
Cardiorobotics, Inc.	Articulated Robotic Medprobe (ARM) Robotic System	\$244,479.25	
Catabasis Pharmaceuticals, Inc	Fatty Acid Salicylate Conjugates as Novel Therapeutics for the Treatment of Type 2 Diabetes	\$244,479.24	
Celexion LLC	Isolation of Therapeutic Binders to Oncogenic Targets	\$78,118.00	\$166,361.24
Cellay, Inc.	New Method for Cancer Diagnosis	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Cellceutix Corporation	KM-133 for Treatment of Psoriasis	\$141,984.50	\$102,494.75
Cellceutix Corporation	Kevetrin for Cancer Treatment	\$244,479.25	
Cellceutix Corporation	KM-391 For Treatment of Autism	\$142,830.00	\$101,649.25
Celldex Therapeutics Inc	CDX-301	\$244,479.24	
Celldex Therapeutics Inc	CDX-1307	\$244,479.24	
Celldex Therapeutics Inc	CDX-011	\$244,479.24	
Celldex Therapeutics Inc	CDX-1127	\$244,479.24	
Celldex Therapeutics, Inc.	Rindopepimut (CDX-110)	\$244,479.24	
Celldex Therapeutics, Inc.	CDX-1135	\$133,360.50	\$111,118.74
Celldex Therapeutics, Inc.	CDX-1401	\$244,479.24	
CellThera, Inc.	Functional restoration of a large-scale skeletal muscle defect using dedifferentiated cells	\$219,093.50	\$25,385.74
Celthera, Inc.	Regenerative Platform	\$25,716.54	\$4,803.25
Cephalogics LLC	high-Density Diffuse Optical Tomography for Real-Time Neurological Assessment in Infants	\$67,612.00	\$93,531.70
Cequent Pharmaceuticals, Inc.	CEQ508	\$244,479.25	
Cequent Pharmaceuticals, Inc.	CEQ626	\$244,479.25	
CeQur Corporation	CeQur Insulin Delivery Device for Use in Type 2 Diabetes	\$244,479.24	
Cerenova, Inc	Neurostimulation for neurotrauma rehabilitation		\$244,479.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Cerulean Pharma Inc	CRLX101 (formerly IT-101)A Novel Nanopharmaceutical Oncology Agent in Phase 2	\$244,479.25	
Cerulean Pharma Inc	Nanopharmaceutical Docetaxel-A Promising Next Generation Oncology Agent	\$244,479.25	
Cerulean Pharma Inc.	Nanopharmaceutical Drug Delivery Patform Enabling RNA Interference Therapy		\$244,479.25
Claros Diagnostics, Inc.	Point-of-Care Diagnostic System for Urologist Office Use	\$244,479.24	
CombinatoRX ,Inc	Synavive Project	\$244,479.24	
Combinent Biomedical Systems, Inc.	CBMS-10	\$221,188.93	\$23,290.31
Concert Medical, LLC	Concert Conductor Guidewire		\$35,650.50
Concert Medical, LLC	"Concert N2009 Guidewire		\$24,927.00
Concert Pharmaceuticals, Inc	Novel HIV protease inhibitor not requiring co-dosing with a pharmacokinetic boosting agent	\$244,479.24	
Concert Pharmaceuticals, Inc	Novel Treatment for Diabetic Nephropathy	\$244,479.24	
Constellation Pharmaceuticals, Inc	New Therapeutics That Target Epigenetic Regulatory Proteins in Cancer	\$244,479.25	
CorNova Inc	The FiberHalo Catheter	\$244,479.25	
Correx Inc	Correx 18-mm Aortic Valve Bypass Kit	\$244,479.25	
Creagen Biosciences, Inc	Anticancer agents based on a dual function structures	\$205,841.50	\$38,637.74
Curaxis Pharmaceutical Corporation	ALADDIN Clinical trials		\$39,154.00
CuriRx Inc	Novel anti-cancer drug	\$15,410.00	\$109,750.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	candidate		
Curis Inc	Multi-targeted network inhibitor platform for cancer	\$244,479.25	
Curis, Inc	CUDC-101, a Phase 1 cancer agent	\$244,479.25	
CYTOCURE LLC	Novel Combination Immunotherapy of Cancer: Drugs that Enhance Tumor Antigens	\$120,224.00	\$124,255.25
Cytonome/ST, LLC	Therapeutic Cell Sorter for Blood Cancers	\$244,479.25	
CytoVera Inc	High Potency Cord Blood Stem Cells as Therapeutics for Treatment for Treating Blood Cancers in Adults.	\$7,926.50	\$125,000.00
Daktari Diagnostics Inc.	Development of a Handheld CD4 Cell Counter for Point-of-Care Monitoring of HIV Patients	\$244,479.24	
Dicerna Pharmaceuticals Inc	A Novel Castration Resistant Prostate Cancer Treatment Targeting Androgen Receptor	\$244,479.24	
Dicerna Pharmaceuticals Inc	Dicer Substrate Technology™, a new and novel RNAi-based drug development platform	\$244,479.24	
Differential Proteomics, Inc.	Antibody Repertoire Profiling for Enabling Detection, Diagnosis and Treatment of Diseases	\$132,836.84	\$111,642.41
DNA Medicine Institute, Inc.	Universal Blood Sensor	\$54,048.50	\$168,950.00
Dragonfly Sciences, Inc	Etanercept Biosimilar	\$244,479.25	
Dune Medical Devices Inc	MarginProbe System	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Dyax Corp	FcRn (DX-2500)	\$220,011.50	\$24,467.75
Dyax Corp	DX-88 HAE KALBITOR	\$244,479.25	
Dyax Corp	DX-2400	\$244,479.25	
Dyax Corp	ACE inhibitor Induced Angioedema	\$179,610.00	\$64,869.25
Dyax Corp.	MMP-9 (DX-2802)	\$244,479.25	
Dyax Corp.	Plasma Kallikrein Inhibitor	\$244,479.25	
EarthGenes Pharmaceuticals LLC	Antibiotic Drug Discovery from Environmental DNA Expression Libraries	\$69,882.50	\$166,689.50
Echo Therapeutics, Inc	Symphony Transdermal Continuous Glucose Monitoring System	\$244,479.25	
ECW Therapeutics, Inc	Adults & Neonatal Stem Cell Separation Device		\$80,000.00
Edimer Pharmaceuticals	EDI200, a recombinant protein for treatment of X-linked hypohidrotic ectodermal dysplasia.	\$244,479.24	
Eleven Biotherapeutics Inc	Protein based drug discovery project Myostatin for Muscle wasting		\$244,479.25
Eleven Biotherapeutics, Inc.	Protein-based drug discovery project: T helper cell, 17 in inflammatory diseases		\$244,479.25
Eleven Biotherapeutics, Inc.	Protein-based drug discovery project: Factor VIII for the treatment of Hemophilla A		\$244,479.25
Elixir Pharmaceuticals, Inc	Development of a Small Molecule Ghrelin Antagonist, EX-1832, for the Treatment of Metabolic Disorders	\$244,479.25	
Enanta Pharmaceuticals	Novel Oral Antibiotic for the		\$211,295.50

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Inc	treatment of MRSA, VRE and Resistant Strep Infections		
Enanta Pharmaceuticals Inc	Novel NS5A Inhibitors for the treatment of Hepatitis C Infection	\$244,479.24	
Enanta Pharmaceuticals Inc.	Novel I.V. Antibiotic for the treatment of MRSA, VRE and resistant Strep Infections		\$49,673.00
Enanta Pharmaceuticals, Inc	Novel Cyclophilin inhibitors for the Treatment of Hepatitis C Infection	\$244,479.24	
Endra Inc	Thermoacoustic imaging device for point of care diagnostic applications	\$129,189.02	\$115,290.23
Energesis Pharmaceuticals Inc	Discovery of Novel Brown Fat Targeting Drugs for Obesity		\$244,479.24
Enlight Biosciences, LLC	Enigma Liver Toxicity	\$41,214.64	\$79,990.33
Enlight Biosciences, LLC	Ensof Biomarker Discovery	\$27,992.37	\$216,486.88
Enlight Biosciences, LLC	Entrega Drug Delivery	\$118,888.34	\$125,590.91
Ensemble Therapeutics Corporation	DNA-Programmed Chemistry and its Application for the Discovery of Novel Oncology Drugs.	\$244,479.24	
Ensemble Therapeutics Corporation	New Personalized Medicine Diagnostics for Predicting Drug Resistance in Breast Cancer	\$244,479.24	
Ensemble Therapeutics Corporation	Oral Macrocyclic Drugs for Treatment of Rheumatoid Arthritis & Other Inflammatory Diseases.	\$244,479.24	
Entra Pharmaceuticals Inc	Novel Biopharmaceuticals Drug Delivery System	\$244,479.25	
Epizyme Inc	WHSC1 Therapeutic Project		\$244,479.24

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Epizyme Inc	DOT1L Therapeutic Project	\$244,479.24	
Epizyme Inc	EZH2 Therapeutic Project	\$244,479.24	
ETEX Corporation	Bone Regenerating Biomaterial	\$244,479.24	
Euthymics Bioscience, Inc	EB-1020: A novel treatment for adult Attention Deficit Hyperactivity Disorder (ADHD)	\$5,802.50	\$238,676.75
Euthymics Bioscience, Inc.	EB-1010: A NOVEL ANTIDEPRESSANT TO PATIENTS NOT RESPONDING ADEQUATELY TO SSRIs	\$52,224.00	\$192,255.25
Eutropics Pharmaceuticals	Developing BH3 profiling as a predictive diagnostic test for multiple myeloma	\$32,910.50	\$105,652.50
Eutropics Pharmaceuticals	Developing Small molecule inhibitor of Mcl-1 to treat blood cancer	\$78,719.00	\$165,760.25
Excelimmune Inc.	Development and Manufacture of Human Recombinant Polyclonal Antibodies (HRPA)	\$244,479.24	
Eyegate Pharmaceuticals Inc	Biologics	\$56,500.00	\$173,500.00
EyeGate Pharmaceuticals Inc	Nanoparticles	\$174,500.00	\$69,979.25
Eyegate Pharmaceuticals Inc	EGP 437	\$244,479.25	
Eyegate Pharmaceuticals, Inc	EyeGate III	\$244,479.25	
Fifth Base, LLC	Prevention of Tumor Recurrence via Flexible Chemotherapy-Eluting Strips	\$55,799.14	\$22,539.94
First Light Biosciences, Inc	Novel low-cost automated platform for rapid and sensitive detection of resistant bacteria	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Flexion Therapeutics Inc	FX005 Intra-articular Injection for Treatment of Pain in Osteoarthritis of the Knee	\$244,479.25	
Flexion Therapeutics, Inc.	FX004- Acamprosate for the Treatment of Tinnitus	\$137,784.50	\$106,694.75
FoldRx Pharmaceuticals	Tafamidis for the treatment of TTR Amyloidosis	\$244,479.25	
Forma Therapeutics, Inc	Unduggable Targets Important for Cancer Treatment (Protein/Protein Interactions)	\$244,479.25	
Forma Therapeutics, Inc	NAMPT	\$244,479.25	
Forma Therapeutics, Inc	Diversity-Oriented Synthesis (DOS) Chemistry	\$244,479.25	
Formatech Inc	Miradocetaxel Development	\$15,635.50	\$113,901.50
Foundation Medicine, Inc.	Molecular Cancer Diagnostics		\$244,479.25
Galenea Corp.	5-HT6 Antagonists for cognitive improvement in schizophrenia	\$65,651.00	\$178,828.25
GALENEA CORP.	5-HT2C Agonists for Appetite Suppression in Obesity	\$244,479.25	
Galenea Corp.	Discovery of novel mechanism-based therapies for Schizophrenia	\$244,479.25	
Gelesis Inc	Gelesis Novel Hydrogels	\$244,479.25	
Gene Network Sciences, Inc	Collaboration with Biogen Idec Phase I		\$28,457.50
Genetix Pharmaceuticals Inc	Lentiglobin	\$244,479.24	
Genetix Pharmaceuticals Inc	Lenti-D	\$244,479.24	
Genocea Biosciences, Inc	Development of a Chlamydia	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Vaccine Based on Natural Immunity in Humans		
Genocea Biosciences, Inc.	Development of Vaccines for Genital Herpes Based on Natural Immunity in Humans	\$244,479.24	
GI Dynamics, Inc.	The EndoBarrier for treatment of type 2 diabetes and obesity	\$244,479.25	
GLSynthesis Inc	Hybrid Molecules Designed to Enhance Antibiotic Activity	\$244,479.24	
GLSynthesis Inc.	Novel drugs to treat Urinary Incontinence	\$244,479.24	
GLSynthesis Inc.	Preclinical development of a novel antibacterial for Clostridium difficile disease		\$219,164.00
GLSynthesis Inc.	Novel Antithrombotic Diadenosine Tetrphosphate Analogs	\$151,747.00	\$92,732.24
GLSynthesis, Inc.	Rapid in vitro Substrate Assay for the multi-drug Resistant P-glycoprotein	\$107,992.00	\$132,649.50
Glycosyn, Inc.	Oligosaccharides to Prevent Infectious Diarrhea	\$155,208.00	\$89,271.24
Good Start Genetics	GSG Molecular Genetic Screen Platform	\$145,925.39	\$98,553.86
Grove Instruments Inc	Noninvasive glucose monitor for diabetic patients	\$244,479.25	
Healthrageous, Inc.	SmartHealth: Hypertension Self-Management		\$244,479.25
Helicos BioSciences Corporation	Non-invasive detection of genetic disorders for prenatal diagnostics	\$138,671.50	\$93,884.50
Helicos BioSciences Corporation	Identification of disease-specific mutations and polymorphisms in affected individuals	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Helicos BioSciences Corporation	Detection of pathogen nucleic acid contamination in body fluids & in biological therapeutics	\$88,828.50	\$155,650.75
Hemedex, Inc.	Novel Device to Diagnose Conditions of Compromised Blood Flow and to Quantify Edema	\$244,479.25	
Highland Instruments	Electrosonic Stimulation for Noninvasive deep Brain Stimulation	\$47,534.00	\$68,890.00
Histogenics Corporation	NeoCart (Cultured Autologous Neo-Cartilage)	\$244,479.24	
Hybrid Silica Technologies Inc	Multimodal Silica Nanoparticles as Cancer Targeted Probes for Clinical Translation	\$228,130.00	\$16,349.25
Hydra Biosciences, Inc	TRPA1 Antagonists as a Broad Medical Countermeasure to Biological and Chemical Threats	\$200,753.50	\$43,725.74
Hydra Biosciences, Inc.	TRPA1 Antagonists as New Treatments for Pain due to injury or inflammation	\$244,479.24	
Hydra Biosciences, Inc.	TRPV3 Antagonists as New Treatments for Chronic and Acute Pain	\$244,479.24	
ImmuneXcite, Inc	A unique Herceptin conjugate directs neutrophils to fight breast cancer	\$42,352.50	\$68,737.50
ImmunoDiagnostics, Inc	Jak2/Hexim1 kinase inhibitors as therapeutics for the treatment of viral (HIV) disorders	\$107,730.00	\$136,749.25
ImmunoGen Inc	IMGN009- Antibody-drug conjugate to fight cancer	\$244,479.24	
ImmunoGen Inc.	IMGN007 Antibody-drug	\$153,250.00	\$91,229.24

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	conjugate to fight cancer.		
ImmunoGen Inc.	IMGN529 Antibody-drug conjugate.	\$244,479.24	
ImmunoGen Inc.	IMGN388 antibody-drug conjugate	\$244,479.24	
ImmunoGen, Inc.	Lorvotuzumab mertansine - IMGN901 - antibody-drug conjugate	\$244,479.24	
Inanovate Inc	Development of a low-cost, accurate cancer diagnostic platform.	\$227,192.05	\$17,287.19
InaVein, LLC	Office-based Varicose Vein Treatment with Local Anesthesia		\$38,494.50
Infinity Discovery, Inc	Hsp90 Chaperone Inhibitor Program	\$244,479.24	
Infinity Discovery, Inc	IPI 926 Hedgehog Pathway Inhibitor Program	\$244,479.25	
Infinity Discovery, Inc	IPI-940 Fatty acid Amide Hydrolase Inhibitor Program	\$244,479.25	
InfraReDx, Inc	Clinical validation of near-infrared spectroscopy for diagnosing high risk coronary plaques	\$244,479.25	
InfraReDx, Inc	LipiScan™ IVUS Diagnostic System	\$244,479.25	
InnerSea Technology Inc	Early Warning System for Spinal Cord injured at Risk for Autonomic Dysreflexia	\$103,489.50	\$106,677.00
Inotek Pharmaceuticals Corporation	INO-8875	\$244,479.24	
Inotek Pharmaceuticals Corporation	Development of PARPs for use in oncology treatment	\$178,152.67	\$66,326.58

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Inotek Pharmaceuticals Corporation	INO-4885	\$182,507.61	\$27,493.59
Intact Medical Corp	Breast Lesion Excision System	\$244,479.24	
Intellect Medical, Inc.	Novel Programming Device to Further the Delivery of Deep Brain Stimulation Devices	\$244,479.25	
Intelligent Bio-Systems	DNA Sequence Based Cancer Diagnostic System	\$244,479.25	
Intelligent Medical Devices Inc	XMRV and other molecular factors to assess prostate cancer	\$11,214.00	\$96,384.50
Intelligent Medical Devices Inc	Low Cost Screening for Healthcare Associated infections	\$209,418.00	\$35,061.25
Intelligent Medical Devices Inc	Detection and Resistance Screening for Influenza	\$244,479.25	
Intelligent Medical Devices, Inc	Monitoring Viruses Associated with Transplant Rejection	\$117,346.50	\$73,475.50
Intelligent Medical Devices, Inc.	Comprehensive Test to Guide Treatment and Prevent Outbreaks of Whooping Cough	\$97,308.50	\$147,170.75
Interlace Medical, Inc	MyoSure Rod Lens Hysteroscope Development Project	\$244,479.25	
Interleukin Genetics	Osteoarthritis	\$128,071.00	\$100,843.50
Interleukin Genetics Inc	Perilipin	\$227,377.00	\$17,102.25
InVivo Therapeutics Corporation	Safety and Efficacy of an Implanted Biodegradable Polymeric Scaffold to Treat Spinal Cord injury	\$244,479.25	
IQuum, Inc	Rapid Point of Care Molecular Diagnostics for Influenza; Seasonal & Pandemic H1N1 Assays	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Iquum, Inc.	Rapid, Point of Care Molecular Diagnostic Assay for Detection of Fungemia	\$76,541.00	\$167,938.25
Ironwood Pharmaceuticals Inc	Development of Novel CRTH2 Inhibitor, IW-1221, for Treatment of Asthma		\$244,479.25
Ironwood Pharmaceuticals Inc	FAAH Inhibitor, IW-6118 to Treat Pain and Inflammation	\$244,479.25	
Ironwood Pharmaceuticals, Inc	Linacotide, A Novel Guanylate Cycase C Agonist	\$244,479.25	
Ironwood Pharmaceuticals, Inc.	IW-9179, for Treatment of Gastroparesis and Functional Dyspepsia.	\$180,000.00	\$64,479.25
Ischemix LLC	CMX-2043	\$244,479.24	
Jasco Pharmaceuticals, LLC	The Pim Inhibitor Project	\$244,479.24	
JB Therapeutics Inc	Clinical Development of an oral, non-psychoactive CB1/CB2 Cannabinoid Agonist for the treat Chronic Pain	\$19,587.50	\$224,891.75
JEF Core, Incorporated	Development of a Lead Based System for Respiratory Variation Monitoring	\$41,392.00	\$160,749.50
Kala Pharmaceuticals, Inc.	Development of KALA617, a once-daily inhalable b-lactam to treat Cystic Fibrosis infections	\$12,500.00	\$231,979.24
KARYOPHAM THERAPEUTICS	NOVEL CRM1 INHIBITORS FOR THE TREATMENT OF CANCER	\$92,500.00	\$151,979.25
Ligon Discovery Inc	Development of HIF inhibitors for Renal Cell Carcinoma	\$244,479.25	
Link Medicine Corporation	LNK-3248: Treating Alzheimer's Disease by Clearing Toxic Proteins	\$63,348.00	\$181,131.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Link Medicine Corporation	LNK-754 Enhancing Autophagy and Mitochondrial Function to Treat Alzheimer's Disease	\$244,479.25	
Link Medicine Corporation	LNK-3186: Developing Novel Treatments for Alzheimer's Disease	\$166,439.00	\$78,040.25
LOGICAL THERAPEUTICS, INC	LT-NS001 (NAXPROXEN ETEMESIL)	\$244,479.25	
Lubris LLC	Prevention and Treatment of Osteoarthritis	\$23,550.00	
Marine Polymer Technologies Inc	Development of Novel Biomaterial for Trauma Hemorrhage, Diabetic, & Infected Wound Care	\$201,000.50	\$43,478.75
Marine Polymer Technologies Inc	Development of IL-15 Protein Complex as a Therapy for Lymphopenia & Cancer	\$79,633.00	\$45,878.00
MC10, Inc.	Conformal Electronics for Diagnosing and Treating Heart Disease	\$204,079.79	\$40,399.46
Medical Discovery Partners LLC	A Blood Test for the Early Detection of Cancer	\$60,887.00	\$163,617.50
Medwell Foods, Inc	Medwell 1-2-3 Molecular Baking	\$244,479.25	
Mercator Therapeutics, Inc.	The Tumor Targeting Project		\$244,479.25
Mercury Therapeutics, Inc	Development of Direct AMP Kinase Activators for Type 2 Diabetes	\$184,696.97	\$59,782.28
Merrimack Pharmaceuticals Inc	MM-151	\$244,479.24	
Merrimack Pharmaceuticals Inc	MM-141	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Merrimack Pharmaceuticals Inc	MM-121	\$244,479.24	
Merrimack Pharmaceuticals Inc	MM-302	\$244,479.24	
Merrimack Pharmaceuticals Inc	MM-111	\$244,479.24	
Merrimack Pharmaceuticals Inc.	MM-POD2	\$184,931.50	\$59,547.74
Merrimack Pharmaceuticals, Inc	MM-POD3	\$86,698.50	\$157,780.74
Merrimack Pharmaceuticals, Inc	MM-131	\$244,479.24	
Merrimack Pharmaceuticals, Inc.	MM-POD1	\$193,380.50	\$51,098.74
Merrimack Pharmaceuticals, Inc.	MM-398	\$9,228.50	\$235,250.74
Mersana Therapeutics Inc	XMT-1001	\$244,479.25	
Mersana Therapeutics Inc	siRNA	\$244,479.25	
Mersana Therapeutics, Inc	XMT-1107	\$244,479.25	
Metamark Genetics Inc	Development of function-based prognostic assays to optimize and personalize cancer care	\$244,479.24	
Microbiotix	Preclinical development of antagonists of host immunity	\$9,586.88	\$10,187.29
Microbiotix, Inc	Preclinical development of bacterial replication inhibitors	\$244,479.24	
Microbiotix, Inc	Preclinical Inhibitors of Botulinum Neurotoxin A	\$244,479.24	
Microbiotix, Inc	Preclinical development of novel anti-biofilm coatings for implanted medical devices	\$15,526.04	\$64,817.83

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Microbiotix, Inc	Preclinical development of novel broad-spectrum hemorrhagic fever virus inhibitors	\$118,957.83	\$125,521.41
Microbiotix, Inc.	Clinical development of MBX400: a novel inhibitor of human cytomegalovirus infection	\$244,479.24	
Microbiotix, Inc.	Preclinical inhibitors of non-replication essential bacterial targets	\$244,479.24	
Microbiotix, Inc.	Preclinical Inhibitors of bacterial virulence factors	\$160,378.98	\$84,100.26
MicroCHIPS Inc	Development of an implantable one year Continuous Glucose Monitoring System	\$244,479.25	
MicroCHIPS Inc	Development of an implantable drug delivery device controlled release of PTH for one year	\$244,479.25	
MindChild Medical Inc	Meridian Monitor	\$111,795.00	\$132,684.24
MINERVA BIOTECHNOLOGIES CORP	THERAPEUTIC DISABLES PRIMAL GROWTH MECHANISM ON CANCER STEM CELLS	\$244,479.24	
Mobius Imaging LLC	SurgiTom	\$244,479.25	
Modular Genetics, Inc.	Biosynthetic Meridamycin Analogs for Neurological Disorders	\$170,718.50	\$73,760.75
MOLECULAR INSIGHT PHARMACEUTICALS INC	ZEMIVA	\$244,479.25	
Molecular Insight Pharmaceuticals Inc	Trofex	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
MOLECULAR INSIGHT PHARMACEUTICALS INC	SOLAZED	\$211,316.50	\$33,162.75
Molecular Insight Pharmaceuticals, Inc	Azedra - Neuroblastoma	\$244,479.25	
Molecular Insight Pharmaceuticals, Inc.	Azendra - Pheochromocytoma	\$244,479.25	
Molecular Insight Pharmaceuticals, Inc.	Onalta	\$244,479.25	
Momenta Pharmaceuticals, Inc	M118, a novel anticoagulant to treat patients diagnosed with Acute Coronary	\$244,479.25	
Momenta Pharmaceuticals, Inc	Platform for Glycosaminoglycan Therapeutics-Novel Multimodal Drugs for Multifaceted diseases	\$244,479.25	
Momenta Pharmaceuticals, Inc	M402- A novel multimodal inhibitor of tumor metastasis	\$244,479.25	
Momenta Pharmaceuticals, Inc	Development of a biologics platform utilizing through characterization to ensure purity	\$244,479.25	
Nano Surfaces, Inc.	Drug Delivery Micelles	\$244,479.25	
Nanobiosym Diagnostics	Gene-RADAR for Medical Molecular Diagnostics	\$72,164.00	\$172,315.24
Nanobiosym, Inc	Single Molecule Drug Discovery	\$244,479.24	
NetBio, Inc	Rapid Nucleic Acid-Based Diagnosis of STDs at the Point-of -Care	\$244,479.24	
NeurAxon (USA) Inc.	NXN-462 for chronic daily headache and post-herpetic neuralgia	\$42,011.00	\$202,468.24
NeurAxon (USA), Inc.	NXN-188 for acute migraine	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
NeuroHealing Pharmaceuticals, Inc.	NH001	\$180,467.50	\$64,011.75
Neurometrix Inc	Precision Targeted Therapeutic Delivery System for Peripheral Nerve Indications	\$244,479.24	
Neuron Systems, Inc	Development of a definitive treatment for dry amd and stargardt's disease	\$244,479.25	
NeuroPhage Pharmaceuticals, Inc.	NPT001, a novel disease-modifying treatment for Alzheimer's Disease	\$244,479.25	
Neuroptix Corporation	Ocular Diagnostic Test for Alzheimer's Disease	\$244,479.24	
Nextcea, Inc	Diagnosis and Therapy of Drug-Induced Phospholipidosis and of Niemann-Pick Diseases		\$66,107.24
Nikan Pharmaceuticals, LLC	Development of Novel Compounds for Treatment of Inflammatory Disorders in Humans	\$6,333.50	\$2,855.00
Nimbus Apollo, Inc.	Preclinical R&D to advance lead molecules targeting ACC for obesity and diabetes		\$196,019.50
Nimbus Discovery Inc	R&D to advance programs targeting PFKFB3 and ZAP70 kinases for cancer & inflammation	\$71,412.50	\$173,066.75
Nimbus Iris Inc	Preclinical R&E to advance lead molecules targeting IRAK4 for inflammatory disease		\$244,479.25
NinePoint Medical, Inc.	N-lighten Optical Diagnostic and Therapeutic System		\$244,479.25
NKT Therapeutics INC	Development of Antibodies Directed Towards NKT Cells	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
NormOxys, Inc	Development of OXY111A for the Treatment of Cancer and Cardiovascular Disease	\$244,479.25	
Novelos Therapeutics, Inc.	NOV-002 Development	\$244,479.25	
Nuclea Biotechnologies LLC	Therapeutic Diagnostic/Prognostic Assay Development Program	\$244,479.25	
Nuclea Biotechnologies, LLC	Research Methodology for Therapeutic/Diagnostic Discovery	\$228,990.00	\$15,489.25
Nuclea Biotechnologies, LLC	Humanized Anti-Cancer Monoclonal Antibodies	\$79,104.00	\$165,375.25
Ocular Therapeutix, Inc	Epi-Coat	\$132,373.00	\$112,106.24
Ocular Therapeutix, Inc.	ReSure Adherent Ocular Bandage	\$244,479.25	
Ocular Therapeutix, Inc.	Punctum Drug Depot	\$244,479.25	
On-Q-ity Inc.	Breast Biopsy Tumor Tissue test to predict response to anthracycline treatment	\$244,479.25	
On-Q-ity Inc.	Lung Biomarker Tumor Tissue test to predict cisplatin response in lung cancer patients	\$200,422.50	\$44,056.75
On-Q-ity Inc.	HER-2 Circulating Tumor Cell test to inform therapeutic choice for breast cancer patients	\$93,187.00	\$151,292.25
On-Q-ity Inc.	EGFR circulating tumor cell test to inform therapeutic choice for lung cancer patients	\$86,661.50	\$157,817.75
OPK Biotech LLC	HBOC-201/cGMP Manufacturing Facility		\$244,479.25
ORA, Inc	Novel Immunotherapy Treatment for Dry AMD	\$99,743.00	\$144,736.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
ORA, Inc	Novel Cerumenolytic	\$31,599.50	\$18,486.00
ORA, Inc	Novel Anti-Allergic	\$191,293.50	\$53,185.75
ORA, Inc	Novel Nasal Treatment for MRSA	\$90,844.50	\$142,004.50
Orban Biotech LLC	Insulin B Chain to Treat Type 1 Diabetes Mellitus		\$244,479.25
Orbital Therapy, LLC	Self-shielding radiotherapy device	\$244,479.24	
Ore Pharmaceutical Holdings Inc	ORE1001	\$244,479.25	
PAKA Pulmonary Pharmaceuticals Inc	SP-B-Polymyxin Conjugate For Lung Infection		\$34,230.00
Paloma Pharmaceuticals, Inc	Palomid 529, a First -in-Class Dual TORC 1/2 Inhibitor of the P13k/Akt/m TOR Pathway	\$244,479.24	
Paratek Pharmaceuticals Inc	Development of Oral Therapies for Major Chronic AutoImmune Diseases: MS, RA, IBD	\$244,479.25	
Paratek Pharmaceuticals, Inc	Gram-Negative Hospital Bacterial Infections; Treatment and Prophylaxis	\$244,479.25	
Paratek Pharmaceuticals, Inc	PTK 0796- A First-in-Class Oral & IV antibiotic in Phase 3 for Serious Infections, incl. MRSA	\$244,479.25	
Pear Tree Pharmaceuticals, Inc	Treatment of Moderate to Severe Vulvar and Vaginal Atrophy in Menopausal Patients	\$152,775.40	\$91,703.85
Peptimmune, Inc.	PI-2301 for thre ftreatment of Relapsing and Remitting Multiple Sclerosis (RRMS)	\$244,479.25	
Pervasis Therapeutics, Inc	Development of PVS-10200 for Peripheral Artery Disease	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Pervasis Therapeutics, Inc.	Development of Vascugel® to Sustain Arteriovenous Access for Hemodialysis	\$244,479.25	
Pervasis Therapeutics, Inc.	Development of Tissue-Engineered Endothelial Cell Therapy for Brain and Prostate Cancer	\$30,307.90	\$161,113.04
Pervasis Therapeutics, Inc.	Devel. Of Tissue-Engineered Endothelial Cell Therapy to Supplement Orthopedic Procedures	\$35,022.33	\$209,456.92
PGxHealth LLC	Vilazodone: A novel treatment for major depressive disorder	\$244,479.25	
PGxHealth LLC	Apadenoson: A novel pharmacologic stress agent for myocardial perfusion imaging	\$244,479.25	
Pharmalucence, Inc	Lymph Node Localization by Tc-99m Sulfur Colloid Injection	\$85,732.00	\$158,747.24
Phase Design Research	CNS penetrating anti-inflammatory/metal chelators for treating neuroinflammation	\$29,921.79	\$37,500.00
Physical Sciences Inc	Continuous Automated Mandibular Distractor	\$71,626.00	\$166,094.50
Physical Sciences Inc.	Breath Test for Cancer Therapy	\$106,900.50	\$137,578.75
Physical Sciences Inc.	Dosimeters for Photodynamic Cancer Therapy (PDT)	\$242,635.00	\$1,844.24
Physical Sciences Inc.	Image-Guided Intervention for Pancreatic Cysts	\$128,383.00	\$116,096.25
Physical Sciences, Inc	Retinal Imaging for Disease Detection	\$244,479.24	
PLC Medical Systems Inc	RenalGuard: A Novel Therapy to Prevent Contrast Induced Nephropathy	\$244,479.25	
Predictive Biosciences,	Bladder Cancer Recurrence	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Inc.	Monitoring Triage Test		
Predictive Biosciences, Inc.	Test for Prognosis of Bladder Cancer	\$244,479.25	
Pressure BioSciences, Inc.	Pressure Cycling Technology	\$244,479.25	
PrimeradX, Inc.	ViraQuant: Automated Quantitative Multi-Plex Viral Load Assay System	\$244,479.25	
Privo Technologies	Insulin Chewing Gum		\$4,000.00
Pro-Pharmaceuticals, Inc.	Treatment and reversal of liver fibrosis using galectin blockers GRGs	\$10,083.67	\$234,395.57
Pro-Pharmaceuticals, Inc.	Anticancer treatments using galectin blockers combined with chemotherapies or biologics.	\$244,479.24	
Proteon Therapeutics, Inc.	PRT-201 for Vascular Access in Chronic Hemodialysis Patients	\$244,479.24	
Provasculon, Inc	Modified SDF-1 for the treatment of myocardial infarct and ischemic tissue	\$244,479.25	
Provenance Biopharmaceuticals Corp	DI-Leu16-IL2 Anti-cancer Therapeutic	\$33,421.77	\$211,057.48
Provenance Biopharmaceuticals Corp	Veterinary immunocytokines to aid development of therapies for treatment of human cancers	\$29,117.77	\$131,895.54
pSivida US Inc	Sustained Release Brimonidine		\$110,062.00
pSivida US, Inc.	Antibodies for Treatment of Wet-Acute Macular Degeneration (Wet-AMD)		\$98,087.00
Pulmatrix Inc.	Inhaled Cationic Lining Modulators for Treatment and Prevention of Pulmonary Disease	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Pulsar Clinical Technologies	Multiplex Microarray for Pre-Type 1 Diabetes Autoantibodies	\$65,183.30	\$54,437.03
PureTech Ventures, LLC	Inflammatory Bowel Disease (IBD)	\$76,490.76	\$164,028.87
PureTech Ventures, LLC	Autism	\$60,835.08	\$86,590.68
PureTech Ventures, LLC	Karuna	\$109,573.80	\$134,905.45
Quanterix Corporation	Development of the First Blood-based Diagnostic test for Alzheimer's Disease	\$244,479.24	
Quanterix Corporation	A TNF-alpha Companion Diagnostic to Predict Response to Therapy in Crohn's Disease	\$127,716.00	\$116,763.24
Quanterix Corporation	Development of a Single Molecule Array Test for Prostate Cancer Recurrence Monitoring	\$244,479.24	
Radius Health Inc	RAD1901	\$244,479.25	
Radius Health Inc	BA058	\$244,479.25	
Radius Health, Inc	SARM/RAD140	\$244,479.25	
Rapid Micro Biosystems, Inc	Enhanced Robustness of Rapid, Automated Microbial Enumeration	\$244,479.25	
Reflectance Medical Inc	Non-Invasive Tissue Perfusion for Therapeutic Admin.	\$101,592.50	\$142,886.74
Repligen Corporation	RG3039-DcpS inhibitor for treatment of patients with Spinal Muscular Atrophy (SMA)	\$201,583.50	\$42,895.75
Repligen Corporation	RG2833, an inhibitor of HDAC-3 for the treatment of Friedreich's ataxia	\$244,479.25	
Repligen Corporation	RG1068 - Synthetic Human Secretin for Pancreatic Imaging	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Resolvix Pharmaceuticals Inc	DEVELOPMENT OF RESOLVINS TO TREAT Chronic Inflammatory Disease	\$244,479.24	
RESOLVYX PHARMACEUTICALS, INC	DEVELOPMENT OF RESOLVINS TO TREAT SIGHT-THREATENING DISEASE	\$244,479.24	
RFE Pharma Corp	RFE-007 CAI injectable for treating diabetic retinopathy & age-related macular degeneration	\$38,561.00	\$92,144.00
Rhythm Pharmaceuticals Inc	Rm-493		\$244,479.25
Rhythm Pharmaceuticals, Inc	RM-131		\$244,479.25
Rxi Pharmaceuticals Corporation	Development of self-delivering RNA Interference (RNAi) therapeutic for the fibrotic disease	\$244,479.25	
Rxi Pharmaceuticals Corporation	Oral Delivery of Glucose Encapsulated siRNAs for Rheumatoid Arthritis (RA)	\$244,479.25	
Rxi Pharmaceuticals Corporation	Self-Delivering RNA Interference Therapeutic for Age-Related Macular Degeneration (AMD)	\$66,002.17	\$178,477.08
Rxi Pharmaceuticals Corporation	Self-Delivering RNA Interference Therapeutic for ALS (Lou Gehrig's Disease)	\$237,273.92	\$7,205.33
Satori Pharmaceutcals Incorporated	Gamma-Secretase Modulators for the treatment of Alzheimer's Disease	\$244,479.24	
SBH Sciences Inc	Development of a Therapy for Liver Fibrosis by Specific Targeting of Galectin-3	\$98,932.50	\$112,000.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
SBH Sciences, Inc	Developing Therapy for Pancreatic Cancer Targeting Nuclear Export by CRM-1	\$44,600.00	\$140,100.00
Sci Dose LLC	Ulcerative Colitis	\$188,828.00	\$55,651.25
SciDose, LLC	Docetaxel	\$244,479.25	
Seahorse Bioscience, Inc	Prevention and treatment of age-related diseases by targeting defects in mitochondria.	\$244,479.25	
Seahorse Bioscience, Inc.	Diagnosis of Metabolic and Age-Related Diseases	\$244,479.25	
Seaside Therapeutics Inc	Development of Arbaclofen (STX209) for the Treatment of Fragile X Syndrome	\$244,479.25	
Seaside Therapeutics Inc,	Development of Novel M1 Modulators for the Treatment of Autism and Fragil X syndrome		\$244,479.25
Seaside Therapeutics Inc.	Discovery Project to identify biomarkers related Autism Spectrum Disorders(ASD)	\$244,479.25	
Seaside Therapeutics, Inc.	Development of mGluR5 Modulators for the Treatment of Autism and Fragile X Syndrome	\$244,479.25	
Seaside Therapeutics, Inc.	Development of STX107 for the Treatment of Fragile X Syndrome	\$244,479.25	
Seaside Therapeutics, Inc.	Development of Arbaclofen (STX209) for the Treatment of Autism Spectrum disorders (ASD)	\$244,479.25	
Selecta Biosciences, Inc	Nicotine Vaccine for Smoking Cessation and Relapse Prevention	\$244,479.25	
Selecta Biosciences, Inc	A synthetic Nanoparticle Vaccine Platform to induce a	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Cytolytic T-Cell Response		
Selecta Biosciences, Inc.	Development of a Synthetic Nanoparticle Vaccine Platform to Induce Protective Antibodies	\$244,479.25	
SelectX Pharmaceuticals Inc	SXP2554: A Novel Inhaled Antibiotic		\$244,479.25
SelectX Pharmaceuticals, Inc.	SXP2523: A Novel Antibiotic for Serious Gram-Negative Infections	\$244,479.25	
Semaco Inc.	Targeting Telomere-Associated Werner Protein to Treat Hematologic Malignancy	\$156,500.00	\$87,979.24
Semprus BioSciences	Semprus PICC (Peripherally Inserted Central Catheter)	\$244,479.25	
Sentien Biotechnologies, Inc.	Stem Cell Therapeutic Devices for Critical Care		\$244,479.25
SetPoint Medical Corporation	Immune System Regulator Therapy	\$244,479.25	
Seventh Sense Biosystems, Inc.	On Vivo, A Fully Integrated Blood Collection and Diagnostic Test Device	\$244,479.24	
Shape Pharmaceuticals, Inc.	SHP-141 for the treatment of Cutaneous T-Cell Lymphoma(CTCL)	\$244,479.25	
SimulConsult, Inc	SimuConsult Diagnostic Decision Support Software	\$244,479.25	
SmartCells, Inc	SmartInsulin-The First Glucose-regulated insulin for Treating Diabetes	\$244,479.24	
Soteira, Inc	Soteira Shield Kyphoplasty System	\$244,479.25	
Speech Technology and Applied Research Corp	Objective Acoustic Speech Analysis for Post Concussional Blast Effects	\$626.50	\$15,329.50

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Speech Technology and Applied Research Corp	System for DBS Programming for Speech Functionality in Parkinson's Disease	\$146,055.50	\$98,423.75
Spring Bank Pharmaceuticals, Inc	SB 9000	\$244,479.24	
Still River Systems, Inc.	Proton Beam Radiotherapy System (PBRT)	\$244,479.25	
Strohl Medical Technologies Inc	SEP-RAD Stroke Detection Device		\$34,975.00
Stromedix, Inc.	Development of STX-100 as a novel therapeutic for the treatment of fibrotic diseases	\$244,479.24	
Sunshine Medical LLC	Interactive feeding system for the premature infant		\$244,479.25
Surface Logix, Inc	SLx-2119, a small molecule inhibitor of Rho kinase 2 (ROCK2) for oncology and fibrosis	\$244,479.24	
Surface Logix, Inc	Intestinally selective small molecule activators of satiety	\$244,479.24	
Surface Logix, Inc	SLx-2101, a small molecule PDES inhibitor targeting cardiovascular disease	\$244,479.24	
Surface Logix, Inc	SLx-4090 Microsomal Triglyceride Transfer Protein (MTP)	\$244,479.24	
Surface Logix, Inc	50 Soldiers Field Place	\$244,479.24	
Surface Logix, Inc.	Intestinally selective small molecule inhibitors of DGAT for obesity and diabetes	\$232,867.49	\$11,611.75
Synageva BioPharma Corp	Enhancement of the glycosylation machinery of the Synageva Expression Platform	\$16,995.76	\$107,290.28
Synageva BioPharma	SBC-101	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Corp			
Synageva BioPharma Corp	SBC-091	\$244,479.24	
Synageva BioPharma Corp	SBC-014	\$244,479.24	
Synageva BioPharma Corp	SBC-055	\$244,479.24	
Synageva BioPharma Corp	SBC-103	\$24,026.32	\$105,693.33
Synageva BioPharma Corp	SBC-105		\$91,706.28
Synageva BioPharma Corp.	SBC-104		\$244,479.25
Synageva BioPharma Corp.	SBC-102	\$244,479.24	
Synageva BioPharma Corp.	SBC-201	\$182,911.81	\$55,148.08
Synageva BioPharma Corp.	SBC-202	\$89,388.76	\$47,469.53
Synageva BioPharma Corp.	PTR-302		\$101,394.51
SynapDx Corporation	Retrospective Study and Prospective Trial to Develop Autism Spectrum Disorder Diagnostic		\$244,479.25
Syndax Pharmaceuticals Inc	Syndax Pharmaceuticals Entinostat for the Treatment of Breast Cancer and HL	\$244,479.24	
SynDevRX, Inc	High potency polymer/metAP2 inhibitors for the treatment of cancer	\$216,825.00	\$27,654.24
Syndexa Pharmaceuticals Corp	ISR Modulators as Novel Drugs for the Treatment of Type 2	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Diabetes and Metabolic Diseases		
Syndexa Pharmaceuticals Corp.	Novel Bivalent JNK Modulators for the Treatment of Obesity and Type 2 Diabetes	\$244,479.24	
Synovex Corporation	SDP051 is a Cad-11 antagonist antibody for the treatment of rheumatoid arthritis	\$244,479.25	
Synta Pharmaceuticals Corp	Development of elesclomol as a cancer therapeutic	\$244,479.24	
Synta Pharmaceuticals Corp	Development of a novel, small molecule Hsp90 inhibitor, STA-9090, as a cancer therapeutic	\$244,479.24	
Synta Pharmaceuticals Corp.	Oral CRAC channel inhibitor therapeutics for inflammatory diseases and cancer	\$244,479.25	
Synta Pharmaceuticals Corp.	Oral Hsp90 inhibitor therapies for cancer, inflammatory and neurodegenerative diseases.	\$244,479.24	
T2 Biosystems, Inc	Tacrolimus and Creatinine Project	\$244,479.25	
T2 Biosystems, Inc	Dx Platform Project	\$244,479.25	
T2 Biosystems, Inc.	Candida Project	\$244,479.25	
Taligen Therapeutics, Inc.	TT30 therapeutic recombinant fusion protein to modulate Complement system	\$244,479.24	
Targeted Cell Therapies, LLC	Development of a Novel Oral Delivery Technology or Large Molecule Therapeutics	\$73,440.50	\$131,500.00
TARIS Biomedical Inc	A novel drug-device combination prod. To improve the treatment of superficial bladder cancer	\$244,479.25	
Taris Biomedical, Inc	LiRIS: A novel local therapy for	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	the management of discomfort associated with ureteral stent		
TARIS Biomedical, Inc	LiRIS: A novel drug-device combination product for the treatment of Interstitial Cystitis	\$244,479.25	
Temple Therapeutics, LLC	New Therapies for Cancer using Mesenchymal Stem Cells (MSC's) expressing TRAIL		\$244,479.25
Tepha Inc	Hernia Mesh with Therapeutic Coating	\$244,479.24	
Tetraphase Pharmaceuticals Inc	TP-834:A Promising New Oral Antibiotic for Community Acquired Pneumonia(CABP)	\$244,479.25	
Tetraphase Pharmaceuticals, Inc.	TP-434: A Potent New Antibiotic To Treat a Broad Range of Multi-Drug Resistant "Superbugs" 834:A Promising New Oral Antibiotic for Community Acquired Pneumonia(CABP)	\$244,479.25	
Tetraphase Pharmaceuticals, Inc.	TP-2758: A Novel and Exciting Oral Antibiotic for Complicated Urinary Tract Infections (cUTI)	\$244,479.25	
Theracrine Inc	Monoclonal antibodies targeting cancer-specific osteopontin (vOPN)		\$244,479.24
Theracrine, Inc	Dual CXCR/1CXCR2 Inhibitor for the Treatment of Metastatic Cancer		\$244,479.25
Theracrine, Inc	Fascin inhibitor for the Treatment of metastatic Cancer		\$244,479.24
Tokai Pharmaceuticals, Inc.	TOK-001	\$244,479.25	
Tolerx, Inc.	Development of a Targeted Immunotherapeutic for the	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Treatment of Type 1 Diabetes.		
Tolerx, Inc.	Development of Novel Anti-ILT Immunotherapeutics for the Treatment of Cancer	\$110,144.11	\$134,335.13
Tolerx, Inc.	Development of a Novel Anti-GITR Monoclonal Antibody as an Immunotherapy for Cancer.	\$244,479.24	
Tomophase Corporation	Optical Coherence Tomographic Imaging System (OCTIS™)	\$242,476.00	\$2,003.24
Translational Therapeutics Inc.	Cancer Therapeutics System	\$55,532.00	\$188,947.25
U.S. Genomics Inc	Highly Multiplexed Infectious Disease Diagnostics Based on Single Molecule DNA Analysis	\$244,479.25	
VANAS ONCOLOGY, INC	BCP-21, A Novel Anti-Cancer Molecule	\$136,512.91	\$107,966.33
Variation Biotechnologies (US), Inc c/o Variation Biotechnologies Inc	Thermostable Vaccine		\$244,479.25
Variation Biotechnologies (US), Inc, c/o Variation Biotechnologies Inc.	Oral Shigella Vaccine		\$244,479.25
Variation Biotechnologies (US), Inc.	Variosite Technology	\$235,077.50	\$9,401.75
Variation Biotechnologies (US), Inc. c/o Variation Biotechnologies Inc.	Oral Vaccine	\$244,479.25	
VasoTech, Inc.	A Novel Drug-Eluting Stent -- Power Stent® -- for Coronary Arterial Disease Treatment	\$110,119.50	\$134,359.75

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Velico Medical, INC	Refrigerated Platelets	\$7,500.00	\$59,733.00
VELICO MEDICAL, INC.	SPRAY DRIED PLASMA	\$244,479.25	
Verax Biomedical Incorporated	PGD Platelet Test Device	\$244,479.24	
Veritas Health Solutions LLC	Information Technology Management of Adolescent Depression (iTAD)	\$53,427.50	\$11,455.50
Virdante Pharmaceuticals, Inc	sFc-Recombinant Sialylated Immunoglobulin G (IgG) Fc fragments		\$244,479.24
Virdante Pharmaceuticals, Inc	Svig - Sialylated Intravenous Immunoglobulin	\$244,479.24	
Visterra, Inc (f/k/a Parasol Therapeutics, Inc	PAR401: A Potent, Selective Anti-Influenza Therapeutic and Prophylactic	\$244,479.24	
ViThera LLC	Development of an engineered bacterial therapy of Inflammatory Bowel Disease	\$5,739.16	\$216,250.00
Vortex Medical Inc	AngioVac	\$244,479.24	
Wadsworth Medical Technologies, Inc.	Novel Device to Reduce Surgical Site Infection	\$71,683.00	\$172,796.24
X-BODY, Inc	XB-387, a PDGFRB Antibody Therapeutic for Non-Small Cell Lung Cancer	\$244,479.24	
Xcellerex Inc	XRX-001 Inactivated Yellow Fever Vaccine	\$244,479.24	
Zafgen Inc	T2D Program	\$244,479.25	
Zafgen, Inc.	ZGN-440	\$244,479.25	
ZIOPHARM Oncology, Inc.	Indibulin	\$244,479.25	
ZIOPHARM Oncology,	Palifosfamide	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Inc.			
ZIOPHARM Oncology, Inc.	Darinaparsin	\$244,479.25	

Michigan \$18,138,110.55

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Aastrom Biosciences, Inc.	A Phase III Stage Expanded, Autologous Stem Cell Product to Treat Severe CV Disease	\$244,479.24	
Accord Biomaterials Inc	Improved central venous and hemodialysis catheters to minimize infection and clotting	\$211,615.81	\$32,863.44
Accord Biomaterials, Inc.	Coronary stent with passivated surfaces to address restenosis and late-stage thrombosis	\$178,815.24	\$65,664.01
Accord Biomaterials, Inc.	Point-of-Care Diagnostic and Therapy Management Tool for Pulmonary Arterial Hypertension	\$20,493.75	\$189,918.09
Accuri Cytometers Inc	Development of the Accuri CS Clinical Flow Cytometry System	\$244,479.25	
Adeona Pharmaceuticals, Inc.	Estriol (Trimesta)	\$35,493.50	\$208,985.75
Adeona Pharmaceuticals, Inc.	Zinthionein and ZincMonoCysteine	\$133,439.00	\$111,040.25
AlphaCore Pharma, LLC	Treatment of Acute Coronary Syndromes with Recombinant LCAT Infusion	\$244,479.25	
Angott Medical Products, LLC	Multi-modality Breast Cancer Tester	\$19,157.00	\$225,322.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
ApoLife, Inc	Secretary IgA for orally applied therapy for treatment of Clostridium difficile infection.	\$57,509.66	\$143,400.00
Armune BioScience Inc	Molecular Diagnostics for Early Detection of Cancer	\$244,479.24	
Art Optical Contact Lens, Inc.	Therapeutic treatment of irregular corneas	\$39,571.00	\$44,847.50
AureoGen Bioscience Inc.	A novel antibiotic for the treatment of drug resistant bacterial infections	\$136,897.60	\$107,581.64
Aursos, Inc.	Aursos BB for primary & secondary osteoporosis and bone-building (anabolic) activity	\$36,335.00	\$4,618.00
Cardiavent Inc.	Development of CARD-024 for the treatment of hypertension and heart failure	\$66,868.50	\$177,610.75
Cayman Chemical Company Inc	EP4 Project		\$172,016.50
Cayman Chemical Company Inc	H-PGDS Inhibition Project	\$96,509.00	\$31,848.00
Cayman Chemical Company, Inc	Tetranor Prostaglandin E Metabolite ELISA Project	\$11,769.00	\$11,557.50
Cerenis Therapeutics Inc	HDL-Mimetic Peptide/Phospholipid complex (CER-522)	\$165,319.49	\$79,159.76
Cerenis Therapeutics Inc.	CER-627 Low Flushing Niacin	\$117,626.86	\$63,100.93
Cerenis Therapeutics, Inc.	CER-002	\$43,428.26	\$95,307.06
Compendia Bioscience, Inc.	Oncopredictor	\$122,116.50	\$122,362.74
CytoPherx, Inc	Selective CytoPheretic Device	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Delphinus Medical Technologies, inc.	Commercialization of SoftVue for early detection of Breast cancer	\$238,705.00	\$5,774.25
Esperion Therapeutics, Inc	ETC-1002	\$244,479.24	
Genetics Squared, Inc.	Commercialization of a Stage I and II colorectal Cancer Recurrence Prognostic Technology	\$244,479.24	
Great Lakes BioSciences	Noninvasive cortical stimulation treatment of pain in fibromyalgia	\$118,246.00	\$126,233.25
Housey Pharmaceutical Research Laboratories, LLC	Novel Inhibitors for the Treatment of Highly Drug-Resistant Chronic Myelogenous Leukemia	\$62,210.50	\$182,268.75
HOUSEY PHARMACEUTICAL RESEARCH LABORATORIES, LLC	DISCOVERY AND DEVELOPMENT OF ANTI DIABETIC DRUGS	\$201,356.00	\$43,123.25
Hygieia Inc	PRIVATE-DOC	\$80,761.72	\$163,717.53
Innovative BioTherapies, Inc	Bioengineered Cellular/ Biomimetic-based Therapeutic System for treatment of SIRS	\$244,479.24	
Integrated Sensing Systems	Wireless Pressure Monitoring Implant for Tailored Medication of Cardiovascular Diseases	\$244,479.24	
Integrated Sensing Systems	A Microfluidic-Based Therapeutic Drug Infusion System	\$244,479.25	
IPGDx LLC	Determining an infectious process prior to syndromic findings as a biosurveillance tool		\$244,479.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
IPGDx, LLC	Detection of Disease Severity & Progression, Treatment Effectiveness & Survival in Cancer		\$244,479.24
Life Magnetics, Inc	Sensitive, Rapid Diagnostic device for Antibiotic Susceptibility Testing		\$162,127.08
LPIT SOLUTIONS, INC	TRACKCORE SOFTWARE FOR OR IMPLANT MANAGEMENT	\$210,295.33	\$34,183.92
LVAD Technology Inc.	Via-Derm-2, a novel long-term percutaneous access device	\$85,079.32	\$159,399.93
Lycera Corp	ATPase Oral Therapeutic	\$244,479.24	
Lycera Corp.	RoR Gamma Therapeutic	\$244,479.24	
Meditrina Pharmaceuticals Inc.	MPI-676	\$12,860.00	\$99,477.63
Metabolic Solutions Development Company	Novel Insulin Sensitizing Agents for Therapy in Type 2 Diabetes	\$244,479.24	
Michigan Critical Care Consultants Inc DBA MC3 Inc	Hyperthermia device for cancer treatment	\$36,179.85	\$98,601.27
Michigan Critical Care Consultants Inc DBA MC3 Inc	Catheter Enterogenesis Device Development		\$40,746.68
Michigan Critical Care Consultants, Inc. DBA MC3, Inc.	Pediatric blood pump development	\$93,822.77	\$150,656.47
Michigan Critical Care Consultants, Inc. DBA MC3, Inc.	Artificial Lung Development	\$93,587.07	\$150,892.17
Michigan Critical Care Consultants, Inc., DBA MC3, Inc.	Bidirectional Arterial Cannula Development	\$80,991.20	\$163,488.04

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Michigan Critical Care Consultants, Inc., DBA MC3, Inc.	Annuloplasty Ring for Heart Valve Disease	\$17,393.01	\$46,276.11
Michigan Critical Care Consultants, Inc., DBA MC3, Inc.	Automatic Perfusion System Development	\$13,314.69	\$70,696.82
Michigan Critical Care Consultants, Inc., DBA MC3, Inc.	Simple Ventricular Assist Device Development		\$53,422.38
MICHIGAN TECHNOLOGY & RESEARCH INSTITUTE, LLC	GENETIC CHARACTERIZATION OF FIBROSIS & INFLAMMATORY SUSCEPTIBILITY IN CHRONIC KIDNEY DISEASE	\$22,191.00	\$8,518.71
NanoBio Corporation	Novel Nebulized Therapy for Cystic Fibrosis	\$244,479.25	
NanoBio Corporation	Novel Topical Therapy for Herpes Labialis	\$244,479.25	
NanoBio Corporation	Novel Intranasal Vaccine Adjuvant	\$244,479.25	
NanoBio Corporation	Novel Intranasal 23- Valent Pneumococcal Vaccine	\$244,479.25	
NanoBio Corporation	Novel Topical Anti-fungal Therapy for Tinea Capitis and Onychomycosis	\$244,479.25	
NanoVir, L.L.C.	Therapeutic Development of Antiviral Compounds that Target Human Papillomaviruses (HPV)	\$244,479.24	
Nephrx Corporation	NX001 Treatment of Acute Kidney injury	\$244,479.24	
NEPHRX Corporation	NS002 Treatment of Oral Mucositis	\$91,845.50	\$152,633.74

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
NeuroNexus Technologies, Inc.	Deep Brain Stimulation	\$162,088.50	\$47,855.50
Novalung, Inc.	Development of pump for use with artificial lung	\$226,495.16	\$17,984.08
Nustep, Inc	Metabolic Cost of Recumbent Exercise in Overweight Individuals		\$24,330.00
Nymirum Inc	Alzheimer's Project	\$17,248.00	\$227,231.25
Nymirum Inc	Hepatitis C Project	\$9,764.50	\$234,714.75
Nymirum, Inc	Myotonic Dystrophy Project	\$30,283.50	\$214,195.75
OtoMedicine Inc	Prevention of Drug Induced Hearing Loss (DIHL) by AuraQuell	\$98,011.00	\$146,468.25
Phrixus Pharmaceuticals, Inc	Heart Failure	\$168,430.00	\$76,049.24
Phrixus Pharmaceuticals, Inc	Duchenne Muscular Dystrophy	\$168,430.00	\$76,049.24
ProNAI Therapeutics, Inc	A Phase 1 Study of PNT2258 in Patients with Advanced Solid Tumors	\$30,965.00	\$213,514.24
QuatRx Pharmaceuticals Company	Ospemifene	\$244,479.25	
RealBio Technology, Inc.	Biorealistic Tissue models for Drug Discovery and Testing	\$93,800.00	\$150,679.24
RetroSene Therapeutics LLC aka RetroSense Therapeutics LLC	Gene therapy for vision restoration	\$1,750.00	\$161,094.43
Rockwell Medical Technologies, Inc.	Soluble Ferric Pyrophosphate (SFP) indicated for the treatment of iron deficiency anemia	\$244,479.24	
Rubicon Genomics, Inc	Development of PicoPlex - NGS Kits	\$85,674.50	\$99,166.50

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Rubicon Genomics, Inc.	Development of MethylPlex™ -NGS Kits	\$80,501.00	\$129,187.00
Sonetics Ultrasound, Inc.	Fully-sampled 2D/planar ultrasound transducer technology	\$185,276.47	\$59,202.78
Swift Biosciences Inc	Development of High Sensitivity Genetic Tests for Detection and Assessment of Cancer		\$244,479.24
Tangent Medical Technologies	Peripheral intravenous therapeutic delivery device		\$244,479.25
TCH Pharmaceuticals, Inc	Imidazoline-based Inhibitors	\$17,519.50	\$26,431.62
Therapeutic System Research Laboratories, Inc. (TSRL)	Anti-Influenza Therapeutic	\$53,603.56	\$43,987.62
Therapeutic Systems Research Laboratories, Inc (TSRL)	Cidofovir, Nucleoside Prodrug for Antiviral Treatment	\$244,479.25	
Therapeutic Systems Research Laboratories, Inc. (TSRL)	Bile Acid Carrier	\$85,919.29	\$24,184.42
Therapeutic Systems Research Laboratories, Inc. (TSRL)	Inflammatory Bowel Disease Therapeutic	\$45,127.53	\$75,793.37
Tolera Therapeutics, Inc	TOL 101 in Phase 2 short course immune induction therapy for chronic immune disease	\$244,479.24	
Ultrasound Medical Devices Inc	imaging of cardiovascular mechanical function for assessment diagnosis and therapy guidance	\$221,258.00	\$23,221.25
Velcura Therapeutics, Inc.	VEL-0230 an Orally Available, Disease Modifying	\$194,016.10	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Anti-Rheumatic Drug (DMARD)		
Xoran Technologies Inc	Xoran xCAT	\$244,479.25	
Xoran Technologies, Inc.	Xoran MiniCAT	\$244,479.25	
zuSyn, Inc.	Development of Novel Taxanes for the Treatment of Cancer	\$3,280.20	\$1,704.58

Minnesota \$22,469,564.39

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Advanced Healing Systems	Redesign of AHS Wound Data Reporting Electronic Medical Record		\$195,000.00
Alwyn Company, Inc	Alwextin	\$86,952.70	\$157,526.55
American Telecare Inc.	American Telecare Advanced Care Management Expansion	\$244,479.25	
Antares Pharma Inc.	VIBEX Methotrexate Subcutaneous Auto-injector (VIBEX MTX) to treat Rheumatoid Arthritis	\$184,415.00	\$60,064.25
Antares Pharma, Inc.	Anturol oxybutynin Advanced Transdermal Delivery gel for treatment of overactive bladder	\$244,479.25	
Anulex Technologies Inc	Versaclose Tissue Repair	\$231,323.50	\$13,155.75
Anulex Technologies Inc	Large Defect Tissue Repair	\$45,075.00	\$49,702.50
Anulex Technologies, Inc.	Xclose Tissue Repair	\$244,479.25	
Apnex Medical, Inc.	Hypoglossal Nerve	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Stimulation(HGNS™ System		
Ativa Medical Inc	Point of Care Testing Module	\$244,479.25	
Atritech Inc	WATCHMAN Left Atrial Appendage System	\$244,479.25	
AUM Cardiovascular, LLC	CADence	\$20,500.00	\$98,516.99
BIOE LLC	PREPACYTE REAGENT TECHNOLOGY	\$67,018.50	\$177,460.74
BIOE LLC	Multi-Lineage Progenitor Cell (MLPC)	\$21,475.00	\$180,049.00
Bioe, Inc.	Multi-Lineage progenitor cell (MLPC)	\$188,626.50	
Bioenergy Inc	I.V. Ribose for the Enhancement of Recovery of Myocardial Function after CABG Surgery	\$173,037.50	\$71,441.75
Biothera, Inc.	Imprime PGG Cancer Drug Development	\$244,479.25	
Breast-Med Inc.	Implantable Soft Tissue Marker for Multimodal Breast Imaging with Positive MRI Contrast	\$14,663.00	\$229,816.25
BridgePoint Medical, Inc.	Interventional Treatment of Advanced Vascular Disease-Alternative to Bypass Surgery	\$244,479.25	
Camas Incorporated	EGG antibodies as immunoprophylactic agents for the prevention of influenza.	\$27,820.00	\$120,471.50
Camas Incorporated	Utilization of avian antibodies in an oral application to centralize gut bacterial toxins.	\$37,281.00	\$207,198.25
Cardious Inc	Aortic Valve Delivery graft	\$73,045.00	\$110,724.50
Cardiovascular Systems Inc	Coronary Clinical Trial	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Cardiovascular Systems Inc	Diamondback 360 to Prepare Vessels for drug therapy	\$244,479.25	
Celleration Inc	Pain Reduction Following Aesthetic Procedures- A Study Conducted at Northwestern University		\$46,500.00
Celleration, Inc.	Using Therapeutic Low Frequency Ultrasound to Recruit Stem Cells	\$55,000.00	\$127,500.00
Chi's Research Corporation	Drug Discovery of Novel Antimicrobial and Antimalarial Agents	\$5,224.00	
Chi's Research Corporation	Novel Compounds for Treatment of Neuropathic and Inflammatory Pain	\$10,562.50	
Chi's Research Corporation	Novel Compounds for Treatment of Alzheimer's Disease	\$17,447.50	
CNS Therapeutics, Inc.	High Concentration Intrathecal Baclofen for the Treatment of Spasticity	\$244,479.25	
CoAxia Inc	NeuroFlo™ Cerebral Perfusion Augmentation Catheter	\$244,479.24	
CVRx, Inc.	Baroreflex Activation Therapy- Diastolic Heart Failure	\$244,479.24	
CVRx, Inc.	Baroreflex Activation Therapy - Hypertension	\$244,479.24	
DGIMED Ortho, Inc.	DISTALOCK™ Intramedullary (IM) Nail and Drill System	\$244,479.25	
Dymedix Corporation	Dymedix NM System	\$244,479.24	
EnteroMedics Inc	Entero-Medics Maestro System	\$244,479.25	
Exos Corporation	Thermoformable Bracing Devices Using Tri-laminate	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Technology		
ExoStat Medical, Incorporated	Oral Mucosa Carbon Dioxide (CO2) Monitor	\$50,059.17	\$194,420.08
FourSquare Medical, LLC	Novel Therapeutic Device for the Preatment of Pulmonary Hypertension		\$244,479.25
Galvani Ltd	Medium Voltage Therapy to Provide Coronary and Cerebral Perfusion during Cardiac Arrest		\$169,479.25
Gel-Del Technologies Inc	VasoGraft Therapeutic System	\$120,835.50	\$123,643.75
GeneSegues Inc	Tumor-targeted MRI nanoparticles for detecting and diagnosing microscopic metastasis	\$35,086.50	\$15,301.00
GeneSegues Inc	Tissue-targeted sub-50 nanometer particles for subcutaneous delivery of nucleic acid drugs	\$23,611.00	\$77,017.50
Genii, Inc (a MN C Corporation)	Genii GI Development and Submission		\$244,479.24
Heartland Biosciences, Inc	The use of D-Ribose for the treatment of cardiovascular disease	\$170,000.00	\$62,500.00
HEMERUS MEDICAL, LLC	LEUKOSEP® SOLX®	\$244,479.24	
Hemosphere, Inc	HeRO Vascular Access Device- Patency, Access & Development Improvement Project		\$145,716.00
Humanetics Corporation	Development of NICS-15 for Treatment of Alzheimer's Disease	\$50,359.00	\$194,120.24
Humanetics	Development of 7-oxo	\$24,400.00	\$64,900.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Corporation	Dehydroepiandrosterone for the Treatment of PTSD		
IGF Oncology, LLC	IGF-Methotrexate Conjugate to Treat Cancer	\$4,730.00	\$86,552.50
Immunochemistry Technologies LLC	MRI of Apoptosis Using New Tracers Specific for Caspase Activity	\$29,255.00	\$82,131.50
Immunochemistry Technologies, LLC	Near Infrared Tracers For Imaging Apoptosis in Vivo	\$66,810.24	\$176,221.06
IMPRES MEDICAL INC	ELATE SYSTEM	\$244,479.25	
Imricor Medical Systems Inc	MRI Compatible Catheter Ablation System	\$244,479.24	
Inspire Medical Systems, Inc	Inspire therapeutic delivery system for Obstructive Sleep Apnea (OSA) (the "inspire system")	\$244,479.25	
International Cardio Corporation	Non-Invasive Technology to Diagnose and Treat Arterial Plaque in Cardiovascular Disease	\$46,175.00	\$198,304.25
Interrad Medical, Inc	Subcutaneous Catheter Securement System	\$244,479.24	
Ionix Medical, Inc.	Prostate Cancer System	\$140,888.64	\$103,590.61
Ionix Medical, Inc.	Neuflo System	\$244,479.25	
Kinexum Metabolics, Inc (dba Exsulin Corporation)	INGAP PEPTIDE FOR ISLET REGENERATION IN TYPE 1 DIABETES	\$244,479.25	
Lexion Medical LLC	DewHeart CO2 Blower/Mister	\$30,385.00	\$43,989.50
LEXION MEDICAL, LLC	INSUFFLATION GAS CONDITIONING TROCAR	\$26,377.00	\$39,530.50
Lutonix, Inc.	Drug Coated Balloon Catheter	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Martell Biosystems, Inc.	A New Blood Test to Detect, Manage, and Monitor Women with Her-2 Breast Cance		\$40,000.00
Medinvent	Nasal Drug Delivery Catheter		\$120,218.01
Medinvent	NasoNeb Nasal Nebulizer	\$12,376.78	\$232,102.47
Medisyn technologies, Inc	MT103 Project	\$8,845.37	\$9,057.51
Medisyn Technologies, Inc.	Alzheimer's Program	\$46,436.48	\$52,761.45
Medisyn Technologies, Inc.	MT477 Program	\$55,617.62	\$48,911.95
Medisyn Technologies, Inc.	Protease Inhibitor Program	\$32,117.94	\$15,502.85
Nanocopoeia, Inc.	Novel Transdermal Delivery of Therapeutic Nanoparticles for Systemic Treatment of Pain	\$224,034.00	\$20,445.25
Neochord, Inc	NeoChord Model DS 1000	\$244,479.25	
NeuroVasx, Inc	cPax	\$244,479.25	
New Breath Medical, LLC	Sleep Apnea Treatment system		\$27,032.03
NxThera Inc.	NxThera Therapeutic Vapor Ablation and Drug Delivery System	\$244,479.25	
Obstetric Solutions and Interventions, LLC	Uterine Electrical Stimulation for Treating Postpartum Hemorrhage (PPH)	\$85,975.00	\$158,504.24
ORASI MEDICAL, INC.	Alzheimer's disease progression and severity biomarker using magneoenchelography	\$244,479.25	
Parsus Medical, LLC	Ultrasound Blood Filtration/Autotransfusion Project		\$225,000.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
PDAP LLC	Integrated Dispensing Aspirating Device		\$55,000.00
Peytant Solutions Inc	Amnion Stent-graft (Asg) System	\$27,134.00	\$44,392.50
Phraxis, Inc	InterGraft		\$244,479.25
Pursuit Vascular, Inc.	ClearGuard Therapeutic Delivery Device	\$83,835.36	\$160,643.89
Quantum Catch, LLC	Low-Cost Retinal Imaging System	\$49,872.50	\$194,606.74
ScyFix , LLC	Neuromodulation for the treatment of low vision blindness causing diseases	\$244,479.24	
Shape Medical Systems, Inc. (a Minnesota for profit C Corp)	Detection and classification of severity of pulmonary hypertension		\$244,479.24
Softscope Medical Technologies Inc	Propulsive Assist Device	\$244,479.24	
Spineology Inc	Vertebral Compression Fracture & Down-Sized Mesh	\$169,552.00	\$74,927.25
Spineology Inc.	Nucleus replacement and printed mesh	\$201,349.50	\$43,129.75
Steady State Imaging, LLC	SWIFT	\$71,076.74	\$91,233.83
SuperDimension, Inc	Electromagnetic Navigation Bronchoscopy (ENB)	\$244,479.25	
SURMODICS INC	Development of Technology for Controlled Delivery of Therapeutic Proteins	\$175,737.00	\$59,448.50
SURMODICS, INC	DEVELOPMENT OF DRUG DELIVERY BALLOON	\$171,312.00	\$73,167.25
Surmodics, Inc.	Development of sustained release injectable drug delivery	\$130,790.50	\$113,688.75

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	system for ocular administration		
SURMODICS, INC.	Development of Systems for Delivery of Therapeutic siRNA	\$133,857.00	\$110,622.25
SURMODICS, INC.	DEVELOPMENT OF MALTODEXTRIN-BASED DRUG DELIVERY POLYMERS	\$107,037.50	
SURMODICS, INC.	Development of SynBiosys Biodegradable Polymer Drug Delivery System	\$185,084.00	
Synitron LLC	Bacterial Vaccine & Therapeutic Platform Technology	\$244,479.24	
Tactile Systems Technology, Inc.	Multi Center Clinical Wound Study for the Treatment of Venous Stasis Ulcers	\$126,159.50	\$65,540.50
Torax Medical, Inc.	LINX Reflux Management System for treating gastroesophageal reflux disease (GERD)	\$244,479.24	
Tumor Biology Investment Group, Inc (TBIG, Inc)	Development of sHer Theragnostics	\$4,658.76	\$23,420.83
Twin Star Medical, Inc.	Compartment Syndrome	\$244,479.24	
Twin Star Medical, Inc.	Drug Delivery Catheter	\$56,737.94	\$105,455.00
VASAMED Incorporated	PADIQ	\$59,644.35	\$184,834.90
Vatrix Medical, Inc	Diagnosis and Treatment of Abdominal Aortic Aneurysms (AAAs)	\$71,560.81	\$172,918.44
Vital Images Inc	Computed Tomography 3D Body Perfusion	\$23,575.50	\$159,373.50
Vital Images Inc	Myocardial Analysis and Perfusion Imaging Software	\$167,390.00	\$77,089.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Vital Images Inc	CT Brain Analysis Imaging Software	\$68,347.50	\$115,913.00
Vital Images, Inc	Anatomical visualization with Multi-region segmentation (MRS)	\$165,749.00	\$58,887.00
Vital Images, Inc	Automated airways quantification for diagnosis & treatment planning	\$15,937.00	\$40,515.00
Vital Images, Inc	Fully Volumetric, CT-MRI Comprehensive Tumor Response Analysis	\$20,147.00	\$35,603.00
Vital Images, Inc.	Endovascular Stent Planning Imaging Software	\$104,083.50	\$76,467.50
Vital Images, Inc.	CT De-noising Image Enhancement	\$5,729.50	\$83,645.00
Vital Images. Inc	Multi-Chamber Cardiac Function Imaging Software	\$56,687.00	\$183,903.00
VivaQuant, LLC	Development and validation of a novel algorithm for highly accurate ECG analysis	\$20,162.50	\$128,000.00
Wilson Wolf Manufacturing Corporation	Superior cell culture devices for effective delivery of adoptive cell therapeutics	\$153,918.50	\$90,560.74
Zoltan Laboratories LLC	Treatment of Obesity and Diabetes	\$79,878.00	
Zyga Technology, Inc.	Glyder facet resurfacing system	\$244,479.25	

Mississippi \$924,818.96

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
EDWARDS PHARMACEUTICAL,	ANTISPASMODIC ORALLY	\$55,187.50	\$189,291.75

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
INC	DISINTEGRATING TABLET		
Edwards Pharmaceutical, Inc.	Urinary Antispasmodic and Antiseptic	\$191,245.97	\$53,233.28
ElSohly Laboratories, Inc	Artemisinin Dimer Analogs as Anti-cancer Agents	\$32,156.17	\$33,025.00
ElSohly Laboratories, Inc.	Delta-9-Tetrahydrocannabinol Transmucosal Matrix Patch	\$162,395.06	\$82,084.19
ElSohly Laboratories, Inc.	Poison Ivy Allergic Contact Dermatitis Treatment Products	\$22,810.84	\$103,389.20

Missouri \$7,695,336.29

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Antigen Laboratories, Inc	Sublingual CAT Hair Allergenic Extract	\$244,479.25	
APT Therapeutics, Inc.	Therapeutic Use of Human Apyrase	\$244,479.25	
BioMed Valley Discoveries Inc	Combination Bacteriolytic Therapy {COLBALT} Project	\$6,403.00	\$178,957.50
BioMed Valley Discoveries, Inc	Phenix Inflammation Project	\$244,479.25	
BioMed Valley Discoveries, Inc.	In Vivo FIAU Project	\$69,601.00	\$174,878.25
BioMed Valley Discoveries, Inc.	Phenix Chagas Project	\$43,688.50	\$72,998.00
BioMed Valley Discoveries, Inc.	Phenix Diabetes Project	\$116,561.50	\$127,917.75
CardiaLen, Inc.	Low-Energy Atrial Cardioverter	\$42,532.00	\$188,481.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Daya Drug Discoveries Inc	Novel Serotonin Agonists/Antagonists for the Treatment of Neurological Disorders	\$83,759.00	\$102,600.00
Daya Drug Discoveries Inc	Small Molecule Steriod Mimics for Molecular Imaging and Therapy of Breast Cancers		\$20,000.00
ENDOSTIM INC	ENDOSTIM MICROSTIMULATOR	\$152,091.15	\$92,388.10
Evogen, Inc	Fully automated point of care platform for the diagnosis of infectious disease and genotyping	\$244,479.25	
Foundation Care LLC	Cystic Fibrosis Health Management Program	\$110,000.00	\$134,479.24
Galera Therapeutics LLC	Development of a Drug to Prevent Oral Mucositis in Cancer Patients		\$244,479.25
Gerhard W. Cibis, M.D., P.C.	Automated Video Vision Development Assessment (AVVDA)	\$46,300.50	\$44,000.00
Immunophotonics, Inc	Laser-Assisted Immunotherapy	\$7,821.54	\$236,657.71
ISTO Technologies Inc	Cell-based technology platform	\$244,479.25	
Kereos, Inc	Molecularly Targeted Nanostructures for Anticancer Therapy with Cytologic Peptides	\$88,108.50	\$66,696.50
Kereos, Inc	Development of a F-19 Imaging Agent for Early Diagnosis of Cancer and Cardiovascular Disease	\$162,045.00	\$82,434.24
LipoSpectrum LLC	Multi-Dimensional Mass Spectrometry-based Shotgun Lipidomics (MDMS-SL)	\$90,860.00	\$95,111.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Mediomics LLC	Molecular PINCER-based biosensors for point of care diagnosis	\$244,479.24	
Mobius Therapeutics, LLC	Optomycin	\$230,779.50	\$13,699.74
Pepex Biomedical	Composite Conductive Monofilament (CCM) Biosensor Technology- Therapeutic Applications	\$244,479.25	
Sequoia Sciences, Inc.	Novel therapeutic vaccine for urinary tract infections	\$159,106.63	\$85,372.61
Sequoia Sciences, Inc.	Novel Small Molecule Therapeutic for the Treatment of Recalcitrant Bacterial Infections	\$244,479.25	
Shear Kershman Laboratories	A Tamper Resistant Delivery System for Opiods	\$16,408.50	\$95,420.10
Stereotaxis, Inc	V-Drive	\$244,479.25	
Stereotaxis, Inc	TOTAR	\$40,750.00	\$74,000.00
Stereotaxis, Inc	STOP-VT	\$20,580.00	\$101,804.00
Stereotaxis, Inc.	Navigant 3.2	\$244,479.25	
Stereotaxis, Inc.	Vascular Remote Advancement Systems (VRAS) and Next Gen Radiofrequency Generator	\$209,745.50	\$34,733.75
Stereotaxis, Inc.	Odyssey	\$244,479.25	
Stereotaxis, Inc	Next Generation Catheters	\$120,134.00	\$124,345.25
Traxsson, LLC	Biomarkers for Diagnosis and Prognosis of Cancer	\$21,947.00	\$41,950.00
Veran Medical Technologies, Inc	SPiN Drive	\$244,479.25	
VirRx Inc	Cancer Therapy with Oncolytic Adenovirus VRX-007		\$244,479.25
ZeaVision LLC	Macular Pigment Reflectometer	\$55,852.50	\$188,626.74

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	(MPR)		

Montana \$1,296,971.19

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Ateris Technologies, LLC	Organophosphate poisoning detection and diagnostic systems	\$244,479.25	
Bacterin International, Inc	Antimicrobial Orthopedic Surgical Fixation Devices	\$7,500.00	\$236,979.25
Genectar Com LLC	New therapy for metastatic melanoma through expanded comparative genomics.	\$7,836.53	\$13,343.30
LigoCyte Pharmaceuticals, Inc	Development of a Vaccine for the Prevention of Human Norovirus Acute Gastroenteritis	\$244,479.25	
LigoCyte Pharmaceuticals, Inc.	Development of a Novel Virus-like Particle Based Respiratory Syncytial Virus Vaccine	\$244,479.25	
Microbin Corporation	A Novel, Broad-Spectrum Antimicrobial Therapeutic for Treatment of infectious Diseases	\$113,575.50	\$130,903.75
NanoValent Pharmaceuticals, Inc.	Drug delivery system to treat cancer	\$9,712.11	\$13,500.00
SensoPath Technologies, Inc	Targeted Two-photon Photodynamic Therapy Drugs for Treatment of cancer	\$13,730.50	\$16,452.50

Nebraska \$2,379,064.05

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Advanced BioAdjuvants, LLC	Adjuplex, A Novel Vaccine Adjuvant Discovery		\$244,479.24
JN Medical Corporation	Rapid Intervention of Acute Stroke Using NMDAR R-Peptides to prevent Neurotoxicity		\$244,479.24
NATURE TECHNOLOGY CORPORATION	NON-VIRAL GENE THERAPY/VACCINATION VECTOR PLATFORM	\$70,468.00	\$174,011.25
SpineX Tec LLC	Development of a vertically expandable spinal fusion device for IBF applicants		\$125,359.50
Transgenomic, Inc	2D Analysis for Neurodegenerative Disease Diagnosis	\$244,060.76	\$418.49
Transgenomic, Inc	COLD-PCR	\$193,647.31	\$50,831.94
Transgenomic, Inc.	SURVEYOR Scan Kits	\$178,016.85	\$66,462.40
Transgenomic, Inc.	mtDNA Damage Assays	\$128,304.87	\$116,174.38
Transgenomic, Inc.	Mitochondrial Genetics Analysis	\$42,252.39	\$50,283.93
Virtual Incision Corporation	Miniature In Vivo Robotic System for the Surgical Treatment of Diverticular Disease		\$205,334.25
Ximerex, Inc.	Reversal of diabetes with pig islets by inducing immune tolerance in the donor pig	\$244,479.25	

Nevada \$3,068,649.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
AKI Bioscience, Incorporated	NATRIURETIC PEPTIDE RECEPTOR AGONISTS FOR THE TREATMENT OF HEART FAILURE AND	\$31,903.50	\$30,000.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	HYPERTENSION		
CardioVascular BioTherapeutics Inc	Human FGF1 (CVBT-141C) to Treat Peripheral Artery Disease		\$40,365.00
CardioVascular BioTherapeutics Inc	Human FGF-1 (CVBT-141A) to Treat Coronary Heart Disease	\$244,479.25	
Deuteria Pharmaceuticals, LLC	Scale-up of tetradeuterio p- flurobenzaldehyde	\$18,921.50	\$148,647.50
Deuteria Pharmaceuticals, LLC	Deuterium-enriched atorvastatin Derivatives	\$12,500.00	
Deuteria Pharmaceuticals, LLC	Deuterium-enriched oxybutynin derivatives	\$51,420.00	\$110,750.00
LANCO Biosciences Inc	Neridronate		\$244,479.25
NEXGEN MEDICAL SYSTEMS, INC	DEVICES FOR THERAPEUTIC DRUG DELIVERY TO BRAIN TUMORS	\$45,851.00	\$34,506.50
NexGen Medical Systems, Inc	Devices for Therapeutic Drug Delivery	\$91,562.50	\$67,512.50
NexGen Medical Systems, Inc	Devices for Blood Clot Removal	\$228,906.00	\$15,573.25
PEMF SYSTEMS INC	Development of a Pulsed Electro- Magnetic Field generator to treat Osteoarthritis		\$196,000.00
Redlabs, U.S.A. Inc.	Sandwich ELISA for XMRV Detection		\$232,875.00
Samaritan Pharmaceuticals, Inc.	SP-233, A New and Novel Mechanism of Action for the Treatment of Alzheimer Disease		\$244,479.25
Samaritan	SP1000, A Novel Therapy for the		\$244,479.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Pharmaceuticals, Inc.	Removal of Excessive Cholesterol Directly from the Blood		
Samaritan Pharmaceuticals, Inc.	SP-6310, As a Treatment of HIV-infected Patients with Abnormal Cortisol Levels		\$244,479.25
Sierra Sciences, LLC	hTERT	\$244,479.25	
Soar BioDynamics Inc.	Early Detection of High-Risk Prostate Cancer Project	\$244,479.25	

New Hampshire \$2,241,711.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Adimab, Inc	Development of Adimab's fully human antibody discovery and optimization platform	\$244,479.25	
Allyon Solutions, LLC	Commercialization of a fully-implantable anti-biofouling intraperitoneal glucose monitor	\$10,635.00	\$14,887.00
Allyon Solutions, LLC	Commercial Development of a novel Radio-mitigant	\$10,635.00	\$14,887.00
Alternative System Concepts, Inc.	C-Hub: Low-Power Cancer Therapy Control Device	\$13,670.00	\$230,809.24
Balch Hill Medical, Inc	Precision Thread IV Catheter	\$45,000.00	\$199,479.24
Celdara Medical, LLC	Myocardial Infarction (MI) Therapeutic Development	\$13,423.26	\$53,027.24
Celdara Medical, LLC	OnCyte: Cellular Therapy for Cancer	\$1,400.00	\$164,645.46
Celdara Medical, LLC	Scleroderma Diagnostic Services	\$35,665.48	\$126,121.09

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Design Mentor Inc	VentriFlo	\$6,398.42	\$62,841.91
ImmuRX	An Immunotherapy Drug Product for Cancer and Chronic Infectious Disease	\$120,725.00	\$123,754.24
Kaonyx Labs, LLC	Ultrasound Signal Processing Algorithms for Improved Anatomical Definition		\$244,479.25
Mantis Enterprises LLC	ThermoRetractor for Prophylactic Treatment of Retractor Ischemia/Edema		\$45,090.59
Mantis Enterprises LLC	ThermoPad for Traumatic Brain Injury		\$41,629.79
Microwave Imaging System Technologies Inc.	Alternative Breast Imaging Program	\$80,034.00	\$68,519.50
Novoculi Inc	Fully Implantable Chronic Intraperitoneal Glucose Monitoring for CGLCS	\$10,045.93	\$14,949.11
Xemed LLC	Hyperpolarized noble gas MRI of pulmonary function and microstructure	\$244,479.25	

New Jersey \$51,109,445.09

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
3D Biotek, LLC	Bioabsorbable drug-eluting stents	\$14,397.32	\$117,737.43
Actinium Pharmaceuticals, Inc	Alpha Particle Immunotherapy (APIT) drugs development	\$244,479.24	
AD4-PHARMA	STABILIZATION OF EGFR CLOSED FORM USING SMALL MOLECULE	\$238,708.50	\$5,770.75

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	COMPOUNDS		
AD4-Pharma	Small molecule compounds that mimic ERBITUX binding	\$238,708.50	\$5,770.75
AD4-PHARMA	MDM2 INHIBITORS IN COMBINATION WITH EGFR KINASE INHIBITORS	\$119,353.50	\$108,498.00
ADMA Biologics	Resplmmune™ for the treatment of Respiratory Syncytial Virus	\$244,479.25	
Advanced Technologies for Novel Therapeutics, LLC	Preclinical and clinical development of a novel and potent anti-cancer therapeutics	\$191,650.00	\$52,829.25
Advaxis Inc	ADXS11-001, a live attenuated bacterial vaccine for the treatment of cancer	\$244,479.24	
Aegerion Pharmaceuticals, Inc	Aegerion Pharmaceuticals, Inc Iomitapide development program	\$244,479.25	
Aerie Pharmaceuticals Inc	AR-12286	\$244,479.24	
Aestus Therapeutics, Inc	Treating neuropathic pain by means of novel mechanisms		\$244,479.24
Agennix USA, Inc	RGB-286638	\$244,479.25	
Agile Therapeutics, Inc.	Agile Therapeutics' Skinfusion - Low Dose Contraceptive Patch	\$244,479.25	
Alitair Pharmaceuticals Inc DBA The cough Company	Method for reducing or preventing overdose events with pharmaceuticals		\$244,479.24
Amicus Therapeutics, Inc.	Early Onset Familial Alzheimers Disease	\$175,445.00	\$69,034.25
Amicus Therapeutics Inc	Sporadic Alzheimer's Disease	\$244,479.25	
Amicus Therapeutics, Inc	AT1001 for Fabry Disease	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Amicus Therapeutics, Inc	AT1001 in Combination with Enzyme Replacement Therapy for Fabry Disease	\$244,479.25	
Amicus Therapeutics, Inc	Alpha-One Antitrypsin Deficiency	\$244,479.25	
Amicus Therapeutics, Inc.	Pharmacological Chaperones for Parkinson's Disease	\$244,479.25	
AMORCYTE INC	AMR-001 Phase 2 Trial	\$244,479.25	
Angel Medical Systems Inc	Nextgen R & D Project	\$244,479.24	
Angel Medical Systems, Inc	Alerts R&D Project	\$244,479.24	
Antyra Inc	Treatment of Cancer with a novel IGF-1R antagonist, ANT-429	\$204,273.00	\$40,206.24
Arno Therapeutics Inc	Dev of AR-67: A Novel, Third-generation Comptohecin Analogue for the Treatment of Cancer	\$244,479.24	
Arno Therapeutics Inc	Development of AR-42: A Novel, pan-DAC Inhibitor for the Treatment of Cancer	\$244,479.24	
Arno Therapeutics, Inc.	Dev. Of AR-12: A Novel and Potentially First-in-class Agent for the Treatment of Cancer	\$244,479.24	
BeFree! LLC	BeFree!	\$1,453.43	\$26,782.00
Bioscience Development Inc	Diagnostic Test for Lyme & Tick-borne Diseases		\$244,479.24
Bioscience Development Inc	Vaccines and diagnostic tests for Burkholderia Infections	\$57,899.00	\$186,580.24
Bright Cloud International	Arm Motor Rehabilitation, Entertainment and Cognition System for the Elderly		\$32,143.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Cahaba Pharmaceuticals, Inc.	TCN-P (tricitabine phosphate) Cancer Treatment		\$244,479.25
Cahaba Pharmaceuticals, Inc.	1UO (.1% uracil topical) DPD Inhibitor	\$244,479.25	
Cancer Genetics, Inc.	MatBA	\$244,479.25	
Cancer Genetics, Inc.	FISH-based HPV-associated Cancer Test (FHACTION)	\$209,466.50	\$35,012.75
Cancer Genetics, Inc.	FISH-based Renal Cancer Diagnostics (FReCAD)	\$125,680.50	\$118,798.75
Celator Pharmaceuticals, Inc	CPX-351 (Cytarabine:Daunorubicin) Liposome Injection	\$244,479.25	
Chemo Dynamics Inc	A Drug Discovery Program Based on Metalloporphyrin with Peptide end links	\$42,222.00	\$46,250.00
Chromocell Corporation	Development of novel, selective NaV1.7 antagonists for treatment of chronic pain	\$244,479.25	
ChromoDynamics	Novel PAP assay with automated hyperspectral imaging slide reader	\$177,631.12	\$66,848.12
Circulite Inc.	Circulite Synergy Endovascular System	\$244,479.25	
Circulite Inc.	Circulite Synergy Surgical System	\$244,479.25	
Circuport, Inc	Circuport Vascular Access Systems for Hemodialysis	\$98,515.43	\$145,963.82
Columbia Laboratories, Inc	Evaluate CRINONE ®/ PROCHIEVE ® for Reduction of Preterm Births in Women	\$244,479.24	
CorMedix Inc	Deferiprone	\$244,479.25	
CorMedix Inc	Neutrolin	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Cornerstone Pharmaceuticals Inc	Development project of Emulsiphan Platform (EmPA)	\$121,668.91	\$122,810.34
Cornerstone Pharmaceuticals, Inc.	AEMD	\$244,479.25	
CytoSorbents Inc	EntericSorb Anti-inflammatory therapy for life-threatening disease		\$244,479.25
CytoSorbents Inc	CytoSorb Autologous Blood Transfusion	\$244,479.25	
Derma Sciences Inc	DSC 127 Clinical Development Program	\$244,479.25	
DiamiR, LLC	Development of ASDmiR, molecular test for early detection and monitoring of Alzheimer's Disease.		\$156,600.00
Drais Pharmaceuticals, Inc.	DTS-108 anti-cancer chemotherapy drug	\$244,479.24	
E2	The EndoTube Duodenal Drug Delivery Reservoir	\$25,000.00	\$35,000.00
E2, LLC	The EndoSleeve Project	\$244,479.25	
Eagle Pharmaceuticals, Inc.	Ready-to-Use Oncology Product "P"	\$20,500.00	\$114,501.00
Eagle Pharmaceuticals, Inc.	Diluent for Oncology Product "A"	\$244,479.25	
Eagle Pharmaceuticals, Inc.	Nanosuspension for Treatment of Malignant Hyperthermia	\$244,479.25	
Eagle Pharmaceuticals, Inc.	Diluent for Oncology Product "D"	\$244,479.25	
Eagle Pharmaceuticals, Inc.	Ready-to-use Oncology Product "B"	\$244,479.25	
EDG Therapeutics, Inc.	New Drugs to treat Angiogenesis in Cancer		\$50,000.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Edge Therapeutics, Inc	NimoGel to prevent secondary stroke (vasospasm) and improve outcome after sudden brain injury.	\$42,203.50	\$202,275.75
Edusa Pharmaceuticals, Inc.	Pumosestrag Clinical Trials	\$108,798.50	\$135,680.75
ElectroCore LLC	Resolve System for treating acute Bronchoconstriction	\$244,479.25	
ElectroCore LLC	Rejuvenation System for Treating Chronic Obstructive Pulmonary Disease (COPD)	\$244,479.25	
ElectroCore LLC	Revive System for treating Sepsis and Septic Shock	\$244,479.25	
ElectroCore LLC	Resolution System for Treating Post-Operative Ileus	\$244,479.25	
Eleison Pharmaceuticals, Inc.	Inhaled Liposomal Cisplatin for Treatment of Recurrent Pulmonary Pediatric Osteosarcoma		\$244,479.25
Eleison Pharmaceuticals, Inc.	Development of Glufosfamide for the Treatment of Second-line Pancreatic Cancer	\$29,112.50	\$215,366.75
Elusys Therapeutics Inc.	Development of a Monoclonal Antibody for Prevention and Treatment of Anthrax	\$244,479.25	
Emisphere Technologies, Inc	Eligen Oral B12	\$244,479.24	
Endovalve, Inc.	Delivery System Development for Foldable Suture-free Mitral Valve Prosthesis	\$244,479.24	
Enzon Pharmaceuticals Inc	Androgen Receptor (AR) Antagonist (EZN-4176)	\$244,479.24	
Enzon Pharmaceuticals, Inc	HER3 Antagonist (EZN-39200)	\$78,521.50	\$165,957.74

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Enzon Pharmaceuticals, Inc	PEG-SN38	\$244,479.24	
Enzon Pharmaceuticals, Inc.	Survivin Antagonist (EZN-3042)	\$244,479.24	
Enzon Pharmaceuticals, Inc.	HIF-1alpha Antagonist (EZN-2968)	\$244,479.24	
EnzymeRx, LLC	Pegsiticase	\$244,479.25	
Flexible Stenting Solutions, Inc	Peripheral Vascular Self Expanding (SE) Stenting System (the "FlexStent")	\$244,479.24	
Follica Incorporated	Drug Delivery Program for inducing Follicular Neogenesis for Scarless Wound Healing	\$237,563.01	\$6,916.23
Follica Incorporated	Clinical Program for Inducing Follicular Neogenesis for Scarless Wound Healing	\$244,147.19	\$332.05
Galaxy Bio Inc	Development of NAL 1606 as a New Delivery System for Migraine	\$146,928.00	\$97,551.24
Genta Incorporated	Tesetaxel	\$244,479.24	
Genta Incorporated	Oblimersen	\$244,479.24	
HDL Therapeutics LLC	Selective HDL Delipidation Therapy (Delipidation Therapy)		\$104,429.50
Healthy Functions, LLC	Pressure Ulcer Prevention and Treatment Mattress	\$15,058.00	\$229,421.24
Healthy Functions, LLC	Pressure Ulcer Prevention and Treatment Wheelchair Cushion	\$4,078.50	\$194,000.00
HiLin Life Products, Inc	KNOWHEN ®	\$87,739.50	\$79,842.00
HMGene Inc	Development of Adiptin as a Biotherapeutic to treat Obesity	\$188,500.00	\$55,979.25
Humigen, LLC	Humigen IBD1:Use of the IL-32R "Delta-9" variant to	\$146,003.00	\$98,476.24

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	monitor prognosis and progression.		
Immunomedics Inc	hLL1 Dox for multiple myeloma	\$244,479.25	
Immunomedics Inc	TF4 for NHL	\$244,479.25	
Immunomedics Inc	F-18 labeling technique for imaging	\$244,479.25	
Immunomedics Inc	hRS7-SN-38 for lung and breast cancers.	\$244,479.24	
Immunomedics Inc	Veltuzumab as a subcutaneous formulation for NHL	\$244,479.25	
Immunomedics, Inc	20-2b for NHL	\$138,342.50	\$106,136.75
Immunomedics, Inc	22-20 for NHL	\$157,091.50	\$87,387.75
Immunomedics, Inc	hLL1 for multiple myeloma and NHL/CLL	\$244,479.25	
Immunomedics, Inc.	TF2 for colorectal cancer	\$244,479.25	
Immunomedics, Inc.	hPAM4 for early diagnosis, imaging and therapy of pancreatic cancer	\$244,479.24	
Immunomedics, Inc.	hMN14-SN-38	\$244,479.25	
Immunomedics, Inc.	IMMU-114 for B-cell lymphoma	\$41,460.50	\$157,955.50
IntelliSante Corporation	Psytracker		\$102,500.00
JS Genetics, Inc.	X Chromosome Abnormality Test-Fragil X (XCAT-FX)	\$22,480.53	\$118,702.53
JS Genetics, Inc.	X Chromosomal Abnormality Test-Turner Syndrome Test (XCAT-TS)	\$101,275.94	\$60,182.91
JS Genetics, Inc.	Novel Therapeutic for Priventricular White Matter (Brain White Matter) Injury PWMI	\$30,157.94	\$134,739.08

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Life Recovery Systems HD, LLC	The ThermoSuit System	\$194,228.80	\$50,250.45
Linkwireless LLC	RXManager		\$34,500.00
Lux Biosciences Inc	LX214-Voclosporin as a topical solution for the treatment of dry eye syndrome.	\$244,479.24	
Lux Biosciences Inc	LX211-Voclosporin for the treatment of Non-infectious Uveitis	\$244,479.25	
Lux Biosciences, Inc.	LX212 Treatment of severe dry eye syndrome with a voclosporin implant	\$219,361.50	\$25,117.75
MEDASYS INCORPORATED	PROMETRA II MRI SAFE PROGRAMMABLE DRUG INFUSION PUMP	\$244,479.24	
Medasys Incorporated	Prometra Programmable Drug Infusion System	\$244,479.24	
Medical Nutrition USA, Inc	Katz Study	\$23,791.50	\$18,627.45
Medical Nutrition USA, Inc	EVANS STUDY	\$64,698.04	\$64,698.04
Med-In-Touch LLC	Health E-Dose Medication Adherence System for Improved Outcomes and Reducing Costs	\$185,000.00	\$59,479.24
MicroDose Therapeutx Inc	MUDI-Multi Use Dry Powder Inhaler	\$244,479.25	
MicroDose Therapeutx, Inc	MDT-637 - Respiratory Syncytial Virus (RSV)	\$244,479.24	
MicroDose Therapeutx, Inc.	MDT-011 - Breath for Life!	\$244,479.25	
MicroDose Therapeutx, Inc.	MDT 006 - Treatment for Gastrointestinal Diseases	\$244,479.25	
Moerae Matrix, Inc.	Pre-Clinical Development of		\$244,479.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Novel Peptide Therapeutics		
Monosol Rx, LLC	Fast Dissolving Film Drug Delivery	\$244,479.24	
Monosol Rx, LLC	Nanoparticle Technology-Insulin Film Delivery	\$51,449.00	\$193,030.24
MONOSOL RX, LLC	SUBLINGUAL AND BUCCAL FILM DRUG DELIVERY	\$244,479.24	
Nephrogenex Inc.	Pyridorin Clinical Trials	\$244,479.25	
Neurologix, Inc	NLX-P101	\$244,479.24	
Neurotez Inc.	Leptin as a Therapy for Alzheimer's disease	\$244,479.24	
Niiki Pharma, Inc.	NKP-46	\$244,479.24	
Niiki Pharma, Inc.	NKP-1339	\$244,479.24	
NovaDel Pharma Inc	Duromist--Sildenafil Oral Spray for the treatment of Erectile Dysfunction		\$244,479.24
NPS Pharmaceuticals Inc	Teduglutide	\$244,479.24	
NPS Pharmaceuticals, Inc	NPSP558	\$244,479.24	
Nymox Corporation	NX-1207 for the Treatment of Benign Prostatic Hyperplasia		\$244,479.25
Oceana Therapeutics Inc	Solesta: novel product to treat fecal incontinence	\$244,479.24	
Omthera Pharmaceuticals, Inc	Epanova	\$182,843.50	\$61,635.75
Oncobiologics, Inc	Novel immuno-oncology biopharmaceutical drug development for treatment of cancer	\$125,000.00	\$119,479.25
Ophthotech Corporation	Volociximab	\$244,479.24	
Ophthotech Corporation	E10030	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Ophthotech Corporation	ARC1905	\$244,479.24	
Orphan Therapeutics, LLC	Lucassin (terlipressin) for Hepatorenal Syndrome (HRS) Type 1	\$244,479.25	
ORTHOBOND CORPORATION	ANTI-MICROBIAL SURFACES FOR IMPLANTABLE MEDICAL DEVICES		\$244,479.25
ORTHOBOND CORPORATION	OSTEOCONDUCTIVE SURFACES FOR IMPLANTABLE MEDICAL DEVICES	\$202,421.64	\$42,057.61
Orthogen LLC	Improved Cost Effective Dental and Orthopaedic Bone Grafts		\$123,479.24
PALATIN TECHNOLOGIES, INC	MELANOCORTIN AGONIST FOR OBESITY AND RELATED METABOLIC SYNDROME	\$244,479.25	
PALATIN TECHNOLOGIES, INC	Melanocortin Agonists for Sexual Dysfunction	\$244,479.25	
PALATIN TECHNOLOGIES INC	PL-3994 NATRIURETIC PEPTIDE MMETIC FOR ACUTE ASTHMA	\$113,330.00	\$131,149.25
PALATIN TECHNOLOGIES, INC	Subcutaneous Natriuretic Peptide Mimetic for Cardiovascular Disease	\$244,479.25	
Panoptica inc	PAN-90716-DES	\$85,755.50	\$158,723.75
Panoptica Inc	PAN-90806	\$104,577.00	\$139,902.25
Panoptica Inc	PAN-90716-2	\$85,755.50	\$158,723.75
Pestka Biomedical Laboratories, Inc.	Synferon	\$191,859.59	\$52,619.66
Pestka Biomedical Laboratories, Inc.	Human Interferon Beta Elisa Kit	\$180,733.27	\$63,745.98

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Pharmalead Therapeutics Inc	Breast Cancer Drug		\$42,500.00
PharmaSeq, Inc	Use of Silver Nanostructures on Mirotransponders in Ultra-sensitive Assay	\$48,727.56	\$95,142.25
PharmaSeq, Inc	Microtransponder-based Prostate Cancer Multiplex Assay	\$61,475.69	
PharmaSeq, Inc	Cystic Fibrosis DNA-based Assay on Microtransponders	\$244,479.25	
Pharmasset, Inc	PSI-7977	\$244,479.25	
Pharmasset, Inc.	PSI-938 and PSI-661	\$244,479.25	
Pharmos Corporation	Dextofisopam to treat Irritable Bowel Syndrome	\$244,479.24	
Phytomedics, Inc.	PMI-001 for Treatment of Rheumatoid Arthritis (RA)	\$244,479.25	
Piasek Biotech, Inc	Innovative therapy for nasal allergies and related disorders	\$74,340.01	\$169,439.50
ProFACT Proteomics Inc	SeraFILE {TM}: Conformational Variants {Conformers} for Drug and Biomarker Discovery	\$61,831.50	\$120,260.50
Prolong Pharmaceuticals, LLC	Sanguinate - A broad based Oxygen Therapeutic	\$244,479.25	
Prosidyan, Inc.	FIRBERGRAFT Anti-mircobial, Ultra-porous, Bioactive, Osteostimulative, bone graft substitute	\$119,005.00	\$125,474.25
PROVID PHARMACEUTICALS, INC	Development of PV-267 A DR2 inhibitor for the treatment of Multiple Sclerosis	\$6,696.50	\$159,000.00
PTC Therapeutics Inc	Development of small molecules to treat spinal mucular atrophy via modulation	\$62,136.00	\$18,224.50

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	of		
PTC Therapeutics Inc	Novel Broad Spectrum Antibacterials	\$244,479.25	
PTC Therapeutics Inc	Development of small molecules to treat spinal muscular atrophy via modulation of alternative splicing	\$244,479.24	
PTC Therapeutics Inc	Discovery & Development of Novel Small Molecule Antiviral Agents against Hepatitis C	\$244,479.25	
PTC Therapeutics Inc	Upregulation of the muscle specific form of insulin like growth factor (mIGF-1) to treat muscular dystrophies	\$219,521.50	
PTC Therapeutics, Inc	Identification of Compounds that Increase Utrophin Protein to delay progression of DBMD	\$219,521.50	\$24,957.75
PTC Therapeutics, Inc	Inhibition of Myostatin to slow the Progression of Muscular Dystrophies	\$219,521.50	
PTC Therapeutics, Inc.	Discovery & Development of Small Molecules that Increase the Translation of Tumor	\$162,655.00	\$81,824.24
PTC Therapeutics, Inc.	Development of Ataluren as a Treatment for Nonsense Mutation Genetic Disorders	\$244,479.25	
PTC Therapeutics, Inc.	Development of a Novel Glioblastoma treatment that selectively reduces Bmi-1	\$206,480.50	\$37,998.75
PTC Therapeutics, Inc.	Development of PTC299 as a Treatment for Cancer and other Neoplastic Conditions	\$244,479.25	
PTC Therapeutics, Inc.	Development of small molecules to treat spinal	\$45,110.00	\$17,140.50

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	muscular atrophy by a novel		
QRS Systems, Inc	Implantable Heart Monitor and Telemetry Reporting System	\$244,479.24	
QrxPharma Inc	TorsinA Activators for Disease Modifying Activity in Protein Misfolding Diseases	\$244,479.24	
QRxPharma, Inc	MoxDuo CR- a controlled release oral treatment for moderate to severe chronic pain.	\$244,479.24	
QRxPharma, Inc	MoxDuo IR-an immediate release oral treatment for moderate to severe acute pain.	\$244,479.24	
REDPOINT BIO CORPORATION	ORAL DRUGS REGULATING INSULIN & INCRETIN SECRETION FOR DIABETES TREATMENT	\$244,479.25	
Regado Biosciences, Inc.	REG2	\$244,479.24	
Regado Biosciences, Inc.	REG3	\$244,479.24	
Regado Biosciences, Inc.	REG1	\$244,479.24	
Replication Medical Inc.	GelStix	\$244,479.25	
Samos Pharmaceuticals LLC	Oral and Parenteral Multi-day Delivery of Drugs	\$53,230.00	\$108,543.00
Savient Pharmaceuticals, Inc	Pegloticase	\$244,479.24	
Scivanta Medical Corporation	Development of a Minimally-invasive Cardiac Monitor	\$112,500.00	\$131,979.25
Secant Therapeutics, Inc.	Percutaneous Transcatheter Direct Plication Annuloplasty (DPA)		\$58,500.00
Semorex Incorporated	Targeted Intracellular Photodynamic Therapy (TIP)	\$244,479.24	
Senesco Technologies,	Use of SNSO1-T as a	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Inc	Therapeutic for Multiple Myeloma		
Signum Biosciences Inc	Development of Novel Therapeutics for Acne	\$188,551.00	\$55,928.24
Signum Biosciences, Inc	Development of Novel Therapeutics for Alzheimer's Disease	\$244,479.24	
Signum Biosciences, Inc	Development of Novel Therapeutics for Rosacea	\$182,012.50	\$62,466.74
SIGNUM BIOSCIENCES, INC.	Development of Novel Therapeutics for Parkinson's Disease	\$244,479.24	
Simon Wiiliams Pharma Consulting LLC	VaccJect drug delivery sytem		\$244,479.25
Soligenix, Inc. (formerly known as DOR BioPharma, Inc.)	orBec (oral BDP) for the Treatment/Prevention of Acute Graft-versus-Host Disease (GVHD)	\$244,479.25	
SOMNUS THERAPEUTICS, INC.	SKP-1041 CLINICAL TRIALS	\$244,479.25	
SVELTE MEDICAL SYSTEMS, INC	Stent on a wire delivery system	\$244,479.25	
TAXIS Pharmaceuticals, Inc.	Novel Antibiotic Drug Development - Unique Mechanism of Action to Overcome Resistance	\$106,853.50	\$137,625.74
Thymon LLC	Synthetic HIV-1 Tat epitope vaccine	\$127,606.50	\$116,872.74
Transave Inc	Arikace Cystic Fibrosis (CF) Program	\$244,479.24	
Transave Inc	Arikace Nontuberculous Mycobacteria (NTM) Program		\$244,479.24
Transave Inc	Arikace Non-CF Bronchiectasis Program	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
TRIM-edicine, Inc.	Treatment of muscular dystrophy by protein therapeutics.	\$244,479.25	
Tyrx Pharma, Inc	ASTRA Antibacterial il for Soft Tissue ReINFORCEMENT AND Infection Control	\$244,479.24	
Tyrx Pharma, Inc.	AIGIS Product Family Antibacterial Mesh for Infection Control in Cardiac Rhythn devices	\$244,479.24	
Unigene Laboratories Inc	ANNEXIN	\$244,479.25	
Unigene Laboratories, Inc	ORAL PTH	\$244,479.25	
Unigene Laboratories, Inc	SITE-DIRECTED BONE GROWTH (SPBG)	\$188,972.00	\$55,507.25
Unigene Laboratories, Inc	SATIETY	\$232,812.50	\$11,666.75
UROVALVE, INC	Surinate Bladder Management System	\$244,479.25	
Valeritas Inc	V-Go™ Disposable Insulin Delivery Device	\$244,479.25	
VASCULAR DEVICES LLC	RESEAL Vascular Access Graft for Early Access Hemodialysis - For chronoc kidney dise	\$243,000.00	\$1,479.24
Vascular Therapies, LLC	Coll-R Collagen Rapamycin Matrix Project	\$244,479.25	
Vaxinnate Corporation	Novel Vaccine Technology for Influenza	\$244,479.24	
VectraCor, Inc.	VectraplexPDA Holter System	\$140,925.67	\$103,553.57
Venenum Biodesign, LLC	Venenum CIP2A Development and high throughput screening of an assay designed to isolate. Development and high throughout screening of an	\$102,851.50	\$141,627.75

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	assay designed to isolate small molecules blocking C-Myc binding to cancerous inhibitor of protein phosphatase 2A (CIP		
Venenum Biodesign, LLC	Venenum SiRNA: The corresponding proteins expressed by the cancer genes isolated... The isolation of novel biomarkers and cancer drug targets through high throughput SiRNA screening for genes required for cancer cell viability.	\$99,135.50	\$145,343.75
Vicus Therapeutics LLC	VT-122 Development Program	\$192,251.49	\$52,227.76
VYTERIS, INC.	Lutrepach™	\$244,479.25	
VYTERIS, INC.	Glucagon-like peptide 1 (GLP-1)	\$244,479.25	
WellGen, Inc	Using nutrigenomics discovery tools for novel medical foods to treat chronic disease	\$244,479.24	
XEME Biopharma Inc	Therapeutic Cancer Vaccines	\$48,313.00	
ZBV II LLC	Phase III Trial of Myocet Trastuzumab (T) and Paclitaxel(P) vs T&P for 1st Line HER2+MBC	\$244,479.25	

New Mexico \$4,423,671.65

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Accent Alternatives, Inc.	Prostate Cancer Prevention Using Tocopherylquinone (TQ)	\$750.00	\$116,500.00
ATOF, Inc	Development of BiosparQ Instrument for rapid microbial		\$244,479.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	characterization of clinical samples.		
Azano Pharmaceuticals Inc	C-Reactive Protein Therapy for Lupus Nephritis in Systemic Lups Eryrhematosus	\$53,920.50	\$33,952.50
Biomoda, Inc.	Diagnostic Assay for Detection of Early-Stage Lung Cancer	\$244,479.25	
Caldera Pharmaceuticals Inc.	Diagnostics for Trauma Injuries	\$205,791.33	\$38,687.91
Exagen Diagnostics Inc	Exagen Gastrointestinal Discoveries	\$244,479.25	
Exagen Diagnostics, Inc.	Exagen Autism Spectrum Disorder Discoveries	\$19,164.00	\$139,724.50
InLight Solutions, Inc	Noninvasive Glucose Monitoring for Gestational Diabetes	\$151,661.50	\$92,817.75
Intellicyt Corporation	Biomarker Discovery Platform to Accelerate Development of Cancer Therapies	\$244,479.25	
Manhattan Isotope Technology	Recycling of the Cardiac Imaging Agent, Strontium-82, from Spent Generators		\$244,479.25
Mesa Tech International, Inc.	Point of care molecular diagnostic device for respiratory diseases	\$244,479.25	
nanoMR, Inc.	Miniature NMR Pathogen Detection System	\$244,479.25	
Samitaur Medical Technologies, LLC	Neurological Stimulation for Samitaur Medical Technologies		\$90,000.00
Senior Scientific LLC	A Biomagnetic Method for Detecting and treating breast cancer	\$152,704.00	\$63,661.00
Senior Scientific	A Biomagnetic Method for	\$79,805.50	\$44,762.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
LLC	Determining Transplant Rejection and Monitoring Therapy		
Senior Scientific LLC	Magnetic Biopsy Needle for Minimum Residual Disease Detection in Luekemia	\$130,914.00	\$105,725.00
Senior Scientific LLC	Biomagnetic In-vivo Imaging and Image-Guided Therapy of Ovarian Cancer	\$54,528.00	\$70,799.50
SK Infrared LLC	Early Detection of skin cancer using non-invasive infrared imaging.		\$35,283.64
TECMED, INC.	SURGICAL SUITE UNIT: Automated Blood Analyte Monitoring System	\$5,502.50	\$7,891.00
TruTouch Technologies, Inc.	Noninvasive alcohol diagnostic device for emergency care facilities	\$169,386.21	\$75,093.04
VeraLight Inc	SCOUT	\$244,479.24	
Visionquest Biomedical LLC	Automatic eye disease diagnosis system	\$244,479.25	
Visionquest Biomedical LLC	Stroke risk stratification through plaque motion analysis of longitudinal carotid		\$39,853.78
Vista Therapeutics, Inc	NanoBiosensor for Continuous Biomarker Monitoring	\$244,479.25	

New York \$48,158,586.22

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
22nd Century Limited, LLC	X-22 Prescription Smoking Cessation Aid	\$20,939.50	\$223,539.75

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
AccuVein, LLC	Development of Light Reflective Vein Visualization Device - AV300	\$244,479.25	
Adarza Biosystems, Inc.	Novel Molecular Profiling Tool for Diagnosing, Guiding Therapy and Reducing Cancer Costs.	\$169,837.27	\$74,641.98
Advance Biofactures Corporation	Collagenase for Tissue Dissociation-New Cellular Therapies	\$51,186.62	\$130,736.83
Advance Biofactures Corporation	The use of Collagenase Therapy in the Treatment of Human Lipoma	\$51,138.20	\$193,341.05
Advanced BioMedical Technologies Inc.	Bio-degradable Polymer Orthopedic Internal Fixation Devices	\$196,382.50	\$48,096.75
Advanced Monitoring Caregiving, Inc	Development of an Interactive Voice Rdsponse Clinical Application	\$244,479.25	
Advanced Monitoring Caregiving, Inc.	Development of a Predictive Model for Assessing Telehealth Impactability	\$47,306.00	\$74,189.50
Advanced Monitoring Caregiving, Inc.	Integration of a Clinical Televideo Solution into a Web-Based Telehealth Software Application	\$23,750.00	\$112,199.00
Aggamin Pharmaceuticals LLC	Novel therapy for the treatment of preeclampsia in pregnant women		\$244,479.24
Ambulatory Monitoring Inc	Development of a Compact, High-Performance Wrist-Worn Motionlogger Actigraph Device	\$151,083.00	\$93,396.25
ANDROBIOSYS, INC	PROSTATE DISEASE TREATMENT	\$166,822.00	\$77,657.25
Angioblast Systems Inc	Allogeneic Adult Stem Cells to	\$200,149.50	\$44,329.74

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Treat and Reverse Wet Age Related Macular Degeneration		
Angioblast Systems Inc	Allogenic Adult Stem Cells to Treat Reverse Congestive Heart Failure	\$244,479.24	
Angioblast Systems Inc	Adult Stem Cells to Treat Type 2 Diabetes by regenerating Beta Islet Cells	\$237,301.00	\$7,178.24
Angioblast Systems Inc	Allogenic Adult Stem Cells for the Treatment of Acute Myocardial Infarction (AMI)	\$237,509.50	\$6,969.74
Angioblast Systems Inc	Cord Blood Expanded by Allogeneic Adult Stem Cells to Treat Hematologic Malignancies	\$244,479.24	
Angion Biomedica Corp	4 Phenylphtalazione, other projects: BB3, Ang797, Rac1, Dual Kinase, Atra	\$244,479.24	
Angion Biomedica Corporation	Rac1,	\$2,374.99	\$56,433.08
Angion Biomedica Corporation	BB3 Other projects: Ang797, Rac1, Dual Kinase, Atra, 4-Phenylphalazionone	\$244,479.24	
Angion Biomedica Corporation	Dual Kinase, Other Projects: BB3, Rac1, Atra, Ang797, 4 Phenylphthalazinone		\$61,001.01
Angion Biomedica Corporation	ATRA, Other Projects: BB3, Ang797, Rac1, Dual Kinase, 4 Phenylphthalazinone		\$30,785.58
Angion Biomedica Corporation	ANG-797, Other Projects: BB3, Rac 1, Dual Kinase, Atra, 4 Phenylphthalazinone	\$16,966.56	
Anterios, Inc (formerly known as Encapsion, Inc)	New Treatments for Hyperhidrosis and Acne	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Apath LLC	Research and Development Tools for the Treatment of Viral Infections	\$244,479.25	
Apath, LLC	Drug Discovery: Specific and broad spectrum antivirals	\$244,479.25	
AptaMatrix, Inc.	New diagnostics for epigenetic disorders with applications to mental health diseases		\$87,981.00
AptaMatrix, Inc.	New diagnostics for thrombosis, bleeding disorders, and proliferatives diseases	\$244,479.25	
Archer Biosciences Inc	TPI-287, a novel anti-microtuble agent for the Treatment of Cancer	\$244,479.25	
Ariston Pharmaceuticals, Inc.	AST-726 for the treatment of Vitamin B-12 Deficiency		\$244,479.25
Aureon Laboratories, Inc	Prognostic Model for Active Surveillance in Prostate Cancer Patients	\$244,479.24	
Avatar Medical, LLC	Dityrosine (DT) stabilization of an HIV-1 Env vaccine immunogen	\$53,960.00	\$190,519.25
Biomedica Management Corporation	Hemostatic Agent for use in non-compressible hemorrhage	\$183,491.99	\$60,987.26
Biomerix Corporation	therapeutic Devices Using the Novel Biomerix Biomaterial	\$244,479.25	
BIO-SIGNAL GROUP CORP	Putting EEG in the Emergency Department	\$51,605.84	\$192,873.40
Bio-Signal Group Corp	The Home Epilepsy Monitoring Unit	\$190,184.75	\$54,294.49
BIOSOF LLC	IMPROVED MANUSCRIPT SEARCH THROUGH PUBSEQ	\$19,981.50	\$34,272.00
BioSource Pharm, Inc.	Design and Synthesis of Novel	\$61,791.50	\$182,687.75

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Antibiotics Against Resistant Gram Positive Bacteria		
Buffalo Biolabs LLC	Development of Dual Cargo Liposomes Containing Cytotoxic Drugs and Reversan	\$44,955.82	\$97,977.53
Celmatix, Inc.	FertilArray: In Vitro Diagnostic for Oocyte (Egg) Quality and Female Infertility	\$16,125.00	\$228,354.25
Celtic Pharma Development Services America Inc	Xercept	\$244,479.25	
Celtic Pharma Development Services America, Inc.	TDT 067	\$244,479.25	
Cerebral Assessment Systems Inc	Cognivue Development	\$244,479.25	
CEROVENE INC	New Dosage Latform Project	\$138,050.50	\$106,428.74
Chembio Diagnostic System Inc	DPP Multiplex Rapid Test for Detection of HIV P24 Antigen & HIV 1/2 Antibodies	\$51,575.50	\$192,903.75
Chembio Diagnostic Systems , Inc	DPP® Multiplex Rapid Test for Detection of Antibodies to Hep-C & HIV1/2	\$118,840.00	\$125,639.25
Chembio Diagnostic Systems Inc	Sure-Check Unitized Home Use Finger-stick Whole Blood Rapid HIV 1/2 Test		\$244,479.25
Chembio Diagnostic Systems, Inc.	DPP® Rapid Test for the Detection of Antibodies to Hepatitis-C	\$71,649.50	\$172,829.75
Chembio Diagnostic Systems, Inc.	DPP® Rapid Test for Detection of Antibodies to HIV1/2 in Oral Fluid	\$233,578.00	\$10,901.25
Chembio Diagnostic Systems, Inc.	DPP ® Multiplex Rapid Test for Diagnosing Active,	\$144,961.50	\$99,517.75

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Untreated Syphilis		
Cleveland BioLabs Inc	Protectan CBLB502	\$244,479.24	
Codevax	Vaccine against Respiratory Syncytial Virus (RSV)	\$2,500.00	\$18,500.00
Codevax	Anti-Autolysin Passive Immunity for MRSA Osteomyelitis	\$30,426.50	\$60,250.00
Coronado Biosciences	CNDO102 for Treatment of Cancer	\$244,479.25	
Coronado Biosciences	CNDO101 for Treatment of Cancer	\$244,479.25	
Coronado Biosciences	C1 for Treatment of Cancer	\$244,479.25	
Critical Care Diagnostics, Inc.	sST2 Guided Personalized Management of Cardiovascular Disease and Cancer Treatment	\$244,479.25	
Curemark LLC	CM-AT Therapeutic FDA authorized Phase III clinical trials for the treatment of autism	\$244,479.25	
Cynvec LLC	CYN 101 onvolytic vector for the diagnosis and treatment of cancer	\$244,479.25	
Delcath Systems, Inc	Delcath Chemosaturation System	\$244,479.25	
Diffinity Genomics, Inc.	Enhanced Genetic Sample Analyst and Use	\$174,809.78	\$69,669.47
Dipexium Pharmaceuticals, LLC	Pexiganan cream for treatment of diabetic foot infection (DFI)		\$244,479.24
Durata Therapeutics, Inc.	Dalbavancin	\$244,479.25	
Egenix, Inc	Chemically-distinct low molecular weight compounds against validated cancer targets	\$244,479.24	
ELLIQUENCE, LLC	RD-ELL 10-1003		\$197,000.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Empire Genomics LLC	Non-invasive Bladder Cancer Molecular Diagnostic test.		\$244,479.25
Endocrine Technology, L.L.C.	ET002 Therapy of Colon Cancer	\$244,479.24	
EpiCept Corporation	Crolibulin novel small molecule vascular disruption agent for the treatment of solid tumors	\$244,479.25	
EpiCept Corporation	NP-1 is a novel approach in the management of pain associated with neuropathies.	\$244,479.25	
EpiCept Corporation	Ceplene, Immunotherapy for remission maintenance in AML	\$244,479.25	
ET Neuron Inc	ETN 002: Therapy of Amyotrophic Lateral Sclerosis (ALS)	\$244,479.24	
ET Neuron Inc	ETN 001: Therapy of Alzheimer's Disease	\$244,479.24	
ET Transplant, Inc.	ETR 001: Therapeutic Project for Renal Transplant Tolerance	\$244,479.24	
ETVaccine Technology, Inc.	ETV003: Factor H binding Meningococcal Vaccine	\$244,479.24	
Evidence-Based Solutions, Inc	Evidence-Based Diagnostic Device/Solution	\$244,479.24	
Exosome Diagnostics Inc	Diagnosis of Cancer, Staging and Patient Stratification from Exosome Content Analysis	\$244,479.25	
Fonar Corporation	Fonar Upright MRI Diagnostic Technology	\$244,479.25	
Foresight Biotherapeutics Inc	FST-200, a novel Otic Suspension for the Treatment of Acute Otitis	\$244,479.25	
Foresight Biotherapeutics Inc	FST-100, a Novel Ophthalmic Suspension for the Treatment of Adenoviral Conjunctivitis	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Garnett McKeen Laboratory, Inc.	Novel Organo-Metallic Compounds in the Treatment of Cancer	\$244,479.25	
Garnett McKeen Laboratory, Inc.	Palladium-Lipoic Acid Formulation in the Treatment of Brain Cancer	\$7,500.00	\$95,000.00
Glycobia, Inc.	Manufacturing Therapeutic Glycoproteins in E. Coli	\$52,269.43	\$139,127.56
iCardiac Technologies, Inc.	Diagnosing Acute Coronary Syndrome in patients with Chest Pain	\$23,465.50	
ImaCor Inc	TEE Monitoring for Intensive Care	\$244,479.25	
Immco Diagnostics, Inc.	Autoimmune Disease Markers		\$65,480.00
IMMCO DIAGNOSTICS, INC.	DETECTION OF CHRONIC SINUS		\$44,705.00
Immune Pharmaceuticals Corp	Therapeutic monoclonal antibody drug for the treatment of IBD and Severe Asthma	\$125,000.00	\$119,479.25
Immune Pharmaceuticals Corporation	Monoclonal antibody for the treatment of the treatment of Graft versus Host Disease (GVHD)	\$50,000.00	\$194,479.25
Immune Pharmaceuticals Corporation	Therapeutic Targeting Cancer Stem Cells	\$237,500.00	\$6,979.25
Immune Pharmaceuticals Corporation	BI-specific antibodies for the treatment of fatal Chronic Lymphocytic Leukemia (CLL)	\$225,000.00	\$19,479.25
Impulse Dynamics USA, Inc	Optimizer III System (medical device) for Treatment of Chronic Heart Failure (CHF)	\$244,479.25	
Incuron LLC	Development of Curaxins as novel anticancer agents		\$244,479.25
INSPIRION DELIVERY	ABUSE DETERENT OPIOIDS	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
TECHNOLOGIES LLC			
Integrated Nano-Technologies, LLC	An Automated Point-of-Care Molecular Diagnostic System	\$244,479.25	
Intercept Pharmaceuticals	INT-747	\$244,479.25	
INTERCEPT PHARMACEUTICALS	INT-777	\$244,479.25	
Intra-Cellular Therapies, Inc	ITI-007 for the treatment of insomnia and sleep disorders	\$244,479.25	
Intra-Cellular Therapies, Inc	ITI-007 for the treatment of Schizophrenia and Depression	\$244,479.25	
Intra-Cellular Therapies, Inc.	ITIPDE1	\$244,479.25	
Intra-Cellular Therapies, Inc	PET Ligands	\$166,269.00	\$78,210.25
IRX Therapeutics Inc	IRX-2 Patented novel biologic to treat newly-diagnosed advanced head and neck cancer	\$244,479.24	
IRX Therapeutics, Inc	Skin Test: Patented novel diagnostic device to determine immune competency.	\$12,136.14	\$96,923.56
IRX Therapeutics, Inc.	IRX-4: Patented novel therapeutic cancer vaccine to treat prostate and brain cancer	\$244,479.25	
IRX Therapeutics, Inc.	IRX-2 Patented novel therapeutic vaccine to treat HPV infected women	\$244,479.25	
IRX Therapeutics, Inc.	MIMP: Patented novel small molecule to restore immune protection against influenza A virus	\$26,118.23	\$218,361.02
Isoflux Inc	Drug Delivery from Nanoporous Inorganic Structures	\$124,861.14	\$119,618.10

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
JARVIK HEART, INC	Development & Clinical Trials of Highly Miniaturized Heart Assist Therapeutics	\$244,479.25	
Kadmon Corporation LLC	Targeted therapy for treatment of advanced gastric cancer		\$244,479.24
Karos Pharmaceuticals, Inc.	Novel tryptophan hydroxylase 1 (TPH1) inhibitors		\$244,479.25
Keryx Biopharmaceuticals, Inc	Perifosine	\$244,479.24	
Keryx Biopharmaceuticals, Inc.	Zerenex (ferric citrate)	\$244,479.25	
Kinentia Biosciences LLC	Flt-3 Kinase Inhibitor Program	\$1,641.50	\$3,724.50
Kinentia Biosciences, LLC	Mu Opioid Moderator Program	\$1,928.50	\$10,323.50
KINEX PHARMACEUTICALS	KX01	\$244,479.24	
KINEX PHARMACEUTICALS, LLC	KX03	\$244,479.24	
KINEX PHARMACEUTICALS, LLC	KX02	\$244,479.24	
Kite Pharma, Inc.	Development of Adv-GM-CAIX: A Novel Immunotherapy for the Treatment of Cancer	\$23,027.14	\$221,452.10
Lambda Max, LLC	Electrical Inhibition of Human Preterm Uterine Contractions	\$2,605.00	\$179,976.00
LighTouch Medical Inc	Non-Invasive Platform Technology for The Molecular Analysis of Blood Analytes	\$205,000.00	\$39,479.25
Litron Laboratories Ltd	Development of a Novel method for quantifying splenic	\$7,170.50	\$6,032.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	function		
Lixte Biotechnology Holdings Inc	LB-1 an inhibitor of protein phosphatase 2A is a novel effective anticancer drug	\$127,994.00	\$116,485.25
Lucid Inc	VivaScope Confocal Imaging for the early detection of Melanoma and other skin cancers	\$244,479.25	
Lumetrics Inc	Portable Fundus Camera	\$13,119.10	\$71,223.75
Medicon Inc.	A novel agent for colon cancer prevention	\$7,722.00	\$236,757.24
Mela Sciences Inc	MelaFind	\$244,479.25	
Misonix Inc.	Sonatherm 600i System	\$74,283.50	\$40,107.00
Myeloma Health LLC	Gene Expression Profiles (GEPs) for the Effective Treatment of Multiple Myeloma (MM)	\$12,786.00	\$231,693.25
MyoCardioCare Inc	Development of mechanical cardiac and circulatory support device for cardiac arrest patients	\$164,982.41	\$79,496.84
NaniRx Therapeutics Inc	Breast Cancer Precision Immune Stimulants (PINS)	\$244,479.24	
Natrogen Therapeutics International, Inc	Development of new drug (Natura-alpha) for treating autoimmune diseases	\$244,479.24	
Neogenix Oncology Inc	Advancing Two Novel Biomarkers for Diagnosing Pancreatic and Colorectal Cancers.	\$244,479.25	
Neogenix Oncology, Inc	Development of h16C3 mAb as a Novel Treatment for Colorectal, Pancreatic & Lung Cancers	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Neogenix Oncology, Inc	NPC-1C (ensituximab) as a Target Therapy for Pancreatic and Colorectal Cancers	\$244,479.24	
Nex Genix Pharmaceuticals Holdings Inc	NX101 Novel Non-Surgical Treatment for Dermal Neurofibromas	\$35,292.76	\$204,382.47
NexGenix Pharmaceuticals Holdings Inc	Hsp90 Inhibitors for Glioma and Other Primary Tumors of the Central Nervous System (CNS)	\$244,479.25	
NexGenix Pharmaceuticals Holdings, Inc	Hsp90Inhibitors for Neurodegenerative Diseases	\$244,479.25	
NexGenix Pharmaceuticals Holdings, Inc	Hsp90 Inhibitors for Solid Tumors including Refractory Tumors with Brain Metastases	\$91,940.11	\$152,539.14
Nomir Medical Technologies Inc	Antimicrobial resistance reversal and bio-burden reduction of bacterial and fungal pathogens	\$244,479.25	
NovaSterilis Inc.	Terminal Sterilization of Allograft Tissue	\$37,866.00	\$170,050.00
Nutrition 21, Inc.	Cr-enhanced insulin for the treatment of type 1 and type 2 diabetes	\$4,350.00	\$100,000.00
Ohr Pharmaceutical, Inc.	OHR/AVR118 for Cachexia	\$65,121.68	\$179,357.56
ONY Inc.	Testing an Aerosol System fo Lung Surfactant Delivery		\$40,000.00
Oratel Diagnostics LLC	Saliva assay for endometriosis	\$43,298.00	\$85,500.00
Ort, Inc F/K/A Oncology Research Therapeutics, Inc	Clinical study to demonstrate the use of in-vitro chemofit assay	\$21,679.50	
Orthocon Inc	The ORTHOstat-L project	\$244,479.25	
Oxyvita, Inc.	OxyVita®	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Palyon Corporation	Paylon Implantable Drug Delivery System (IDDS)	\$244,479.25	
Penwest Pharmaceuticals Co	A0001, a coenzyme Q analog for treatment of mitochondrial diseases	\$244,479.25	
PERICOR THERAPEUTICS, INC	GP-531 AS A TREATMENT FOR ACUTE HEART FAILURE	\$244,479.25	
Pharmadva, LLC	Automatic Home Medication Dispenser (AHMD)		\$244,479.25
PharmaNova Inc	PN 200: A New Topical Treatment for Genital Herpes	\$63,611.94	\$180,867.31
PharmaNova Inc	PN203: Targeted Nanoparticles for Oncology Medicines	\$60,893.93	\$183,585.32
PharmaNova, Inc	Implantable, refillable, reprogrammable, rechargeable drug delivery device	\$17,852.88	\$37,451.00
PharmaNova, Inc.	AP022 A New Topical Treatment for Glaucoma	\$28,100.12	\$92,274.00
Pneuma Pharmaceuticals Inc	Calfactant for Acute Respiratory Distress Syndrome (CARDS study)	\$244,479.25	
Population Diagnostics Inc	A rational & systematic approach to parkinson's disease ("PD") drug therapy development		\$244,479.25
Population Diagnostics Inc	Development of an Autism early Detection Genetic Test		\$244,479.25
Primros Therapeutics, Inc	XL647 PKD Therapeutic		\$244,479.24
Progenics Pharmaceuticals Inc	PSMA ADC	\$244,479.24	
PROGENICS PHARMACEUTICALS, INC	PRO 140	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
PROGENICS PHARMACEUTICALS, INC.	HCV ENTRY INHIBITOR	\$244,479.24	
PsychoGenics Inc	Clinical Development of Eltoprazine	\$244,479.24	
PsychoGenics Inc.	Discovery and development of Adenosine	\$244,479.24	
PsychoGenics Inc.	Partnered Drug Discovery	\$244,479.25	
PsychoGenics Inc.	Discovery and Development of Peptides for CNS Disorders	\$244,479.24	
PsychoGenics Inc.	Development of Novel Nicotinic for Treatment of Resistant Depression	\$244,479.24	
Pulmokine, Inc	A PDGFR inhibitor for the treatment of pulmonary arterial hypertension		\$134,390.00
Pulmokine, Inc.	A novel JAK inhibitor for the treatment of pulmonary arterial hypertension		\$115,043.00
Recor Medical Inc	Therapeutic Ultrasound For The Treatment Of Mitral Regurgitation	\$244,479.24	
Redox Pharmaceutical Corporation	Doxovir™ ("Doxovir")	\$244,479.25	
Remedy Pharmaceuticals Inc	Development of intravenous glyburide to treat acute ischemic stroke	\$244,479.24	
Remedy Pharmaceuticals Inc	Development of intravenous glyburide to treat acute spinal cord injury	\$244,479.24	
Remedy Pharmaceuticals, Inc	IV glyburide to reduce edema and steroid use and improve outcomes following brain tumor surgery	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Sarentis Therapeutics, Inc.	Neurotensin pain medication	\$69,755.00	\$174,724.25
Sarentis Therapeutics, Inc.	Silk Corneal Inlay (herein "Silk Film")		\$244,479.25
Savvipharm Inc	Development of a Safer Version of Doxorubicin to Diminish Cardiotoxicity in Cancer Patients	\$56,069.00	\$188,410.24
Scientific Optics, Inc	Development of Specialized Contact Lens for Dyslexic and Macular Degeneration Patients	\$83,956.02	\$93,870.62
Senex Biotechnology, Inc	Drugs inhibiting damage response mechanism of cancer, Alzheimer's and viral diseases.	\$219,179.20	\$25,300.04
Serometrix LLC	Drug targeting Androgen receptor DNA binding to block progression of prostate cancer	\$68,115.00	\$176,364.25
Serometrix LLC	Peptimer Drugs That Inhibit Binding of PCSK9 to LDLR to lower Blood Cholesterol	\$40,146.00	\$119,593.00
Sherrington Pharmaceuticals Inc	Resiniferatoxin (RTX)		\$244,479.25
SIGA Technologies, Inc	Development of Arenavirus Antivirals	\$109,775.00	\$87,503.50
SIGA Technologies, Inc.	ST-246 Orthopoxvirus Antiviral Program	\$244,479.24	
SIGA TECHNOLOGIES, INC.	DENGUE ANTIVIRAL DEVELOPMENT PROGRAM	\$111,466.50	\$94,596.00
SKS Ocular, LLC	A novel dry AMD animal model for drug screening and mechanistic studies		\$244,479.25
SONOSTICS, INC.	ASSESSMENT OF MUSCLE FORCE FOR DIAGNOSIS OF MUSCULOSKELETAL DISEASE	\$169,032.50	\$75,446.74

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Stemline Therapeutics, Inc	SL-401	\$244,479.24	
Synergy Pharmaceuticals Inc	Agonists of Guanylate Cyclase-C	\$244,479.24	
T3 Therapeutics LLC	Thyroid hormone treatment of Diastolic Heart Failure	\$84,000.00	\$100,000.00
Tactical Therapeutics Inc	Safety of Carboxyamidotriazole orotate in age-related macular degeneration Diabetic Retinopathy		\$244,479.24
Tactical Therapeutics inc	Safety of Carboxyamidotriazole orotate (CTO) in Adult Advanced and Metastatic Cancer Patients as Monotherapy and in Combination with Temozolomide in Patients with Glioblastoma Multiforme in Phase I.	\$244,479.24	
Tactical Therapeutics, Inc	Safety of Carboxyamidotriazole orotate (CTO) in Pediatric Cancer Patients as Monotherapy and in Combination with Temozolomide in Pediatric Patients with Glioblastoma Multiform in Phase 1	\$100,000.00	\$144,479.24
Tartis, Inc.	Novel Agents for Treatment of Hematological Diseases	\$5,848.47	\$108,273.03
TechnoVax Inc	Development of Virus-Like Particles {VLPs} Influenza Vaccines	\$17,834.00	\$226,645.24
TechnoVax, Inc	Development of Universal Influenza Vaccine using Virus-like Particles (VLP's)		\$41,800.00
TechnoVax, Inc	Development of Universal		\$35,150.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Virus-Like Particles(VLP) based HIV vaccine		
TechnoVax, Inc	Development of a Multivalent Dengue Virus-Like Particle (VLP) Vaccine		\$127,000.00
TechnoVax, Inc.	Respiratory Syncytial Virus Vaccine Based on Virus-Like Particles (VLPs)		\$41,800.00
Tetragenetics, Inc	Tetra Express Protein Manufacturing Platform	\$244,479.25	
The SmartPill Corporation	SmartPill Wireless Motility Capsule { WMC }	\$244,479.24	
Therasis Inc	Therasis Filter	\$190,861.00	\$53,618.25
Therasource LLC	Development of Human AM/AMBP-1 as Critical Care Therapeutics	\$200,076.50	\$44,402.75
TheraSource LLC	Preclinical Development of Alpha2A-Adrenoceptor Antagonist: A Novel Anti-Sepsis Therapy	\$28,583.00	\$46,404.00
Therex LLC	Therapeutics for the prevention and treatment of resistant Staphylococcus aureus infections.	\$108,128.00	\$42,887.50
Thermal Gradient Inc.	Rapid, Portable Molecular Diagnostic System	\$56,152.00	\$188,327.24
Tracon Pharmaceuticals Inc	TRC105	\$244,479.25	
Tracon Pharmaceuticals Inc % Paramount Biocapital Inc	TRC102	\$244,479.25	
Tracon Pharmaceuticals, Inc.C/O Paramount Biocapital Inc.	TRCO93	\$236,050.02	\$8,429.23

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Transcendent International LLC	Collaborative IVR Platform for Multilingual Patient Outreach and Treatment Adherence (a.k.a VoiceReach)	\$175,725.07	\$68,754.18
TRANSLUMINAL TECHNOLOGIES LLC	VELOX CD		\$244,479.25
TransTech Systems Inc	Non-Invasive Continuous Glucose Monitor for Diabetes	\$45,777.76	\$83,961.29
Ultradian Diagnostics, LLC	Research and Development of a Continuous Glucose Monitoring System	\$134,180.00	\$110,299.24
United Biomedical, Inc	Humanized Antibody [UB-421] Targets HIV Receptor for "Entry Inhibitor" Immunotherapy	\$244,479.25	
United Biomedical, Inc.	Preventative AIDS Vaccine by Targeting HIV-1 gp120	\$96,807.01	\$147,672.24
United Biomedical, Inc.	Alzheimer's Disease Vaccine by Targeting Amyloid-beta Peptide	\$227,385.87	\$17,093.38
United Biomedical, Inc.	HIV Therapeutic Vaccine by Targeting Host Cell HIV Receptor	\$244,479.25	
Vaccinex, Inc	VX-35 Project	\$244,479.24	
Vaccinex, Inc.	VX-5 Project	\$244,479.24	
Vaccinex, Inc.	VX-15 Project	\$244,479.24	
Vitatex Inc	Vitatex Functional Cell Adhesin Matrix (fCAM)	\$33,874.61	\$138,799.28
Vivaldi Biosciences Inc	Novel Small-Molecule Antiviral Therapeutics for Influenza	\$145,419.50	\$99,059.75
Vivaldi Biosciences Inc	Live Attenuated Influenza Vaccine (LAIV) for Greater Efficacy in the Elderly	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Vybion, Inc.	ProCode	\$127,412.00	\$117,067.24
X-Ray Optical Systems, Inc	Body-fluids trace-element analyzer to detect disease and guide therapeutic decisions	\$244,479.25	
Zeomedex, LLC	Improving the tolerability of lipase inhibitors		\$244,479.25

North Carolina \$35,707,613.85

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Advanced Liquid logic, Inc	Development of a Digital Microfluidic Platform for Newborn Screening and Other Diagnostics	\$244,479.25	
Affinergy, Inc	Localized delivery of therapeutics for sugical hernia repair meshes	\$103,735.44	\$140,743.81
Affinergy, Inc	Biologic Delivery Carrier for Spine Fusion	\$175,877.60	\$68,601.64
Affinergy, Inc.	Peptide Linkers and antimicrobial therapeutics for orthopedic surgery	\$244,479.24	
Affinergy, Inc.	Enhanced Delivery of Protein Growth Factors for Trauma Fractures	\$244,479.24	
Affinergy, Inc.	A Biological Cell-Binding Matrix for Treating Cardiovascular Disease	\$109,816.62	\$69,122.45
Agarigen, Inc	Mushrooms: A novel Platform for the Accelerated Production of Biopharmaceuticals	\$244,479.25	
Agile Sciences, Inc	Development of Therapeutics	\$25,353.50	\$111,250.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	for Treating Multidrug Resistant Bacterial Infections		
Aldagen, Inc	Treatment of Critical Limb Ischemia Patients-No Revascularization Options - (CLI) ALD-301	\$244,479.25	
Aldagen, Inc.	Treatment of Ischemic Heart Disease Patients - No Revascularization Options-ALD-201	\$244,479.25	
Aldagen, Inc.	Treatment of Post Acute Ischemic Stroke Patients - ALD-401		\$244,479.25
Algenomics, Inc	Novel Analgesic Discovery Project	\$65,881.50	\$103,459.00
Algenomics, Inc.	Diagnostic Genetic Tests for Chronic Pain Project	\$85,428.00	\$150,104.00
AlphaVax Human Vaccines Inc	Cytomegalovirus (CMV) Vaccine	\$244,479.25	
AlphaVax Human Vaccines, Inc.	Scale-up Program	\$244,479.25	
Arbovax, Inc	Host Range Mutants of Dengue Virus as Basis for Vaccine Development		\$230,000.00
Argos Therapeutics, Inc	AGS-004	\$244,479.25	
Argos Therapeutics, Inc	AGS-003	\$244,479.25	
Argos Therapeutics, Inc	AGS-009 (Interferon-alpha antibody)		\$244,479.25
ASKLEPIOS BioPharmaceutical, Inc	Gene Transfer of AAV Galanin for Epilepsy	\$149,171.00	\$95,308.25
Asklepios BioPharmaceuticals,	Gene Transfer of AAV Minidystrophin for Muscular	\$220,191.00	\$24,288.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Inc.	Dystrophy		
Attogene, Inc.	Predicting resistance of cancer to chemotherapy by profiling activities of transcription factor	\$244,479.25	
Avioq Inc.	Avioq HIV-1 Microelisa System	\$244,479.25	
Avioq Inc.	Avioq HTLV I/II Microelisa System for Use in Blood Screening and Diagnosis	\$67,913.46	\$176,565.79
b3 bio, inc	Targeted delivery of nucleic acids to silence cancer genes	\$244,479.24	
BioCytics Inc	Molecular Profiling of Circulating Tumor Cells	\$133,946.50	\$61,991.50
BioDelivery Sciences International, Inc	Medical therapies utilizing BioErodible MucoAdhesive (BEMA) technology	\$244,479.25	
BioKier, Inc.	Development of an Oral Therapeutic for the Treatment of Type 2 Diabetes	\$79,194.50	\$165,284.75
Biolex Therapeutics, Inc.	Locteron for the treatment of chronic hepatitis C virus	\$244,479.24	
BioLink Life Sciences, Inc	Novel calcium nanoparticles for cancer detection & site-specific drug delivery	\$4,426.50	\$21,112.50
BioLink Life Sciences, Inc	Novel valproate salts with enhanced patient benefits	\$186,238.00	\$44,162.00
BioLink Life Sciences, Inc	Novel phosphate binders for treatment of hyperphosphatemia	\$13,424.50	\$231,054.74
BioMarck Pharmaceuticals Ltd	A Phase 2 Clinical Study of a COPD Therapeutic with a Novel Dual Mechanism of Action	\$244,479.24	
BioMedomics, Inc.	Development of molecular diagnostic platforms & tests for personalized medicine diagnosis	\$136,875.50	\$107,603.74

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Brighthaven Ventures LLC	Formulation and Pharmacokinetics Study of Remogliflozin		\$236,350.00
CALVERT RESEARCH, LLC	Calvert T1-1081	\$195,750.00	\$48,729.25
Cardioxyl Pharmaceuticals, Inc	Oral HNO donors for treatment of Congestive Heart Failure (CHF)	\$244,479.24	
Cardioxyl Pharmaceuticals, Inc.	CXL-1020: A Novel Intravenous Treatment for Acute Decompensated heart Failure (ADHF)	\$244,479.24	
Catena Pharmaceuticals Inc	Peclinical Development of VPC51299 a Novel LPA Receptor Antagonist	\$7,500.00	\$10,000.00
CEM-102 Pharmaceuticals Inc	CEM-102 (TAKSTA) Pre-clinical and clinical development	\$244,479.25	
Cempra Pharmaceuticals, Inc	CEM-101 (Solithromycin)	\$244,479.25	
CeNeRx BioPharma Inc	TriRima	\$244,479.24	
CeNeRx BioPharma, Inc.	Pivagabine	\$244,479.24	
Centice Corporation	PASS Rx	\$244,479.24	
Centice Corporation	Diagnostic reader for cardiac biomarkers	\$244,479.25	
Chelsea Therapeutics, Inc	Droxidopa	\$244,479.24	
Chelsea Therapeutics Inc	Antifolates RA	\$244,479.24	
Chimerix Inc	CMX001 dsDNA Antiviral Project	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Chimerix, Inc	HCV Polymerase Inhibitors for the treatment of Hepatitis C	\$244,479.25	
CivaTech Oncology Inc.	CivaTech Oncology Novel Brachytherapy Device	\$178,979.00	
Cognosci, Inc.	Novel Remyelinating Therapy for Multiple Sclerosis	\$244,479.24	
Cognosci, Inc.	Novel Targeted Therapy for Cancer	\$206,132.60	\$38,346.64
Cognosci, Inc.	Novel Therapy for Traumatic Brain Injury (TBI) and Neurotrauma	\$244,479.24	
CoLucid Pharmaceuticals, Inc.	Lasmiditan (COL - 144) - Neurally Acting Anti-Migraine Agent	\$244,479.25	
Cytex Therapeutics, Inc.	Bioartificial Hip Replacement	\$18,086.00	\$226,393.25
DARA Pharmaceuticals, Inc.	DB959 for Type 2 Diabetes & Dyslipidemia	\$244,479.24	
DARA Therapeutics, Inc	KRN5500 for Neuropathic Pain in Patients with Cancer	\$244,479.24	
Diagnosoft, Inc	Diagnosoft Heat Platform	\$149,187.00	\$95,292.24
Endacea Inc	Develop Endacea's lead compound, L-97-1, as an oral treatment for renal impairment with HF	\$10,150.00	\$6,716.00
Endls Optics, Inc.	Optical Assay for the Therapeutic Monitoring and Diagnosis of Cancer	\$51,610.50	\$152,184.08
Exela Pharma Sciences, LLC	Nitrofurantoin Sodium Injection	\$244,479.25	
FSC Laboratories, Inc	Liquid Fosfomycin Tromethamine		\$244,479.25
Furiex Pharmaceuticals	JNJ-IBS		\$244,479.24

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Inc			
Furiex Pharmaceuticals, Inc	JNJ-Q2		\$244,479.24
Furiex Pharmaceuticals, Inc.	PPD 10558		\$244,479.24
Genova Diagnostics, Inc.	Irritable Bowel Syndrome Evaluation & Treatment in Primary Care	\$4,319.00	\$80,078.00
GlycoMark Inc	Novel Early Detection Algorithm for Diabetes and Per-Diabetes	\$244,479.25	
G-Zero Therapeutics Inc	G-Zero Pharmacokuiescence and Companion Diagnostic	\$46,989.00	\$197,490.25
High Point Pharmaceuticals LLC	HPP404 - H3 Antagonist - Novel New Therapeutic for Treatment of Obesity and Diabetes	\$244,479.25	
High Point Pharmaceuticals, LLC	HPP593 - PPAR Delta Agonist - Novel New Therapeutic for Dyslipidemia and Diabetes	\$244,479.25	
High Point Pharmaceuticals, LLC	HPP854 - BACE Inhibitor - Novel New Therapeutic for Treatment of Alzheimer's Disease	\$244,479.25	
High Point Pharmeceuticals	HPP851-11B-HSD1 Antagonist - Novel New Therapeutic for Primary Open Angle Glaucoma	\$244,479.25	
Humacyte Inc	New Therapy for kidney failure and vascular disease	\$244,479.25	
Hyperbranch Medical Technology Inc	Therapeutic Hydrogels	\$244,479.24	
Icagen, Inc	Novel Selective Sodium Channel Drugs to Treat chronic Pain	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Icagen, Inc.	Novel KCNQ Agonists for the Treatment of Epilepsy and Pain	\$244,479.25	
Icagen, Inc.	Novel TRPA1 Drugs to Treat Inflammatory Pain	\$244,479.25	
InnerPulse, Inc.	Percutaneous Implantable Cardioverter-Defibrillator (PICD)	\$244,479.25	
Inspire Pharmaceuticals Inc	Rho kinase inhibitors for ophthalmic and pulmonary diseases	\$244,479.25	
Inspire Pharmaceuticals Inc	Latrunculin Platform for Glaucoma	\$244,479.25	
Inspire Pharmaceuticals, Inc	Blepharitis	\$244,479.25	
Inspire Pharmaceuticals, Inc	Denufosal Tetrasodium	\$244,479.25	
Kainos Medicine USA, Inc.	NNRTI KM-023		\$135,303.61
KeraNetics LLC	Product for Fluid Resuscitation	\$205,053.00	\$39,426.25
KeraNetics LLC	Product for Site-Directed Drug Delivery	\$244,479.25	
LIPOSCIENCE, INC.	IMPACT OF LIPOPROTEIN PARTICLE ANALYSIS IN CARDIOVASCULAR RISK	\$39,875.00	\$87,975.00
Liquidia Technologies	Nanoparticle Vaccines Using PRINT Platform for Influenza and other Diseases	\$244,479.25	
Liquidia Technologies, Inc.	PRINT Particle Engineering Platform and Inhaled Antiviral Therapeutics Development	\$244,479.25	
Mast Cell Pharmaceuticals Inc	Effect of Ketotifen on Advfensiz Events Associates	\$19,377.50	\$51,962.00
Medicago USA	Demonstration of Scalable		\$244,479.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Manufacturing of Plant-Expressed Virus-Like Particles Vaccines		
Metabolon Inc	Quantose Diagnostic	\$244,479.25	
Metabolon, Inc	Platform Technology	\$244,479.25	
Morphormics, Inc.	Auto-segmentation to Improve Radiation Therapy Cancer Treatment	\$244,479.24	
MYCOSYNTHETIX INC	NEW CANCER MEDICINES FROM UNUSUAL FUNGI	\$25,244.50	\$13,231.50
Mycosynthetix, Inc	New Antibiotics for TB from Unusual Fungi	\$56,676.00	\$13,231.50
Nanocor Therapeutics Inc	Carfostin	\$244,479.25	
nContact Surgical Inc	nContact's Focus: The Cure for Atrial Fibrillation	\$244,479.24	
NextRay, Inc	NextRay	\$69,255.20	\$175,224.04
Novan, Inc	Nitric Oxide-Releasing Technology (nitricil™) to Fight Infection	\$244,479.25	
NovaTarg	AMPK Activator for Cancer and Metabolic Diseases	\$7,061.52	\$216,500.00
NovaTarg	LKB1-AMPK Pathway Activator for Cancer	\$7,061.52	\$237,417.72
NovaTarg (Kenneth William Batchelor)	Liver Selective AMPK Activator for Type 2 Diabetes	\$7,061.52	\$237,417.72
Ocean Therapeutics Inc	Identification of medicinal drug candidates from marine organisms		\$87,000.00
Ocean Therapeutics Inc	Development of a new class of anti infectives from culturable marine organisms		\$104,500.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Ocean Therapeutics Inc	Development of Brevenal, a new therapy for Cystic Fibrosis		\$244,479.25
Onconix, Inc.	Cervical Cancer Blood Test		\$25,000.00
Oncoscope, Inc.	Development of optical biopsy device for detecting pre-cancerous tissue in the esophagus	\$244,479.24	
OptoSonics, Inc	Photoacoustic Imaging and Breast Cancer Therapy	\$244,479.24	
Oxygen Biotherapeutics	Oxycyte drug for traumatic brain and spinal cord injury	\$244,479.25	
Parion Sciences, Inc	Novel Treatment of Sjogren's Syndrome Xerostomia	\$244,479.24	
Parion Sciences, Inc.	Novel Hydration Treatment for Dry Eye Disease	\$227,856.50	\$16,622.74
Pathfinder Pharmaceuticals, Inc	Restoration of Host Defense Leading to Safe, Effective Anticancer and Antiviral Drugs	\$38,426.00	\$26,500.00
Piedmont Pharmaceuticals LLC	Novel Head Lice Product	\$106,524.00	\$103,892.50
Pique Therapeutics Inc	Clinical Development of PT 107, Novel Therapy to Treat Non-Small Cell Lung Cancer(NSCLC)	\$101,250.00	\$82,364.50
Pisgah Laboratories Inc D/B/A Pisgah Labs, Inc	Abuse Deterrent Hydrocodone Controlled Substance		\$244,479.24
PLEXIGEN INC	PLEXSTACK, A FOUR-DIMENSIONAL BIO-CHIP SYSTEM FOR PERSONALIZED MEDICINE	\$180,657.50	\$63,821.75
POZEN Inc	PA640	\$244,479.25	
POZEN Inc.	PN400 / VIMOVO	\$244,479.25	
POZEN Inc.	PA32540	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Precision BioSciences, Inc.	BioProduction	\$190,983.76	\$53,495.48
Salzburg Therapeutics, Inc	FdUMP(N)Therapeutics for Cancer Treatment	\$5,904.94	\$1,880.84
SCYNEXIS Inc	SCY-641 cyclophilin inhibitor for treatment of keratoconjunctivitis	\$244,479.25	
SCYNEXIS Inc	SCY-644 Single Drug Cyclophilin Inhibitor for HIV and HCV in Coinfected Population	\$244,479.25	
SCYNEXIS Inc	Cyclophilin D Inhibitors as Protective Therapies in Muscle Injury and Disease	\$244,479.25	
Scynexis, Inc	SCY-524 Oral Hepatitis C Therapy	\$244,479.25	
Seachaid Pharmaceuticals Inc	Pre-clinical development of a novel glycopeptide for intravenous and oral delivery	\$114,330.50	\$130,148.75
Seachaid Pharmaceuticals, Inc	Oral delivery of the intravenous antibiotic cefepime	\$191,602.50	\$52,876.75
Searchaid Pharmaceuticals, Inc	Development of Oratonin, and Oral Derivative of Calcitonin	\$244,479.25	
Sicel Technologies Inc	DVS Dosimeter Lung Project	\$33,407.65	
Sicel Technologies, Inc.	DVS Electron Project	\$31,874.17	\$5,000.00
Sicel Technologies, Inc.	Ultra - HFT	\$40,760.50	
Sicel Technologies, Inc.	F-18 - Sensor Technology	\$546.75	\$75,000.00
Sirga Advanced Biopharma, Inc	HIV drug development	\$87,179.00	\$47,302.00
SureMilk, LLC	Diagnosing and treating low	\$34,877.00	\$44,484.69

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	caloric content in breast milk by means of a modified surface		
Synecor LLC	Interventional Autonomics	\$26,886.00	\$217,593.25
Synecor, LLC	Inventional Oncology	\$112,395.50	\$132,083.75
Synereca Pharmaceuticals, Inc.	RecA inhibitors to restore and potentiate antibiotic effectiveness	\$896.50	\$87,078.50
Targacept Inc	Nueronal Nicotinic Receptor Modulators as treatments for Smoking Cessastion	\$244,479.25	
Targacept, Inc	TC-5214 as a Treatment for Major Depressive Disorder (MDD)	\$239,077.50	\$5,401.75
Targacept, Inc	TC-6499 as a Treatment for Constipation Predominant Irritable Bowel Syndrome (IBS-C)	\$214,447.14	\$30,032.11
Targacept, Inc	TC-5619 as a Treatment for Various Cognitive Disorders	\$244,479.25	
Targacept, Inc.	TC-6987 as a Treatment for Various Inflammator Disorders	\$244,479.25	
Targacept, Inc.	Neuronal Nicotinic Receptor Modulators as Treatments for Parkinson's Disease	\$244,479.25	
TearScience, Inc	Thermal Pulsation System ("LipiFlow")	\$244,479.24	
TearScience, Inc	LipiView Ocular Surface Interferometer ("LipiView")	\$244,479.24	
Tensive Controls, Inc.	Melanocortin Ligands in Disease Cachexia	\$13,940.60	\$46,965.09
TheraLogics, Inc	Treatmentof Inflammatory disorders & cancer with inhibitors of NF-kappaB	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
TomoSoft Technologies, LLC	Radiation dose reduction and image enhancement in medical diagnostic imaging	\$78,246.50	\$166,232.75
Trana Discovery, Inc	Staph aureus Antibiotic Drug Discovery Assay	\$100,462.50	\$144,016.75
Trana Discovery, Inc	Application of a Novel Anti-HIV Drug Discovery Assay	\$63,719.00	\$66,900.00
TranS1, Inc	Delivery of Therapeutic Nucleus Material Using a Minimally Invasive Implant System	\$244,479.25	
TransEnterix, Inc.	The TransEnterix SPIDER Platform for Treatment of Obesity-Related Disorders and Cancer	\$244,479.24	
TransS1, Inc	Modular Fusion Implant System for Fixation and Delivery of Therapeutic Agents	\$244,479.25	
TRANSTECH PHARMA INC.	TTP4000-Rage Ligand Decoy - Novel New Therapeutic for Alzheimer's Disease	\$244,479.25	
TRANSTECH PHARMA, INC	TTP054 - Glucagon-like Peptide 1 Agonist Novel New Therapeutic for Type 2 Diabetes	\$244,479.25	
TRANSTECH PHARMA, INC.	TTP-GLUCOKINASE ACTIVATOR - NOVEL NEW THERAPEUTIC FOR TREATMENT of TYPE 2 DIABETES	\$244,479.25	
TRANSTECH PHARMA, INC.	TTP607 Aurora Kinase Inhibitor Novel New Therapeutic for treatment of cancer	\$244,479.25	
TRANZYME, INC	TZP-102	\$244,479.25	
TRANZYME, INC.	ULIMORELIN	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Vascular Pharamaceuticals, Inc	Treatment of IGF-1 mediated atherosclerosis in diabetics via aVB3 receptor antagonism	\$161,905.50	\$82,573.74
Viamet Pharmaceuticals Inc	Novel Therapaeutic for the treatment of advanced prostate cancer (APO)	\$244,479.25	
Viamet Pharnaceuticals, Inc	Novel Therapaeutic for the treatment of invasive fungal infection in humans	\$244,479.25	
Yukon Medical, LLC	Advanced Drus Access and Delivery System	\$151,615.00	\$92,864.25
Zinfandel Pharmaceuticals Inc	Opportunity for the preventio of Alzheimers Disease	\$132,056.50	\$112,422.75
Zor Pharmaceuticals, LLC	Virulizin ®	\$244,479.25	

North Dakota \$733,437.72

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Aldevron LLC	Egc Superantigens for Treatment of Stage IIIB NSCLC with Pleural Effusion	\$52,015.00	\$192,464.24
Altravax Inc	A Therapapeutic Vaccine for Treatment of Chronic Hepatitis B Infection		\$244,479.24
NovaDigm Therapeutics, Inc	Vaccine against Staphylococcus aureus and Candida	\$244,479.24	

Ohio \$14,680,074.39

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
ABT Holding Company (a subsidiary of Athersys Inc)	MultiStem IV to treat multiple diseases involving acute tissue damage & chronic inflammation	\$244,479.24	
ABT Holding Company (a subsidiary of Athersys, Inc)	Development of proprietary pharmaceutical products for the treatment of obesity by ABT	\$244,479.24	
ABT Holding Company (a subsidiary of Athersys, Inc)	MultiStem-LD for treatment of AMI (heart attack) and other forms of cardiovascular disease	\$244,479.24	
Airway Therapeutics	Development of Surfactant Protein-D to Prevent Occurrence of Bronchopulmonary Dysplasia	\$1,338.50	\$69,736.00
Akebia Therapeutics, Inc.	AKB-6548 for anemia associated with chronic kidney disease	\$244,479.24	
Akebia Therapeutics, Inc.	AKB-9778 for vascular leak	\$244,479.24	
Akebia Therapeutics, Inc.	AKB-4924 for serious infections and post-surgery wound healing	\$216,473.50	\$28,005.74
AnalizaDx, LLC	PSA/SIA A new test for improved diagnosis of Prostate cancer	\$244,479.24	
ApneiCare, LLC	Patient Study	\$116,000.00	\$108,000.00
Arteriocyte Medical Systems, Inc.	Development of Rapid, Point of Care Stem Cell Therapeutics	\$216,663.88	\$27,815.36
Arteriocyte, Inc	Advanced Stem Cell Based Cancer Diagnostics and Drug Discovery	\$65,810.00	\$178,669.24
Arteriocyte, Inc	Nanomaterials Based Production System for Therapeutic Stem Cells		\$239,575.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
AssureRx Health, Inc.	GeneSightRx Psychiatric Pharmacogenetics Product and Clinical Development	\$244,479.25	
AtriCure, Inc	AtriClip Left Appendage Exclusion Clip Development and Associated EXCLUDE Clinical Trial	\$244,479.25	
AtriCure, Inc.	Synergy RF Ablation Development and Associated ABLATE clinical Trial	\$244,479.25	
AXIOMED SPINE CORPORATION	FREEDOM ® LIMBAR DISC	\$244,479.25	
Bionix Development Corporation	Development of a Neonatal Lighted Endotracheal tube Stylet	\$7,020.16	\$59,451.79
Bionix Development Corporation	Development of a Non-Contact Electrocardiogram Monitoring Pad for Infants		\$31,172.95
Bionix Development Corporation	Development of ThermoBrachytherapy Surface applicators for Treating Cancer	\$39,398.45	\$33,460.80
Blue Ash Therapeutics, LLC	Azimilide-A Late Phase III Approvable Ventricular Antiarrhythmic		\$244,479.25
CardioInsight Technologies, Inc	CardioInsight Electrocardiograph Mapping System	\$244,479.25	
Cardiox Corporation	Stroke Prevention through Development of Non-Invasive Method for Detection of Cardiac Shunts	\$244,479.25	
Cervilenz Inc	Cervilenz	\$244,479.25	
ChanRx Corporation	Vanoxerine Development	\$76,000.00	\$168,479.24
Checkpoint Surgical,	Surgical instruments for		\$244,479.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
LLC	evaluating nerve integrity		
Cleveland Medical Devices, Inc.	Movement Disorders Diagnostics	\$44,197.00	\$52,573.00
Consolidated Research of Richmond, Inc	Zmachine for Chronic Insomnia	\$162,575.00	\$81,904.24
Copernicus Therapeutics, Inc	Cystic Fibrosis Therapeutic	\$118,458.00	\$126,021.25
Copernicus Therapeutics, Inc	Retinitis Pigmentosa (RP) Treatment	\$244,479.25	
Copernicus Therapeutics, Inc.	Parkinson's Diseases Therapeutic	\$28,348.00	\$177,412.50
Dermatopathology Laboratory of Central States	Advancing molecular probes for melanoma diagnosis		\$186,000.00
Estrocept Diagnostics, Inc	Estrocept Breast Cancer Test		\$55,000.00
EXCMR Ltd	Exercise stress cardiac magnetic resonance imaging	\$27,391.88	\$217,087.37
Frantz Medical Development, Ltd.	Miniaturized Distal Vibration System for Penetrating Vascular Occlusions	\$193,725.00	\$50,754.25
Great Lakes Pharmaceuticals Inc	Development of B-Lock, an anti-biofilm catheter lock solution		\$244,479.25
Imalux Corporation	Optical coherence tomography:use for preinvasive and invasive epithelial cancer		\$244,479.24
Jagle Biopharma LLC	Formulation Development		\$35,000.00
Juventas Therapeutics Inc	JVS-100 for Treatment of Chronic Heart Failure	\$244,479.25	
Juventas Therapeutics Inc	JVS-100 for Treatment of Critical Limb Ischemia	\$110,013.50	\$134,465.75

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Leadscope, Inc	Creation of molecular feature-based QSAR toxicity prediction models.	\$244,479.24	
m2m Imaging Corporation	Cryogenic MRI Coil Project	\$168,994.74	\$50,380.09
Metallopharm LLC	Catalytic Metallo drugs	\$51,492.50	\$127,000.00
MetaMol Theranostics LLC	Diagnostics and Therapies for Cancer Metastasis	\$59,767.11	\$38,625.00
NDI Medical LLC	Therapeutic relief of post-amputation pain		\$244,479.25
NEO PROTEOMICS, INC.	Drug development for Serotonin Receptors		\$150,000.00
Neoprobe Corporation	Lymphoseek	\$244,479.24	
Neuros Medical, Inc	Peripheral Nerve Block Stimulation for Residual Limb Pain	\$83,245.93	\$161,233.31
NeuroWave Systems Inc	NeuroSENSE Monitor	\$15,758.50	\$63,400.50
NovelMed Therapeutics, Inc	Humanized YalcioMab for Rheumatoid Arthritis	\$244,479.24	
Optimum Therapeutics, LLC	Tumor-penetrating microparticles for treating peritoneal cancers	\$89,823.77	\$65,105.67
Optimum Therapeutics, LLC	Development of siRNA cancer therapeutics	\$87,375.47	\$56,021.15
Optimum Therapeutics, LLC	Instantaneous-release paclitaxel gelatin nanoparticles for treating superficial bladder cancer	\$87,107.80	\$157,371.45
Optimum Therapeutics, LLC	Clinical Development of suramin as a nontoxic chemosensitizer for treating advanced cancer	\$157,755.83	\$86,723.42

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
OtoSonics Inc.	ConfirMEE - Ear Effusion Detection and Characterization System	\$244,479.25	
Percuision, LLC	Visually Guided Catheter	\$244,479.25	
Peritec Biosciences Ltd	Commercialization of Tissue Lined for Stent for Peripheral Arterial Disease	\$244,479.25	
PneumoSonics Inc	PneumoScan-Non-Invasive Pneumothorax Detector	\$244,479.25	
Polgenix Inc	Two Photon Ophthalmoscope	\$108,557.48	\$42,361.15
Portal Capital LLC	Prophylactic Therapies for Diseases with Airborne Transmission Vectors	\$61,027.82	\$111,375.00
Preciss (DBA Language Access Network, LLC)	Increasing Language Access in Clinical Environments	\$222,413.39	\$22,065.86
RhinoSystems Inc	Navage Nasal Hygiene Clinical Test		\$25,000.00
Sonogage Inc	Serial Tonometer for measurement of intraocular pressure	\$73,549.73	\$170,929.52
Surgical Energetics, Inc	FiberSecure wound closure device		\$50,000.00
Syncro Medical Innovations, Inc.	Development of a Tracheal Avoidance Feeding Tube with Bedside Confirmation	\$244,479.25	
Technology Medical Partners, L.L.C.	Quality of Care Management System	\$11,433.95	\$93,774.17
Tersus Pharmaceuticals	Commercial Development of Provinal TM		\$244,479.24
The Daavlin Distributing Company	Staph Therapeutic Delivery System	\$4,889.50	\$12,731.50
The Utopia Group,	Joey Spray Guard Delivery	\$88,082.69	\$156,396.56

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
LLC	System		
TheraVasc Inc.	Treatment of Peripheral Artery Disease and Diabetic Ischemic Leg Problems with TV1001	\$17,562.50	\$226,916.75
Thermalin Diabetes Incorporated	Development of Next Generation Insulin Analogs - 1	\$11,538.39	\$67,582.71
Thermalin Diabetes, LLC	Development of Next Generation Insulin Analogs - 2		\$244,479.24
Vertebration Inc	Xycor Spinal Implant for Minimally Invasive Spine Surgery	\$244,479.25	
ViewRay Incorporated	The ViewRay Renaissance™ real-time image-guided radiation therapy system	\$244,479.25	
ZIN Technologies Inc	Vmetrics		\$37,370.25

Oklahoma \$2,985,538.68

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Altheus Therapeutics, Inc	ALTH12: Novel combination treatment for inflammatory bowel disease	\$244,479.24	
Charlesson, LLC	Nanotechnology-based Formulations for Efficient and Long-Term Ophthalmic Drug Delivery	\$244,479.24	
Charlesson, LLC	Development of a novel Stat3 inhibitor for the treatment of Diabetic Retinopathy and AMD	\$75,048.69	\$169,430.55
Charlesson, LLC	Preclinical development of CLT-003 for the treatment of	\$216,861.53	\$27,617.71

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Diabetic Macular Edema		
COARE BIOTECHNOLOGY	COARE PROJECT		\$244,479.25
DormaTarg, Inc.	Development of Small Molecule Therapeutics to Target Micrometastatic Cancer Cells	\$84,821.78	\$88,222.34
Immuno-Mycologics Inc (IMMY)	High Impact Point-of-Care Cytococcosis diagnostic test	\$77,995.52	\$85,538.45
Midwest Medical Isotopes LLC	Identifying early Recurrence of Braintumor using 18-Fluorothymidine	\$244,479.25	
Midwest Medical Isotopes LLC	Staging and Monitoring Therapy in Patients with Prostate Cancer with 18 Fluorothymidine	\$244,479.25	
NanoBioMagnetics Inc	MNP technology for the delivery of chemotherapeutics	\$33,960.15	\$140,000.00
NanoMed Targeting Systems Inc.	Magnetic Targeting of Therapeutics for Atrial Fibrillation		\$244,479.24
OMEDtech LLC	Diagnostic Test of Low Protein Levels For Early Detection and Prevention of Preterm Birth		\$30,208.00
Selexys Pharmaceuticals Corporation	A Humanized Anti-P-selectin Antibody to Treat Sickle Cell Disease	\$244,479.24	
Siwa Biotech Corporation	Development of TPST Inhibitors as Non_Hormonal Male Contraceptives	\$122,089.50	\$122,389.75

Oregon \$5,447,316.68

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
13therapeutics, Inc	Commercialization of Novel Therapeutic (P13) for Treatment of Inflammatory Diseases	\$244,479.24	
Artielle Immuno Therapeutics, Inc.	Development of a T Cell Specific Drug Against Multiple Sclerosis	\$244,479.24	
Bioject Medical Technologies, Inc.	Dose Sparing Needle-free Injection Delivery Systems	\$244,479.25	
Blacktoe Medical III, Inc	Miniaturized Finger-Wearable Ultrasound Transducer	\$244,479.24	
Calypte Biomedical Corp & Sub	Aware 2, A Rapid Test for Antibodies Against HIV-1/2 in Oral Fluid	\$73,331.49	\$171,147.76
Cascade Prodrug Inc	Anti-cancer therapeutics targeting tumor hypoxia		\$244,479.25
Chemica Technologies, Inc.	Agent to Enhance Tumor Radiometal Uptake	\$45,708.50	\$16,852.00
DesignMedix, Inc	Dual-action drugs to overcome drug resistance in parasitic and bacterial disease	\$152,186.50	\$92,292.74
Electrical Geodesics, Inc.	Dense Array Electroencephalography (EEG) for Neurosurgical Planning in Epilepsy	\$244,479.25	
Epley Medical Inc. Db a Vesticon	Device of New Diagnosis and treatment of Benign Paroxysmal Positional Vertigo	\$149,875.00	\$94,604.25
HOME DIALYSIS PLUS, LTD.	Development of Novel Portable Nocturnal Hemodialysis System	\$51,809.00	\$192,670.25
Inovise Medical, Incorporated	Cardiopulmonary Holder	\$244,479.24	
Mitosciences Inc	MET3D	\$244,479.25	
Molecular MD Corp	Molecular Diagnostics c-KIT Cancer Gene Mutation Assay for Metastatic Melanoma patients	\$103,615.00	\$140,864.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
MolecularMD Corp	Molecular Diagnostics standardized BCR-ABL cancer gene quantization	\$244,479.25	
MolecularMD Corp	Molecular Diagnostics EGFR T790M Cancer Gene Mut Assy for relapsing NSCLC patients	\$103,615.00	\$140,864.25
MolecularMD Corp.	Molecular Diagnostics b-RAF V600E Cancer gene Mutation Assay for metastatic melanoma	\$103,615.00	\$140,864.25
Najit Technologies, Inc.	Development and optimization of dual-detection diagnostics	\$244,479.24	
Najit Technologies, Inc.	Development of a novel hydrogen peroxide-based vaccine platform	\$183,931.19	\$60,548.05
Pulse Health LLC	Breath Aldehyde Measurement System for the Quantitative Determination of Oxidative Stress	\$244,479.25	
River Point LLC, DBA Riverpoint Medical	Cancer Detection and Radiation Delivery Devices	\$201,866.98	\$42,612.27
Sedia Biosciences Corporation	Rapid Oral Fluid HIV Test	\$10,279.00	\$38,421.00
Sedia Biosciences Corporation	Novel Collection Devices	\$4,125.00	\$8,825.00
Tree Star Inc	FlowDx: Clinical Cytometry Analysis Software with Automated Gating	\$70,507.00	\$81,535.00
UbiVac LLC	New Cancer Vaccine Technology Based on Dribbles Produced by Tumor Cells	\$15,196.39	\$229,282.86
Yainax Medical, LLC	Microfluidics Transtympanic Delivery System for Controlled Delivery of Drugs to Inner Ear		\$37,000.00

Pennsylvania \$46,936,906.41

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Absorption Systems LP	The CellPort Technologies Project	\$146,819.00	\$97,660.24
Acne E-Visit	Acne E-Visit (Virtual Office Visit/Virtual Doctors Office)		\$244,479.25
Adolor Corporation	Delta Opioid Receptor Agonists, ADL5859 and ADL5747	\$244,479.25	
Adolor Corporation	Beloxepin Norepinephrine Reuptake Inhibitor/5HT Antagonist	\$244,479.25	
Adolor Corporation	Entereg (alvimopan), a peripherally acting mu-opioid receptor agonist	\$244,479.25	
Adolor Corporation	Peripherally acting mu opioid receptor antagonists	\$244,479.25	
Alung Technologies, Inc.	Blood-oxygenating and carbon dioxide removal device, treating acute respiratory failure.	\$244,479.24	
Apogee Biotechnology Corporation	New Drugs for Inflammatory Bowel Diseases	\$244,479.25	
Apogee Biotechnology Corporation	New Topoisomerase Inhibitors to Treat Cancer	\$375.00	\$86,737.50
Apogee Biotechnology Corporation	Improvement of Liver Transplantation	\$3,000.00	\$139,736.50
Apogee Biotechnology Corporation	New Drugs for Lymphoma		\$106,866.05
Apogee Biotechnology Corporation	New Drugs Arthritis	\$90,742.54	\$153,736.71

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Apreece Pharmaceuticals Company	Apreece Fast Metal medication (AFMM)	\$244,479.24	
Aptagen LLC	Aptabodies	\$44,862.13	\$85,044.66
Ascenta Therapeutics Inc	AT-406, an oral, pan-IAP inhibitor (SMAC mimetic), for treatment of advanced malignancies	\$244,479.24	
Ascenta Therapeutics Inc	AT-101, an oral, pan-Bcl-2 family protein inhibitor, for treatment of advanced malignancies	\$244,479.24	
Assistive Technology Products, Inc.	HydroCare	\$36,464.50	\$208,014.75
Aviana Molecular Technologies, LLC	Cost Effective Point of Care Diagnostic Platform Technology	\$32,036.50	\$118,934.00
Avid Radiopharmaceuticals Inc.	Application of Florbenazine-F18 in diagnosis of Parkinson's Disease and Diabetes	\$244,479.25	
Avid Radiopharmaceuticals, Inc.	Application of Florbetapir-F18 in diagnosis of Alzheimer's Disease	\$244,479.25	
Azevan Pharmaceuticals, Inc.	A New Drug for Depression	\$244,479.25	
Bio Capture LLC	Improved Stem Cell Separation for Cell Therapeutics		\$191,024.50
BIOFLUID TECHNOLOGY, INC	NON-INVASIVE URETHRO-CYSTOMETER		\$244,479.24
Biometric Imaging Inc	Metrobolic Imaging in 3 Dimensions Apparatus and Clinical Trials	\$95,246.50	\$149,232.74

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
BioNanomatrix Inc	Development of an advanced genome analysis system for use in research and diagnostics	\$244,479.24	
Blue Belt Technologies, Inc	Precision Freehand Sculptor (PFS)	\$244,479.24	
BroadSources, Inc.	Development of Dual MetAP2 and Sirt1 Inhibitors as Anti-Cancer Drugs	\$2,610.00	\$114,480.50
Caliber Therapeutics, Inc.	TADD	\$244,479.25	
Cardiokine Inc	Lixivaptan	\$244,479.25	
Carmell Therapeutics Corporation	REPAIR bone putty	\$95,028.50	\$149,450.74
Carmell Therapeutics Corporation	REPAIR tendon repair scaffold	\$16,374.50	\$142,726.50
Catherex Inc.	Clinical development of G207 oncolytic HSV cancer therapy for brain cancer.		\$212,433.00
Catherex Inc.	Clinical development of NV1020 oncolytic HSV cancer therapy for bladder cancer.		\$232,558.00
Celsense, Inc.	The Development of Perfluorocarbon MRI Cell Tracking Reagents	\$244,479.24	
Cernostics, Inc	Tissue Systems Pathology for Barrett's Esophagus Testing	\$115,894.81	\$128,584.43
COGNITION THERAPEUTICS, INC.	DISCOVERING AND DEVELOPING SMALL MOLECULE DISEASE-MODIFYING THERAPEUTICS FOR	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	ALZHEIMER'S DISEASE		
Cohera Medical, Inc.	Clinical Trial of Preventative Therapy for Post-surgical Seroma	\$244,479.24	
CONREX PHARMACEUTICAL CORPORATION	Project RPM	\$129,367.00	\$115,112.24
Controlled Chemicals, Inc.	BACE 1 Inhibitors for Delaying the Onset and Progression of Alzheimer's Disease	\$56,936.70	\$80,000.00
COR Innovations	Preventing Heart Failure	\$113,000.00	\$131,479.25
Cutanea Life Sciences, Inc.	The Development of Omiganan Topical Gel for Atopic Dermatitis	\$244,479.25	
Cytokine Pharmasciences, Inc	CPSI-2364 A Small-Molecule Inhibitor of Cytokine Production	\$244,479.24	
Cytokine Pharmasciences, Inc.	The MISODEL VAGINAL INSERT		\$244,479.24
Cytokine Pharmasciences, Inc	CPSI-306 A SMALL MOLECULE INHIBITOR OF IVIF	\$141,943.50	\$102,535.75
Diamyd Incorporated	NP2 Chronic Pain Therapy	\$244,479.25	
Diasome Pharmaceuticals, Inc	HDV-Insulin	\$244,479.24	
Digestive Care Inc	Pancreatic Cancer Clinical Trial and Complete NDA Requirements	\$244,479.24	
Discovery Laboratories, Inc.	Aerosurf® (aerosolized LUCINACTANT) for prevention of neonatal RDS	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Dynamis Therapeutics, Inc	Inhibitors of FN3K Enzyme as a treatment for Diabetic Complications	\$115,528.00	\$128,951.25
EAGLE VISION PHARMACEUTICAL CORP	SEEMORE: NOVEL INTRACELLULAR MOLECULAR ENHANCEMENT FOR MAGNETIC RESONANCE IMAGING	\$79,637.00	\$81,792.00
Enantigen Therapeutics Inc	Novel Antimicrobial Agents Targeting Drug Resistant Bacterial Biofilms	\$28,060.00	\$10,347.50
Enantigen Therapeutics, Inc	Development of a therapy for Dengue Virus infection	\$72,652.50	\$32,358.50
Eusa Pharma (USA) Inc	Capromab Pendetide Scanning-Optimizing Patient Selection	\$32,786.19	\$25,002.08
Eusa Pharma (USA), Inc	Samarium SM-153 Combined with Docetaxel	\$137,957.66	\$68,302.99
EUSA PHARMA (USA), INC.	PROSTASCINT FOR BRACHYTHERAPY IN LOCALIZED PROSTATE ADENOCARCINOMA	\$70,088.95	\$55,489.78
EUSA PHARMA (USA), INC.	CAPHOSOL FOR THE REDUCTION OF MUCOSITIS IN HEAD AND NECK CANCER PATIENTS	\$244,479.25	
EyeIC Incorporated	MatchedFlicker: A Novel Tool for Early Detection of Important Eye Diseases	\$244,479.25	
Falcon Genomics, Inc.	The Cancer BioChip System	\$76,417.50	\$168,061.75

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
FemmePharma Global Healthcare, Inc	Use of Dermodel™ Danazol for the Treatment of Fibrocystic Breast Disease (FBD)	\$244,479.25	
FemmePharma Global Healthcare, Inc.	PARDEL Oxybutynin, a Novel. Patented Delivery for the Treatment of Interstitial Cystitis in	\$244,479.25	
Fibrocell Technologies, Inc.	Platform Autologous Fibroblast Therapy	\$244,479.24	
FLEXUSPINE INC.	Flexuspine FSU (Functional Spinal Unit) Total Spinal Segment Replacement	\$244,479.25	
Formula Pharmaceuticals, Inc	WT-1 vaccine		\$244,479.25
Fox Chase Chemical Diversity Center Inc	Porphobilinogen Synthase Assembly-State Regulators to Treat Infectious Disease.	\$49,532.00	\$102,250.50
Fox Chase Chemical Diversity Center Inc.	Small Molecule Therapeutics for Botulinum Neurotoxin A.	\$56,019.50	\$156,958.00
Fox Chase Chemical Diversity Center, Inc.	Riluzole Prodrugs for Melanoma and ALS		\$26,875.00
Galactica Pharamceuticals, Inc.	Development of Galactica's RAGE-Ig fusion protein through completion of a first human proof-of-concept clinical trial in diabetic macular edema.	\$94,189.50	\$18,200.00
Galleon Pharmaceuticals Inc	Postoperative Pain Prophylaxis	\$244,479.24	
Galleon Pharmaceuticals, Inc	Apnea of Prematurity	\$33,004.56	\$211,474.68
Galleon Pharmaceuticals, Inc.	Prevention of Opiate	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Induced Respiratory Depression		
Gemin X Pharmaceuticals US, Inc	Obatoclax	\$244,479.24	
Genisphere LLC	Improvement of RNA amplification methods for use in molecular diagnostics/prognostics	\$12,668.50	\$115,422.50
Genisphere, LLC	Improvement of microRNA labeling technology for use in molecular diagnostics/prognostics	\$34,953.00	\$63,155.00
Gentis, Inc	Polymerizabel Reverse Emulsions as a Platform Technology	\$244,479.25	
GLYCADIA, Inc	Clinical Development of NCE GLY-230 to Treat or Prevent Complications of Diabetes	\$200,620.00	\$43,859.24
HALARE, LLC	ASTHMA TREATMENT-PRODUCT DEVELOPMENT AND TRIALS		\$244,479.24
Hemispherx Biopharma Inc	Ampligen	\$244,479.25	
Hemispherx Biopharma, Inc.	Alferon N Injection	\$244,479.25	
HRP Imaging Technologies, LLC	Development of 3-D gamma camera for high-resolution imaging intra-oro		\$232,814.00
Hybridyne Imaging Technologies, Inc	Development of Compact Gamma Camera for Detection of Prostate Carcinoma		\$56,479.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
IMC Biotechnology	Novel Small Molecule Therapy for ANCA Associated Vasculitis	\$15,641.86	\$15,000.00
Imiplex LLC	Engineered Protein for Cancer and Alzheimers Disease Diagnostics	\$6,170.04	\$50,025.52
IMMUNOME, INC.	Development of a native human antibody-based therapeutic for C. difficile infection.	\$116,847.00	\$127,632.24
Immunomic Therapeutics Inc	Immunotherapeutic Vaccine for Treatment of Cedar Pollenosis.		\$244,479.25
Immunotope Inc	Multiepitope therapeutic vaccine for drug resistant ovarian cancer	\$77,830.00	\$46,014.50
Immunotope Inc	Development of "ImmuChip" an Early Diagnostic Test for Ovarian and Prostate Cancer		\$157,720.50
Immunotope Inc	Multiepitope Universal Dengue virus vaccine	\$24,081.50	\$35,377.00
Immunotope Inc	Synthetic Nanoparticle based Universal influenza Vaccine		\$40,269.50
Immunotope, Inc.	Hepatocellular carcinoma (HCC) diagnostics defined by fucosylated serum biomarkers	\$242,468.50	\$2,010.75
Infacare Pharmaceuticals Corp	Stanate	\$244,479.25	
InfraRed Imaging Systems, Inc (INRIS)	Vascular Viewer	\$157,520.03	\$86,959.21
InfraScan, Inc.	Infrascanner	\$159,484.11	\$84,995.13

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Inovio Pharmaceuticals Inc	SYNCON TM Vaccines for emerging infectious disease	\$244,479.25	
INOVIO Pharmaceuticals Inc.	Clinical Development of a novel Therapeutic Vaccine for Cervical Cancer	\$244,479.25	
INOVIO PHARMACEUTICALS, INC	DEVELOPMENT OF A UNIVERSAL INFLUENZA VACCINE	\$244,479.25	
INRange Systems, Inc	INRange Electronic Medication Management Assistant (EMMA)	\$244,479.25	
Insituvue Inc.	Sonic Flashlight		\$244,479.25
Integral Molecular Inc	Isolating Antibodies and Mapping Immune Responses to Viral Vaccines and Pathogens	\$179,877.81	\$64,601.44
Integral Molecular Inc	Molecular Determinants of Drug and Antibody Recognition	\$144,693.13	\$99,786.12
Integral Molecular Inc	Detection of Dengue Neutralizing and Enhancing Antibodies	\$244,479.25	
Integral Molecular, Inc	Influenza Drug Development	\$104,554.83	\$123,145.24
Integrated Technologies & Services International LLC	Breast Cancer Diagnostic Test	\$90,015.78	\$92,969.65
Iroko Pharmaceuticals, LLC	Diclofenac	\$244,479.25	
Iroko Pharmaceuticals, LLC	Indomethacin	\$244,479.25	
Iroko Pharmaceuticals, LLC	Naproxen	\$244,479.25	
JDP Therapeutics Inc	JDP-205	\$26,972.00	\$217,507.25
Jenrin Discovery Inc	Peripheral-Selective CB1	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Antagonists as a New treatment Option for Metabolic Diseases		
Keystone Biologics, Inc.	Ulcerative Colitis		\$244,479.25
Keystone Nano Inc.	NanoJackets	\$244,479.25	
Kibow Biotech, Inc	Further drug-Like Clinical Validation for Kidney Health Probiotic Supplement Product	\$36,916.50	\$207,562.74
Knopp Neurosciences Inc	KNS-760704 for treatment of ALS (Amyotrophic Lateral Sclerosis)	\$244,479.25	
Lazarus Therapeutics, Inc.	GM1 Ganglioside for Parkinson's Disease	\$150,177.50	\$94,301.75
LifeSensors, Inc	Myostatin pro-peptide and regulation of muscle growth: A Novel Therapeutic Approach	\$244,479.25	
LifeSensors, Inc.	Biomarker Discovery: Ubiquitin Pathway Protein Microarrays	\$231,140.06	\$13,339.19
Lipella Pharmaceuticals, Inc.	Intravesical Liposomal Therapy	\$103,000.16	\$141,479.08
Locus Pharmaceuticals, Inc	THERAPEUTICS TO ADDRESS CHEMOTHERAPY RESISTANCE	\$244,479.25	
Longevity Biotech, Inc	VIP Hybridtide agonist for the treatment Small Cell Lung Cancer		\$30,967.51
Longevity Biotech, Inc	VPAC1 Hybridtide antagonist for the treatment Colon Cancer		\$30,967.51

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Longport, Inc.	Clinical and Finacial Impact of High Frequency Ultrasound	\$17,804.57	\$18,329.56
Marillion Pharmaceuticals Inc	Novel Diagnostic & Therapeutic Agency for Hormone Refractory Prostate Cancer	\$131,820.15	\$6,000.00
Marillion Pharmaceuticals Inc	Phase II study of a pilocarpine buccal insert for the treatment of dry mouth		\$35,000.00
Mauna Kea Technologies Inc	Cellvizio- probe based Confocal Laser Endomicroscopy (pCLE) system	\$244,479.25	
Melior Discovery, Inc	MLR-1362	\$149,799.48	\$74,220.67
Melior Discovery, Inc	MLR-1023	\$244,479.24	
Midway Pharmaceuticals, Inc	Development of MDY-1001 to Prevent Radiation Enteritis and Other GI Diseases	\$46,690.50	\$6,163.00
Molecular Detection , Inc	Diagnosis Test for the Identification of MRSA Carriers as Part pf Hospital Based Screening		\$244,479.24
Molecular Targeting Technologies, Inc	Cardiac Imaging With tc-Glucarate	\$234,444.50	\$10,034.74
Neograft Technologies, Inc.	Angioshield Vascular Reinforcement for Saphenous Veins	\$244,479.25	
Neotropix, Inc	NTX-010	\$244,479.24	
Neuro Kinetics Inc	Sports Concussion Project	\$26,950.00	\$217,529.24
NeuroDX Development LLC	ShuntCheck, Thermal Dilution Device for	\$20,817.26	\$78,017.43

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Detecting CSF Shunt Failure in Hydrocephalus		
NEUROINTERVENTIONAL THERAPEUTICS, INC. D/B/A NEUROINTERVENTIONS, INC.	NIT ISCHEMIC STROKE INTERVENTION SYSTEM	\$182,020.00	\$62,459.24
Neuronetics, Inc.	NeuroStar Transcranial Magnetic Stimulation (TMS) Therapy System	\$244,479.25	
Nitric Bio Therapeutics, Inc.	Treatment of Tinea Pedis with Gaseous Nitric Oxide (gNO)	\$244,479.24	
Nitric BioTherapeutics, Inc.	Treatment of Onychomycosis through Iontophoretic Delivery of Terbinafine	\$38,706.50	\$205,772.74
Novira Therapeutics	Development of novel and first in class antiviral therapeutic for HIV targeting viral assembly	\$146,194.34	\$98,284.91
Novira Therapeutics Inc	Development of a novel, first-in-class antiviral for Hepatitis B virus targeting viral assembly	\$82,447.50	\$104,873.00
Numoda Biotechnology Inc.	Vitreosolve		\$244,479.25
NuPathe Inc	Zelrix	\$244,479.25	
NuPathe Inc	NP202		\$161,000.00
NuPathe Inc	NP201: Novel treatment for the symptomatic treatment of Parkinson's disease	\$177,100.00	\$67,379.25
Nuron Biotech Inc	Nuron 200 recombinant human Epidermal Growth Factor		\$244,479.24

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Nuron Biotech, Inc	BaroFeron (Interferon beta-1b) for subcutaneous injection		\$244,479.24
Onconova Therapeutics, Inc.	ON01910Na Therapeutic	\$244,479.24	
Onconova Therapeutics, Inc.	Anti-MPD Therapeutic	\$244,479.24	
Onconova Therapeutics, Inc.	ON13105 Anti- Cancer Therapeutic	\$188,572.21	\$55,907.03
Onconova Therapeutics, Inc.	Ex-Rad radioprotectant	\$244,479.24	
OPTINOSE US, INC	Further Deveopment of a device to deliver pharmaceutical products.		\$244,479.25
Optinose US, Inc.	Further development of a device to deliver pharamaceutical products.		\$244,479.25
Othera Pharmaceuticals, Inc	OT-551: A potential First-Ever Therapeutic for Dry AMD	\$244,479.25	
Othera Pharmaceuticals, Inc.	OT-440: A Novel Neuroprotectant Therapeutic for Glaucoma	\$157,301.00	\$11,340.00
Penn-Century Inc.	Aerosolized delivery of Cisplantin:an effective, less toxic, less costly lung cancer treatment	\$101,237.26	\$143,241.99
Pharmabridge Inc	Novel HBV Therapeutic with Potential for Treatment of Drug-Resistant Infection	\$91,944.62	\$44,553.20
PhaseBio Pharmaceuticals Inc.	PB1023 (GLP-1-ELP-120) a Novel Long Acting GLP-1 Analog for the Treatment of T2DM	\$244,479.24	
PhaseBio Pharmaceuticals Inc.	PB1120 (VIP-ELP-120) Novel Long Acting VIP	\$131,194.00	\$113,285.24

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	for Resistant and Uncontrolled Essential HTN		
Piezo Resonance Innovations, Inc	Miniaturized, Hi-Performance, MRI-Compatible, Bioinstrumentation Ultrasonic Motor Platform	\$139,711.00	\$75,884.00
Piezo Resonance Innovations, Inc	Active Medical Devices for Clearing Feeding Tubes In-situ	\$71,629.00	\$150,937.00
Pinmed Inc	A low -cost, personalized cardiorespiratory profiling and monitoring system	\$59,875.51	\$53,765.14
PolyMedix, Inc	Synthetic Defensin Biomimetics for Use in treating Infectious Diseases	\$244,479.25	
PolyMedix, Inc.	Synthetic Anticoagulant Reversing Agent	\$244,479.25	
Precision Therapeutics, Inc.	Extension of application of ChemoFx® Drug Response Marker	\$244,479.24	
Prescient Medical, Inc.	vPredict Optical Diagnostic Catheter	\$244,479.24	
Prime Synthesis, Inc.	Hybrid Support Technology	\$115,877.44	\$128,601.80
Progenra Inc	USP20/33 inhibitor for treatment of renal cancer	\$244,479.25	
Progenra Incorporated	USP7 inhibitor for treatment of multiple myeloma	\$244,479.24	
Progenra, Incorporated	inhibitors of MuRF-1 for muscle wasting	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Promedior Inc	Development of PRM-151 for the treatment and prevention of fibrosis	\$244,479.25	
Pulsar Informatics Inc	System to individually tailor therapeutics delivery with fewer visits to physician's office.	\$174,902.50	\$69,576.75
QR Pharma Inc	POSIPHEN	\$183,376.00	\$61,103.25
Ras Therapeutics, Inc	A Phase 1 clinical trial utilizing a targeted therapy for the treatment of pancreatic cancer	\$53,361.50	\$104,785.00
Recro Pharma, Inc	Non-IV dexmedetomidine for pain	\$244,479.25	
RedPath Integrated Pathology Inc	Metastatic vs. Primary Cancer (MvPDx)	\$183,075.50	\$61,403.75
RedPath Integrated Pathology Inc	PathFinderTG Pancreatic Cyst Assay	\$244,479.25	
Richard J. Arnott	Add-on device for treatment of various respiratory conditions via metered variable pressure.	\$53,244.24	\$127,688.25
Russell Biotech Inc.	Ferromagnetic Dense Particle-based Early Diagnostic Test for Liver Cancer.	\$55,691.00	\$5,325.00
Saladax Biomedical Inc	Paciliaxel Dose Management Assay	\$103,686.00	\$140,793.24
Saladax Biomedical, Inc	Docetaxel Dose Management Assay	\$106,285.50	\$138,193.74
Saladax Biomedical, Inc	Imatinib Dose Management Assay	\$112,542.00	\$131,937.24
Saladax Biomedical, Inc	Alzheimer's Disease Biomarker Assays		\$244,479.24

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Seneb BioSciences, Inc	Glycolipid Replacement Therapy as a Treatment for Parkinson's Disease		\$28,753.40
Separation Design Group, LLC	Light Weight PORTABLE Medical OXYGEN CONCENTRATOR (POC)	\$144,533.42	\$95,322.28
SERENITY PHARMACEUTICALS LLC	SER-120	\$189,813.50	\$54,665.75
Shifa Biochemical Corporation	Novel Antithrombotic Drugs	\$23,602.84	\$10,104.97
Shifa Biomedical Corporation	Drugs for Hormone Refractory Prostate Cancer	\$35,163.69	
Shifa Biomedical Corporation	Novel Modulators of Cholesterol Metabolism	\$198,898.33	\$45,580.91
Solixia Inc.	Targeted Radiotherapy of Ovarian Cancer with a Novel, High Payload Radioligand	\$4,015.88	\$2,218.83
Sonitu Pharmaceuticals LLC	Small molecule inhibitor of PI-3AKt/mTOR for treatment of hepatocellular carcinoma	\$21,153.00	\$22,516.50
Sonitu Pharmaceuticals LLC	Broad spectrum antidote/vaccines for treatment of Staphylococcal & Streptococcal Disease		\$60,425.00
Specialty Pharmaceutical Products, L.L.C.	Advanced Therapeutic SPP Systems	\$143,722.91	\$35,316.26
SpectraGenetics LLC	Epitope-tagged Transcription Factor for Epigenetic Signatures in Human Cancer	\$71,581.00	\$107,908.50

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Stemnion, inc	Commercialization- Stemnion Proprietary cell technology platform for regenerative medicine	\$244,479.24	
Tarsa Therapeutics, Inc.	Oral recombinant calcitonin for prevention & treatment of post menopausal osteoporosis	\$244,479.24	
TegoPharm Corporation	Non-covalent masking of therapeutic monoclonal antibodies to enhance the therapeutic index	\$7,500.00	\$20,000.00
Tengion, Inc	Tengion Neo-Kidney Augment (NKA)	\$244,479.25	
Tengion, Inc.	Tengion Neo-Bladder Augment (NBA)	\$244,479.24	
Tengion, Inc.	Tengion Neo-Esophagus Augment (NEA)	\$68,457.06	\$166,049.83
Tengion, Inc.	Tengion Neo-Urinary Conduit (NUC)	\$244,479.25	
TenX Biopharma Inc	Development of Zanolimumab, a Fully Humanized Anti CD4 Monoclonal Antibody for Cancer	\$244,479.25	
Tetralogic Pharmaceuticals Corporation	Treatment of Traumatic Brain Injury using TL14077, a Selective Inhibitor of RP1 Kinase	\$244,479.24	
TetraLogic Pharmaceuticals Corporation	Treatment of Cancer using a First in Class, Selective IAP Antagonist, TL32711	\$244,479.24	
Thar Pharmaceuticals, Inc	Thar Pharmaceuticals:IV to Oral Zoledronic Acid	\$211,486.50	\$32,992.75
Thermal Therapeutic Systems,	Perfusion system to heat,	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Inc	circulate and monitor chemotherapeutic solutions		
Third Eye Diagnostics, Inc.	CerePress	\$51,095.00	\$193,384.24
Topaz Pharmaceuticals, Inc.	Novel and Safe Treatment of Head Lice Infections in Children and Adults.	\$244,479.24	
Toph Biologics	Novel Reagents For The Diagnosis of Cancer specific Glycoforms.		\$31,812.50
Transdermal Specialties, Inc	Ultrasonic Drug delivery System	\$244,479.25	
Transmolecular, Inc	TM601 Tumor Targeting Project	\$244,479.25	
Trevena, Inc	Signal selective kappa opioid receptor ligand for the management of chronic pain	\$244,479.25	
Trevena, Inc.	Signal selective mu opioid receptor ligand for the management of acute and chronic pain	\$244,479.25	
Trevena, Inc.	Signal selective angiotensin receptor ligand for the treatment of acute failure	\$244,479.25	
TREVENTIS Corporation	Amyloid Oligomer-Specific Antagonists as a Therapeutic for Alzheimer's Disease	\$33,837.50	\$210,641.74
Varinel, Inc.	Multifunctional Drugs Treating Neurodegenerative Diseases and Wound Healing		\$48,311.50

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
VascularStrategies LLC	Development of high-throughput assay for measurement of global cellular cholesterol efflux		\$46,450.00
VaxForm, LLC	Development of protein fusion vaccine protective against Streptococcus Pyogenes		\$5,498.53
Vicept Therapeutics, Inc.	V-101	\$244,479.24	
Vironika, LLC	Development of Inhibitors of Latent Epstein-Barr Virus Infection	\$16,552.41	\$118,226.61
VIROPHARMA INCORPORATED	NON-TOXIGENIC COLSTRIDIUM DIFFICILE (NTCD)	\$244,479.25	
Vitae Pharmaceuticals Inc	Development of LXR Agonists for the prevention and Treatment of Atherosclerosis	\$244,479.24	
Vitae Pharmaceuticals Inc	Development of BACE Inhibitors for the Treatment of Alzheimer's Disease	\$244,479.24	
Vitae Pharmaceuticals Inc	Development of 11Beta-HSD1 inhibitors for Treatment of Diabetes and Metabolic Syndrome	\$244,479.24	
Vitae Pharmaceuticals Inc	Development of Renin inhibitor for Treatment of Hypertension and Chronic Kidney Disease	\$244,479.24	
Vytrace Corporation	Continuous glucose monitor for the acute care setting	\$122,501.00	\$95,511.00
Xylos Corporation	Biocellulose technology solutions for the	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	treatment, repair, and replacement of human tissue		
Yaupon Therapeutics, Inc.	Evaluation of Clearazide for CTCL	\$244,479.24	
YM Biosciences USA Inc.	Nimotuzumab	\$244,479.25	
YM BioSciences USA Inc.	CYT997		\$244,479.25
ZaBeCor Pharmaceuticals, LLC	Excellair: A New Frontier in the Treatment of Asthma and Inflammation.	\$244,479.24	

Rhode Island \$4,681,937.18

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
BCR Diagnostics, Inc.	Engineered Spores as Fluorogenic Biological Indicators for Sterility Testing	\$158,237.00	\$46,393.00
Beech Tree Labs, Inc.	BTL-ng for a Reduction in Nicotine Craving	\$30,636.00	\$133,237.50
Calmar Pain Relief, LLC	Calmar Pain Relief Therapy- pain clinics	\$51,501.00	\$192,978.25
Collegium Pharmaceutical, Inc	COL-003 Extended-Release, Tamper-Resistant Opiod ("COL-003")	\$244,479.24	
EpiVax, Inc.	EpiVax Therapeutic HIV Vaccinc	\$26,625.06	\$11,344.20
EpiVax, Inc.	Development of Tregitopes as a Novel Therapeutic for Immune Modulation	\$64,778.30	\$149,973.96
IlluminOss Medical Inc	Photodynamic Therapeutic	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Bone Stabilization System		
In Cytu Inc	Late Stage Melanoma Vaccine Development	\$244,479.24	
In Cytu, Inc.	Early (Stage I/II) Melanoma Cancer Vaccine Development		\$126,434.50
In Cytu, Inc.	Lung Cancer Vaccine Development	\$3,105.00	\$25,374.50
InCytu, Inc.	Glioma Cancer Vaccine Development	\$21,062.00	\$94,239.00
ISIS BIOPOLYMER, INC	ISIS Patch	\$244,479.25	
MultiCell Technologies Inc	MCT-475	\$26,551.00	\$217,928.24
MultiCell Technologies, Inc	MCT-465	\$159,305.00	\$85,174.24
MultiCell Technologies, Inc	MCT-125	\$244,479.24	
MYOMICS, INC	Treatment of skeletal muscle weakness and fatigue disorders with MYO13	\$208,970.50	\$35,508.74
NABsys, Inc.	Development of Clinically Relevant DNA Sequencing Technology	\$244,479.25	
Neurotech USA Inc	NT-502	\$244,479.24	
Neurotech USA Inc	NT-501	\$244,479.24	
Neurotech USA, Inc	NT-503	\$244,479.24	
PROTHERA BIOLOGICS LLC	Therapeutic Tole of Inter-Alpha Inhibitor Proteins	\$78,475.50	\$166,003.75
Rhode Island Mood & Memory Research	Rhode Island Mood & Memory Research Institute		\$123,308.50

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Institute			
Tivorsan Pharmaceuticals Inc.	Biglycan for the Treatment of Duchenne Muscular Dystrophy	\$75,423.88	\$169,055.37

South Carolina \$2,554,777.26

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Avancen MOD Corporation	Portable Secure Dispenser For Oral Opioids To Promote Compliance and Prevent Diversion	\$15,681.00	\$139,588.50
Avancen MOD Corporation	An Electronic Oral Medication Device for Hospital Pain Management	\$244,479.25	
Charleston Laboratories, Inc.	Charleston Laboratories, Inc - CL - 108 a Novel approach to pain management reducing OINV	\$244,479.25	
CharlestonPharma LLC	Development of antibodies to nucleolin for the treatment of cancer		\$183,925.00
CreatiVasc Medical LLC	Heparin-infused Valve System to Assure Access for AV Graft Dialysis Patients	\$244,479.24	
FibroTherapeutics, Inc	Novel Treatment for Currently Untreatable Lung Diseases		\$16,500.00
FirstString Research, Inc.	ACT-1 Therapeutic	\$244,479.24	
IDTX Systems, Inc	Automated aerosol drug delivery		\$115,738.50

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Immunologix, Inc.	The production of fully human therapeutic monoclonal antibodies		\$244,479.24
KIYATEC Inc	3D Cell/Scaffold Constructs for Drug Development and Personalized Medicine	\$33,261.37	\$98,250.00
Poly-Med Inc.	Bioactive Absorbable Polymeric Luminal Liners	\$85,841.00	\$99,491.00
S & H Development Company, LLC	Development of a novel molecule for the treatment of solid tumors		\$244,479.25
SphingoGene	Acid Ceramidase, Target for cancer	\$57,000.24	\$123,074.62
Vortex Biotechnology Corporation	New Pim Protein Kinase Inhibitors to Treat Cancer	\$2,703.56	\$116,847.00

South Dakota \$244,479.24

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Braasch Biotech LLC	Treatment of Human Obesity by a Therapeutic Vaccination Approach.	\$11,737.50	\$232,741.74

Tennessee \$6,731,451.41

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Advanced Breath Diagnostics, LLC	13C-Spirulina Gastric Emptying Breath Test ("GEBT")	\$244,479.24	
Asklepion	Citrulline	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Pharmaceuticals LLC			
Asklepiion Pharmaceuticals LLC	Cholic Acid	\$72,395.14	\$172,084.11
BioMimetic Therapeutics Inc	Orthopedic Program	\$244,479.25	
BioMimetic Therapeutics Inc	Sports Medicine Research and Development Program	\$244,479.25	
Cumberland Pharmaceuticals Inc	Cumberland TPr Antagonist	\$13,483.50	\$230,995.75
Cumberland Pharmaceuticals Inc.	Cumberland Caldolor Pediatrics	\$57,556.50	\$186,922.75
Cumberland Pharmaceuticals Inc.	Cumberland Acetadote ALF	\$51,000.00	\$77,229.50
Cumberland Pharmaceuticals, Inc	Cumberland Acetodate EF	\$67,886.00	\$176,593.25
ED Laboratories, Inc	EDL 2000	\$104,060.50	\$140,418.75
EDP Biotech Corporation	ColoMarker	\$244,479.25	
ExtraOrtho Inc	Biopolymer Sponge		\$244,479.25
Glenveigh Pharmaceuticals LLC	Belfort-Dildy Obstetric Tamponade System (BD OTS)	\$244,479.25	
GLENVEIGH PHARMACEUTICALS, LLC	DEVICE FOR MEASURING CERVICAL DILATION DURING ACTIVE LABOR	\$48,589.50	\$32,607.50
Glenveigh Pharmaceuticals, LLC	Development of Therapeutic and Diagnostic for Preeclampsia (Project DIF)	\$109,469.00	\$46,957.50
GTx	ALK Inhibition Therapy	\$244,479.24	
GTx, Inc	Toremifene 20mg	\$244,479.24	
GTx, Inc.	Ostarine	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
GTx, Inc.	GTx-758	\$244,479.24	
GTx, Inc.	Toremifene 80mg	\$244,479.24	
Hematotypes, Inc.	Rapid multiparameter immunophenotyping of target cell populations	\$5,182.00	\$3,956.00
Insight Genetics, Inc	Novel Molecular Diagnostic Tests for Cancers Driven by Anaplastic Lymphoma Kinase (ALK)	\$244,479.25	
InVivoLink, LLC	InVivoLink Implant Registry	\$80,621.00	\$163,858.25
Molecular Design International, Inc.	Compound 49b prevents retinopathy	\$225,000.00	\$19,479.24
NellOne Therapeutics Inc	Development of novel cardiac and skeletal muscle regenerating therapy	\$113,397.50	\$131,081.74
Pathfinder Therapeutics, Inc	Image-Guided Cancer Therapeutic Delivery System	\$244,479.25	
Provectus Pharmaceuticals, Inc.	Pharmaceutical agent PV-10	\$244,479.24	
RxBio, Inc.	Rx100	\$182,397.50	\$62,081.75
Surgivision, Inc	ClearPoint	\$244,479.25	
SURGIVISION, INC.	SafeLead	\$244,479.25	

Texas \$34,166,951.65

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Access Pharmaceuticals Inc	Tumor targeted docetaxel nanoparticle	\$65,000.00	\$179,479.24

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Access Pharmaceuticals inc	Colalamin Insulin Oral drug delivery	\$216,000.00	\$28,479.24
Access Pharmaceuticals Inc	Mucoadhesive Liquid Drug Delivery		\$168,750.00
Access Pharmaceuticals Inc	Cobalamin siRNA Delivery Vehicle		\$244,479.24
Access Pharmaceuticals, Inc	ProLindac	\$244,479.24	
Access Pharmaceuticals, Inc	Thiarabine for the treatment of hematologic cancers	\$15,000.00	\$229,479.24
Access Pharmaceuticals, Inc	Polymer-Based Platinum (IV) Prodrugs		\$87,500.00
Agennix, Inc	TALACTOFERRIN	\$244,479.25	
AKELA PHARMA USA INC	FENTANYL TAIFUN® AS A RAPID-ACTING INHALED OPIOID ANALGESIC FOR TREATING CANCER PAIN	\$244,479.25	
Albumetrix, Inc	EPR Spectrometer for Sepsis and Cancer Diagnostics	\$244,479.25	
America Stem Cell Inc	Engraftin	\$244,479.25	
Aperion Biologics, Inc	Humanization and Rational Engineering of Xenograft Tissues for Regenerative Medicine	\$244,479.25	
APOCELL INC	DEP Technology		\$244,479.25
Apollo Endosurgery Inc	Overstitch™ Endoscopic Suturing System	\$244,479.25	
Apollo Endosurgery Inc.	SuMO Submucosal Operation	\$244,479.25	
Applied Nanotech Inc	Breath analysis for identification of lung cancer	\$81,893.30	\$78,942.24
AROG Pharmaceuticals	Development of Novel Anticancer Drug, PDGFR		\$244,479.24

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Inhibitor, CP-868, 596 for Treatment of GIST		
AROG Pharmaceuticals LLC	Development of Novel Anticancer Drug, PDGFR Inhibitor, CP-868,596 for Pediatric Gliomas		\$244,479.24
AROG Pharmaceuticals LLC	Development of Novel Anticancer Drug, PDGFR Inhibitor, CP-868, 596 for Adult Gliomas		\$244,479.24
AROG Pharmaceuticals LLC	Development of Enteric-Coated Tablet Formulation for Novel Anti-Cancer Drug, CP-868,596		\$95,850.00
Articulate Labs Inc	Improving Neuromuscular Electrical Stimulation for Ambulatory Osteoarthritic Knee Treatment	\$4,308.37	\$2,347.06
Assurance Biosciences, Inc.	Salivary Breast Cancer Marker		\$235,443.00
Asuragen Inc	Comprehensive Test for Fragile X Syndrome	\$112,026.00	\$28,376.00
Asuragen Inc.	Comprehensive Molecular Diagnostic Assay for Thyroid Cancer	\$67,481.00	\$176,998.25
Asuragen, Inc	Assay for monitoring and early detection of pancreatic cancer	\$35,991.00	\$188,136.50
Asuragen, Inc.	Cystic Fibrosis Test for Detection of Genetic Mutations	\$10,518.50	\$583.50
Asuragen, Inc.	BCR/ABL1 Quant™ Test for Monitoring Treatment in Chronic Myeloid Leukemia	\$53,827.00	\$190,652.25
Asuragen, Inc.	Diagnostic Assays for Detection of Cancer in Biofluids	\$101,141.00	\$71,369.00
Atumida, Inc.	Transforming Clinical Outcomes	\$29,104.10	\$51,221.67

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	for Hemorrhagic Shock And Vascular Ischemic Diseases		
AuricX Pharmaceuticals Inc	Oral Vancomycin	\$128,739.10	
AZAYA THERAPEUTICS INC	Clinical Development of Liposomal Formulation of Docetaxel (AT1-1123)	\$244,479.25	
Bellicum Pharmaceuticals, Inc	Development of Therapeutic Vaccine BPX-101 for the Treatment of Prostate Cancer	\$244,479.24	
BiO2 Medical, Inc.	Device for the prevention and treatment of Pulmonary Embolism in hospitalized patients	\$244,479.24	
Biomedical Development Corporation	Evaluate Unique Antimicrobial Oral Rinse in a Human Trial of Chronic Oral Imflammation and Investigate its Effects on Biological Markers indicative of Systemic Diseases	\$22,550.53	\$80,571.50
BioNumerik Pharmaceuticals, Inc	Karenitecin Phase III Development Project	\$244,479.25	
BioNumerik Pharmaceuticals, Inc	Tavocept Phase III Lung Cancer Project	\$244,479.25	
BIOO SCIENTIFIC CORPORATION	BIOO-2010-018-Rriptrp	\$15,000.00	\$25,000.00
BioTex, Inc.	Rapid Microbial Identification by MALDI-TOF Mass Spectrometry of Ribosomal RNA	\$166,817.51	\$77,661.73
BIOOTHER Corporation	Novel Cancer Vaccine Protein Therapeutic T1-IR for Skin, Breast and Pancreatic Tumors	\$10,000.00	\$234,479.24
Blue Box Health Inc.	Improvement of Survival, Rehospitalization Rates and Treatment Costs for Heart Failure Patie		\$244,479.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Castle Biosciences, Inc.	Proprietary DecisionDx family of molecular diagnostic assays	\$122,741.50	\$121,737.75
Clear Vascular, Inc.	Diagnostic & Therapeutic Application of Tin-117m/Annexin	\$244,479.24	
Conductance Technologies, Inc	Admittance for Heart Failure Detection		\$19,250.00
Convergen LifeSciences, Inc.	CNVN Nanoparticle Targeted Therapy for Cancer		\$244,479.25
Cormedics Corporation	PeriPort Delivery Device	\$94,317.50	\$103,500.00
Difusion Technologies, Inc	CleanFUZE antibiotic therapeutic delivery system	\$244,479.24	
DisperSol Technologies, LLC	Novel drug formulation method based on thermokinetic mixing.	\$148,944.90	\$95,534.35
DNatrix, Inc.	Tumor-specific adenovirus Delta24-RGD for malignant glioma		\$65,752.50
DuoPhos, LLC	Therapeutic control of dietary phosphorus absorption in CRF, ESRD, and hypertension	\$117,563.50	\$126,915.74
Electrochemical Oxygen Concepts, Inc.	TransCu 02 Project	\$230,664.00	\$13,815.24
Ensysce Biosciences Inc.	Therapeutic siRNA for the treatment of cancer with delivery using SWCNT	\$186,436.50	\$58,042.74
Entrigue Surgical, Inc.	Middle Turbinate Implant	\$164,784.00	\$72,127.50
Entrigue Surgical, Inc.	Sinus Dilation and Patency System	\$116,192.00	\$128,287.25
EverHeart Systems	Fully Implantable Left Ventricular Assist Device (LVAD) System	\$95,719.73	\$56,414.03
Excel Diagnostics, Ltd.	177Lu-DOTATATE	\$33,330.00	\$133,750.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Fabre-Kramer Holdings Inc	Gepirone-ER	\$244,479.25	
GenSpera, Inc	G-115 Prodrug for treatment Of Prostate Cancer		\$244,479.25
GenSpera, Inc	G-202 Prodrug for Solid Tumor Cancers	\$244,479.25	
Gradalis Inc	FANG Vaccine	\$244,479.24	
Gradalis inc	bi-shRNA-1 lipoplex	\$160,052.17	\$84,427.07
Gradalis, Inc (formerly known as Murex Pharmaceuticals, Inc	Development of a bifunctional shRNASTathmin (bi-shRNASTMN1)	\$244,479.24	
Gradalis, Inc.	GNE Lipoplex	\$146,480.82	\$97,998.42
GreenVax, LLC	Vaccine development for pandemic diseases	\$31,849.41	\$212,629.84
Halsa Pharmaceuticals, Inc	Zag as a therapeutic for the treatment of type 2 diabetes and obesity	\$244,479.25	
Incell Corp LLC	Cell Manufacturing and Testing for personalized therapies	\$118,391.50	\$126,087.75
Influmedix Inc	Development of Drugs that Target the Influenza Virus M2 Proton Channel	\$244,479.25	
InGeneron, Inc.	Autologous Cell Therapy for Myocardial Infarction at Point-of-Care	\$244,479.25	
Introgen Research Institute Inc	Nanoparticle therapy for lung cancer	\$78,566.50	\$100,000.00
Iso Therapeutics Group, LLC	Liquid Brachytherapy-A Novel Treatment for Solid Inoperable Tumors	\$44,500.00	\$188,500.00
IsoTherapeutics Group, LLC	A Novel Therapeutic Radiopharmaceutical for the Treatment of Metastatic Bone	\$22,500.00	\$219,000.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Cancer		
Joyian Pharmaceuticals	Diazonamide Analogs: A new Class of Anti-mitotic Cancer Therapeutic without Overt Toxicity	\$244,479.25	
Joyian Pharmaceuticals, Inc.	Smac Mimetics as Novel Anti-Cancer Therapy	\$244,479.25	
Keraplast Technologies, Ltd	Intravaginally delivered functional keratin for the treatment of atrophic vaginitis.		\$156,100.00
Keraplast Technologies, Ltd.	Second Degree Burns Keratin Efficacy vs. Standard of Care Clinical Study Protocol, 2010-010		\$244,479.25
LASER TISSUE WELDING, INC	LASER TISSUE WELDING-PRE-CLINICAL RESEARCH	\$16,996.00	\$227,483.25
LDR SPINE USA, INC	MOBI-C CERVICAL DISC PROSTHESIS	\$244,479.24	
Lynntech Inc	An Improved Diagnostic for Lyme Arthritis		\$42,115.50
Lynntech Inc	Xanapath	\$200,307.09	\$18,497.25
Lynntech Inc	A New Hyperspectral Image Capture Tool for Evaluating TBI		\$24,156.08
Lynntech, Inc	Ultrasensitive, Label-Free Nanowire Biosensing Arrays	\$45,326.78	\$8,967.86
Lynntech, Inc	Novel Nanostructures for Topical Photodynamic Therapy	\$113,909.62	\$20,417.96
Lynntech, Inc	Novel Fluid Management System for Microfluidic Devices	\$188,810.52	\$55,668.73
Lynntech, Inc.	Photodynamic Therapy of Disseminated Peritoneal Tumor Using New Photosensitizers	\$101,600.83	\$142,878.42
Lynntech, Inc.	Compact, Lightweight,	\$44,234.95	\$871.81

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Disposable Electrochemical Pump for Portable Drug Infusion with Direct Flow Monitoring		
Lynntech, Inc.	Portable Cathode-Air-Vapor-Feed Electrochemical Medical Oxygen Concentrator Phase II		\$82,342.12
Lynntech, Inc.	An Integrated Optical DNA Detector for Portable PCR	\$80,654.34	\$65,854.53
Lynntech, Inc.	Sequential Isoelectric Point Separation of Proteins Using Non-Gel, Microfluidic System	\$52,453.51	\$136,615.77
MacuCLEAR, Inc.	Treatment for dry Age Related Macular Degeneration	\$244,479.24	
Marval Biosciences Inc	NCTX-140	\$236,215.14	\$8,264.11
MDx BioAnalytical Laboratory, Inc.	Development of diagnostic tests based on polypeptide biomarker panels	\$44,500.00	\$199,979.24
med fusion, LLC	med fusion clin-labs * clin-trials		\$244,479.25
Medical Nanotechnologies, Inc	Targeted nanotubes for photothermal ablation therapy		\$63,868.00
Memgen, LLC	ISF35 Active Immunogene Therapy for Chronic Lymphocytic Leukemia	\$244,479.25	
MetronomX	Nifurtimox for treating neutoblastoma		\$244,479.25
MicroTransponder, Inc	Breaking the Blood Brain Barrier for Treatment of Glioblastoma BBB	\$244,479.24	
MILLAR INSTRUMENTS INC	MPVS Cardia PV System	\$244,479.25	
Millar Instruments Inc	Mikro-Cath	\$62,068.00	\$17,571.50
Mirna Therapeutics, Inc.	MicroRNA-Based Targeted Therapies for Cancer	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Molecular Templates Inc	Engineered Toxin Bodies (ETBs), a new class of biologic therapeutics, to treat cancers.	\$90,549.00	\$153,930.24
Moleculin, LLC	Commercialization of p-STAT3 inhibitor	\$52,383.50	\$192,095.74
Mystic Pharmaceuticals, Inc	VersiDoser Drug Delivery Platform	\$244,479.25	
NanoMedical Systems, Inc	Development of Molecular Drug Delivery System	\$244,479.24	
NanoRelease Technologies, LLC	Nanoparticle and Microparticle Vaccine Delivery Systems	\$75,836.50	\$77,546.50
Nanospectra Biosciences Inc	Multi-Functional Nanotheragnostic for Cancer Identification and Ablation	\$244,479.24	
Neos Therapeutics LP	Novel Once Daily Extended Release Therapeutics for ADHD	\$218,184.00	\$26,295.25
Neuro Resource Group, Inc	The development of a Single Patient InterX that will fit into existing Medicare Reimbursement.	\$244,479.24	
Nimbic Systems, Inc	Air Barrier System (ABS)	\$98,195.09	\$146,284.16
Norwell, Inc	HER2 Peptide Immunotherapy (GP2) for Breast Cancer in Adjuvant Setting	\$244,479.25	
Nventa Inc	HspE7 Therapeutic Vaccine for HPV Diseases	\$43,762.50	\$200,716.75
Nventa, Inc	Poly-ICR: A Toll-like Receptor agonist adjuvant for vaccine focusing on HPV.	\$43,762.50	\$200,716.75
Omm Scientific, Inc.	Preclinical Development of QseC Antagonists as novel antivirulence therapies for Gram	\$109,905.99	\$115,000.00
On-X Life Technologies Inc	On-X Prosthetic Heart Valve (PROACT)	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
On-X Life Technologies Inc	On-X PreChords Mitral Chordae Repair/Replacement	\$147,251.50	\$97,227.74
Opexa Therapeutics, Inc	Tovaxin therapeutic	\$244,479.24	
Ortho Kinematics Inc	Development of the KineGraph Vertebral Motion Analyzer	\$244,479.24	
p53 Inc.	Biomarker Directed p53 Tumor Suppressor Therapy of Head and Neck Cancer	\$244,479.25	
PALMAZ SCIENTIFIC INC.	Advanced Surface Nanotechnology and Therapeutic Platform for Implantable Biomaterials	\$244,479.25	
Pecan Biotherapeutics Inc	Tat Oyi	\$244,479.25	
PHOTO IMMUNE BIOTECHNOLOGY, INC	METHODOLOGY FOR DEVELOPMENT PREVENTIVE	\$85,913.00	
PHusis Therapeutics Inc.	Development of PDPK1 inhibitor PHT-427 for the treatment of non small cell lung cancer	\$1,500.00	\$242,979.24
PLx Pharma Inc	PL3100, 25 mg GI-safer naproxen capsules	\$244,479.24	
PLx Pharma Inc.	PL2200, 325 mg GI-safer aspirin capsules	\$244,479.24	
Protec Maternity Wear, LLC	Prevention of Fetal Electromagnetic Field Exposure	\$10,200.00	\$90,000.00
Pulmotect Inc.	Boosting the Innate Immune System of the Lungs	\$71,260.28	\$117,500.00
RadioMedix, Inc.	Metabolic targeting imaging and therapy of cancer	\$123,639.67	\$120,839.58
Rarecells USA Inc.	ISET Theranostics Project	\$1,322.08	\$86,524.92
Reata Pharmaceuticals	Development of RTA 744 for the	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Inc	treatment of Brain Cancer.		
Reata Pharmaceuticals Inc	Reata Bardoxolone methyl (Bardoxolone) for Chronic Kidney Disease	\$244,479.25	
Reata Pharmaceuticals Inc.	Reata Antioxidant Inflammation Modulators for Central Nervous System Disease	\$244,479.25	
Reata Pharmaceuticals, Inc	Reata Antioxidant inflammation Modulators for Cancer	\$244,479.25	
Reata Pharmaceuticals, Inc.	Reata Antioxidant Inflammation Modulators for Pulmonary Diseases (Reata AIMs PD)	\$244,479.25	
Receptor Logic, Inc	T Cell Receptor mimic (TCRm)	\$244,479.25	
Repair Technologies Inc	Activated audit marrow stromal cells (aMSCs) for treatment of immune diseases	\$244,479.24	
REPAIR Technologies Inc.	Universal RS-MSC's for Treatment of Ischemic Cardiovascular Disease	\$244,479.24	
Repros Therapeutics Inc	Proellex	\$244,479.24	
Resonant Sensors Incorporated	Label-free, high throughput screening tool for medical diagnostics and drug discovery	\$43,918.00	\$144,275.00
Resonant Sensors Incorporated	Rapid diagnostic tool for microbial and toxin detection		\$51,893.23
Resonant Sensors Incorporated	Portable photonic sensor system as an early detection tool for ovarian cancer	\$35,467.35	\$160,355.65
Risk Assessment Laboratories LLC	PTD	\$244,479.25	
Rochal Industries LLP	Delivery of Antimicrobials for Biofilm Disruption and Prevention	\$28,604.50	\$91,804.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Rules Based Medicine Inc	Development of molecular diagnostic test for complex diseases	\$244,479.25	
RyMed Technologies, Inc	Chlorhexidine Silver	\$110,000.00	\$110,000.00
Salient Pharmaceuticals Incorporated	CASAD COMMERCIALIZATION	\$244,479.25	
Savara, Inc	Budesonide for Treatment of Non-Small Cell Lung Cancer	\$244,479.25	
Seno Medical Instruments Inc	Imagio Clinical System for Early Detection and Treatment of Cancer.	\$244,479.24	
Smart Imaging Technologies Co.	Automated High Volume Screening Technology for Routine IVD tests	\$164,927.00	
Southwest Genetics PA	Midgestation Screen for Preterm Birth	\$7,850.00	\$50,900.00
Spinal Restoration, Inc	Biostat System for the relief of chronic discogenic lumbar back pain	\$244,479.24	
Stematix Inc	ALLOSTROME	\$244,479.25	
Telehealth Holdings, LLC	An Innovative Drug Delivery and Adherence System for Oncology Patients	\$183,757.50	\$60,721.75
TOMOWAVE LABORATORIES	OPTOACOUSTIC BIOSENSOR FOR FAST AND SENSITIVE DETECTION OF PATHOGENS IN BLOOD		\$119,500.00
TomoWave Laboratories	Three-Dimensional Optoacoustic tomography systems for diagnostic imaging of breast cancer		\$244,479.25
Trinity Laboratories	TLI-1026: A novel multi-modal	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Inc.	therapy to treat Fibromyalgia and Diabetic Neuropathy		
Trinity Laboratories, Inc.	Development of Novel Stable Lipid Nanoparticles of Docetaxel for Treatment of Cancer	\$167,309.78	\$44,940.51
UroResearch Inc	Tissue Bonding Cystostomy {TCB}	\$27,149.50	\$78,750.00
Vapogenix, Inc	Novel, non-opioid localized analgesics	\$119,191.12	\$125,288.13
VIDACARE CORPORATION	OnControl™ Powered Bone Marrow Aspiration and Core Biopsy System	\$244,479.25	
Vidacare Corporation	EZ-IO® Intraosseous Infusion System	\$104,053.25	\$140,425.99
ViroXis Corporation	Albuterpenoid Product Development Project	\$25,682.50	\$218,796.74
Wenzel Spine, Inc.	VariLift Interbody Fusion System	\$244,479.24	
Womens3D, Inc	Womens3D automated ultrasound breast imaging		\$244,479.24
Xbiotech USA Inc	MABp2		\$122,915.52
ZS Pharma, Inc	ZS-9	\$244,479.25	
ZZ Biotech LLC	An activated protein C variant therapeutic for stroke and neurological disorders	\$244,479.25	

Utah \$12,700,060.87

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Aciont Inc	Non-Invasive Treatment for Severe Uveitis and Related Posterior Eye Inflammation	\$101,144.50	\$143,334.75

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Diseases		
Aciont Inc	Iontophoretic Treatment for Age-related Macular Degeneration and Diabetic Retinopathy	\$51,409.00	\$193,070.25
Activatek Inc	ActivaPatch Active Drug delivery	\$149,402.50	\$95,076.74
Allocure Inc.	Multipotent Marrow Stromal Cells for Acute Renal Failure	\$244,479.25	
BIOMERICS, LLC	QUADRABAN	\$244,479.25	
Bio-Path Holdings, Inc.	Phase 1 Clinical Trial of Liposomal Grb-2		\$244,479.25
BSD Medical Corporation	MTX-180	\$244,479.25	
BSD Medical Corporation	BSD-2000 Hyperthermia System	\$244,479.25	
Catheter Connections Inc	DualCap for infection control during infusion therapy	\$167,500.11	\$76,979.14
COHEREX MEDICAL INC	Left Atrial Appendage ("LAA") Occlusion System	\$244,479.25	
Coherex Medical, Inc	Polymer-Based Closure System for Treatment of Patent Foramen Ovale ("PFO")	\$244,479.25	
DxNA, LLC	DxNA GeneSTAT PCR System	\$244,479.25	
Echelon Biosciences Inc	Development of Tools to Study Diseases Associated with Altered Autotaxin and LPA Levels	\$23,265.29	\$15,177.37
Echelon Biosciences, Inc	Sphingolipid Kinase Screening Platforms for the identification of Novel Anti-Cancer Therapie	\$8,860.81	\$4,815.64
Echelon Biosciences, Inc	Assays to detect RAGE-LIGAND INTERACTIONS IN DISEASE DETECTION AND DRUG DISCOVERY		\$11,634.42

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Echelon Biosciences Inc	Broad-spectrum antibiotic development targeting the MEP pathway		\$15,542.50
Fresh Medical Laboratories Inc.	Transthoracic Bioconductance Scanning Device Development as a Lung Cancer Diagnostic	\$136,133.50	\$108,345.75
Frontier Scientific Inc	Biliverdin IX alpha as an anti-inflammatory therapeutic agent	\$3,677.50	\$4,150.50
Frontier Scientific Inc	Frontier Scientific Inc	\$106,321.00	\$60,284.50
Frost Biologic, Inc	Development of WNK kinase inhibitors as anti-cancer drugs	\$27,140.00	\$217,339.24
Glyco Mira LLC	Sulphated Polysaccharide Derivatives	\$104,784.50	\$139,694.74
Glycosan BioSystems Inc	HyStem	\$42,879.50	\$201,599.75
INTEGRATECH PROTEOMICS LLC	DEVELOPMENT OF SMALL MOLECULE HIV INTEGRASE INHIBITOR		\$169,700.00
JSK Therapeutics, Inc (JSK-T)	New Class of Cancer Therapy Drugs	\$52,600.00	\$37,475.00
LineaGen Inc	Identification of Genetic, Proteomic and Serological Biomarkers for COPD	\$23,885.00	\$16,246.50
LineaGen, Inc	Development of Genetic Markers for the Dagnosis of Autism Spectrum Disorders	\$244,479.25	
LineaGen, Inc.	Development of Genetic and Serological Markers for the Diagnosis of Multiple Sclerosis	\$204,287.50	\$40,191.75
Lipocine Inc	Oral Sirolimus for Treatment of Progressive Glioblastoma Multiforme (LPCN 1105)	\$160,092.50	\$84,386.74
Lipocine Inc	Oral Testosterone Replacement	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Therapy (LPCN 1021)		
LIPOCINE INC	ORAL PROGESTERONE FOR HIGH-RISK PREGNANCY SUPPORT (LPCN 1002)	\$5,242.00	\$239,237.24
Lipocine Inc.	Benzonatate for Opioid Resistant Cough in Advanced Cancer Patients (LPCN 1035)	\$124,945.50	\$119,533.74
Max International LLC	Project Heart-RiboCeine		\$244,479.25
Max International, LLC	Max GlutathioCeine		\$244,479.25
Myrexix Inc	Azixa	\$244,479.25	
Myrexix Inc	MPC-9528	\$244,479.25	
Myrexix Inc	MPC-3100	\$244,479.25	
Myrexix, Inc	MPC-4326	\$244,479.25	
Myrexix, Inc	MPI-485520	\$244,479.25	
Navigen Pharmaceuticals, Inc	SecinH3 project	\$244,479.25	
Navigen Pharmaceuticals, Inc	Semaphorin 3E - anti platelet project	\$176,636.00	\$67,843.25
Navigen Pharmaceuticals, Inc.	Slit2N to Prevent Cytokine-Induced Vascular Leak	\$244,479.25	
NeuroAdjuvants, Inc.	Development of Galanin-Based Therapy for Treatment of Epilepsy	\$210,661.44	\$33,817.81
NuView Life Sciences, Inc	NuView Life Sciences Research and Development FXA-18	\$49,985.30	\$194,493.94
NuView Life Sciences, Inc	NuView Life Sciences Research and Development PCO-Cataract		\$244,479.24
NuView Life Sciences, Inc	NUView Life Sciences Research and Development Breast Cancer	\$10,362.50	\$234,116.75

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	biomarker		
NuView Life Sciences, Inc	NuView Life Sciences Research and Development FMAU		\$244,479.24
NuView Life Sciences, Inc.	NuView Life Sciences Research and Development Lymphoma biomarker	\$239,840.73	\$4,638.51
PPR Group, Inc.	PRLX93936	\$244,479.25	
Q Therapeutics, Inc.	Human Glial Progenitor Cells for Treatment of Amyotropic Lateral Sclerosis	\$174,764.62	\$69,714.63
Sera Prognostics, Inc.	Preterm Birth Serum Biomarker Test	\$74,479.17	\$143,391.78
Taueret Laboratories	Preeclampsia and Preterm Labor Gene Mapping	\$244,479.25	
TK Biotech, Inc	TK1 as a Diagnostic, Prognostic and Therapeutic Cancer Marker	\$60,550.00	\$133,000.00
TransDerm Inc	Development of siRNA Therapeutics for Treatment of Skin Disorders	\$244,479.25	
Viropan Inc	30-Day Intravaginal Ring for Prevention of Sexually-Transmitted HPV Infection in Women	\$34,875.00	\$209,604.25
Vital Access Corporation	Vital Access' Venous Windowtm Needle Guide (VWNG)	\$177,017.28	\$67,461.97
Vital Access Corporation	Vital Access - Access Device: a novel minimally-invasive medical device	\$244,479.25	
World Hearts Inc	Levacor VAD	\$244,479.25	
ZARS Pharma, Inc.	Flexicaine for Treating Post-herpetic Neuralgia	\$221,565.00	\$22,914.25
ZARS Pharma, Inc.	Triamcinolone DuraPeel TM to Treat Hand Dermatitis	\$244,479.25	

Vermont \$244,479.24

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Ascension Technology Corp	Development of magnetic and optical medical navigation technology	\$120,659.09	\$123,820.15

Virginia \$10,613,092.92

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Adaptive Methods, Inc	Rapid Portable Biosensor	\$75,000.00	\$169,479.25
Api Genesis LLC	Therapeutic Flavonoid Formulations		\$244,479.25
Axon Nutritioinals Inc	Food and Therapeutic Supplement Development and Contaminant	\$7,500.00	\$1,000.00
Bioproximity, LLC	Amyloidosis Diagnostic Development via Global Proteomic Characterization	\$76,303.90	\$64,787.94
BIOSPHEREX LLC	Human Microblome Blowmarkers and Molecular Diagnostic Discovery Project	\$58,692.50	\$185,786.75
Biovista Inc	Dimebon (BVA-101) Drug Candidate for Proressive Multiple Sclerosis	\$151,577.50	\$92,901.74
Biovista, Inc	Dimebon (BVA-601) Drug Candidate for Epilepsy	\$143,491.50	\$100,987.74
Biovista, Inc.	Pirlindol Mesylate (BVA-201), Drug Candidate for Progressive Multiple Sclerosis	\$171,976.00	\$72,503.24
Cary Pharmaceuticals Inc.	Quitpak Smoking Cessation Drug	\$5,600.22	\$238,879.02
CEL-SCI	MULTIKINE	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
CORPORATION	IMMUNOTHERAPY AGENT FOR HEAD AND NECK CANCER ("Multikine")		
CEL-SCI Corporation	CEL-2000 Therapeutic drug for rheumatoid arthritis (CEL-2000)	\$83,182.50	\$161,296.75
CEL-SCI Corporation	Leaps H1N1 Therapeutic Agent for H1N1 Pandemic Influenza (Leaps H1N1)	\$244,479.25	
Ceres Nanosciences	Ceres Nanotrap	\$170,228.00	\$74,251.25
Clavgen Therapeutics LLC	Development of Universal Multivariate Biomarkers for Predicting Chemotherapeutic Response in Bladder and Ovarian Cancers	\$195,820.48	
Dalos BiopHARMA LLC	Flavokine's effect in basal cell carcinomas		\$24,000.00
Dalos BioPharma, LLC	Flavokine's effect in Staphylococcus bacterial infections, including MRSA		\$24,000.00
Diffusion Pharmaceuticals, LLC	Trans Sodium Crocetin (TSC) for the Treatment of Hypoxic Conditions	\$244,479.24	
Dilon Technologies, Inc	BREAST SPECIFIC GAMMA IMAGING FOR EARLY DETECTION OF BREAST CANCER AND MONITORING OF TUMOR RESPONSE IN NEOADJUVANT CHEMOTHERAPY PATIENTS	\$100,361.00	\$144,118.24
Euclid Systems Corporation	Decorin Ophthalmic Solution	\$244,479.24	
EYERX Research Inc	Lacritin, a novel therapeutic for dry eye		\$13,819.50
Gencia Corp	Pre-Clinical Development for the treatment of Alzheimer's and	\$224,164.00	\$20,315.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Sarcopenia		
Gene Solutions, LLC	Parkinson's Disease Diagnostic Development	\$17,147.50	\$5,352.50
GPB Scientific, LLC	Therapeutic Stem Cells from Umbilical Cord Blood	\$244,479.25	
Health Diagnostic Laboratory Inc	High Density Lipoprotein Associated Apolipoprotein E Quantitation	\$244,479.25	
Health Diagnostic Laboratory, Inc.	Vitamin and Mineral Testing for Nutritional Status	\$244,479.25	
HemoShear LLC	Human Surrogate Model of the Liver	\$79,221.00	\$165,258.24
HemoShear, LLC	Human Surrogate Diabetes Vascular Model		\$244,479.24
Hypogen Inc	Targeted Therapeutics for Hypertension and/or Salt Sensitivity		\$5,000.00
Hypogen Inc	Salt Sensitivity Urine Test		\$5,000.00
Innovative Technologies, LLC	Breast Cancer Diagnostic Drug(ITL-1636)	\$244,479.25	
Instantlabs Medical Diagnostic Corporation	Enabling Accel. Real-Time Polymerase Chain Reaction (ART-PCR) at point -of-need	\$244,479.25	
Jericho Sciences, LLC	Novel Long-term Antiviral Therapeutic	\$2,365.00	\$242,114.24
John F. Hunt	Alkalinization of Inhaled Therapeutics.	\$5,760.00	\$3,667.00
Lestoni Corp	Targeting Tumor Hypoxia as New Cancer Therapy	\$99,303.00	\$145,176.24
Medgenics, Inc.	The Biopump Protein Factory	\$244,479.25	
Medical Predictive Science Corporation	Impact of HeRO Monitoring in Neonates	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Molecules for Health, Inc	Accelerating Development of Didox, a Unique Multifaceted Drug, Towards Clinical Usage	\$32,518.00	\$119,588.50
OCUCURE THERAPEUTICS, INC.	OC-10X: Topical treatment of Macular Degeneration and Diabetic Retinopathy	\$244,479.24	
OCULAR OPTICS, INC.	Sapphire TM Auto Focal IOL	\$244,479.25	
Osteologix Inc	NB S101	\$244,479.24	
Parabon NanoLabs Inc	A novel Nano-Pharmaceutical for the treatment of Glioblastoma Multiforme	\$38,352.47	\$92,028.90
Phthisis Diagnostics, LLC	R-Sphere Cypto-Giardia Detect	\$173,299.50	\$71,179.74
Phtsisis Diagnostics, LLC	R-Sphere Microsporidia Detect		\$35,916.50
PluroGen Therapeutics, Inc.	New Topical Antibiotic with Unique Antimicrobial, Physical, Bio-impace and Multi-function	\$160,570.31	\$83,908.94
Pocketsonics Inc	Pocket-Sized, Low-Cost, Ultrasound Imaging Device	\$143,783.00	\$100,696.25
Revivacor Inc	New therapies using human compatible cells and organs from genetically engineered pigs	\$244,479.25	
Skyentia Technologies, LLC	Novel Therapeutic for Neuroprotection in Stroke and Traumatic Brain injury	\$1,592.48	\$1,790.41
SYNTHONICS INC	METALLO-ZANAMIVIR	\$62,737.00	\$86,333.50
Synthonics Inc	Metallo-SAHA	\$64,834.50	\$76,873.00
Synthonics Inc	Metallo - Topiramate	\$61,746.50	\$66,791.50
Synthonics, Inc	Metallo-Levodopa	\$118,318.00	\$126,161.25
Tau Therapeutics	Interlaced Therapy with Mibefradil	\$169,518.52	\$74,960.73

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
LLC	for the Treatment of Glioblastoma Multiforme		
Techulon, Inc.	Glycofect Biodegradable Transfection Reagent	\$48,619.50	\$84,000.00
Toxem LLC	Botanical Drug for DIC in snakebite, sepsis and traumatic brain injury	\$51,360.92	\$193,118.33
WellAWARE Systems, Inc	WellAWARE	\$244,479.25	
Zansors LLC	Commercializing Micro/Nana sensors for obesity detection using bio-sensor technologies		\$244,479.24

Washington \$33,108,644.56

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
AcciumBio Sciences, Inc	Personalized treatment of glioblastoma multiforme and other cancers	\$65,700.00	\$178,779.25
Adaptive TCR Corporation	Prediction of Anti-TNF Response in Patients with Crohn's Disease		\$146,958.50
Adaptive TCR Corporation	Development of a Pre-symptomatic Biomarker for Type 1 Diabetes		\$244,479.25
Adaptive TCR Corporation	Prediction of Active Disease State in Crohn's Disease		\$167,559.50
Adaptive TCR Corporation	Identification of Immune System Signatures in Patients with Ovarian Cancer		\$244,479.24
Adaptive TCR Corporation	Immune System Profiling as a Measure of Vaccine Efficacy		\$244,479.24
ADVANCED	Molybdenum-99	\$205,129.00	\$39,350.24

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
MEDICAL ISOTOPE CORPORATION			
ADVANCED MEDICAL ISOTOPE-CORPORATION	Brachytherapy		\$244,479.24
Agave Pharma Inc	A novel nucleic acid delivery technology for RNAi therapeutics	\$244,479.24	
Alder Biopharmaceuticals, Inc	ALD518 humanized monoclonal antibody therapeutic project	\$244,479.24	
Allozyne Inc	AZ01 treatment of Multiple Sclerosis(MS)	\$244,479.24	
Allozyne Inc	AZ17 for the treatment of Crohn's Disease(CD)	\$244,479.24	
Aminex Therapeutics, Inc	Polyamine-Based Therapy (PBT) Approach for Head and Neck Cancer	\$6,980.73	\$237,498.51
Amnis Corporation	An Immune Monitoring Test to prevent Kidney Transplant Rejection	\$244,479.25	
Anergix LLC	Peptide Delivery for Downregulating the Autoimmune Response in Multiple Sclerosis		\$244,479.25
AVI BioPharma Inc	Duchenne Muscular Dystrophy (DMD) Therapeutic Program	\$244,479.25	
AVI BioPharma Inc	Junin Therapeutic Program	\$244,479.24	
AVI BioPharma, Inc.	Marburg Therapeutic Program	\$244,479.24	
AVI BioPharma, Inc.	Ebola Virus Therapeutic Program	\$244,479.25	
AVI BioPharma, Inc.	Influenza (H1Na virus) Therapeutic Program	\$244,479.25	
Blood Cell Storage, Inc.	Molecular Diagnostic Nucleic Acid Extraction Device	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Blood Cell Storage, Inc.	Device to improve efficacy of therapeutic platelets	\$244,479.25	
Calistoga Pharmaceuticals, Inc	CAL-263-Therapeutic for Inflammation and Auto-immunity Targeting P13 Kinase Delta	\$244,479.25	
Calistoga Pharmaceuticals, Inc	CAL-120-Therapeutics for Solid Tumor Cancers Targeting the P13 Kinase Beta/Delta Pathway	\$244,479.25	
Calistoga Pharmaceuticals, Inc	CAL-101-Therapeutic for Hematologic Malignancies and other Cancers	\$244,479.25	
Calypso Medical Technologies, Inc	Guiding Therapeutic Radiation of Tumors Without Respiratory Motion	\$244,479.25	
Calypso Medical Technologies, Inc.	Guiding Therapeutic Radiation of Tumors With Respiratory Motion	\$244,479.25	
Cancer Targeted Technology, LLC	Development of Innovative Enzyme Inhibitors for Cancer Treatment and Imaging	\$59,683.09	\$124,245.06
CARDIAC DIMENSIONS, INC.	Carillon Mitral Contour System	\$244,479.24	
Cell Therapeutics Inc & Subsidiary	Pixantrone	\$244,479.24	
Cell Therapeutics Inc & Subsidiary	Bisplatinatate		\$244,479.24
Cell Therapeutics, Inc. & Subsidiary	BROSTALLICIN	\$244,479.24	
CELL THERAPEUTICS, INC. & SUBSIDIARY	OPAXIO	\$244,479.24	
Cerevast Therapeutics, Inc	Sonothrombosis	\$153,880.34	\$90,598.91
CG Therapeutics, Inc	Cancer Vaccine Targeting Human	\$239,500.00	\$4,979.24

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Chorionic Gonadotropin		
Cocrystal Discovery, Inc	Influenza: New therapeutic and technology for broad-spectrum antivirals	\$112,530.50	\$131,948.74
Cocrystal Discovery, Inc	Human rhinovirus: New therapeutic and technology for broad-spectrum antivirals	\$168,796.50	\$75,682.74
Cocrystal Discovery, Inc.	Hepatitis C: New therapeutic and technology for broad-spectrum antivirals	\$244,479.24	
Columbia Northwest Pharmaceuticals LLC	PTSD		\$244,479.25
Columbia Northwest Pharmaceuticals, LLC	LifePro	\$12,831.00	\$231,648.25
EKOS Corporation	Transfuser Performance Improvement	\$90,579.50	
EKOS Corporation	Mach4e Product Development	\$200,704.50	
EKOS Corporation	ULTIMA clinical study	\$6,400.00	
Emergent Detection, Inc.	BodyKey FatLoss Sensor		\$229,900.00
Enject, Inc.	GlucaPen™ Emergency Auto-Injector for Severe Hypoglycemia	\$244,479.24	
Epigenomics Inc	Epi-proColon, an in-vitro diagnostic blood test for colorectal cancer	\$244,479.25	
Etubics Corporation	Development of a novel CEA Expressing Adenovirus for Cancer Treatment	\$244,479.24	
Focused Scientific Inc	Aldehyde Dehydrogenase Modulators	\$11,475.00	\$11,757.00
Healionics Corporation	Highly Integrative Biomaterial Structures for Therapeutic Devices	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Hema Quest Pharmaceuticals Inc	Novel Therapy for Cystic Fibrosis (CF)	\$111,169.50	\$95,967.00
HemaQuest Pharmaceuticals Inc	Novel Therapy for Beta-Thalassemia	\$244,479.25	
HemaQuest Pharmaceuticals Inc	Novel Therapy for Sickle Cell Disease (SCD)	\$244,479.25	
HemaQuest Pharmaceuticals Inc	Novel Treatment for EBV-related Lymphoid Malignancies	\$244,479.25	
Hyprotek, Inc	Topical Solutions and Devices for Antimicrobial Action and Reduction of CRBSI	\$8,549.00	\$11,829.00
Immune Design Corp	IDC-G103, a Therapeutic Vaccine for the Treatment of Herpes Simplex Virus Type 2	\$244,479.25	
Immune Design Corp	A Therapeutic Vaccine for Prostate Cancer Based on a Lentivirus Vector Delivery Platform	\$244,479.25	
Impel NeuroPharma, Inc	Pressurized Olfactory Delivery (POD) device	\$112,886.11	\$131,593.14
Implicit Bioscience Inc.	Development of IC 14 for acute lung injury	\$10,706.50	\$233,772.74
Inimex Pharmaceuticals USA, Inc	Amelioration of chemotherapy-induced mucositis in cancer patients		\$244,479.25
Insilicos LLC	Diagnosing Cardiovascular Disease Via Molecular Changes to HDL Particles	\$218,730.00	\$25,749.25
Integrated Diagnostics Inc	An In Vivo Diagnostic for Early Detection of Lung Cancer Using Synthetic Antibodies	\$244,479.25	
Intergrated Diagnostics	A Molecular Diagnostic Test for the Early Detection of Alzheimer's Disease	\$122,561.50	\$121,917.75

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Intergrated Diagnostics, Inc	A molecular Diagnostic Test for the Early Detection of Lung Cancer	\$24,310.00	\$220,169.25
IsoRay Medical Inc	Brachytherapy Utilizing Balloon & Liquid Radiation source for Operable Brain Cancer	\$852.00	\$234,886.00
IsoRay Medical, Inc	APBU using cesium-131 sources following lumpectomy for early stage breast cancer	\$48,911.00	\$127,308.00
IsoRay Medical, Inc.	Cesium-131 Lung Brachytherapy and Sub-Lobar Resection in Stage I NSCLC	\$59,553.00	\$55,000.00
KINETA ONE, LLC	ShK-186 AUTOIMMUNE PROGRAM	\$244,479.25	
Kineta TWO, LLC.	Antiviral protein Therapeutic		\$244,479.25
Kineta, Inc	RIG-1 Antiviral Program	\$160,600.44	\$83,878.81
Koronis Pharmaceuticals Inc	KP-1461 An Innovative Therapy for the Treatment and Possible Cure of HIV	\$244,479.25	
Kurve Technology, Inc	Controlled Particle Dispersion Technology Platform (CPD)	\$132,374.54	\$112,104.70
Light Sciences Oncology, Inc	Light-Activated Talaporfin Sodium for Primary and Secondary Liver Tumors	\$244,479.25	
Light Sciences Oncology, Inc.	Light-Activated Talaporfin Sodium for Treatment of Benign Prostatic Hyperplasia	\$244,479.24	
MDRNA, Inc.	RNA-interference (RNAi) Therapeutics	\$244,479.24	
MediQuest Therapeutics, Inc	Vascana	\$244,479.24	
Micronics, Inc.	Advancement of Novel Molecular Diagnostic Platform for Acute & Chronic Disease Detection	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Mirabilis Medica Inc	Mirabilis HIFU device for the treatment of uterine fibroids	\$244,479.24	
Mirina Corporation	Novel MicroRNA Antagonists for the Treatment of Cancer	\$244,479.24	
Mirina Corporation	Novel MicroRNA Antagonists for the Treatment of Fibrotic Liver Disease	\$146,478.18	\$98,001.06
Nanoquantum Sciences, Inc	Development of Novel Photosensitizers with Cellular Targeting for Cancer Therapy	\$51,790.46	\$192,688.79
NanoString Technologies, Inc.	The NanoString nCounter Breast Cancer Subtyping Molecular Diagnostic Test	\$244,479.24	
Nortis Inc.	Microvascular assays for research and drug testing in cancer and other diseases	\$28,823.50	
Oasis Diagnostics Corporation	Development of a new tool for the collection of DNA from saliva specimens	\$8,130.00	\$6,237.00
Omeros Corporation	Development of PDE7 inhibitor as a novel approach for the treatment of Parkinson's disease.	\$191,898.62	\$52,580.63
Omeros Corporation	Development of Novel Treatment for Addiction	\$64,477.37	\$54,453.25
Omeros Corporation	Development of novel treatments for osteoarthritis and the protection of articular cartilage	\$84,255.58	\$53,024.81
Omeros Corporation	New Drug Product to Treat Pain, Inflammation and Spasm of the Urinary Tract, OMS201	\$204,440.36	\$40,038.89
Omeros Corporation	MASP-2 MoAb Treatment for Traumatic Injury	\$244,479.25	
Omeros Corporation	Development of novel medications for schizophrenia	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	treatment		
Omeros Corporation	Intracameral OMS302 to Maintain Intraoperative Mydriasis and Reduce Pain and Inflammation	\$208,240.95	\$36,238.30
Omeros Corporation	Novel Drug Product to Improve Function and Reduce Pain Following Arthroscopic Surgery	\$244,479.25	
OncoGenex Pharmaceuticals, Inc.	Use of OGX-011 to Enhance the Effects of Chemotherapy in Prostate Cancer	\$244,479.25	
OncoGenex Pharmaceuticals, Inc.	Use of OGX-427 to Enhance the Effects of Chemotherapy	\$244,479.25	
Onconome Inc	Colon Cancer Rule Out Test	\$117,093.50	\$113,923.00
Onconthyreon Inc	PX-866 PI-3 Kinase Inhibitor	\$244,479.24	
Oncothyreon Inc	ONT 10 Novel Therapeutic Cancer Vaccine	\$69,733.00	\$174,746.24
Ondine Research Laboratories Inc	Nasal decolonization of methicillin-resistant Staphylococcus aureus (MRSA)	\$140,717.01	\$103,762.24
Onkor Pharmaceuticals, Inc	Pivotal study of small cell lung cancer therapeutic agent	\$80,300.00	\$28,582.50
Onkor Pharmaceuticals, Inc	Pivotal study of hepatoma therapeutic agent		\$1,169.00
Pacific Biomarkers, Inc.	PBI Organ Injury Biomarker Initiative	\$73,350.00	\$171,129.25
Pathway Medical Technologies Inc	Jetstream Catheter	\$244,479.25	
PhaseRx, Inc	Polymeric Delivery System of Macromolecules (RNA) to Hepatocytes	\$244,479.25	
PhaseRx, Inc.	Targeted Therapeutic Delivery Polymers for Oncology	\$121,525.00	\$122,954.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	Applications		
PhenoPath Laboratories PLLC	Improving and expanding testing available for detecting cancer and other diseases	\$244,479.25	
Poniard Pharmaceuticals, Inc	Phase 3 Studies of Picoplatin, a New-Generation Platinum-Based Chemotherapeutic	\$244,479.25	
Presage Biosciences, Inc	Development of an In Vivo Assessment Platform for Preclinical and Clinical Testing of Novel Therapeutics	\$17,320.36	\$227,158.88
ProFibrix Inc	PRO-0510: a Fibrin Sealant for Severe Bleeding	\$244,479.24	
Proteo Tech, Inc.	Systebryl for the Treatment of Systemic AA Amyloidosis	\$233,727.93	\$10,751.32
ProteoTech Inc.	Synuclere for the Treatment of Parkinson's Disease	\$244,479.25	
ProteoTech, Inc.	Pepticlere for the Treatment of Alzheimer's Disease	\$52,550.57	\$87,197.78
ProteoTech, Inc.	PET Imaging for Diagnosis of Parkinson's Disease	\$95,204.31	\$90,276.21
ProteoTech, Inc.	Exebryl-1 for the Treatment of Alzheimer's Disease	\$134,205.07	\$110,274.18
Qwell Pharmaceuticals, Inc.	Development of Avicin D for cancer treatment	\$244,479.25	
RareCyte, Inc.	Detection and Characterization of Circulating Tumor Cells	\$244,479.25	
Rhine Pharmaceuticals LLC	Symmetrin		\$244,479.25
SCOLR Pharma nc	24 mg Ondansetron Extended Release Tablets	\$4,191.50	
Scolr Pharma Inc	Oral Dosage Form of Peramivir	\$2,417.00	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
SCOLR Pharma Inc	600 mg Ibuprofen - Extended Release	\$244,479.24	
Silere Medical Technology, Inc	Therapeutic Electrical Neurostimulation Prosthesis for Suppression of Chronic Tinnitus	\$244,479.24	
Sound Pharmaceuticals Inc	Otoprotection of noise hearing loss	\$244,479.25	
Sound Pharmaceuticals Inc	Regeneration of hearing after sensorineural hearing loss	\$95,123.00	\$149,356.25
Sound Pharmaceuticals Inc	Chemoprotection in chemotherapy receiving cancer patients	\$4,286.00	\$240,193.25
STB LTD	Development of the novel FAST Dressing for Immediate Control of Life Threatening Bleeding	\$244,479.25	
Stratos Genomics Inc	SBX™ Genome Analyzer	\$186,876.34	\$57,602.91
Syntrix Biosystems	M1-Tramadol: A new therapeutic for patient to Tramadol		\$206,169.50
Syntrix Biosystems	Development of CXCR1/2 Antagonists for the Treatment of Pulmonary Inflammatory Diseases	\$207,498.73	\$36,980.52
Syntrix Biosystems	L/D-aminopterin as a novel once-weekly oral and low-cost alternative to costly biologics	\$239,613.28	\$4,865.97
Syntrix Biosystems Inc	Snap-To-It Probes	\$151,226.36	\$93,252.89
Theraclone Sciences, Inc.	Theraclone Anti-M2e Influenza Monoclonal Antibody Project	\$244,479.24	
Theraclone Sciences, Inc.	Theraclone Universal Anti-HIV Monoclonal Antibody Project	\$244,479.24	
Theraclone Sciences, Inc.	Theraclone Anti-HA Influenza Monoclonal Antibody Project	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Theraclone Sciences, Inc.	Theraclone Universal Anti-HCMV Monoclonal Antibody Project	\$166,838.50	\$77,640.74
Tissue Regeneration Systems, Inc.	Resorbable Implant for Bone Replacement and Regeneration in Craniomaxillo Facial Surgery		\$244,479.24
Trubion Pharmaceuticals Inc	TRU-016	\$244,479.24	
Trubion Pharmaceuticals Inc	Annika Vanghagen	\$244,479.24	
Trubion Pharmaceuticals Inc	X1 Scorpion	\$244,479.25	
Trubion Pharmaceuticals Inc.	TSCORP	\$244,479.25	
Trubion Pharmaceuticals, Inc.	X2 Scorpion	\$244,479.25	
Unigen, Inc.	Obesity Program	\$229,286.50	\$15,192.75
Unigen, Inc.	UP780 Diabetes Treatment	\$195,924.50	\$48,554.75
UPTAKE MEDICAL CORPORATION	BTVA FOR BRONCHOSCOPIC LUNG VOLUME REDUCTION FOR SEVERE EMPHYSEMA	\$244,479.25	
Viral Logic Systems Technology Corporation	Human FcRn Antagonist (FcRn Antagonist)	\$244,479.25	
Viral Logic Systems Technology Corporation	VLST is developing a novel product for the treatment of Rheumatoid arthritis (RA) and other chronic inflammatory autoimmune diseases. VLST's human CD200-Fc agonist therapeutic delivers immunoregulatory signals	\$244,479.25	
Viral Logic Systems Technology	Anti-human Beta-Chemokine Antibody	\$244,479.25	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Corporation			
VisionGate Inc.	Microvascular assays for research and drug testing in cancer and other diseases	\$32,318.50	\$82,685.00
VisionGate Inc.	New 3D imaging platform for diagnostic applications in lung cancer and other diseases	\$244,479.25	
VPDiagnostics Inc	Non-Invasive Accurate Assessment of Atherosclerosis for Effective Stroke and MI Prevention	\$244,479.25	
XL Sci-Tech, Inc	Absorbable and Low-Cost Radioseeds for Malignant Tumors	\$96,780.87	\$88,629.12
XORI Corporation	An Innovative Ex Vivo Platform for Discovery and Optimization of Therapeutic Antibodies	\$244,479.24	

West Virginia \$488,958.50

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Nexeon Medsystems, Inc	Protex	\$244,479.25	
Protea Biosciences Inc.	LAESI	\$147,899.50	\$96,579.75

Wisconsin \$12,886,764.62

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Addiction Therapeutix, Inc.	Addiction Therapeutix - Opioid Addiction	\$2,308.75	\$41,551.75
Addiction	Addiction Therapeutix-	\$40,922.00	\$69,079.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Therapeutix, Inc.	Alcoholism & Co-Morbid Anxiety		
AhR Pharmaceuticals Inc	Development of ITE into an Efficacious and Sustainable but Low Side-Effect Therapeutic Agent in Combating Cancer	\$883.44	\$3,550.00
BioSentinel, Inc.	Botulinum neurotoxin detection and antidotes/antagonists: A model of cost-effective drug development for unmet biothreat and patient safety needs	\$244,479.24	
Botanic Oil innovations, Inc.	Phase 1 IND Clinical Trial of Novel Biotherapeutic for cancer treatment		\$137,285.75
Cambridge Major Laboratories Inc	Advanced Development of Anti-Cancer Drug - Abiraterone ACetate	\$244,479.25	
cdi Bioscience, Inc	High Yield Protein Technology and Cell Lines for Biologic Therapeutics	\$197,160.50	\$47,318.74
Collectar, Inc.	I-131-CLR1404 For Cancer Therapy	\$244,479.24	
Cellular Dynamics International Inc (DCI)	Efficient, large -scale and parrallel manufacture of induced pluripotent stem cell (iPSC) panels.	\$244,479.25	
Cellular Dynamics International, Inc ("CDI")	Neurons derived from human induced pluripotent stem cells (iPSCs)	\$222,120.00	\$22,359.25
Cellular Dynamics International, Inc. ("CDI")	Endothelial cells derived from human induced pluripotent stem cells (iPSCs)	\$27,764.50	\$216,714.75
Cellular Dynamics International, Inc.("CDI")	Hepatocytes derived from human induced pluripotent stem cells (iPSCs)	\$101,805.50	\$142,673.75

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Compact Particle Acceleration Corporation (CPAC)	Highly Compact and Lower Cost Proton Therapy System	\$244,479.24	
ConjuGon, Inc	Novel Therapeutic for the Prevention of Catheter Associated Urinary Tract Infections	\$126,059.50	\$118,419.74
Core Products International, Inc	Effects of a Novel Compound Ibuprofen Cream in the Management of Back and Knee Pain	\$31,750.00	\$212,729.24
Cytometix, Inc	Peptide Therapy for Asthma	\$22,625.00	\$141,119.50
Cytometix, Inc.	Lipid Therapeutics for ain	\$92,000.00	\$152,479.25
Deltanoid Pharmaceuticals Inc	DAB-8 to control serum phosphorus in patients with chronic kidney disease (CKD)	\$192,718.00	\$51,761.24
Deltanoid Pharmaceuticals Inc	2MD for treatment of postmenopausal osteoporosis	\$156,026.00	\$32,395.00
Deltanoid Pharmaceuticals, Inc	2MD to slow the progression of chronic kidney disease and prevent end-stage renal disease	\$189,883.00	\$54,596.24
ENDECE, LLC	NDC-1308: anovel anticancer therapeutic for controlling tumor growth	\$244,479.24	
EraGen Biosciences Inc	Development and commercialization of FDA approved HSV 1&2 molecular diagnostic kit	\$244,479.25	
Eso-Technologies Inc.	New Approaches to a Minimally-Invasive Cardiac Monitoring System	\$152,919.50	\$91,559.75
Exact Sciences Corporation	Exact Sciences' Next Generation Colorectal Cancer (CRC) Screening Test	\$244,479.24	

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Flex Biomedical, Inc.	Flex Polymer: Novel Treatment for Osteoarthritis	\$210,510.00	\$33,969.24
FluGen, Inc	FP-An Antiviral Against Influenza		\$147,914.50
FluGen, Inc	Intradermal Microneedle Patch for Influenza Vaccine Delivery.	\$244,479.24	
FluGen, Inc.	Cell based M2KO LAIV	\$118,156.09	\$87,495.79
Genetic Testing Institute, Inc	PF4 Rapid Test	\$85,899.00	\$158,580.25
InvivoSciences, LLC	Therapeutics to treat cardiac fibrosis	\$115,504.49	\$128,974.76
ioGenetics LLC	Directed Biocide anticryptosporidial therapeutics	\$244,479.25	
Isomark LLC	Novel system for early detection of sepsis in the critically ill intensive care patient	\$5,734.45	\$66,200.00
Kenergy, Inc.	Unconditional MRI Compatible Implantable pacemaker and Defibrillator	\$244,479.24	
Mithridion, Inc	Development of first-in-class M1 and M4 agonist drugs for Alzheimer's and schizophrenia.	\$244,479.24	
MORTARA INSTRUMENT, INC.	ELI 230 Value Electrocardiograph for Early Detection of Atrial Fibrillation	\$244,479.25	
MORTARA INSTRUMENT, INC.	Mortara ELI PC, Device for Low Cost Digital Acquisition of ECG Data in New Drug Development	\$200,069.50	\$44,409.75
NanoMedex Pharmaceuticals Inc	Manotechnology Drug Formulation	\$93,257.94	\$151,221.31
NanoOncology	Preclinical development of a nanoparticle drug to treat lung cancer		\$244,479.25

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
Nerites Corporation	Dural Membrane Sealant	\$244,479.25	
NeurEndo Pharma LLC	Neuro-endocrine control as treatment for Type-2 diabetes and other metabolic disorders.	\$72,500.00	\$171,979.25
NeuWave Medical, Inc	Therapeutic Microwave Energy Delivery to Treat Cancer Tumors	\$244,479.25	
NorthStar Medical Radiostopes LLC	Production and purification of Ac225/Bi213 alpha-emitting isotopes used in delivery of therapeutic molecules for the destruction of cancer cells	\$210,580.00	\$33,899.25
Perscitus Biosciences LLC	Compsitions and Method for Protecting Cells from Toxic Compounds	\$32,866.50	\$211,612.75
Pharmasan Labs , Inc	Immune Tolerance Test (ITT)-Cytokine Platform Project	\$172,146.03	\$72,333.22
Pharming Healthcare Inc	rhC1NH: Treatment of Hereditary Angioedema and other Clinical Applications	\$244,479.25	
Pharming Healthcare Inc	Recombinant Human Fibringen for treatment of fibrinogen deficiencies	\$244,479.25	
PreventionGenetics LLC	High Density Gene-Centric Deletion and Amplification Array CGH		\$79,250.50
ProCertus BioPharm Inc	Prevention of oral mucositis in patients receiving cancer treatments	\$62,090.50	\$111,598.00
Promentis Pharmaceuticals, Inc	Cystine-Glutamate Exchange Project	\$45,995.50	\$198,483.74
Quintessence Biosciences Inc	Naked Evade [tm] Rnase QBI-139 for cancer product development	\$244,479.24	
Ratio Inc	Development of a novel drug	\$12,652.00	\$137,750.00

Applicant Name	Project Name	Grants Awarded for 2009	Grants Awarded for 2010
	delivery device: Ratio's microneedle pump-patch		
Scarab Genomics, LLC	Treatment for Sepsis and Related Syndromes	\$187,377.91	\$57,101.34
Smoke-Break Inc	Smoke-Break Liquid Nicotine Dispenser	\$13,898.50	\$169,460.50
Spectrocon International LLC	Therapeutic management of venous congestion with AutoFlow, a novel medical device	\$203,001.50	\$41,477.75
StableBody Technologies, LLC	Antibody Stabilization Technology for Therapeutic Drug Applications		\$232,436.00
Stemina Biomarker Discovery	Biomarkers of Cardiomyopathy	\$19,100.89	\$20,134.23
Stemina Biomarker Discovery	Biomarkers of Autism	\$785.29	\$30,800.34
Stratatech Corporation	Development and Clinical Evaluation of Novel Advanced Wound Care Therapies	\$244,479.25	
Waypoint Health Innovations, LLC	COPE Development Project	\$41,620.84	\$124,853.17
Wilson-Hurd Manufacturing Company	INEEDMD 12-Lead ECG Glove Project	\$139,950.00	\$104,529.25
ZyStor Therapeutics, Inc.	XC-701 for the treatment of Pompe disease	\$244,479.25	